# EDGAR Filing Document

**Accession Number:** 0001644515
**File Stem:** 0001575872-23-000123
**Filing Date:** 2023-1
**Character Count:** 890338
**Document Hash:** 603a060d57708b730b51f8eb48cab13f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-23-000123.hdr.sgml**: 20231026

**ACCESSION NUMBER**: 0001575872-23-000123

**CONFORMED SUBMISSION TYPE**: DRS

**PUBLIC DOCUMENT COUNT**: 25

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Docola, Inc.
- **CENTRAL INDEX KEY:** 0001644515
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **IRS NUMBER:** 463626795
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DRS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 377-06563
- **FILM NUMBER:** 23544582

**BUSINESS ADDRESS:**
- **STREET 1:** 801 WEST BAY DR #506
- **CITY:** LARGO
- **STATE:** FL
- **ZIP:** 33770
- **BUSINESS PHONE:** 17163088199

**MAIL ADDRESS:**
- **STREET 1:** 801 WEST BAY DR #506
- **CITY:** LARGO
- **STATE:** FL
- **ZIP:** 33770

**This is a confidential draft submission to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012 on January 23, 2023 and is not being filed publicly under the Securities Act of 1933, as amended.**

**Registration No. 333-_________**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT<br> UNDER THE SECURITIES ACT OF 1933**

**Docola, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **7372** | **46-3626795** |
| (State or other jurisdiction<br> of incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification Number) |

---

**Docola, Inc.**

**801 W. Bay Drive #506**

**Largo, FL 33770** 

**Telephone: (888) 981-8111**<br> (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Eran Kabakov** 

**Chief Executive Officer**

**Docola, Inc.**

**801 W. Bay Drive #506**

**Largo, FL 33770** 

**Telephone: (888) 981-8111**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

---

| | |
|:---|:---|
| **Laura Anthony, Esq.**<br> **Craig D. Linder, Esq.**<br> **Anthony L.G., PLLC**<br> **625 N. Flagler Drive, Suite 600**<br> **West Palm Beach, Florida 33401**<br> **Telephone: (561) 514-0936**<br> **Facsimile: (561) 514-0832** | **Ross D. Carmel, Esq.** <br>**Barry P. Biggar, Esq.** <br> **Carmel, Milazzo & Feil LLP** <br> **55 West 39th Street, 18th Floor** <br> **New York, New York 10018** <br> **Telephone: (212) 658-0458<br> Facsimile: (646) 838-1314** |

---

Approximate date of commencement of proposed sale to the public: **As soon as practicable after the effective date of this registration statement.** 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check market if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a) may determine.**

**The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted.**

---

| | | |
|:---|:---|:---|
| **PRELIMINARY PROSPECTUS** | **SUBJECT TO COMPLETION** | **DATED JANUARY 23, 2023** |

---

[●] **Units**

 **Each Unit Consisting of**

**One Share of Common Stock**

**and**

**One Warrant to Purchase One Share of Common Stock**

We are offering [●] units of Docola, Inc., a Delaware corporation. The initial public offering price is expected to be between $**____** and $**____** per unit. For purposes of this prospectus, the assumed public offering price per unit is $[●], the low-end of the anticipated price range between $[●] and $[●] per unit. Each unit consists of one share of our common stock, par value $0.0001 per share, and one warrant to purchase one share of our common stock at an exercise price per share of $[●] (100% of the assumed public offering price of one unit in this offering). The warrants will expire on the five-year anniversary of the initial issuance date. The units will have no stand-alone rights and will not be issued or certificated as stand-alone securities. Purchasers will receive only shares of common stock and warrants. The shares of common stock and warrants may be transferred separately, immediately upon issuance. The offering also includes the shares of common stock issuable from time to time upon exercise of the warrants.

Prior to this offering, there has been no public market for our securities. We intend to apply to list our common stock and warrants (forming part of the units offered hereby) on the Nasdaq Capital Market ("Nasdaq Capital Market") under the symbols "[●]" and "[●]W" respectively. There is no assurance that our listing application will be approved by the Nasdaq Capital Market. The approval of our listing on the Nasdaq Capital Market is a condition of closing this offering.

We are also seeking to register the issuance of warrants to purchase [●] shares of common stock (the "Representative's Warrants") to the underwriters (assuming the exercise of the over-allotment option by the underwriters in full), as well as [●] shares of common stock issuable upon exercise by the underwriters of the Representative's Warrants at an exercise price of $[●] per share (100% of public offering price).

The actual offering price per unit will be as determined WallachBeth Capital LLC (the "Representative" or the "Underwriter") and us at the time of pricing. Factors to be considered will include our historical performance and capital structure, prevailing market conditions and overall assessment of our business.

We are an "emerging growth company" under applicable federal securities laws and are subject to reduced public company reporting requirements for future filings.

**Investing in our securities involves a high degree of risk. See "Risk Factors" on page [●] of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

---

| | | |
|:---|:---|:---|
|  | **Per Unit** | **Total** |
| Public offering price (1) | $[●] | $[●] |
| Underwriting discounts and commissions (2) | $[●] | $[●] |
| Proceeds, before expenses, to us (3) | $[●] | $[●] |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The public offering price and underwriting discount and commissions in respect of each unit correspond to a public offering price per share of common stock of $[●] and a public offering price per accompanying warrant of $[●].

(2) This table depicts broker-dealer discounts of 8.00% of the gross offering
proceeds. The underwriters will receive compensation in addition to the underwriting discount. As additional compensation to the underwriters,
upon consummation of this Offering, we will issue to the Representative or its designees a non-redeemable warrant (the "Representative's
Warrant") to purchase an aggregate number of shares of our common stock equal to six and a half (6.5%) of the number of shares of
common stock underlying the units issued in this offering, and the terms of the Representative's Warrant will be identical to the
terms of the warrants being offered in this Offering as part of the units. See "Underwriting" beginning on page [●]
of this prospectus for additional information regarding underwriting compensation.

(3) We have also agreed to reimburse the
 representative of the underwriters for non-accountable expenses of up to 1.5%
 of the gross offering proceeds. In addition, we have agreed
 to reimburse the representative of the underwriters for up to $145,000 for all of its agreed-upon,
 actual and out-of-pocket expenses, including but not limited to reasonable and documented travel,
 legal fees and other expenses, incurred in connection with the Offering. We estimate the total
 expenses of this offering will be approximately $[●]. Assumes no exercise of the over-allotment
 option we have granted to the Representative as described below.

We have granted to the Representative an option for a period of 45 days from the date of this prospectus to purchase, on one or more occasions and in any combination thereof, up to an additional [●] shares of common stock and/or warrants to purchase [●] shares of common stock (equal to 15% of the number of shares of common stock and/or warrants underlying the units sold in this offering) at the public offering prices per share and per warrant (the "Over-Allotment Option"), less the underwriting discount and commissions solely to cover over-allotments, if any.

The underwriters expect to deliver our securities to purchasers in the offering on or about , 2023.

*Book-Running Manager*

**WallachBeth Capital LLC**

The date of this prospectus is , 2023

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#a_001) | [1](#a_001) |
| [INDUSTRY AND MARKET DATA](#a_002) | [2](#a_002) |
| [TRADEMARKS AND COPYRIGHTS](#a_003) | [2](#a_003) |
| [PROSPECTUS SUMMARY](#a_004) | [2](#a_004) |
| [THE OFFERING](#a_005) | [14](#a_005) |
| [RISK FACTORS](#a_006) | [18](#a_006) |
| [USE OF PROCEEDS](#a_007) | [34](#a_007) |
| [CAPITALIZATION](#a_008) | [34](#a_008) |
| [MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS](#a_009) | [35](#a_009) |
| [DILUTION](#a_010) | [36](#a_010) |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_011) | [37](#a_011) |
| [DESCRIPTION OF THE BUSINESS](#a_012) | [42](#a_012) |
| [REGULATORY](#a_013) | [57](#a_013) |
| [MANAGEMENT](#a_014) | [60](#a_014) |
| [EXECUTIVE COMPENSATION](#a_015) | [65](#a_015) |
| [BENEFICIAL OWNERSHIP OF SECURITIES](#a_016) | [68](#a_016) |
| [CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS](#a_017) | [69](#a_017) |
| [UNDERWRITING](#a_018) | [70](#a_018) |
| [DESCRIPTION OF SECURITIES](#a_019) | [79](#a_019) |
| [MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK AND WARRANTS](#a_020) | [82](#a_020) |
| [LEGAL MATTERS](#a_021) | [88](#a_021) |
| [EXPERTS](#a_022) | [88](#a_022) |
| [DISCLOSURE OF COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES](#a_023) | [89](#a_023) |
| [WHERE YOU CAN FIND ADDITIONAL INFORMATION](#a_024) | [89](#a_024) |

---

**No dealer, salesperson or other individual has been authorized to give any information or to make any representation other than those contained in this prospectus in connection with the offer made by this prospectus and, if given or made, such information or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation. Neither the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in our affairs or that information contained herein is correct as of any time subsequent to the date hereof.**

**For investors outside the United States: We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States.**

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This prospectus contains forward-looking statements. Specifically, forward-looking statements may include statements relating to:

● Our future financial performance;

● Changes in the market for our products and services;

● Our expansion plans and opportunities; and

● Other statements preceded by, followed by or that include the words "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "target" or similar expressions.

These forward-looking statements are based on information available as of the date of this prospectus and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:

● The level of demand for our products and services;

● Competition in our markets;

● Our ability to grow and manage growth profitably;

● Our ability to access additional capital;

● Changes in applicable laws or regulations;

● Our ability to attract and retain qualified personnel;

● The possibility that we may be adversely affected by other economic, business, and/or competitive factors; and

● Other risks and uncertainties indicated in this prospectus, including those under "Risk Factors."

**INDUSTRY AND MARKET DATA**

We are responsible for the disclosure in this prospectus. However, this prospectus includes industry data that we obtained from internal surveys, market research, publicly available information and industry publications. The market research, publicly available information and industry publications that we use generally state that the information contained therein has been obtained from sources believed to be reliable. The information therein represents the most recently available data from the relevant sources and publications, and we believe remains reliable. We did not fund and are not otherwise affiliated with any of the sources cited in this prospectus. Forward-looking information obtained from these sources is subject to the same qualifications and additional uncertainties regarding the other forward-looking statements in this prospectus.

**TRADEMARKS AND COPYRIGHTS**

We own or have rights to trademarks or trade names that we use in connection with the operation of our business, including our corporate names, logos and website names. In addition, we own or have the rights to copyrights, trade secrets and other proprietary rights that protect the content of our products and the formulations for such products. This prospectus may also contain trademarks, service marks and trade names of other companies, which are the property of their respective owners. Our use or display of third parties' trademarks, service marks, trade names or products in this prospectus is not intended to, and should not be read to, imply a relationship with or endorsement or sponsorship of us. Solely for convenience, some of the copyrights, trade names and trademarks referred to in this prospectus are listed without their©,® and™ symbols, but we will assert, to the fullest extent under applicable law, our rights to our copyrights, trade names and trademarks. All other trademarks are the property of their respective owners.

**PROSPECTUS SUMMARY**

*This summary highlights certain information about us, this offering, and selected information contained in this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our units. For a more complete understanding of the Company and this offering, we encourage you to read and consider the more detailed information in this prospectus, including "Risk Factors" and the financial statements and related notes. Unless the context otherwise requires, "Docola," "we," "us," "our," or "the Company" refers to Docola, Inc., a Delaware corporation. Docola has no subsidiaries.*

*Unless otherwise noted, the share and per share information in this prospectus reflects a forward stock split of the outstanding common stock of the Company at a 1199.298126-for-1 ratio, which was effected on December 13, 2022.*

**Overview**

Docola, Inc. was incorporated in the state of Delaware on September 5, 2013. Docola aims to be a social good organization offering a free care communication platform that seeks to consolidate thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one online marketplace called Docola at the following websites: https://www.doco.la and https://www.docola.com (the "Platform"). The information contained on our websites is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our websites as part of this prospectus or in deciding whether to purchase our securities. Additionally, our Platform allows users to easily create and upload their own resources. With the use of our Platform, clinicians and patient-facing professionals can ePrescribe personalized information to an individual patient or groups of patients. Patients can review the information and ask questions in the comfort of their own homes before, between, or after in-person or virtual visits. We aim to proactively meet people's informational needs, so they understand why it is important, possible, and safe to participate in their own medical care. We aim to save time both for the patient and provider and improve patient satisfaction and patient outcomes.

Our Platform was developed by a team of clinicians who know from experience that better communication is essential to better patient care, understanding, and outcomes. We believe that patient centricity, collaboration, and transparency are the best ways to improve patient care. We continuously aim to learn from millions of digital interactions, conversations with clinicians and patients, and ongoing research in asynchronous education. On our Platform, healthcare providers, hospitals, and clinics can find free and low-cost patient education and resources, or upload and create their own, and deliver them to patients before, between, and after visits on any web-enabled device. As a social good organization, our Platform is free to all healthcare providers, patients, advocates, and content providers. We intend that it always will be free in the future. There are also optional services that users can select on our Platform that come with an associated fee as further described in detail below.

We are passionately committed to unifying the healthcare experience. We believe access to information and care should be available to everyone. We aim to make it possible for patients and families to receive the right information at the right time, so they can act on it. We believe that when we proactively meet people's informational needs, they understand why it's important, possible, and safe to participate in their care. This also helps people think about their goals and preferences, in order to have better conversations. To date, our Platform has approximately 58,042 users, including clinicians and patients, across the U.S., Canada and the U.K.

To support our free Platform, we offer optional paid services and license a separate product called DocolaRx, to research organizations, medical devices, biotech and pharmaceutical companies for their projects. The proceeds provide financial funding but they do not have any influence or interaction with our free Platform.

To date, the Company has funded operations primarily through equity and debt financings. For the fiscal years ending December 31, 2021 and 2020, the Company generated revenues of $111,318 and $137,482, respectively, and reported net loss of $4,439,303 and $1,219,317, respectively; and cash flow used in operating activities of $413,952 and $306,880, respectively. As noted in our financial statements, as of December 31, 2021, the Company had an accumulated deficit of $6,546,227 and working capital deficit of $6,489,880. There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and debt financings. See "Risk Factors—We have a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2021 and 2020."

**Industry Overview**

The Company operates in the healthcare industry and specifically in the telehealth industry, which has grown substantially since the start of the Covid-19 pandemic and which continues to grow at this time. According to an article published by McKinsey & Company on July 9, 2021, titled "Telehealth: A quarter-trillion-dollar post-COVID-19 reality?" in April of 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February of 2020. According to the same article, since the initial spike in April of 2020, telehealth adoption overall has approached up to 17% of all outpatient and office visit claims with evaluation and management ("E&M") services.

According to the same article:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Telehealth utilization has stabilized at levels 38 times higher than before the pandemic. After
an initial spike to more than 32% of office and outpatient visits occurring via telehealth in April of 2020, utilization levels
have largely stabilized, ranging from 13% to 17% across all specialties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Similarly, consumer and provider attitudes toward telehealth have improved since the pre-COVID-19
era. Perceptions and usage have dropped slightly since the peak in spring of 2020. Some barriers—such as perceptions of technology
security—remain to be addressed to sustain consumer and provider virtual health adoption, and models are likely to evolve
to optimize hybrid virtual and in-person care delivery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Some regulatory changes that facilitated expanded use of telehealth have been made permanent, for
example, the Centers for Medicare & Medicaid Services' expansion of reimbursable telehealth codes for the 2021 physician
fee schedule. But uncertainty still exists as to the fate of other services that may lose their waiver status when the public health
emergency ends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Investment in virtual care and digital health more broadly has skyrocketed, fueling further innovation,
with 3 times the level of venture capitalist digital health investment in 2020 than it had in 2017.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Virtual healthcare models and business models are evolving and proliferating, moving from purely
"virtual urgent care" to a range of services enabling longitudinal virtual care, integration of telehealth with other
virtual health solutions, and hybrid virtual/in-person care models, with the potential to improve consumer experience/convenience,
access, outcomes, and affordability.

According to an article published by Fierce Healthcare on December 22, 2021 titled "2022 Forecast: Investors will double down on these hot digital health markets," the first nine months of 2021 alone brought in a total of $21.3 billion for digital health startups across 541 investment deals, dwarfing the $14.6 billion record of 2020, according to Rock Health, a venture fund dedicated to digital health. According to the same article, industry experts say the telehealth industry is becoming more mature and is shifting away from just urgent care visits to focus on more specialized care, or what some call "telehealth 2.0." Further, according to an article published by MarketWatch on June 23, 2022, titled "Telehealth Market in US 2022-Growth Strategy, Top Trends And Business Opportunity" the US telehealth market is expected to grow at a compound annual growth rate of over 29% during the period 2022-2031.

**Our Products and Services**

Built by clinicians, we believe that our healthcare communication Platform makes it easy for healthcare providers to improve patient understanding, engagement and measure care participation. Through our Platform we aim to:

&nbsp;&nbsp;&nbsp;&nbsp;· *Educat* e: Healthcare providers can use our Platform
to curate their own library and E-prescribe education and resources to their patients from a central hub.

&nbsp;&nbsp;&nbsp;&nbsp;· *Empower*: We believe that our Platform makes it easier
for patients and families to confidently participate in their own care.

&nbsp;&nbsp;&nbsp;&nbsp;· *Better Outcomes*: We believe that our Platform improves
both the patient and clinician healthcare experience.

&nbsp;&nbsp;&nbsp;&nbsp;· *Insights*: We believe that on our Platform, healthcare
providers can learn how patients utilize online resources through feedback reports and reviews.

We seek to serve clinicians, patients, education providers as well as pharmaceutical and medical device companies. Through our platform we aim to serve:

&nbsp;&nbsp;&nbsp;&nbsp;· *Clinicians*: On our Platform clinicians can engage
with patients by ePrescribing and tracking interactive resources.

&nbsp;&nbsp;&nbsp;&nbsp;· *Patients*: On our Platform patients can take control
of their care with online health information, selected by their care team.

&nbsp;&nbsp;&nbsp;&nbsp;· *Education and Content Providers*: On our Platform educational
and content providers can create a free distribution channel by adding their resources so clinicians can find and utilize them.

&nbsp;&nbsp;&nbsp;&nbsp;· *Pharmaceutical/Medical Device Companies*: On our Platform
pharmaceutical and medical device companies can create interactive resources to support sales, marketing and research and development.

***Clinicians***

Clinicians can use our Platform to create a free account and use this account to create their own patient education library of videos, handouts and interactive decision aids as well as communicate with patients. On our Platform clinicians can:

&nbsp;&nbsp;&nbsp;&nbsp;· Upload their own resources by simply using drag and drop;

&nbsp;&nbsp;&nbsp;&nbsp;· Choose from thousands of free and low-cost resources on the
Platform;

&nbsp;&nbsp;&nbsp;&nbsp;· Pull in free resources from the web;

&nbsp;&nbsp;&nbsp;&nbsp;· Use the tools in the Platform to easily create videos, surveys,
quizzes, for their patients; and

&nbsp;&nbsp;&nbsp;&nbsp;· Market their practice to current and prospective patients.

Clinicians can then combine any of these interactive resources to create courses. Clinicians can use our Platform to create their own courses for the most common diagnoses and procedures and share them with just one or many patients with just the click of a button, as well as easily modify courses for individual needs, specific combinations of conditions, and health changes over time. They can also ePrescribe courses to an individual, group, or all of their patients. Clinicians can also use the dashboard on our Platform to monitor patient care and progress and to provide follow up and pre-visit guidance. With the use of our Platform, we believe that clinicians can reclaim their time so that it can be dedicated to better personal conversations with patients. We believe that with our Platform, healthcare providers, case managers, educators and advocates can ensure patients and families receive the right information at the right time as well as improve in-person and virtual visits by giving patients consistent, actionable information they can view anytime, anywhere, on any web-enabled device. We believe that our Platform's feature set makes it effective at population health management.

We believe that when you meet their informational needs, people feel cared for and empowered, which makes them less likely to search for answers on the internet, which may lead to sources that provide misinformation. This improves their ability to engage in their care plans. On our Platform, clinicians can support patients between visits by e-prescribing actionable information to help them understand their conditions, treatments, procedures, recovery, medications, and self-care.

As the Platform expands and connects with other solutions, we intend that there will be optional features offered by third parties to our clinician users for a fee. Currently there is the option for clinicians to request a managed account for a onetime fee of $499. With this offering Docola handles all technology and content management, thereby simplifying the experience, speeding up implementation and saving time. Over the years clinicians have asked for additional help creating their account, uploading their educational resources, creating courses, and training their team members on using the Platform. This one time set up service includes 90 days of dedicated phone support for practice staff. There is also the option for clinicians to elect for ongoing account management for a monthly fee of $129. Included in this offering are ongoing help with content management, monthly usage and key performance indicator ("KPI") reporting, and dedicated phone support for staff.

We believe that the benefits of our Platform for clinicians, include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· Reduce Repetition: clinicians don't have to feel like
a parrot, a virtual course lets patients review information as many times as they want.

&nbsp;&nbsp;&nbsp;&nbsp;· Improve Relationships: clinicians can communicate and pre-educate
patients prior to appointments and as a result can have more productive conversations with their patients.

&nbsp;&nbsp;&nbsp;&nbsp;· Extend Care Team: clinicians can extend the care team with
resources for conditions, meds, and procedures from our Platform.

&nbsp;&nbsp;&nbsp;&nbsp;· Optimize Processes: clinicians can improve patient selection,
speed time to procedures, enhance marketing initiatives, and coordinate clinical and administrative staff.

&nbsp;&nbsp;&nbsp;&nbsp;· Enhance and Support Self Care: clinicians can give patients
info they can understand and act on and as a result reduce the need for searching the internet .

&nbsp;&nbsp;&nbsp;&nbsp;· Increase Satisfaction: clinicians can exceed patient expectations
and reduce clinical team burnout.

&nbsp;&nbsp;&nbsp;&nbsp;· Track and document: clinicians can monitor if patients start
and complete courses.

&nbsp;&nbsp;&nbsp;&nbsp;· Gather insights: clinicians can collect patient feedback
through surveys and reviews.

&nbsp;&nbsp;&nbsp;&nbsp;· Secure: our Platform aims to meet the highest data compliance
regulations.

 ****

The Platform supports delivery of videos (MP4 format), Microsoft Office documents, Images (PNG and JPG), and PDFs, web assets, quizzes and surveys. Clinicians will be in full control of and solely responsible for all content they post on our Platform. The Platform is designed to enable clinicians to easily update information whenever needed. New materials can be uploaded and replaced within any course. A unique version control feature maintains a record of each item updates.

 ****

 ****

***Patients and Families***

A patient's healthcare provider will send their patient an email with a link to create a free account on our Platform. With our Platform a patient's doctor can easily share or "ePrescribe" videos and other resources to explain conditions, medications, or procedures, help patient's think about treatment decisions, and have better conversations. We believe that this helps patients to better understand their diagnoses or treatment options and relieves the stress and uncertainty of having to search the web for this information. Once a patient creates a free account with our Platform, they can access their account anytime, from any device. With our Platform, patients don't need to spend time searching the web, instead, their care team selects information specifically for them. Then, patients can look at the information on the Platform at the time of their choosing, share the same information with their family and friends, and even leave a review to help others know if the information was helpful.

We believe that the benefits of our Platform for patients, include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· Personalized: the information on our Platform is chosen specifically for the patient
by their care team.

&nbsp;&nbsp;&nbsp;&nbsp;· Better Conversations: on our Platform, patients can have more meaningful conversations
with their care team.

&nbsp;&nbsp;&nbsp;&nbsp;· On Demand: on our Platform, patients can review the information when they have time on
any web-enabled device.

&nbsp;&nbsp;&nbsp;&nbsp;· Secure: our Platform does not share or sell any patient data and aims to uphold the highest
privacy standards and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;· Easy to Share: on our Platform, patients can easily share education and resources with
their family and friends.

To ensure patients only see information that's right for them, they cannot search for content on the Platform. Patients only see the information that their care teams ePrescribe to them. Once a specific course is posted on our Platform for a patient, each course remains active and accessible to patients for 365 days. This means that patients will be able to view the prescribed course for up to 365 days after the date on which the course was first created. Once a course expires, the course title will be visible in the patient's account, but the course will be deactivated (i.e. inaccessible and greyed out). If patients click on the course title, a notification will be displayed to request new access from the prescribing clinician. This is a quality assurance feature that we believe will prevent patients from accessing outdated information.

Further, Privacy and data security are core pillars of our value proposition. We aim to maintain rigorous security and data access controls to protect the information posted on our Platform. User data is encrypted at rest and in transit if data is to be transferred to a third-party service provider. We employ proprietary mechanisms to further protect collected information.

 ****

***Education and Content Providers***

Education and content providers can use our Platform to create a free account and use the account to upload their resources and decide if each resource is free or has a licensing fee. Education and content providers can also use our Platform to combine resources to create courses. Education and content providers can use our Platform to create essential resources to help educate and support patients or healthcare providers.

Our Platform is a care communication platform with a mission to connect education and content providers, clinicians and patients. The Platform is a searchable clearinghouse where care providers can find and license education and content providers' resources, then ePrescribe them to patients to ensure they get the right information at the right time.

We want education and content providers to think of our Platform as an App Store for their content. They can decide the price, if any, for each of their items such as videos, checklists, decision aids, articles, or continuing education for clinicians. Education and content providers maintain full ownership and control and can see who licenses their content and get aggregate data on how it's used on the Platform.

We believe that the benefits of our Platform for education and content providers include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· Our Platform can serve as a free distribution channel to
education and content providers;

&nbsp;&nbsp;&nbsp;&nbsp;· Education and content providers can use our Platform to get
utilization reports; and

&nbsp;&nbsp;&nbsp;&nbsp;· Education and content providers control and own their brand
presence, content offering, and pricing on the Platform.

 **

***Pharmaceutical and Medical Device Companies***

 **

The Company also licenses a separate product, called DocolaRx™, to research organizations and pharmaceutical and biotech companies. They do not have any influence or interaction with the free Platform or community. The revenue from these projects provides financial funding to us, but operates independently from our main Platform.

We believe that pharmaceutical, medical device, and biotechnology brand teams, as well as clinical research organizations ("CROs"), can use DocolaRx™ to enhance patient-centric programs and digital therapeutics and manage clinical trials. They can also use DocolaRx™ to collect data, create reports, track usage, optimize processes, enable patient behavior change, improve patient satisfaction, provide timely information, deliver electronic consents and educate patients. DocolaRx™ aims to provide intuitive content management, powerful scalability and a white-labeled interface.

As pharma evolves into patient centric models, we believe that there are exciting opportunities to connect with patients and caregivers. As remote care, telemedicine, wearable devices and digital therapeutics become integral parts of the medical service delivery chain, we believe that it is imperative to consolidate functions into care communication pathways. DocolaRx was developed by clinicians who are passionate about the successful intersection of medicine and technology. We continuously learn from millions of digital interactions on our Platform, conversations with clinicians and patients, and industry trends.

We believe that in an ever-evolving market, full of advanced therapeutic options, the industry must transform patients into long-term partners. How? By offering consistent, trustworthy, and relevant knowledge – in real time, along the care continuum. DocolaRx optimizes information sharing with healthcare professionals ("HCPs") and patients. DocolaRx enables brand teams to create, customize, and deliver the right information at the right time to support HCPs and patients as well as easily track, monitor, and analyze the digital interactions. Using DocolaRx, the pharma team can provide each HCP with a dedicated account and the HCP can then interact with patients accordingly.

We believe that DocolaRx enables pharmaceutical brand teams to become an objective participant in the care continuum. Providing HCPs or pharma employed nurses, with a care communication platform that delivers information to and from patients. We believe that pharmaceutical, medical device, and biotechnology brand teams, as well as CROs can utilize DocolaRx to support new product launches, expand current therapeutic websites and forums with a patient centric digital environment, sales representative training, HCP education, wearable device connectivity, and virtual reality streaming.

We believe that the pharma industry is going through a major shift and must find new ways to meet the needs of a growing digital healthcare ecosystem. To adapt and succeed in this tech-driven market, we believe that pharmaceutical and medical device companies need the right tools to support a new patient-centric business model that combines connected devices and big data insights. DocolaRx offers content development, KPI measurement, and analysis using cutting edge machine learning and artificial intelligence technology.

With DocolaRx™, we offer both premium and white label options. The enterprise solution pricing is dependent upon the project scope and complexity. Integration levels, language, localization, and regulatory compliance are only some of the considerations that are taken into account. We work closely with our clients throughout the selection process as well as implementation. The pricing set forth below is a starting point for evaluation purposes and describes estimated fees associated with both our premium and white label options. The white label options enable organizations to create a complete custom user experience. The estimated fees are as follows:

---

| | | |
|:---|:---|:---|
| ***Type of Fee*** | ***Premium*** | ***White Label*** |
| Set Up Fee | $3000 | $60000 |
| Annual License Fee | $6000 | $125000 |
| Maintenance Fee | No Fee | $25000 |
| Training Webinars Fee | $3000 | $5000 |
| Custom Reports Fee | $3000 | $5000 |
| Custom Development Work Fee | Not available on Premium | $175 per hour |

---

**How it Works**

Our Platform offers a free care communication platform to connect clinicians and patients to deliver asynchronous patient education. Our Platform is free for healthcare providers, patients, and content providers. Our Platform aims to make it easy for healthcare providers to create their own library by:

&nbsp;&nbsp;&nbsp;&nbsp;· Easily uploading their own existing patient education;

&nbsp;&nbsp;&nbsp;&nbsp;· Importing free resources from the web;

&nbsp;&nbsp;&nbsp;&nbsp;· Using the tools in the Platform to create new videos, surveys;

&nbsp;&nbsp;&nbsp;&nbsp;· Or searching for and licensing resources from the marketplace

Then care teams can combine those resources into courses and ePrescribe them to patients. The Platform aims to be a growing clearinghouse of videos, decision aids, articles, checklists for patients, as well as clinician education. Some of the content is free, and some has licensing fees. This makes it easy for care teams to pick and choose the resources they want to use, versus the costs associated with buying a large content library. To ensure patients only see information that's right for them: they cannot search the Platform. They only see the information their care teams ePrescribe to them.

![](dc001_s1img01.jpg)

**Is our Platform Truly Free?**

The Platform is free to use as-is for all hospitals, clinics, healthcare providers, case managers, patient advocates, patients, and education and content providers. We do not display advertising information, nor do we sell or share user data. Some of the content is free, and some has licensing fees. The Company licenses a separate product, DocolaRx™, to research organizations and pharmaceutical and biotech companies.

There are no fees to use the Platform as is. Much of the patient and clinician education in the marketplace is free. Some of the third-party content has monthly or annual licensing fees, which are clearly labeled. This makes it easy to choose only the resources you want to use and save on the costs associated with buying a large content library. You only pay for what you use. No fees are ever passed on to patients.

There are project fees associated with integrating the Platform into other systems such as electronic health records and telemedicine. Integrating our Platform into a third party health record solution is a project that requires the Company to provide project management personnel and resources, skilled web and database developer personnel and the utilization of a third party that provides linking into the electronic medical records. The foregoing can cost several thousands of dollars per year. Accordingly, we discuss these paid options with any prospective clients and inform them ahead of time if they would like to engage these paid services and provide them with a cost estimate if they wish to do so.

There is the option for clinicians to request a managed account for a onetime fee of $499. With this offering Docola handles all technology and content management, thereby simplifying the experience, speeding up implementation and saving time. Over the years clinicians have asked for additional help creating their account, uploading their educational resources, creating courses, and training their team members on using the Platform. This one time set up service includes 90 days of dedicated phone support for practice staff. There is also the option for clinicians to elect for ongoing account management for a monthly fee of $129. Included in this offering are ongoing help with content management, monthly usage and key performance indicator ("KPI") reporting, and dedicated phone support for staff.

**Our Vision** 

Our vision is to be a social good organization with a free care communication platform that seeks to consolidate thousands of free and low-cost patient education resources from the leading non-profit, government, and commercial organizations in one marketplace. Our Platform was developed by a team of clinicians who know from experience that better communication is essential to better care, understanding, and outcomes. We believe that patient centricity, collaboration, and transparency is the best way to improve care. We believe that healthcare providers, hospitals, and clinics can utilize our Platform to find free and low-cost patient education and resources, or upload and create their own, and deliver them to people before, between, and after visits on any web-enabled device. We are passionately committed to unifying the healthcare experience. We believe access to information and care should be available to everyone. We aim to make it possible for patients and families to receive the right information at the right time, so they can act on it. We believe that when we proactively meet people's informational needs, they understand why it's important, possible, and safe to participate in their own care. This also helps people think about their goals and preferences, in order to have better conversations.

**Competition and Competitive Advantages**

The market for our products and services is subject to rapid and significant change and competition. The market for technology-enabled services that empower healthcare consumers is characterized by rapid technological change, new product and service introductions, evolving industry standards, changing customer needs, existing competition and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to the rapidly evolving nature of the healthcare and technology industries and the substantial resources available to our existing and potential competitors. The market for technology-enabled services that empower healthcare consumers is relatively new and unproven, and it is uncertain whether this market will achieve and sustain high levels of demand and market adoption.

Our success depends to a substantial extent on the willingness of consumers to increase their use of technology platforms to manage their healthcare options, the ability of our Platform to increase consumer engagement, and our ability to demonstrate the value of our Platform to our potential users. If users do not recognize or acknowledge the benefits of our Platform or our Platform does not drive consumer engagement, then the market for our products and services might develop more slowly than we expect, which could adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business. We might make errors in predicting and reacting to relevant business, legal and regulatory trends, which could harm our business. If any of these events occur, it could materially adversely affect our business, financial condition or results of operations.

We believe that our primary direct competitors include Krames, Walter Kluwer and Salesforce and we believe that our primary indirect competitors are Teladoc, EPIC, Oracle Cerner, Nextgen and AMWELL, which competitors provide either patient education products, telehealth services and online healthcare website products that compete with the Company.

The following is a brief description of the foregoing companies which we see as our closest competitors, however it is possible that another company, that is not listed below, can potentially be a major competitor of the Company:

*Direct Competitors:*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Krames – is a private entity that provides patient education products and is one of the oldest
companies in the market of patient education and are widely used;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Walter Kluwer – is a publicly traded entity that provides Emmi® which is an end-to-end
technology suite for patient engagement and partnership; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salesforce – is a publicly traded entity that provides a platform that aims to help patients
manage patient relationships from initial acquisition, service, care management, and ongoing engagement. and is one of the largest
customer relationship management providers on the market.

*Indirect Competitors:*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Teladoc – is a publicly traded entity that provides telehealth services that operates in
130 countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· EPIC – is a private entity that provides a software called MyChart® that holds patient
records with a focus on clinical management and patient engagement features;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Oracle Cerner – is an electronic health records company that was recently acquired by Oracle
Corporation, which is a publicly traded entity for over $28 billion, and offers patient engagement services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Nextgen – is a publicly traded entity that is an electronic health records company that offers
patient education which has a strong presence in the small to mid-size medical group market; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· AMWEL – is a publicly traded telemedicine company that connects patient to doctors over secure
video and is one of the leading telemedicine companies in the U.S.

Our competitors may have the ability to devote more financial and operational resources than we can to developing new technologies and services, including services that provide improved operating functionality, and adding features to their existing service offerings. If successful, their development efforts could render our services less desirable, resulting in the loss of our existing users or a reduction in the fees we earn from our products and services.

We believe that we have certain competitive advantages. For example, research shows when care teams curate and ePrescribe quality resources to patients before, after, and between visits, this can improve:

&nbsp;&nbsp;&nbsp;&nbsp;· Utilization

&nbsp;&nbsp;&nbsp;&nbsp;· Understanding

&nbsp;&nbsp;&nbsp;&nbsp;· Recall

&nbsp;&nbsp;&nbsp;&nbsp;· Health behaviors and outcomes

&nbsp;&nbsp;&nbsp;&nbsp;· Self-efficacy; and

&nbsp;&nbsp;&nbsp;&nbsp;· Patient-provider conversations and relationships.

Additionally, we believe that it has been shown that people feel safer honestly disclosing sensitive information about things like mental health, alcohol, drugs, abuse, or food security.

We believe that our competitive advantages are that our Platform enables:

&nbsp;&nbsp;&nbsp;&nbsp;· Better care communication and conversations (less need for Dr. Google)

&nbsp;&nbsp;&nbsp;&nbsp;· Improved patient and provider experience

&nbsp;&nbsp;&nbsp;&nbsp;· Value-based healthcare

&nbsp;&nbsp;&nbsp;&nbsp;· More effortless population health

&nbsp;&nbsp;&nbsp;&nbsp;· Virtual care

&nbsp;&nbsp;&nbsp;&nbsp;· Patient and family caregiver engagement; and

&nbsp;&nbsp;&nbsp;&nbsp;· Health literacy.

Unlike some of our competitors, our Platform provides more than just patient data, scheduling and record keeping, and also allows for informational courses, that are prescribed to support patients and families along the care continuum.

**Recent Developments**

 

*<u>Issuance of Convertible Notes</u>*

In July of 2022, the Company issued 2 convertible notes for proceeds of $50,000 each. The notes call for 6% simple interest and have a conversion feature whereby they will automatically convert into common stock upon consummation of an Initial Public Offering at a 25% discount to the Initial Public Offering price.

 

*<u>SAFE Cancellation</u>*

On November 15, 2022 the Company cancelled its previously issued Simple Agreements for Future Equity ("SAFE") and issued in exchange 1,379,377 shares of common stock. As a result of this corporate action, the SAFEs are no longer outstanding.

*<u>Increase in Authorized Shares and Forward Stock Split</u>*

On December 13, 2022, the Company amended its Certificate of Incorporation to increase its authorized common shares to 250,000,000 and simultaneously effected a forward split of the existing common stock (on a ratio of 1:1,199.298126) resulting in 3,328,987 common shares outstanding on a post-stock split basis. The par value of the common stock was changed to $0.0001.

*<u>Preferred Stock Authorization</u>*

December 13, 2022, the Company authorized 20,000,000 shares of preferred stock, with a par value of $0.0001.

 

*<u>Start-up Accelerator Stock Issuance</u>*

In December of 2022 the Company issued, per its pre-existing contractual arrangement, 150,663 shares to a New York City-based start-up accelerator.

*<u>Stock Issuance for Services</u>*

 

On December 14, 2022, the Company issued 464,008 shares of common stock to professionals for services rendered.

On December 23, 2022, the Company issued 25,185 shares of common stock to a professional for services rendered.

**Facilities**

Our Company headquarters are located at 801 W. Bay Drive, Suite 506, Largo, Florida 33770. We lease this space for $729 per month pursuant to a written lease agreement, dated May 7, 2015, and amended on July 22, 2015.

**COVID-19**

A pandemic outbreak of novel strains of coronavirus (COVID-19) has occurred across the globe and efforts to mitigate the health impact of the pandemic have profoundly and adversely affected economic activity. National, state and local governments have taken actions to mitigate the impact of the COVID-19 pandemic in a variety of ways, including by declaring states of emergency, issuing stay-at-home orders and ordering certain businesses to close or limit their operations. Due to the digital/remote nature of the Company's business, COVID-19 has had, and is expected to have, only positive effects on the Company's operations since more patients and healthcare providers have switched to remote consultations and visits since the start of the COVID-19 pandemic, which lead to an increased use of the Company's Platform. Additionally, in the U.S., the Centers for Medicare and Medicaid Services ("CMS") has extended physicians' fees for telehealth use in certain specialties until December 2023. CMS has also amended rules and regulations to increase access to healthcare via remote services. We believe that this may present a potential opportunity for the Company to sign on new clients in these specific specialties. Notwithstanding the foregoing, the long-term financial impact of coronavirus on the Company cannot be reasonably estimated at this time and may ultimately have a material adverse impact on our business, financial condition, and results of operations.

The COVID-19 pandemic has also resulted in material adverse national and global economic conditions that. Such conditions may result in an economic recession or prolonged economic downturn, which could result in a material loss of business for the duration of the downturn. Actions taken to mitigate the pandemic and resulting economic conditions are likely to materially and adversely impact our business, financial condition, results of operations and cash flows. The COVID-19 pandemic has also resulted in severe disruption and volatility in the financial markets. Depending on the extent and duration of the COVID-19 pandemic, the price of our common stock may experience declines and volatility which may negatively impact our ability to raise capital through the equity markets if necessary to increase our liquidity.

**Risks Related to Our Business**

Our business and our ability to execute our business strategy are subject to several risks as more fully described in the section titled "Risk Factors" beginning on page ____. These risks include, among others:

● We may require additional funding for our growth plans, and such funding may result in a dilution of your investment;

● If the voting power of our capital stock continues to be highly concentrated, it may prevent you and other minority stockholders from influencing significant corporate decisions and may result in conflicts of interest;

● The COVID-19 pandemic may impact our business, financial condition and results of operations;

● Our industry and the markets in which we operate are highly competitive and increased competitive pressures could reduce our share of the markets we serve and adversely affect our business, financial position, results of operations and cash flows;

● We may not successfully implement our business strategies, including achieving our growth objectives;

● Our success depends on our executive management and other key personnel;

● Any failure, inadequacy, interruption, security failure or breach of our information technology systems, whether owned by us or outsourced or managed by third parties, could harm our ability to effectively operate our business and could have a material adverse effect on our business, financial position results of operations, and cash flows;

● We may not be able to adequately protect our intellectual property, which could harm the value of our brand and adversely affect our business;

● The nature of our Platform requires sophisticated encryption technology to defend against hacking due to the personal information that will be utilized by a consumer/patient;

● We may be subject to data breaches, which could have a material adverse effect on the Company;

● We are subject to various federal, state and local laws and regulations, compliance with which increases our operating costs and non-compliance with which could have a material adverse effect on the Company;

● The healthcare regulatory and political framework is uncertain and evolving, and we cannot predict the effect that further healthcare reform and other changes in government programs may have on our business, financial condition or results of operations;

● We are subject to privacy regulations regarding the access, use and disclosure of personally identifiable information. If we or any of our third-party vendors experience a breach of personally identifiable information, it could result in substantial financial and reputational harm, including possible criminal and civil penalties;

● The healthcare industry is rapidly evolving and the market for technology-enabled services that empower healthcare consumers is relatively immature and unproven. If we are not successful in promoting and improving the benefits of our Platform, our growth may be limited and our business may be adversely affected;

● The amended and restated certificate of incorporation, as amended, and amended and restated bylaws provides that state or federal court located within the state of Delaware will be the sole and exclusive forum for substantially all disputes between us and our shareholders, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees;

● By purchasing common stock in this offering, you are bound by the fee-shifting provision contained in our amended and restated bylaws, which may discourage you to pursue actions against us and could discourage shareholder lawsuits that might otherwise benefit the Company and its shareholders;

● Once our common stock and warrants (forming part of the units offered hereby) are listed on Nasdaq Capital Market, there can be no assurance that we will be able to comply with Nasdaq Capital Market's continued listing standards;

● The price of our common stock could be subject to rapid and substantial volatility;

● As an "emerging growth company" under the JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements';

● Upon becoming a public company, we will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives;

● Our management team will have immediate and broad discretion over the use of the net proceeds from this offering and we may use the net proceeds in ways with which you disagree;

● You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future;

● Anti-takeover provisions contained in our certificate of incorporation, as amended and bylaws, as amended as well as provisions of Delaware law, could impair a takeover attempt; and

● If an active, liquid trading market for our common stock or warrants (forming part of the units offered hereby) does not develop, you may not be able to sell your common stock or warrants quickly or at a desirable price.

We have a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2021 and 2020

**Implications of Being an Emerging Growth Company**

As a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in 2012. As an emerging growth company, we expect to take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:

● being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure in this prospectus;

● not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended;

● reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and

● exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

We may continue to use these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a "large, accelerated filer," our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.

As an emerging growth company, we intend to take advantage of an extended transition period for complying with new or revised accounting standards as permitted by The JOBS Act.

To the extent that we continue to qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (i) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (ii) scaled executive compensation disclosures; and (iii) the requirement to provide only two years of audited financial statements, instead of three years.

**Corporate Information**

We are currently incorporated and in good standing in the State of Delaware. Our principal executive offices are located at 801 W. Bay Drive, Suite 506, Largo, Florida 33770, and our telephone number is (888) 981-8111. Our website addresses are Https://www.doco.la and Https://www.docola.com. The information contained on our websites is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our websites as part of this prospectus or in deciding whether to purchase our securities.

**Nasdaq Listing**

We intend to apply to list of our common stock and warrants (forming part of the units offered hereby) on the Nasdaq Capital Market. There is no assurance that our listing application will be approved by the Nasdaq Capital Market. The approval of our listing of our common stock and warrants (forming part of the units offered hereby) on the Nasdaq Capital Market is a condition of closing. If our application to the Nasdaq Capital Market is not approved or we otherwise determine that we will not be able to secure the listing of the common stock on the Nasdaq Capital Market, we will not complete the offering.

**THE OFFERING**

---

| | |
|:---|:---|
| Issuer: | Docola, Inc. |
| Securities offered by us: | [●] units, each unit consists of one share of our common stock and one (1) warrant to purchase one (1) share of common stock (or [●] units if the Representatives exercise their over-allotment option in full). The units will not be certificated and the shares of our common stock and the warrants are immediately separable at closing and will be issued and tradeable separately, but will be purchased together as a unit in this offering. |
| Public offering price: | $[●] per unit (based on an assumed public offering price per unit of $[●], which is the low-end of the price range set forth on the cover page of this prospectus). The actual offering price per unit will be as determined between the Underwriters and us based on market conditions at the time of pricing. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price. |
| Description of warrants included in units offered by us: | The exercise price of the warrants is $[●] per share (100% of the assumed public offering price of one unit). Each warrant is exercisable for one share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock as described herein. A holder may not exercise any portion of a warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of the outstanding common stock after exercise, as such percentage ownership is determined in accordance with the terms of the warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. Each warrant will be exercisable immediately upon issuance and will expire five-years after the initial issuance date. The terms of the warrants will be governed by a Warrant Agent Agreement, dated as of the effective date of this offering, between us and Equiniti Trust Company, as the warrant agent (the "Warrant Agent"). This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the warrants. For more information regarding the warrants, you should carefully read the section titled "Description of Securities—Warrants" in this prospectus. |

---

---

| | |
|:---|:---|
| Over-Allotment Option: | We have granted the Representatives an option for 45 days from the date of this prospectus to purchase up to an additional [●] shares of common stock and/or warrants to purchase up to [●] shares of common stock (equal to 15% of the number of shares of common stock and warrants underlying the units sold in the offering), from us, on one or more occasions and in any combination thereof, at the public offering price less the underwriting discount and commissions solely to cover over-allotments, if any. The Representative may exercise this option in full or in part at any time and from time to time until 45 days after the date of this prospectus. |
| Common stock outstanding before this offering: | 3,818,180 shares of common stock (1) |
| Common stock to be outstanding after this offering:<br>| [●] shares (assuming that none of the warrants are exercised) and [●] if the warrants offered hereby are exercised in full. If the Representative's over-allotment option is exercised in full, the total number of shares of common stock outstanding immediately after this offering would be [●] (assuming that none of the warrants are exercised) and [●] if the warrants offered hereby are exercised in full. |

---

---

| | |
|:---|:---|
| Representative's Warrant: | As additional compensation to the underwriters, upon consummation of this offering, we will issue to the Representative or its designees a non-redeemable Representative's Warrant to purchase an aggregate number of shares of our common stock equal to six and a half (6.5%) of the number of shares of common stock underlying the Units issued in this offering, and the terms of the Representative's Warrant will be identical to the terms of the warrants being offered in this offering as part of the units. The Representative's Warrant and the underlying shares of common stock shall not be sold during the offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of six months immediately following the commencement of the sale of the public securities in accordance with FINRA Rule 5110(e)(1). |
| Voting rights: | The common stock offered hereby are entitled to one vote per share. |
| Dividend policy: | We do not anticipate declaring or paying any cash dividends on our common stock following our public offering. |

---

---

| | |
|:---|:---|
| Lock-ups: | We and our directors, officers and certain principal shareholders have agreed with the Representative not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock for a period of 180 days after the date of this prospectus. See "Underwriting—Lock-Up Agreements." |
| Use of proceeds:<br>| We expect to receive net proceeds from this offering of approximately $[●] (or approximately $[●] if the Representative exercises in full its over-allotment option) after deducting estimated underwriting discounts (8.00% of the gross proceeds of the offering) and after our offering expenses, estimated at $[●]. We intend to use a portion of the net proceeds from this offering to fund the expansion of our research and development operations for expanding and enhancing our products, the hiring of key management and new team members for executing the Company's sales and marketing initiatives, and working capital and general corporate purposes. See "Use of Proceeds." |
| Trading symbol: | Prior to this offering, there has been no public market for shares of our common stock. |
| Listing application Separation:<br>| We intend to apply to list our common stock and the warrants comprising the units on the Nasdaq Capital Market under the symbols "[●]," and "[●]W," respectively. The approval of our listing on the Nasdaq Capital Market is a condition of closing this offering.<br>We will not be issuing physical units in this offering. At closing, we will issue to investors only the shares of common stock and warrants underlying the units offered hereby. |
| Risk factors: | See "Risk Factors" beginning on page [●] of this prospectus for a discussion of some of the factors you should carefully consider before deciding to invest in our common stock. |
| Unless we indicate otherwise, all information in this prospectus: | Unless we indicate otherwise, all information in this prospectus: |

---

● is based on 3,818,180 shares of common stock issued and outstanding as of January 23, 2023;

● assumes no exercise by the Representatives of their option to purchase up to an additional [●] shares of common stock and/or warrants to purchase [●] shares of common stock to cover over-allotments, if any;

● excludes [●] shares of common stock issuable upon the full exercise of the warrants (included as part of the units and over-allotment option) offered hereby;

● excludes [●] shares of common stock underlying the Representative's Warrant to be issued to the Representative in connection with this offering.

**SELECTED HISTORICAL FINANCIAL DATA**

The following table presents our selected historical financial data for the periods indicated. The selected historical financial data for the years ended December 31, 2021 and December 31, 2020 and the balance sheet data as of December 31, 2021 and December 31, 2020 are derived from the audited financial statements.

Historical results are included for illustrative and informational purposes only and are not necessarily indicative of results we expect in future periods, and results of interim periods are not necessarily indicative of results for the entire year. The data presented below should be read in conjunction with, and are qualified in their entirety by reference to, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and the notes thereto included elsewhere in this prospectus.

---

| | | |
|:---|:---|:---|
|  | **Year Ended** | **Year Ended** |
|  | **December 31, 2021** | **December 31, 2020** |
|  | **(audited)** | **(audited)** |
| **Statement of Operations Data** |  |  |
| Revenues | $111318 | 137482 |
| Cost of revenues | 174839 | 192645 |
| Total gross loss | (63521) | (55163) |
| Total operating expenses | 307563 | 259798 |
| Income (loss) from operations | (371084) | (314961) |
| Total other income (expense) | 4068219) | (904356) |
| Income (loss) before provision for taxes | (4439303) | (1219317) |
| Provision for income taxes | - | - |
| Net loss | $(4439303) | (1219317) |
| Net loss per share – Basic and fully diluted | $2.47 | 0.68 |
|  | $— |  |
| **Balance Sheet Data** |  |  |
| Cash and money market | $9527 | 39615 |
| Working capital (deficit) (1) | $(6489880) | (2087832) |
| Total assets | $75227 | 46351 |
| Total liabilities | $6621274 | 2153.095 |
| Stockholders' equity (deficit) | $(6546227) | (2106744) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Working capital represents total current assets less total current liabilities.

**RISK FACTORS**

*An investment in our securities carries a significant degree of risk. You should carefully consider the following risks, as well as the other information contained in this prospectus, including our historical financial statements and related notes included elsewhere in this prospectus before you decide to purchase our securities. Any one of these risks and uncertainties has the potential to cause material adverse effects on our business, prospects, financial condition, and operating results which could cause actual results to differ materially from any forward-looking statements expressed by us and a significant decrease in the value of our common stock shares. Refer to "Cautionary Statement Regarding Forward-Looking Statements."*

*We may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.*

 

Below is a summary of risks, uncertainties and other factors that could have a material effect on the Company and its operations:

● We have a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2021 and 2020;

● We may require additional funding for our growth plans, and such funding may result in a dilution of your investment;

● If the voting power of our capital stock continues to be highly concentrated, it may prevent you and other minority stockholders from influencing significant corporate decisions and may result in conflicts of interest;

● The COVID-19 pandemic may impact our business, financial condition and results of operations;

● Our industry and the markets in which we operate are highly competitive and increased competitive pressures could reduce our share of the markets we serve and adversely affect our business, financial position, results of operations and cash flows;

● We may not successfully implement our business strategies, including achieving our growth objectives;

● Our success depends on our executive management and other key personnel;

● Any failure, inadequacy, interruption, security failure or breach of our information technology systems, whether owned by us or outsourced or managed by third parties, could harm our ability to effectively operate our business and could have a material adverse effect on our business, financial position results of operations, and cash flows;

● We may not be able to adequately protect our intellectual property, which could harm the value of our brand and adversely affect our business;

● The nature of our Platform requires sophisticated encryption technology to defend against hacking due to the personal information that will be utilized by a consumer/patient;

● We may be subject to data breaches, which could have a material adverse effect on the Company;

● We are subject to various federal, state and local laws and regulations, compliance with which increases our operating costs and non-compliance with which could have a material adverse effect on the Company;

● The healthcare regulatory and political framework is uncertain and evolving, and we cannot predict the effect that further healthcare reform and other changes in government programs may have on our business, financial condition or results of operations;

● We are subject to privacy regulations regarding the access, use and disclosure of personally identifiable information. If we or any of our third-party vendors experience a breach of personally identifiable information, it could result in substantial financial and reputational harm, including possible criminal and civil penalties;

● The healthcare industry is rapidly evolving and the market for technology-enabled services that empower healthcare consumers is relatively immature and unproven. If we are not successful in promoting and improving the benefits of our Platform, our growth may be limited and our business may be adversely affected;

● The amended and restated certificate of incorporation, as amended, and amended and restated bylaws provides that state or federal court located within the state of Delaware will be the sole and exclusive forum for substantially all disputes between us and our shareholders, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees;

● By purchasing common stock in this offering, you are bound by the fee-shifting provision contained in our amended and restated bylaws, which may discourage you to pursue actions against us and could discourage shareholder lawsuits that might otherwise benefit the Company and its shareholders;

● Once our common stock and warrants (forming part of the units offered hereby) are listed on Nasdaq Capital Market, there can be no assurance that we will be able to comply with Nasdaq Capital Market's continued listing standards;

● The price of our common stock could be subject to rapid and substantial volatility;

● As an "emerging growth company" under the JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements';

● Upon becoming a public company, we will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives;

● Our management team will have immediate and broad discretion over the use of the net proceeds from this offering and we may use the net proceeds in ways with which you disagree;

● You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future;

● Anti-takeover provisions contained in our certificate of incorporation, as amended and bylaws, as amended as well as provisions of Delaware law, could impair a takeover attempt; and

● If an active, liquid trading market for our common stock or warrants (forming part of the units offered hereby) does not develop, you may not be able to sell your common stock or warrants quickly or at a desirable price.

**Risks Related to Our Business and Industry**

***We have a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2021 and 2020.***

To date, we have not been profitable and have incurred significant losses and cash flow deficits. For the fiscal years ended December 31, 2021 and 2020, we reported net losses of $4,439,303 and $1,219,317, respectively, and negative cash flow from operating activities of $413,952 and $306,880, respectively. As noted in our financial statements, as of December 31, 2021, the Company had an accumulated deficit of $6,546,227 and working capital deficit of $6,489,880. We anticipate that we will continue to report losses and negative cash flow for at least the next two fiscal years. Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and debt financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2021 and 2020.

Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. These adjustments would likely include substantial impairment of the carrying amount of our assets and potential contingent liabilities that may arise if we are unable to fulfill various operational commitments. In addition, the value of our securities, including common stock issued in this offering, would be greatly impaired. Our ability to continue as a going concern is dependent upon generating sufficient cash flow from operations and obtaining additional capital and financing, including funds to be raised in this offering. If our ability to generate cash flow from operations is delayed or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business even if this offering is successful. For further discussion about our ability to continue as a going concern and our plan for future liquidity, see "Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources."

 ****

***We may require additional funding for our growth plans, and such funding may result in a dilution of your investment.***

We attempted to estimate our funding requirements to implement our growth plans. If our growth exceeds those plans or the costs or cash requirements of implementing such plans should exceed these estimates significantly or if we come across opportunities to grow through expansion plans either internally or through acquisitions which cannot be predicted at this time, and our funds generated from our operations prove insufficient for such purposes, we may need to raise additional funds to meet these funding requirements.

These additional funds may be raised by issuing equity or debt securities or by borrowing from banks or other sources. We cannot assure you that we will be able to obtain any additional financing on terms that are acceptable to us, or at all. If we fail to obtain additional financing on terms that are acceptable to us, we will not be able to implement such plans fully if at all. Such financing even if obtained, may be accompanied by conditions that limit our ability to pay dividends or require us to seek lenders' consent for payment of dividends, or restrict our freedom to operate our business by requiring lender's consent for certain corporate actions.

Further, if we raise additional funds by way of a rights offering or through the issuance of new shares, any shareholders who are unable or unwilling to participate in such an additional round of fund raising may suffer dilution in their investment.

***If the voting power of our capital stock continues to be highly concentrated, it may prevent you and other minority stockholders from influencing significant corporate decisions and may result in conflicts of interest.***

Following the completion of this Offering, Eran Kabakov, our Chief Executive Officer, President and Chairman of the Board, and Tomer Kabakov, our Chief Operating Officer and Director will together control approximately ___% of the voting power of our outstanding capital stock if all the Common Stock being offered are sold. As a result, Eran Kabakov and Tomer Kabakov will have majority voting power over all matters requiring stockholder votes, including: the election of directors; mergers, consolidations, and acquisitions; the sale of all or substantially all of our assets and other decisions affecting our capital structure; amendments to our certificate of incorporation or our bylaws; and our winding up and dissolution.

This concentration of voting power may delay, deter or prevent acts that would be favored by our other stockholders. The interests of Eran Kabakov and Tomer Kabakov may not always coincide with our interests or the interests of our other stockholders. This concentration of voting power may also have the effect of delaying, preventing or deterring a change in control of us. Also, Eran Kabakov and Tomer Kabakov may seek to cause us to take courses of action that, in their judgment, could enhance his investment in us, but which might involve risks to our other stockholders or adversely affect us or our other stockholders, including investors in this offering. As a result, the market price of our common stock could decline, or our other stockholders might not receive a premium over the then-current market price of our common stock upon a change in control. In addition, this concentration of voting power may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant stockholders. See "Executive Compensation" and "Description of Capital Stock."

 ****

***The COVID-19 pandemic may impact our business, financial condition and results of operations.***

A pandemic outbreak of novel strains of coronavirus (COVID-19) has occurred across the globe and efforts to mitigate the health impact of the pandemic have profoundly and adversely affected economic activity. National, state and local governments have taken actions to mitigate the impact of the COVID-19 pandemic in a variety of ways, including by declaring states of emergency, issuing stay-at-home orders and ordering certain businesses to close or limit their operations. Due to the digital/remote nature of the Company's business, COVID-19 has had, and is expected to have, only positive effects on the Company's operations since more patients and healthcare providers have switched to remote consultations and visits since the start of the COVID-19 pandemic, which lead to an increased use of the Company's Platform. Additionally, in the U.S., the Centers for Medicare and Medicaid Services ("CMS") has extended physicians' fees for telehealth use in certain specialties until December 2023. CMS has also amended rules and regulations to increase access to healthcare via remote services. We believe that this may present a potential opportunity for the Company to sign on new clients in these specific specialties. Notwithstanding the foregoing, the long-term financial impact of coronavirus on the Company cannot be reasonably estimated at this time and may ultimately have a material adverse impact on our business, financial condition, and results of operations.

The COVID-19 pandemic has also resulted in material adverse national and global economic conditions that. Such conditions may result in an economic recession or prolonged economic downturn, which could result in a material loss of business for the duration of the downturn. Actions taken to mitigate the pandemic and resulting economic conditions are likely to materially and adversely impact our business, financial condition, results of operations and cash flows. The COVID-19 pandemic has also resulted in severe disruption and volatility in the financial markets. Depending on the extent and duration of the COVID-19 pandemic, the price of our common stock may experience declines and volatility which may negatively impact our ability to raise capital through the equity markets if necessary to increase our liquidity.

 ****

***Our industry and the markets in which we operate are highly competitive and increased competitive pressures could reduce our share of the markets we serve and adversely affect our business, financial position, results of operations and cash flows.***

Our industry and the markets in which we operate are highly competitive and increased competitive pressures could reduce our share of the markets we serve and adversely affect our business, financial position, results of operations and cash flows. Any of our competitors may foresee the course of market development more accurately than we do, provide superior service or products, have the ability to deliver similar services or products at a lower cost, develop stronger relationships with our customers and other consumers, adapt more quickly to evolving customer requirements, devote greater resources to the promotion and sale of their services or access financing on more favorable terms than we can obtain. As a result of any of these factors, we may not be able to compete successfully with our competitors, which could have an adverse effect on our business, financial position, results of operations and cash flows.

  ****

***We may not successfully implement our business strategies, including achieving our growth objectives.***

We may not be able to fully implement our business strategies or realize, in whole or in part within the expected time frames, the anticipated benefits of our various growth or other initiatives. Our various business strategies and initiatives, including our growth, operational and management initiatives, are subject to business, economic and competitive uncertainties, and contingencies, many of which are beyond our control. In addition, we may incur certain costs as we pursue our growth, operational and management initiatives, and we may not meet anticipated implementation timetables or stay within budgeted costs. As these initiatives are undertaken, we may not fully achieve our expected efficiency improvements or growth rates, or these initiatives could adversely impact our customer retention or operations. Also, our business strategies may change from time to time considering our ability to implement our business initiatives, competitive pressures, economic uncertainties or developments, or other factors.

 ****

***If we are unable to hire and retain key personnel, we may not be able to implement our business plan.***

The execution of our business strategy and our financial performance will continue to depend in significant part on our executive management team and other key management personnel, our ability to identify and complete suitable acquisitions and our executive management team's ability to execute new operational initiatives. We rely heavily on Eran Kabakov, the founder and CEO of the Company, to execute our business strategy. Consequently, the loss of Mr. Kabakov may have a substantial effect on our future success or failure. We do not have and generally do not intend to acquire keyman life insurance on any of our executives, including Mr. Kabakov. We may have to recruit qualified personnel with competitive compensation packages, equity participation, and other benefits that may affect the working capital available for our operations. Management may have to seek to obtain outside independent professionals to assist them in assessing the merits and risks of any business proposals as well as assisting in the development and operation of many company projects. No assurance can be given that we will be able to obtain such needed assistance on terms acceptable to us. Our failure to attract additional qualified employees or to retain the services of key personnel could have a material adverse effect on our operating results and financial condition.

 ****

***Future acquisitions or other strategic transactions could negatively impact our reputation, business, financial position, results of operations and cash flows.***

We may acquire businesses or assets in the future. However, there can be no assurance that we will be able to identify and complete suitable acquisitions. For example, due to the highly fragmented nature of our industry, it may be difficult for us to identify potential targets with revenues or profits sufficient to justify taking on the risks associated with pursuing their acquisition. The failure to identify suitable acquisitions and successfully integrate these acquired businesses may limit our ability to expand our operations and could have an adverse effect on our business, financial position, results of operations and cash flows.

In addition, acquired businesses may not perform in accordance with expectations, and our business judgments concerning the value, strengths and weaknesses of acquired businesses may not prove to be correct. We may also be unable to achieve expected improvements or achievements in businesses that we acquire. The process of integrating an acquired business may create unforeseen difficulties and expenses, including the diversion of resources away from our operations; difficulties implementing our strategy at the acquired business; the assumption of actual or contingent liabilities; failure to effectively and timely adopt and adhere to our internal control processes, accounting systems and other policies; write-offs or impairment charges relating to goodwill and other intangible assets; unanticipated liabilities relating to acquired businesses; and potential expenses associated with litigation with sellers of such businesses.

If management is not able to effectively manage the integration process, or if any significant business activities are interrupted because of the integration process, we may not be able to realize anticipated benefits and revenue opportunities resulting from acquisitions and our business could suffer. Although we conduct due diligence investigations prior to each acquisition, there can be no assurance that we will discover or adequately protect against all contingencies and material liabilities of an acquired business for which we may be responsible as a successor owner or operator. ****

 ****

***Our success depends on our executive management and other key personnel.***

Our future success depends to a significant degree on the skills, experience and efforts of our executive management and other key personnel and their ability to provide us with uninterrupted leadership and direction. The failure to retain our executive officers and other key personnel or a failure to provide adequate succession plans could have an adverse impact. The availability of highly qualified talent is limited, and the competition for talent is robust. A failure to replace executive management members or other key personnel efficiently or effectively and to attract, retain and develop new qualified personnel could have an adverse effect on our operations and implementation of our strategic plan.

 ****

 ****

***Adverse litigation judgments or settlements resulting from legal proceedings relating to our business operations could materially adversely affect our business, financial position and results of operations.***

From time to time, we are subject to allegations, and may be party to legal claims and regulatory proceedings, relating to our business operations. Defending against these and other such claims and proceedings is costly and time consuming and may divert management's attention and personnel resources from our normal business operations, and the outcome of many of these claims and proceedings cannot be predicted. If any of these claims or proceedings were to be determined adversely to us, a judgment, a fine or a settlement involving a payment of a material sum of money were to occur, or injunctive relief were issued against us, our business, financial position, results of operations and cash flows could be materially adversely affected.

  ****

***Any failure, inadequacy, interruption, security failure or breach of our information technology systems, whether owned by us or outsourced or managed by third parties, could harm our ability to effectively operate our business and could have a material adverse effect on our business, financial position results of operations, and cash flows.***

We are dependent on certain centralized automated information technology systems and networks to manage and support a variety of our business processes and activities. For example, we aim to maintain rigorous security and data access controls to protect the information posted on our Platform. User data is encrypted at rest and in transit if data is to be transferred to a third-party service provider. We employ proprietary mechanisms to further protect collected information.

Such systems and networks are subject to damage or interruption from power outages, telecommunications problems, data corruption, software errors, network failures, security breaches, acts of war or terrorist attacks, fire, flood, and natural disasters. Our servers or cloud-based systems could be affected by physical or electronic break-ins, and computer viruses or similar disruptions may occur. A system outage may also cause the loss of important data or disrupt our operations. Our existing safety systems, data backup, access protection, user management, disaster recovery and information technology emergency planning may not be sufficient to prevent or minimize the effect of data loss or long-term network outages.

We may periodically upgrade our existing information technology systems with the assistance of third-party vendors, and the costs to upgrade such systems may be significant. Costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations. If we cannot meet our information technology staffing needs, we may not be able to fulfill our technology initiatives while continuing to provide maintenance on existing systems. We could be required to make significant capital expenditures to remediate any such failure, malfunction or breach with our information technology systems or networks. Any material disruption or slowdown of our systems, including those caused by our failure to successfully upgrade our systems, and our inability to convert to alternate systems in an efficient and timely manner could have a material adverse effect on our business, financial position, results of operations, and cash flows.

We rely on commercially available systems, software, tools and monitoring to provide security for processing, transmitting and storing confidential information of our customers, employees and third parties. Unlawful or unauthorized activities by third parties, and failures in systems, software, encryption technology, or other tools may facilitate or result in a compromise or breach of these systems. We are subject to risks caused by data breaches and operational disruptions, particularly through cyber-attack or cyber-intrusion, including by computer hackers, foreign governments and cyber terrorists. Any unauthorized disclosure of confidential information could damage our reputation, interrupt our operations and could result in a violation of applicable laws, regulations, industry standards or agreements and potentially subject us to costs, penalties and liabilities The occurrence of any of these events could have a material adverse impact on our reputation, business, financial position, results of operations and cash flow.

 ****

 ****

***We may not be able to adequately protect our intellectual property, which could harm the value of our brand and adversely affect our business.***

Our ability to implement our business plan successfully depends in part on our ability to further build brand recognition using our trademarks, service marks and other proprietary intellectual property, including our name and logos. While it is our policy to protect and defend vigorously our intellectual property, we cannot predict whether such actions will be adequate to prevent infringement or misappropriation of these rights. Although we believe that we have sufficient rights to all of our trademarks, service marks and other intellectual property rights, we may face claims of infringement that could interfere with our business or our ability to market and promote our brands. If we are unable to successfully defend against such claims, we may be prevented from using our intellectual property rights in the future and may be liable for damages.

Although we make a significant effort to avoid infringing known proprietary rights of third parties, we may be subject to claims of infringement by third parties. Responding to and defending such claims, regardless of their merit, can be costly and time-consuming, and we may not prevail. Depending on the resolution of such claims, we may be barred from using a specific mark or other rights, may be required to enter into licensing arrangements from the third-party claiming infringement or may become liable for significant damages. If any of the foregoing occurs, our ability to compete could be affected or our business, financial position and results of operations may be adversely affected.

***Our business depends on the development and maintenance of the internet infrastructure.***

Our Platform is based in the internet, and accordingly, the success of our business will depend largely on the development and maintenance of the internet infrastructure. This includes maintenance of a reliable network backbone with the necessary speed, data capacity and security, as well as timely development of complementary products, for providing reliable internet access and services. The internet has experienced, and is likely to continue to experience, significant growth in the number of users and amount of traffic. The internet infrastructure may be unable to support such demands. In addition, increasing numbers of users, increasing bandwidth requirements or problems caused by viruses, worms, malware and similar programs may harm the performance of the internet. The backbone computers of the internet have been the targets of such programs. The internet has experienced a variety of outages and other delays as a result of damage to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of internet usage generally as well as the level of usage of our services, which could adversely impact our business.

***The nature of our Platform requires sophisticated encryption technology to defend against hacking due to the personal information that will be utilized by a consumer/patient.***

The art of hacking databases for the purposes of obtaining personal information as well as financial information on individuals is increasing substantially. We are aware of these risks and plan to invest substantially in the continued development of our Platform in accordance with the very latest data encryption/protection technologies; however, there is a real risk that our Platform could be compromised at some point in time exposing the Company to lawsuits and unfavorable attention that would adversely impact our business and affect our ability to add clients, consumer/patients or manage attrition on the Platform.

***We may be subject to data breaches, which could have a material adverse effect on the Company.***

In recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of individuals' personal information. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals and state officials. In addition, under the Health Insurance Portability and Accountability Act of 1996 and its regulations (collectively, "HIPAA"), we must report breaches of unsecured protected health information to our contractual partners within 60 days of discovery of the breach. Notification must also be made to the U.S. Department of Health and Human Services ("HHS") and, in certain circumstances involving large breaches, to the media. Under the General Data Protection Regulation ("GDPR"), the data controller is required to report personal data breaches to the supervisory authority within 72 hours of discovery of the breach.

We have implemented and maintained physical, technical and administrative safeguards intended to protect all personal data, and have processes in place to assist it in complying with all applicable laws, regulations and contractual requirements regarding the protection of these data and properly responding to any security breaches or incidents. However, we cannot be sure that these safeguards are adequate to protect all personal data or to assist us in complying with all applicable laws and regulations regarding the privacy and security of personal data and responding to any security breaches or incidents. Furthermore, in many cases, applicable state laws, including breach notification requirements, are not preempted by the HIPAA privacy and security standards and are subject to interpretation by various courts and other governmental authorities, thereby complicating our compliance efforts. Additionally, state and federal laws regarding deceptive practices may apply to public assurances we give to individuals about the security of services we provide on behalf of our contractual customers. If we become subject to data breaches, it could have a material adverse effect on the Company.

***We are subject to various federal, state and local laws and regulations, compliance with which increases our operating costs and non-compliance with which could have a material adverse effect on the Company.***

 ****

We are subject to various federal, state and local laws and regulations, compliance with which increases our operating costs, limits or restricts the services and products provided by us. Noncompliance with these laws and regulations can subject us to fines or various forms of civil or criminal prosecution, any of which could have a material adverse effect on our reputation, business, financial position, results of operations and cash flows. Participants in the healthcare industry are required to comply with extensive and complex laws and regulations in the United States at the federal and state levels as well as applicable international laws. Similarly, there are a number of legislative proposals in the Unites States, both at the federal and state level, which could impose new obligations in areas affecting our business. We have attempted to structure our operations to comply with applicable legal requirements, but there can be no assurance that our operations will not be challenged or impacted by enforcement initiatives. Healthcare is an extremely complex and regulated industry in the U.S. There are many laws and regulations that could have a material effect on our business, including but not limited to, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), and federal and state regulations controlling patient, provider and intermediary relationships.

Our operations and arrangements with healthcare professionals who use our Platform may subject us to various federal and state healthcare laws and regulations, including without limitation fraud and abuse laws, such as the federal Anti-Kickback Statute; civil and criminal false claims laws; physician transparency laws; and state laws regarding the corporate practice of medicine and fee-splitting prohibitions. These laws may impact, among other things, our sales and marketing operations, and our interactions with healthcare professionals. We continually monitor legislative, regulatory and judicial developments related to licensure and engagement arrangements with professionals; however, new agency interpretations, federal or state legislation or regulations, or judicial decisions could require us to change how we operate, may increase our costs of services and could have a material adverse impact on our business, results of operations or financial condition.

In addition to HIPAA, numerous other U.S. state and federal laws govern the collection, dissemination, use, access to and confidentiality of individually identifiable health information and healthcare provider information. Some states also are considering new laws and regulations that further protect the confidentiality, privacy and security of medical records or other types of medical information. In many cases, these state laws are not preempted by the HIPAA privacy standards and may be subject to interpretation by various courts and other governmental authorities. Further, Congress and a number of states have considered or are considering prohibitions or limitations on the disclosure of medical or other information to individuals or entities located outside of the United States.

We have taken, and will continue to take, precautions to ensure compliance with applicable statutes and regulations; however there is no guarantee we will be success in our efforts, and even an unintentional violation of law could have a material adverse effect on our operations and business.

***The healthcare regulatory and political framework is uncertain and evolving, and we cannot predict the effect that further healthcare reform and other changes in government programs may have on our business, financial condition or results of operations.***

Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. For example, the Affordable Care Act, which includes a variety of healthcare reform provisions and requirements that may become effective at varying times through 2022, substantially changes the way healthcare is financed by both governmental and private insurers, and may significantly impact our industry. Further changes to the Affordable Care Act and related healthcare regulation remain under consideration. In addition, current proposals to implement a single payer or "Medicare for all" system in the U.S., if adopted would likely have a material adverse effect on our business. The full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is unknown, and we are unable to predict accurately what effect the Affordable Care Act or other healthcare reform measures that may be adopted in the future will have on our business.

***We are subject to privacy regulations regarding the access, use and disclosure of personally identifiable information. If we or any of our third-party vendors experience a breach of personally identifiable information, it could result in substantial financial and reputational harm, including possible criminal and civil penalties.***

There are many U.S. federal and state laws and regulations related to the privacy and security of personal health information. Additionally, the Health Insurance Portability and Accountability Act of 1996 and its regulations (collectively, "HIPAA"), establishes privacy and security standards that limit the use and disclosure of protected health information and require the implementation of administrative, physical and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form. The healthcare providers who use our Platform are regulated under HIPAA. The Health Information Technology for Economic and Clinical Health Act ("HITECH"), which became effective on February 17, 2010, significantly expanded HIPAA's privacy and security requirements. Among other things, HITECH makes HIPAA's privacy and security standards directly applicable to "business associates," who are independent contractors or agents of covered entities that create, receive, maintain, or transmit protected health information in connection with providing a service for or on behalf of a covered entity. Under HIPAA and our contractual agreements with our users and customers, we are considered a "business associate" to our customers and thus are directly subject to HIPAA's privacy and security standards. In order to provide our covered entity customers with services that involve the use or disclosure of protected health information, HIPAA requires our customers to enter into business associate agreements with it. Such agreements must, among other things, require us to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limit how we will use and disclose the protected health information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• implement reasonable administrative, physical and technical safeguards to protect such information
from misuse;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into similar agreements with our agents and subcontractors that have access to the information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• report security incidents, breaches and other inappropriate uses or disclosures of the information;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• assist the customer in question with certain duties under the privacy standards.

In addition to HIPAA regulations, we may be subject to other state and federal privacy laws, including laws that prohibit unfair or deceptive practices and laws that place specific requirements on use of data. Such state laws can be similar to or even more protective than HIPAA, in which case we must comply with the more stringent law. As a result, it may be necessary to modify our planned operations in order to ensure we are in compliance with the stricter state laws.

Although we have implemented measures to comply with privacy laws, rules and regulations, we may experience data privacy incidents. Any unauthorized disclosure of personally identifiable information experienced by us or our third-party vendors could result in substantial financial and reputational harm, including possible criminal and civil penalties. In many cases, we are subject to HIPAA and other privacy regulations because we are a business associate providing services to covered entities; as a result, the covered entities direct HIPAA compliance matters in the event of a security breach, which complicates our ability to address harm caused by the breach. Additionally, we may be required to report breaches to partners, regulators, state attorney generals, and impacted individuals depending on the severity of the breach, our role, legal requirements and contractual obligations. Continued compliance with current and potential new privacy laws, rules and regulations and meeting consumer expectations with respect to the control of personal data in a rapidly changing technology environment could result in higher compliance and technology costs for us. If we or any of our third-party vendors experience a breach of personally identifiable information, it could result in substantial financial and reputational harm, including possible criminal and civil penalties.

***Although we do not provide medical care directly, we could be a party to medical malpractice claims, which could have a material adverse effect on our business.***

We do not provide medical care directly. Rather, we help connect users and their providers of medical care, products and services on our Platform. However, we could be a party to lawsuits related to the service we provide, and that could include risk of medical malpractice claims which could increase our insurance premiums, expose us to legal defense cost, and/or impact the brand of the Company, which could lead to a reduction in the number of users we have and could have a material adverse effect on our revenues and profits.

***The healthcare industry is rapidly evolving and the market for technology-enabled services that empower healthcare consumers is relatively immature and unproven. If we are not successful in promoting and improving the benefits of our Platform, our growth may be limited and our business may be adversely affected.***

The market for our products and services is subject to rapid and significant change and competition. The market for technology-enabled services that empower healthcare consumers is characterized by rapid technological change, new product and service introductions, evolving industry standards, changing customer needs, existing competition and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to the rapidly evolving nature of the healthcare and technology industries and the substantial resources available to our existing and potential competitors. The market for technology-enabled services that empower healthcare consumers is relatively new and unproven, and it is uncertain whether this market will achieve and sustain high levels of demand and market adoption.

Our success depends to a substantial extent on the willingness of consumers to increase their use of technology platforms to manage their healthcare options, the ability of our Platform to increase consumer engagement, and our ability to demonstrate the value of our Platform to our potential users. If users do not recognize or acknowledge the benefits of our Platform or our Platform does not drive consumer engagement, then the market for our products and services might develop more slowly than we expect, which could adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business. We might make errors in predicting and reacting to relevant business, legal and regulatory trends, which could harm our business. If any of these events occur, it could materially adversely affect our business, financial condition or results of operations.

Finally, our competitors may have the ability to devote more financial and operational resources than we can to developing new technologies and services, including services that provide improved operating functionality, and adding features to their existing service offerings. If successful, their development efforts could render our services less desirable, resulting in the loss of our existing users or a reduction in the fees we earn from our products and services.

***The amended and restated certificate of incorporation, as amended, and amended and restated bylaws provides that state or federal court located within the state of Delaware will be the sole and exclusive forum for substantially all disputes between us and our shareholders, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.***

This exclusive forum provision may limit a shareholder's ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us or our directors, officers or other employees. In addition, shareholders who do bring a claim in the state or federal court in the State of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The state or federal court of the State of Delaware may also reach different judgments or results than would other courts, including courts where a shareholder would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our shareholders. However, the enforceability of similar exclusive forum provisions in other companies' certificates of incorporation have been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings. If a court were to find the exclusive forum provision contained in our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions.

***By purchasing common stock in this offering, you are bound by the fee-shifting provision contained in our amended and restated bylaws, which may discourage you to pursue actions against us and could discourage shareholder lawsuits that might otherwise benefit the Company and its shareholders.***

 ****

Section 7.4 of our amended and restated bylaws provides that "[i]f any action is brought by any party against another party, relating to or arising out of these Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party reasonable attorneys' fees, costs and expenses incurred in connection with the prosecution or defense of such action, provided that the provisions of this sentence shall not apply with respect to "internal corporate claims" as defined in Section 109(b) of the DGCL."

Our amended and restated bylaws provide that for this section, the term "attorneys' fees" or "attorneys' fees and costs" means the fees and expenses of counsel to the Company and any other parties asserting a claim subject to Section 7.4 of the amended and restated bylaws, which may include printing, photocopying, duplicating and other expenses, air freight charges, and fees billed for law clerks, paralegals and other persons not admitted to the bar but performing services under the supervision of an attorney, and the costs and fees incurred in connection with the enforcement or collection of any judgment obtained in any such proceeding.

We adopted the fee-shifting provision to eliminate or decrease nuisance and frivolous litigation. We intend to apply the fee-shifting provision broadly to all actions except for claims brought under the Exchange Act and Securities Act.

There is no set level of recovery required to be met by a plaintiff to avoid payment under this provision. Instead, whoever is the prevailing party is entitled to recover the reasonable attorneys' fees, costs and expenses incurred in connection with the prosecution or defense of such action. Any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses and other parties, are subject to this provision. Additionally, any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses and other parties, would be able to recover fees under this provision.

In the event you initiate or assert a claim against us, in accordance with the dispute resolution provisions contained in our amended and restated Bylaws, and you do not, in a judgment prevail, you will be obligated to reimburse us for all reasonable costs and expenses incurred in connection with such claim, including, but not limited to, reasonable attorney's fees and expenses and costs of appeal, if any. Additionally, this provision in Section 7.4 of our amended and restated bylaws could discourage shareholder lawsuits that might otherwise benefit the Company and its shareholders.

THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS IS NOT INTENDED TO BE DEEMED A WAIVER BY ANY HOLDER OF COMMON STOCK OF THE COMPANY'S COMPLIANCE WITH THE U.S. FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER. THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS DO NOT APPLY TO CLAIMS BROUGHT UNDER THE EXCHANGE ACT AND SECURITIES ACT.

**Risks Related to Our Common Stock, Our Warrants and the Offering**

***Once our common stock and warrants are listed on the Nasdaq Capital Market, there can be no assurance that we will be able to comply with Nasdaq Capital Market's continued listing standards.***

Prior to this offering, there has been no public market for shares of our common stock. As a condition to consummating this offering, our common stock and warrants offered in this prospectus must be listed on the Nasdaq Capital Market or another national securities exchange. Accordingly, in connection with the filing of the registration statement of which this prospectus forms a part, we intend to apply to list our common stock and warrants (forming part of the units offered hereby) on the Nasdaq Capital Market under the symbols "[●]" and "[●]W," respectively. Assuming that our common stock and warrants are listed and after the consummation of this offering, there can be no assurance any broker will be interested in trading our stock and warrants. Therefore, it may be difficult to sell your shares of common stock or warrants if you desire or need to sell them. Our underwriters are not obligated to make a market in our common stock or warrants, and even if it makes a market, it can discontinue market making at any time without notice. Neither we nor the underwriters can provide any assurance that an active and liquid trading market in our common stock will develop or, if developed, that such market will continue.

Once our common stock and warrants (forming part of the units offered hereby) are approved for listing on the Nasdaq Capital Market, there is no guarantee that we will be able to maintain such listing for any period of time by perpetually satisfying Nasdaq Capital Market's continued listing requirements. Our failure to continue to meet these requirements may result in our common stock being delisted from Nasdaq Capital Market.

***The price of our common stock could be subject to rapid and substantial volatility.***

There have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with recent initial public offerings, especially among those with relatively smaller public floats. As a relatively small-capitalization company with relatively small public float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization companies. In particular, the common stock may be subject to rapid and substantial price volatility, low volumes of trades and large spreads in bid and ask prices. Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.

In addition, if the trading volumes of our common stock are low, persons buying or selling in relatively small quantities may easily influence prices of our common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large percentage changes in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations and general economic and political conditions may also adversely affect the market price of our common stock. As a result of this volatility, investors may experience losses on their investment in our common stock. A decline in the market price of our common stock also could adversely affect our ability to sell additional shares or common stock or other securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our common stock will develop or be sustained. If an active market does not develop, holders of our common stock may be unable to readily sell the common stock they hold or may not be able to sell their common stock at all.

***The market price of our common stock and warrants (forming part of the units offered hereby) may be volatile, and you could lose all or part of your investment.***

We cannot predict the prices at which our common stock and warrants (forming part of the units offered hereby) will trade. The initial public offering price of our common stock and warrants (forming part of the units offered hereby) will be determined by negotiations between us and the underwriters and may not bear any relationship to the market price at which our common stock and warrants will trade after this offering or to any other established criteria of the value of our business and prospects, and the market price of our common stock and warrants following this offering may fluctuate substantially and may be lower than the initial public offering price. The market price of our common stock and warrants following this offering will depend on a number of factors, including those described in this "Risk Factors" section, many of which are beyond our control and may not be related to our operating performance. In addition, the limited public float of our common stock and warrants following this offering will tend to increase the volatility of the trading price of our common stock and warrants. The stock market in general, and companies in the healthcare space in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. These fluctuations could cause you to lose all or part of your investment in our common stock and/or warrants, since you might not be able to sell your shares at or above the price you paid in this offering. Factors that could cause fluctuations in the market price of our common stock and/or warrants include, but are not limited to, the following:

● the success of competitive products or announcements by potential competitors of their product development efforts;

● actual or anticipated changes in our growth rate relative to our competitors;

● regulatory or legal developments in the United States;

● the recruitment or departure of key personnel;

● announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;

● actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

● fluctuations in the valuation of companies perceived by investors to be comparable to us;

● market conditions in the healthcare sector;

● share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;

● announcement or expectation of additional financing efforts;

● sales of our common stock by us, our insiders or our other stockholders;

● expiration of market stand-off or lock-up agreements;

● the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic;

● the availability of fiscal and monetary stimulus measures to counteract the impact of the COVID-19 pandemic; and

● general economic, political, industry and market conditions.

The realization of any of the above risks or any of a broad range of other risks, including those described in this "Risk Factors" section, could have a dramatic and adverse impact on the market price of our common stock.

***If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.***

 ****

The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. We do not currently have and may never obtain research coverage by securities or industry analysts. If no or few securities or industry analysts commence coverage of us, the stock price would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

***Our common stock and our warrants (forming part of the units offered) may be subject to the "penny stock" rules in the future. It may be more difficult to resell securities classified as "penny stock."***

Our common stock may be subject to "penny stock" rules (generally defined as non-exchange traded stock with a per-share price below $5.00) in the future. While our common stock and warrants (forming part of the units offered hereby) will not be considered "penny stock" following this offering since they will be listed on the Nasdaq Capital Market, if we are unable to maintain that listing and our common stock and warrants are no longer listed on the Nasdaq Capital Market, unless we maintain a per-share price above $5.00, our common stock and warrants will become "penny stock." These rules impose additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as "established customers" or "accredited investors." For example, broker-dealers must determine the appropriateness for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide, prior to a transaction in a penny stock not otherwise exempt from the rules, a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, disclose the compensation of the broker-dealer and its salesperson in the transaction, furnish monthly account statements showing the market value of each penny stock held in the customer's account, provide a special written determination that the penny stock is a suitable investment for the purchaser, and receive the purchaser's written agreement to the transaction.

Legal remedies available to an investor in "penny stocks" may include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● If a "penny stock" is sold to the investor in violation of the requirements listed above, or other federal or states securities laws, the investor may be able to cancel the purchase and receive a refund of the investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● If a "penny stock" is sold to the investor in a fraudulent manner, the investor may be able to sue the persons and firms that committed the fraud for damages.

These requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity of our securities. These requirements may restrict the ability of broker-dealers to sell our common stock or our warrants and may affect your ability to resell our common stock and our warrants.

Many brokerage firms will discourage or refrain from recommending investments in penny stocks. Most institutional investors will not invest in penny stocks. In addition, many individual investors will not invest in penny stocks due, among other reasons, to the increased financial risk generally associated with these investments.

For these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We can give no assurance at what time, if ever, our common stock or our warrants will not be classified as a "penny stock" in the future.

***If the benefits of any proposed acquisition do not meet the expectations of investors, stockholders or financial analysts, the market price of our Common Stock may decline.***

If the benefits of any proposed acquisition do not meet the expectations of investors or securities analysts, the market price of our Common Stock prior to the closing of the proposed acquisition may decline. The market values of our Common Stock at the time of the proposed acquisition may vary significantly from their prices on the date the acquisition target was identified.

In addition, broad market and industry factors may materially harm the market price of our Common Stock irrespective of our operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the market for retail stocks or the stocks of other companies which investors perceive to be similar to us could depress our stock price regardless of our business, prospects, financial conditions or results of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future.

***Changes in accounting principles and guidance, or their interpretation, could result in unfavorable accounting charges or effects, including changes to our previously filed financial statements, which could cause our stock price to decline.***

We prepare our financial statements in accordance with GAAP. These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles and guidance. A change in these principles or guidance, or in their interpretations, may have a significant effect on our reported results and retroactively affect previously reported results.

 ****

***As an "emerging growth company" under the JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements.***

We qualify as an "emerging growth company" under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:

● have an auditor report on our internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

● comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors' report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

● submit certain executive compensation matters to stockholder advisory votes, such as "say-on-pay" and "say-on-frequency"; and

● disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer's compensation to median employee compensation.

In addition, Section 102 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

We will remain an emerging growth company until the earliest to occur of: (i) the end of the first fiscal year in which our annual gross revenue is $1.235 billion or more; (ii) the end of the fiscal year in which the market value of our common shares that are held by non-affiliates is at least $700.0 million as of the last business day of our most recently completed second fiscal quarter; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; and (iv) the end of the fiscal year during which the fifth anniversary of this offering occurs.

Until such time, however, we cannot predict if investors will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the price of our securities may be more volatile.

***If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and have an adverse effect on the value of our securities.***

As a public company, we would be required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Further, we will be required to report any changes in internal controls on a quarterly basis. In addition, we would be required to furnish a report by management on the effectiveness of internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. We will design, implement, and test the internal controls over financial reporting required to comply with these obligations. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of its internal control over financial reporting when required, investors may lose confidence in the accuracy and completeness of our financial reports and the value of our securities could be negatively affected. We also could become subject to investigations by the Commission or other regulatory authorities, which could require additional financial and management resources.

***As an emerging growth company, our auditor will not be required to attest to the effectiveness of our internal controls.***

Our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting while we are an emerging growth company. This means that the effectiveness of our financial operations may differ from our peer companies in that they may be required to obtain independent registered public accounting firm attestations as to the effectiveness of their internal controls over financial reporting and we are not. While our management will be required to attest to internal control over financial reporting and we will be required to detail changes to our internal controls on a quarterly basis, we cannot provide assurance that the independent registered public accounting firm's review process in assessing the effectiveness of our internal controls over financial reporting, if obtained, would not find one or more material weaknesses or significant deficiencies. Further, once we cease to be an emerging growth company and cease to be a smaller reporting company (as described below), we will be subject to independent registered public accounting firm attestation regarding the effectiveness of our internal controls over financial reporting. Even if management finds such controls to be effective, our independent registered public accounting firm may decline to attest to the effectiveness of such internal controls and issue a qualified report.

***We believe we will be considered a smaller reporting company and will be exempt from certain disclosure requirements, which could make our Common Stock less attractive to potential investors.***

Rule 12b-2 of the Exchange Act defines a "smaller reporting company" as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:

● had a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter, computed by multiplying the aggregate worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity; or

● in the case of an initial registration statement under the Securities Act, or the Exchange Act of 1934, as amended, which we refer to as the Exchange Act, for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public offering price of the shares; or

● in the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available.

As a smaller reporting company, we will not be required and may not include a Compensation Discussion and Analysis section in our proxy statements; we will provide only two years of financial statements; and we need not provide the table of selected financial data. We also will have other "scaled" disclosure requirements that are less comprehensive than issuers that are not smaller reporting companies which could make our Common Stock less attractive to potential investors, which could make it more difficult for our stockholders to sell their shares.

***Upon becoming a public company, we will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.***

Upon becoming a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act has imposed various requirements on public companies including requiring establishment and maintenance of effective disclosure and financial controls. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain directors' and officers' liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We cannot predict or estimate the amount of additional costs we will incur as a public company or the timing of such costs.

The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. In addition, we will be required to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting the later of our second annual report on Form 10-K or the first annual report on Form 10-K following the date on which we are no longer an emerging growth company or a smaller reporting company. Our compliance with Section 404 of the Sarbanes-Oxley Act will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. If we are not able to comply with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the value of our securities could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.

Our ability to successfully implement our business plan and comply with Section 404 requires us to be able to prepare timely and accurate financial statements. We expect that we will need to continue to improve existing, and implement new operational and financial systems, procedures and controls to manage our business effectively. Any delay in the implementation of, or disruption in the transition to, new or enhanced systems, procedures or controls, may cause our operations to suffer and we may be unable to conclude that our internal control over financial reporting is effective and to obtain an unqualified report on internal controls from our auditors as required under Section 404 of the Sarbanes-Oxley Act. This, in turn, could have an adverse impact on the value of our securities, and could adversely affect our ability to access the capital markets.

 ****

 ****

***Our management team will have immediate and broad discretion over the use of the net proceeds from this offering and we may use the net proceeds in ways with which you disagree.***

The net proceeds from this offering will be immediately available to our management to use at their discretion. We currently intend to use the net proceeds from this offering to expand our research and development operations for expanding and enhancing our products, hire key management and new team members for executing the Company's sales and marketing initiatives, as well as, working capital and general corporate purposes. See "Use of Proceeds." We have not allocated specific amounts of the net proceeds from this offering for any of the foregoing purposes. Accordingly, our management will have significant discretion and flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our management about the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested in a way that does not yield a favorable, or any, return for us or our stockholders. The failure of our management to use such funds effectively could have a material adverse effect on our business, prospects, financial condition, results of operation and cash flow.

***You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.***

You will incur immediate and substantial dilution because of this offering. After giving effect to the sale by us of up to $[●] in units (of which our common stock forms a part) offered in this offering, at a public offering price of $[●] per unit, and after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $[●] per share, or [●]%, at the assumed public offering price. We also have many outstanding warrants to purchase common stock with exercise prices that are below the public offering price of our units. To the extent that these warrants are exercised, you will experience further dilution.

***Shares eligible for future sale may adversely affect the market.***

From time to time, certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144 promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate stockholders may sell freely after six months, subject only to the current public information requirement. Affiliates may sell after six months, subject to the Rule 144 volume, manner of sale (for equity securities), current public information, and notice requirements. Of the approximately [●] shares of our common stock outstanding as of [●], 2022, approximately [●] shares are tradable without restriction. Given the limited trading of our common stock, resale of even a small number of shares of our common stock pursuant to Rule 144 or an effective registration statement may adversely affect the market price of our common stock.

 ****

***Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.***

The Company's certificate of incorporation and bylaws contain provisions that could have the effect of delaying or preventing changes in control or changes in our management without the consent of our board of directors. These provisions include:

● Our certificate of incorporation permits our board of directors to amend or repeal our bylaws;

● Our governing documents do not provide for cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

● limiting the liability of, and providing indemnification to, our directors and officers;

● controlling the procedures for the conduct and scheduling of stockholder meetings;

These provisions, alone or together, could delay hostile takeovers and changes in control of the Company or changes in our board of directors and management.

Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our security holders to receive a premium for their securities and could also affect the price that some investors are willing to pay for our securities.

***If an active, liquid trading market for our common stock or warrants (forming part of the units offered hereby) does not develop, you may not be able to sell your common stock or warrants quickly or at a desirable price.***

The warrants forming a part of the units issued in this offering will be immediately exercisable and expire on the [●] anniversary of the date of issuance. The warrants will have an initial exercise price per share equal to $[●]. In the event that the stock price of our common stock does not exceed the exercise price of the warrants during the period when the warrants are exercisable, the warrants may not have any value.

There is no established trading market for the common stock or warrants sold in this offering, and the market for the common stock or warrants may be highly volatile or may decline regardless of our operating performance. We intend to apply to list the common stock and common stock warrants offered in this offering the Nasdaq Capital Market under the symbols "[●]" and "[●]W," respectively. However, an active public market for our common stock warrants may not develop or be sustained. We cannot predict the extent to which investor interest in our company will lead to the development of an active trading market in our common stock or warrants or how liquid that market might become. If a market does not develop or is not sustained, it may be difficult for you to sell your common stock or warrants at the time you wish to sell them, at a price that is attractive to you, or at all.

***Holders of our warrants (forming part of the units offered hereby) will have no rights as a common stockholder until they acquire our common stock.***

Until you acquire shares of our common stock upon exercise of your warrants, you will have no rights with respect to our common stock. Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.

***We have never paid dividends on our common stock and have no plans to do so in the future.***

Holders of shares of our common stock are entitled to receive such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our shares of common stock, and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any return investors in our common stock may have will be in the form of appreciation, if any, in the market value of their shares of common stock. See "Dividend Policy."

***We will indemnify and hold harmless our officers and directors to the maximum extent permitted by Delaware law.***

Our Bylaws provide that we will indemnify and hold harmless our officers and directors against claims arising from our activities to the maximum extent permitted by Delaware law. If we were called upon to perform under our indemnification agreement, then the portion of our assets expended for such purpose would reduce the amount otherwise available for our business.

**USE OF PROCEEDS**

We estimate that the net proceeds from the sale of units we are offering will be approximately $[●]. If the Representative fully exercises the Over-Allotment Option, the net proceeds of the shares we sell will be $[●]. "Net proceeds" is what we expect to receive after deducting the underwriting discount and commission and estimated offering expenses payable by us.

We intend to use the balance of the net proceeds of this offering primarily to expand our research and development operations for expanding and enhancing our products, hire key management and new team members for executing the Company's sales and marketing initiatives, and for working capital and general corporate purposes. The amounts that we spend for any specific purpose may vary significantly, and will depend on a number of factors including, but not limited to, market conditions. In addition, we may use a portion of any net proceeds to acquire complementary businesses; however, we do not have plans for any additional acquisitions at this time.

The above use of net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors. As a result, our management will retain broad discretion over the use of the net proceeds from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes, and we will have broad discretion in the application of net proceeds from this offering.

**CAPITALIZATION**

The following table shows our capitalization as of December 31, 2021:

● on an actual basis; and

● on an as adjusted basis to reflect the receipt of the net proceeds from the sale by us in this offering of units, after deducting $[●] in estimated underwriting discounts and estimated offering expenses payable by us.

We derived this table from, and it should be read in conjunction with and is qualified in its entirety by reference to, our historical and unaudited financial statements and the accompanying notes included elsewhere in this prospectus. You should also read this table in conjunction with "Selected Historical Financial and Operating Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."

---

| | | |
|:---|:---|:---|
|  | **As of December 31, 2021** | **As of December 31, 2021** |
|  | **Actual** | **As <br> Adjusted <br> (1)** |
| Cash and cash equivalents | $9527 | $[●] |
| SAFE liability | $6550440 | $[●] |
| Notes payable - related parties | 57397 | [●] |
| Stockholders' deficit: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value; 250,000,000 shares authorized, 1,798,947 shares issued and outstanding on an actual basis, and [●] shares issued and outstanding on an as adjusted basis | 180 | [●] |
| Accumulated deficit | (6546227) | [●] |
| Total stockholders' deficit | $(6546047) | [●] |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The number of shares of common stock to be outstanding after the offering
is based on [●] which is the number of shares outstanding on December 31, 2021, assumes no exercise by the underwriters of their
option to purchase up to an additional [●] shares of common stock to cover over-allotments, if any, and excludes:

● [●] shares of common stock issuable upon the full exercise of the warrants (forming part of the units) offered hereby; and

● [●] shares of common stock underlying the Representative's Warrant to be issued to the Representative in connection with this offering.

**MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS**

**Market Information**

Our common stock is not currently listed on any national securities exchange market or quoted on the OTC Markets. We intend to apply to list our common stock and warrants (forming part of the units) on the Nasdaq Capital Market under the symbol "[●]" and "[●]W," respectively. There is no assurance that our listing application will be approved by the Nasdaq Capital Market. The approval of our listing on the Nasdaq Capital Market is a condition of closing this offering.

**Holders of Common Stock**

As of January 23, 2023, there were approximately 23 record holders of our common stock. The number of record holders does not include beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.

We have not paid any cash dividends on our common stock and do not currently anticipate paying cash dividends in the foreseeable future. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business.

**Historical Common Equity Transactions**

The following is a summary of transactions by us since our inception on September 5, 2013 involving registered and unregistered issuances and redemptions of our common equity securities.

On January 1, 2015, the Company issued 719,579 (600 pre-forward stock split) shares of its common stock to Eran Kabakov.

On January 1, 2015, the Company issued 719,579 (600 pre-forward stock split) shares of its common stock to Tomer Kabakov.

On January 1, 2015, the Company issued 359,789 (300 pre-forward stock split) shares of its common stock to Jonathan Cabin in exchange for total cash consideration of $3.00. In 2018 269,842 (225 pre-forward stock split) of these shares were assumed by Eran Kabakov by mutual consent. On August 30, 2022, 52,769 (44 pre-forward stock split) of the remaining 89,947 (75 pre-forward stock split) of these shares held by the Cabin Family Trust, were sold to Eran Kabakov for $2,500.

In July of 2022, we completed a convertible note offering, in which we sold $100,000 of unsecured convertible notes (the "Notes") to 2 investors, in exchange for proceeds of $100,000. The Notes are automatically convertible into shares of our common stock at a conversion price at a 25% discount to the IPO price and have a maturity date one year from the date of issuance.

From November 2014 through July 2021, the Company issued 22 Simple Agreement for Future Equity ("SAFE") to 15 investors for a total aggregate amount of $1,629,625. The SAFE granted each investor rights to receive certain preferred shares of the Company upon the consummation by the Company of an equity financing. On November 15, 2022, the Company cancelled its previously issued SAFEs in exchange for 1,379,377 shares and as a result the SAFEs are no longer outstanding.

In December of 2022 the Company issued, per its pre-existing contractual arrangement, 150,663 shares to a New York City-based start-up accelerator.

On December 14, 2022, the Company issued 464,008 shares of common stock to professionals for services rendered.

On December 23, 2022, the Company issued 25,185 shares of common stock to a professional for services rendered.

Other that the issuances made pursuant to the cancellation of the SAFEs, which were made pursuant to the exemption from registration provided in Section 3(a)(9) of the Securities Act, the remainder of the above issuances/sales were made pursuant to an exemption from registration as set forth in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

**DILUTION**

If you invest in our units (comprised of our common stock and warrants) in this offering, your interest will be diluted to the extent of the difference between the assumed public offering price per share of common stock (which forms a part of a unit) and the pro forma net tangible book value per share of our common stock immediately after this offering.

The net tangible book value of our common stock as of December 31, 2021 was ($4,393) or approximately ($.00234) per share. Net tangible book value per share represents our total tangible assets less our total liabilities, divided by the number of shares of common stock.

Net tangible book value dilution per share of common stock in each unit to new investors represents the difference between the amount per share of common stock in each unit paid by purchasers in this offering and the pro forma net tangible book value per share of our common stock immediately after the completion of this offering. After giving effect to our issuance and sale of units in this offering at the assumed public offering price of $[●] per unit (the low-end of the range set forth on the cover page of this prospectus), and after deducting estimated underwriting discounts and estimated offering expenses, our pro forma net tangible book value as of [●] would have been $[●] or approximately $[●] per share. This represents an immediate increase in net tangible book value of $[●] per share to existing stockholders and an immediate dilution in net tangible book value of $[●] per share to purchasers of units in this offering, as illustrated in the following table:

---

| | | |
|:---|:---|:---|
| Assumed public offering price per unit |  | $[●] |
| Net tangible book value per share as of December 31, 2021 | $(0023) |  |
| Increase in net tangible book value per share attributable to new investors | $&nbsp;&nbsp;&nbsp;&nbsp;[●] |  |
| Less: pro forma net tangible book value per share after giving effect to the offering |  | $[●] |
| Immediate dilution in net tangible book value per share to new investors |  | $[●] |

---

The foregoing illustration also does not reflect the dilution that would result from the exercise of any of the warrants sold in the offering.

The following table sets forth, as of [●], the assumed number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and to be paid by new investors purchasing units (of which shares of common stock form a part) in this offering, after giving pro forma effect to the new investors in this offering at the public offering price of $[●] per unit, together with the total consideration paid an average price per share paid by each of these groups, before deducting underwriting discounts and estimated offering expenses.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Shares Purchased** | **Shares Purchased** | **Total Consideration** | **Total Consideration** | **Average <br> Price** |
|  | **Number** | **Percent** | **Amount** | **Percent** | **per Share** |
| Existing stockholders | 1798947 | [●]% | $[1,629,925]% |  | $0.90 |
| New investors | [●] | [●]% | $[●] | [●]% | $[●] |
| Total | [●] | 100.00% | $[●] | 100.00% | $[●] |

---

If the Representative's Over-Allotment Option is exercised in full for shares of common stock at the assumed offering price, the number of shares held by new investors will increase to [●] (assuming no exercise of the warrants), or approximately [●]% of the total number of shares of common stock outstanding after this offering and the shares held by existing stockholders will be [●] shares of common stock but the percentage of shares held by existing stockholders will decrease to [●]% of the total shares outstanding.

To the extent that the Representative's Over-Allotment Option is exercised or any warrants or options are exercised, there will be further dilution to new investors.

The foregoing discussion and tables above do not give effect to the dilution that would result from (i) [●] shares of common stock issuable upon the full exercise of the warrants (included as part of the units and over-allotment option) offered hereby and (ii) [●] shares of common stock issuable upon exercise of the Representative's Warrant granted to the Underwriter upon completion of this offering, including the exercise of any over-allotment in full.

To the extent that the Representatives' Over-Allotment Option is exercised there will be further dilution to new investors.

The foregoing discussion and tables above do not give effect to the dilution that would result from [●] shares of common stock issuable upon exercise of the Representatives' Warrants granted to the Underwriter upon completion of this offering, including the exercise of any over-allotment in full.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

References in this prospectus to "we," "us" or the "Company" refer to Docola, Inc. The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this prospectus.

**Overview**

Docola, Inc. was incorporated in the state of Delaware on September 5, 2013. Docola aims to be a social good organization offering a free care communication platform that seeks to consolidate thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one online marketplace called Docola at the following websites: Https://www.doco.la and Https://www.docola.com (the "Platform"). The information contained on our websites is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our websites as part of this prospectus or in deciding whether to purchase our securities. Additionally, our Platform allows users to easily create and upload their own resources. With the use of our Platform, clinicians and patient-facing professionals can ePrescribe personalized information to an individual patient or groups of patients. Patients can review the information and ask questions in the comfort of their own homes before, between, or after in-person or virtual visits. We aim to proactively meet people's informational needs, so they understand why it's important, possible, and safe to participate in their own medical care. We aim to save time both for the patient and provider and improve patient satisfaction and patient outcomes.

Our Platform was developed by a team of clinicians who know from experience that better communication is essential to better patient care, understanding, and outcomes. We believe that patient centricity, collaboration, and transparency are the best ways to improve patient care. We continuously aim to learn from millions of digital interactions, conversations with clinicians and patients, and ongoing research in asynchronous education. On our Platform, healthcare providers, hospitals, and clinics can find free and low-cost patient education and resources, or upload and create their own, and deliver them to patients before, between, and after visits on any web-enabled device. As a social good organization, our Platform is free to all healthcare providers, patients, advocates, and content providers. We intend that it always will be free in the future. There are also optional services that users can select on our Platform that come with an associated fee as further described in detail below.

We are passionately committed to unifying the healthcare experience. We believe access to information and care should be available to everyone. We aim to make it possible for patients and families to receive the right information at the right time, so they can act on it. We believe that when we proactively meet people's informational needs, they understand why it's important, possible, and safe to participate in their care. This also helps people think about their goals and preferences, in order to have better conversations. To date, our Platform has approximately 58,042 users, including clinicians and patients, across the U.S., Canada and the U.K.

To support our free Platform, we offer optional paid services and license a separate product called DocolaRx, to research organizations, medical devices, biotech and pharmaceutical companies for their projects. The proceeds provide financial funding but they do not have any influence or interaction with our free Platform.

To date, the Company has funded operations primarily through equity and debt financings. For the fiscal years ending December 31, 2021 and 2020, the Company generated revenues of $111,318 and $137,482, respectively, and reported net loss of $4,439,303 and $1,219,317, respectively; and cash flow used in operating activities of $413,952 and $306,880, respectively. As noted in our financial statements, as of December 31, 2021, the Company had an accumulated deficit of $6,546,227 and working capital deficit of $6,489,880. There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and debt financings. See "Risk Factors—We have a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2021 and 2020."

**Results of Operations**

***Comparison of the year ended December 31, 2021 and 2020***

 

*Revenues*

For the years ended December 31, 2021 and 2020 we generated revenues of $111,318 and $137,482, respectively. This represents a decrease of $26,164 or 19.0%. This decrease is primarily attributed to a write-off of $28,750 deemed uncollectible by the Company.

 

*Cost of revenue–*

For the years ended December 31, 2021 and 2020 our overall cost of revenue was $174,839 and $192,645, respectively. This represents a decrease of $17,806 or 9.2%. This decrease is primarily explained by a reduction in salary paid to the Company's principal executive, a portion of which was allocated to cost of revenue.

 

*Gross loss*

For the years ended December 31, 2021 and 2020 our gross loss was $63,521 and $55,163, respectively. This represents a decrease of $8,358 or 15.2%. This increase can be attributed mainly to a decrease in Sales of $26,164.

 

*Operating Expenses*

For the years ended December 31, 2021 and 2020 we incurred operating expenses of $307,563 and $259,798, respectively. This represents an increase of $47,765 or 18.4%. This increase is explained by an increase of $67,538 in general and administrative expenses primarily attributed to expenses for services of $75,125.

 

*Other income/(expense)*

For the years ended December 31, 2021 and 2020 the Company realized other expense of $4,068,219 and $904,356, respectively. This represents a decrease of $3,163,863 or 349.8%. This decrease is primarily attributed to the change in the fair value of the SAFE agreements in the amount of $4,102,456.

 

*Net loss*

As a result of the above factors, our net loss was $4,439,303 for the year ended December 31, 2021, as compared to a net loss of $1,219,317 for the year ended December 31, 2020

**Liquidity and Capital Resources**

Cash requirements for, but not limited to, working capital, capital expenditures, and debt repayments have been funded from cash balances on hand, SAFE agreements, loans from officers, notes payable and cash generated from operations.

Management has determined that due to its significant negative cash flows from operations since inception and the Company's expectation to incur negative cash flows from operations for at least the next two fiscal years, substantial doubt exists about the Company's ability to operate as a going concern. The auditor of the Company has included an explanatory paragraph relating to the Company's ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2021 and 2020.

The Company will need to obtain additional funding beyond the period that is 12 months from the date these financial statements were available to be issued in order to maintain operations. As a result, in the absence of such funding, substantial doubt exists about the Company's ability to operate as a going concern.

At December 31, 2021, we had cash and cash equivalents of $9,527 as compared to $39,615 as of December 31, 2020, representing a decrease of $30,088. This decrease can be explained by net cash used in operating activities of $413,952; offset by net cash provided by financing activities of $383,864. At December 31, 2021 and 2020, our working capital was a deficit of approximately $6,489,880 and $2,087,832 respectively.

The cash flows from operating activities decreased from net cash used of $306,880 for the year ended December 31, 2020 to net cash used of $413,952 for the year ended December 31, 2021. This decrease of $107,072 is primarily attributed to an increases in accrued income and accounts receivable of $54,470 and $34,475, respectively.

The cash flows from investing activities increased from net cash used of $3,691 for the year ended December 31, 2020 compared to $0 for the year ended December 31, 2021. This increase can be explained by the fact that there were no assets purchases in 2021.

The cash flow from financing activities increased from net cash provided of $149,547 for the year ended December 31, 2020 to net cash provided of $383,864 for the year ended December 31, 2021. This increase is primarily attributed to an increase in proceeds from SAFE agreements of $171,625 and an increase in net borrowings from related parties in the amount of $36,477.

<u>Bank Loans</u>

The Company currently does not have any bank loans.

**Off-balance sheet financing arrangements**

We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

**COVID-19**

A pandemic outbreak of novel strains of coronavirus (COVID-19) has occurred across the globe and efforts to mitigate the health impact of the pandemic have profoundly and adversely affected economic activity. National, state and local governments have taken actions to mitigate the impact of the COVID-19 pandemic in a variety of ways, including by declaring states of emergency, issuing stay-at-home orders and ordering certain businesses to close or limit their operations. Due to the digital/remote nature of the Company's business, COVID-19 has had, and is expected to have, only positive effects on the Company's operations since more patients and healthcare providers have switched to remote consultations and visits since the start of the COVID-19 pandemic, which lead to an increased use of the Company's Platform. Additionally, in the U.S., the Centers for Medicare and Medicaid Services ("CMS") has extended physicians' fees for telehealth use in certain specialties until December 2023. CMS has also amended rules and regulations to increase access to healthcare via remote services. We believe that this may present a potential opportunity for the Company to sign on new clients in these specific specialties. Notwithstanding the foregoing, the long-term financial impact of coronavirus on the Company cannot be reasonably estimated at this time and may ultimately have a material adverse impact on our business, financial condition, and results of operations.

The COVID-19 pandemic has also resulted in material adverse national and global economic conditions that. Such conditions may result in an economic recession or prolonged economic downturn, which could result in a material loss of business for the duration of the downturn. Actions taken to mitigate the pandemic and resulting economic conditions are likely to materially and adversely impact our business, financial condition, results of operations and cash flows. The COVID-19 pandemic has also resulted in severe disruption and volatility in the financial markets. Depending on the extent and duration of the COVID-19 pandemic, the price of our common stock may experience declines and volatility which may negatively impact our ability to raise capital through the equity markets if necessary to increase our liquidity.

**Contractual obligations**

The Company enters into agreements with users of the Docola software to provide general services and specific software developments and enhancements. Currently, its largest contract is with a multinational pharmaceutical company.

**Critical Accounting Policies**

 

*We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this "Management's Discussion and Analysis of Financial Condition and Results of Operation."*

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or "U.S. GAAP." The preparation of these financial statements in accordance with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, assumptions and judgments, including those related to revenue recognition, bad debts, inventories, warranties and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and our revenue recognition. Actual results may differ from these estimates under different assumptions or conditions and the impact of such differences may be material to our financial statements.

Critical accounting policies are those policies that, in management's view, are most important in the portrayal of our financial condition and results of operations. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. These critical accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. Those critical accounting policies and estimates that require the most significant judgment are discussed further below. We consider our most critical accounting policies and estimates to be revenue recognition, gain on settlements, valuation of long-lived assets, income taxes and valuation allowances against net deferred tax assets, derivative liabilities, stock based compensation and accounting for business combinations-acquisition method accounting.

 ****

 ****

***Stock-based compensation*** payments to employees and consultants are recognized as expense in the statements of income. The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award (determined using a Black-Scholes option pricing model for stock options and intrinsic value on the date of grant for non-vested restricted stock), and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity award). Determining the fair value of stock-based awards at the grant date requires significant estimates and judgments, including estimating the market price volatility of our common stock, future employee stock option exercise behavior and requisite service periods.

Stock-based compensation expense is recorded only for those awards expected to vest using actual forfeitures. The estimation of stock awards that will ultimately vest requires judgment, and to the extent that actual results differ from our estimates, such amounts will be recorded as cumulative adjustments in the period the estimates are revised.

 ****

***Equity transactions***, including the accounting and classification of common stock.

 ****

***Debt transactions and fair value measurements***, including the accounting and classification of convertible debt and SAFEs.

 ****

***Cash flow and going concern*** assessment, in accordance with ASU 2014-15, requires us to evaluate the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.

 ****

***Related party transactions*** involve identifying, accounting for, and disclosing relationships and transactions with related parties.

**Recent Accounting Pronouncements**

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. Subsequently, the FASB issued ASU 2019-10 and then ASU 2020-05, both of which adjusted the effective date of ASU 2016-02 for non-public entities. The accounting standard is effective for non-public entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. A modified retrospective transition approach is required at the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has determined that the adoption of this standard has an immaterial impact on the financial statements presented herein.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): *Clarifying the Interaction between Topic 808 and Topic 606*, ("ASU 2018-18"). The amendments in this update clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. ASU 2018-18 is effective for the Company's annual reporting periods beginning after December 15, 2020. The Company has adopted this standard effective January 1, 2021.

In December 2019, the FASB issued ASU 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes* ("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective for the Company beginning January 1, 2021. The Company has adopted this standard effective January 1, 2021.

On August 5, 2020, the FASB issued ASU No. 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity's Own Equity (Subtopic 815-40)*. The amendments remove certain separation models for convertible debt instruments and convertible preferred stock that require the separation of a convertible debt instrument into a debt component and an equity or derivative component. The ASU also amends the derivative scope exception guidance for contracts in an entity's own equity. The amendments remove three settlement conditions that are required for equity contracts to qualify for the derivative scope exception. In addition to the above, the ASU expands disclosure requirements for convertible instruments and simplifies areas of the guidance for diluted earnings-per-share calculations that are impacted by the amendments. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the potential impact this standard may have on its financial statements.

**DESCRIPTION OF THE BUSINESS**

**Overview**

Docola, Inc. was incorporated in the state of Delaware on September 5, 2013. Docola has no subsidiaries. Docola aims to be a social good organization offering a free care communication platform that seeks to consolidate thousands of free and low-cost patient education resources from the leading non-profit, government, and commercial organizations in one online marketplace called Docola at the following websites: https://www.doco.la and https://www.docola.com (the "Platform"). The information contained on our websites is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our websites as part of this prospectus or in deciding whether to purchase our securities. Additionally, our Platform allows users to easily create and upload their own resources. With the use of our Platform, clinicians and patient-facing professionals can ePrescribe personalized information to an individual patient or groups of patients. Patients can review the information and ask questions in the comfort of their own homes before, between, or after in-person or virtual visits. We aim to proactively meet people's informational needs, so they understand why it's important, possible, and safe to participate in their own medical care. We aim to save time both for the patient and provider and improve patient satisfaction and patient outcomes.

Our Platform was developed by a team of clinicians who know from experience that better communication is essential to better patient care, understanding, and outcomes. We believe that patient centricity, collaboration, and transparency are the best ways to improve patient care. We continuously aim to learn from millions of digital interactions, conversations with clinicians and patients, and ongoing research in asynchronous education. On our Platform, healthcare providers, hospitals, and clinics can find free and low-cost patient education and resources, or upload and create their own, and deliver them to patients before, between, and after visits on any web-enabled device. As a social good organization, our Platform is free to all healthcare providers, patients, advocates, and content providers. We intend that it always will be free in the future. There are also optional services that users can select on our Platform that come with an associated fee as further described in detail below.

We are passionately committed to unifying the healthcare experience. We believe access to information and care should be available to everyone. We aim to make it possible for patients and families to receive the right information at the right time, so they can act on it. We believe that when we proactively meet people's informational needs, they understand why it's important, possible, and safe to participate in their care. This also helps people think about their goals and preferences, in order to have better conversations. To date, our Platform has approximately 58,042 users, including clinicians and patients, across the U.S., Canada and the U.K.

To support our free Platform, we offer optional paid services and license a separate product called DocolaRx, to research organizations, medical devices, biotech and pharmaceutical companies for their projects. The proceeds provide financial funding but they do not have any influence or interaction with our free Platform.

To date, the Company has funded operations primarily through equity and debt financings. For the fiscal years ending December 31, 2021 and 2020, the Company generated revenues of $111,318 and $137,482, respectively, and reported net loss of $4,439,303 and $1,219,317, respectively; and cash flow used in operating activities of $413,952 and $306,880, respectively. As noted in our financial statements, as of December 31, 2021, the Company had an accumulated deficit of $6,546,227 and working capital deficit of $6,489,880. There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and debt financings. See "Risk Factors—We have a history of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2021 and 2020."

**Industry Overview**

The Company operates in the healthcare industry and specifically in the telehealth industry, which has grown substantially since the start of the Covid-19 pandemic and which continues to grow at this time. According to an article published by McKinsey & Company on July 9, 2021, titled "Telehealth: A quarter-trillion-dollar post-COVID-19 reality?" in April of 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February of 2020. According to the same article, since the initial spike in April of 2020, telehealth adoption overall has approached up to 17% of all outpatient and office visit claims with evaluation and management ("E&M") services.

According to the same article:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Telehealth utilization has stabilized at levels 38 times higher than before the pandemic. After
an initial spike to more than 32% of office and outpatient visits occurring via telehealth in April of 2020, utilization levels
have largely stabilized, ranging from 13% to 17% across all specialties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Similarly, consumer and provider attitudes toward telehealth have improved since the pre-COVID-19
era. Perceptions and usage have dropped slightly since the peak in spring of 2020. Some barriers—such as perceptions of technology
security—remain to be addressed to sustain consumer and provider virtual health adoption, and models are likely to evolve
to optimize hybrid virtual and in-person care delivery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Some regulatory changes that facilitated expanded use of telehealth have been made permanent, for
example, the Centers for Medicare & Medicaid Services' expansion of reimbursable telehealth codes for the 2021 physician
fee schedule. But uncertainty still exists as to the fate of other services that may lose their waiver status when the public health
emergency ends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Investment in virtual care and digital health more broadly has skyrocketed, fueling further innovation,
with 3 times the level of venture capitalist digital health investment in 2020 than it had in 2017.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Virtual healthcare models and business models are evolving and proliferating, moving from purely
"virtual urgent care" to a range of services enabling longitudinal virtual care, integration of telehealth with other
virtual health solutions, and hybrid virtual/in-person care models, with the potential to improve consumer experience/convenience,
access, outcomes, and affordability.

According to an article published by Fierce Healthcare on December 22, 2021 titled "2022 Forecast: Investors will double down on these hot digital health markets," the first nine months of 2021 alone brought in a total of $21.3 billion for digital health startups across 541 investment deals, dwarfing the $14.6 billion record of 2020, according to Rock Health, a venture fund dedicated to digital health. According to the same article, industry experts say the telehealth industry is becoming more mature and is shifting away from just urgent care visits to focus on more specialized care, or what some call "telehealth 2.0." Further, according to an article published by MarketWatch on June 23, 2022, titled "Telehealth Market in US 2022-Growth Strategy, Top Trends And Business Opportunity" the US telehealth market is expected to grow at a compound annual growth rate of over 29% during the period 2022-2031.

**Our Products and Services**

Built by clinicians, we believe that our healthcare communication Platform makes it easy for healthcare providers to improve patient understanding, engagement and measure care participation. Through our Platform we aim to:

&nbsp;&nbsp;&nbsp;&nbsp;· *Educat* e: Healthcare providers can use our Platform
to curate their own library and E-prescribe education and resources to their patients from a central hub.

&nbsp;&nbsp;&nbsp;&nbsp;· *Empower*: We believe that our Platform makes it easier
for patients and families to confidently participate in their own care.

&nbsp;&nbsp;&nbsp;&nbsp;· *Better Outcomes*: We believe that our Platform improves
both the patient and clinician healthcare experience.

&nbsp;&nbsp;&nbsp;&nbsp;· *Insights*: We believe that on our Platform, healthcare
providers can learn how patients utilize online resources through feedback reports and reviews.

We seek to serve clinicians, patients, education providers as well as pharmaceutical and medical device companies. Through our Platform we aim to serve:

&nbsp;&nbsp;&nbsp;&nbsp;· *Clinicians*: On our Platform clinicians can engage
with patients by ePrescribing and tracking interactive resources.

&nbsp;&nbsp;&nbsp;&nbsp;· *Patients*: On our Platform patients can take control
of their care with online health information, selected by their care team.

&nbsp;&nbsp;&nbsp;&nbsp;· *Education and Content Providers*: On our Platform educational
and content providers can create a free distribution channel by adding their resources so clinicians can find and utilize them.

&nbsp;&nbsp;&nbsp;&nbsp;· *Pharmaceutical/Medical Device Companies*: On our Platform
pharmaceutical and medical device companies can create interactive resources to support sales, marketing and research and development.

***Clinicians***

Clinicians can use our Platform to create a free account and use this account to create their own patient education library of videos, handouts and interactive decision aids as well as communicate with patients. On our platform clinicians can:

&nbsp;&nbsp;&nbsp;&nbsp;· Upload their own resources by simply using drag and drop;

&nbsp;&nbsp;&nbsp;&nbsp;· Choose from thousands of free and low-cost resources on the
Platform;

&nbsp;&nbsp;&nbsp;&nbsp;· Pull in free resources from the web;

&nbsp;&nbsp;&nbsp;&nbsp;· Use the tools in the Platform to easily create videos, surveys,
quizzes, for their patients; and

&nbsp;&nbsp;&nbsp;&nbsp;· Market their practice to current and prospective patients.

Clinicians can then combine any of these resources to create interactive courses. Clinicians can use our Platform to create their own courses for the most common diagnoses and procedures and share them with just one or many patients with just the click of a button, as well as easily modify courses for individual needs, specific combinations of conditions, and health changes over time. They can also ePrescribe courses to an individual, group, or all of their patients. Clinicians can also use the dashboard on our Platform to monitor patient care and progress and to provide follow up and pre-visit guidance. With the use of our Platform, we believe that clinicians can reclaim their time so that it can be dedicated to better personal conversations with patients. We believe that with our Platform, healthcare providers, case managers, educators and advocates can ensure patients and families receive the right information at the right time as well as improve in-person and virtual visits by giving patients consistent, actionable information they can view anytime, anywhere, on any web-enabled device. We believe that our Platform's feature set makes it effective at population health management.

We believe that when you meet their informational needs, people feel cared for and empowered, which makes them less likely to search for answers on the internet which may lead to sources that provide misinformation. This improves their ability to engage in their care plans. On our Platform, clinicians can support patients between visits by e-prescribing actionable information to help them understand their conditions, treatments, procedures, recovery, medications, and self-care.

As the Platform expands and connects with other solutions, we intend that there will be optional features offered by third parties to clinician users for a fee. Currently there is the option for clinicians to request a managed account for a onetime fee of $499. With this offering Docola handles all technology and content management, thereby simplifying the experience, speeding up implementation and saving time. Over the years clinicians have asked for additional help creating their account, uploading their educational resources, creating courses, and training their team members on using the Platform. This one time set up service includes 90 days of dedicated phone support for practice staff. There is also the option for clinicians to elect ongoing account management for a monthly fee of $129. Included in this offering are ongoing help with content management monthly usage and key performance indicator ("KPI") reporting, and dedicated phone support for staff.

We believe that the benefits of our Platform for clinicians, include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· Reduce Repetition: clinicians don't have to feel like
a parrot, a virtual course lets patients review information as many times as they want.

&nbsp;&nbsp;&nbsp;&nbsp;· Improve Relationships: clinicians can communicate and pre-educate
patients prior to appointments and as a result can have more productive conversations with their patients.

&nbsp;&nbsp;&nbsp;&nbsp;· Extend Care Team: clinicians can extend the care team with
resources for conditions, meds, and procedures from our Platform.

&nbsp;&nbsp;&nbsp;&nbsp;· Optimize Processes: clinicians can improve patient selection,
speed time to procedures, enhance marketing initiatives, and coordinate clinical and administrative staff.

&nbsp;&nbsp;&nbsp;&nbsp;· Enhance and Support Self Care: clinicians can give patients
info they can understand and act on and as a result reduce the need for Dr. Google.

&nbsp;&nbsp;&nbsp;&nbsp;· Increase Satisfaction: clinicians can exceed patient expectations
and reduce clinical team burnout.

&nbsp;&nbsp;&nbsp;&nbsp;· Track and document: clinicians can monitor if patients start
and complete courses.

&nbsp;&nbsp;&nbsp;&nbsp;· Gather insights: clinicians can collect patient feedback
through surveys and reviews.

&nbsp;&nbsp;&nbsp;&nbsp;· Secure: our Platform aims to meet the highest data compliance
regulations.

 ****

The Platform supports delivery of videos (MP4 format), Microsoft Office documents, Images (PNG and JPG), and PDFs, web assets, quizzes and surveys. Clinicians will be in full control of and solely responsible for all content they post on our Platform. The Platform is designed to enable clinicians to easily update information whenever needed. New materials can be uploaded and replaced within any course. A unique version control feature maintains a record of each item updates.

 ****

***Patients and Families***

A patient's healthcare provider will send their patient an email with a link to create a free account on our Platform. With our Platform a patient's doctor can easily share or "ePrescribe" videos and other resources to explain conditions, medications, or procedures, help patient's think about treatment decisions, and have better conversations. We believe that this helps patients to better understand their diagnoses or treatment options, and relieves the stress and uncertainty of having to search the web for this information. Once a patient creates a free account with our Platform, they can access their account anytime, from any device. With our Platform, patients don't need to spend time searching the web, instead, their care team selects information specifically for them. Then, patients can look at the information on the Platform at the time of their choosing, share the same information with their family and friends, and even leave a review to help others know if the information was helpful.

We believe that the benefits of our Platform for patients, include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· Personalized: the information on our Platform is chosen specifically for the patient
by their care team.

&nbsp;&nbsp;&nbsp;&nbsp;· Better Conversations: on our Platform, patients can have more meaningful conversations
with their care team.

&nbsp;&nbsp;&nbsp;&nbsp;· On Demand: on our Platform, patients can review the information when they have time on
any web-enabled device.

&nbsp;&nbsp;&nbsp;&nbsp;· Secure: our Platform does not share or sell any patient data and aims to uphold the highest
privacy standards and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;· Easy to Share: on our Platform, patients can easily share education and resources with
their family and friends.

To ensure patients only see information that's right for them, they cannot search for content on the Platform. Patients only see the information that their care teams ePrescribe to them. Once a specific course is posted on our Platform for a patient, each course remains active and accessible to patients for 365 days. This means that patients will be able to view the prescribed course for up to 365 days after the date on which the course was first created. Once a course expires, the course title will be visible in the patient's account but the course will be deactivated (i.e. inaccessible and greyed out). If patients click on the course title, a notification will be displayed to request new access from the prescribing clinician. This is a quality assurance feature that we believe will prevent patients from accessing outdated information.

Further, Privacy and data security are core pillars of our value proposition. We aim to maintain rigorous security and data access controls to protect the information posted on our Platform. User data is encrypted at rest and in transit if data is to be transferred to a third-party service provider. We employ proprietary mechanisms to further protect collected information.

 ****

 ****

***Education and Content Providers***

Education and content providers can use our Platform to create a free account and use the account to upload their resources and decide if each resource is free or has a licensing fee. Education and content providers can also use our Platform to combine resources to create courses. Education and content providers can use our Platform to create essential resources to help educate and support patients or healthcare providers.

Our Platform is a care communication platform with a mission to connect education and content providers, clinicians and patients. The Platform is a searchable clearinghouse where care providers can find and license education and content providers' resources, then ePrescribe them to patients to ensure they get the right information at the right time.

We want education and content providers to think of our Platform as an App Store for their content. They can decide the price, if any, for each of their items such as videos, checklists, decision aids, articles, or continuing education for clinicians. Education and content providers maintain full ownership and control and can see who licenses their content and get aggregate data on how it's used on the Platform.

We believe that the benefits of our Platform for education and content providers include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;· Our Platform can serve as a free distribution channel to
education and content providers;

&nbsp;&nbsp;&nbsp;&nbsp;· Education and content providers can use our Platform to get
utilization reports; and

&nbsp;&nbsp;&nbsp;&nbsp;· Education and content providers control and own their brand
presence, content offering, and pricing on the Platform.

 **

***Pharmaceutical and Medical Device Companies***

 **

The Company also licenses a separate product, called DocolaRx™, to research organizations and pharmaceutical and biotech companies. They do not have any influence or interaction with the free Platform or community. The revenue from these projects provides financial funding to us, but operates independently from our main Platform.

We believe that pharmaceutical, medical device, and biotechnology brand teams, as well as clinical research organizations ("CROs"), can use DocolaRx™ to enhance patient-centric programs and digital therapeutics and manage clinical trials. They can also use DocolaRx™ to collect data, create reports, track usage, optimize processes, enable patient behavior change, improve patient satisfaction, provide timely information, deliver electronic consents and educate patients. DocolaRx™ aims to provide intuitive content management, powerful scalability and a white-labeled interface.

As pharma evolves into patient centric models, we believe that there are exciting opportunities to connect with patients and caregivers. As remote care, telemedicine, wearable devices and digital therapeutics become integral parts of the medical service delivery chain, we believe that it is imperative to consolidate functions into care communication pathways. DocolaRx was developed by clinicians who are passionate about the successful intersection of medicine and technology. We continuously learn from millions of digital interactions on our Platform, conversations with clinicians and patients, and industry trends.

We believe that in an ever-evolving market, full of advanced therapeutic options, the industry must transform patients into long-term partners. How? By offering consistent, trustworthy, and relevant knowledge – in real time, along the care continuum. DocolaRx optimizes information sharing with healthcare professionals ("HCPs") and patients. DocolaRx enables brand teams to create, customize, and deliver the right information at the right time to support HCPs and patients as well as easily track, monitor, and analyze the digital interactions. Using DocolaRx, the pharma team can provide each HCP with a dedicated account and the HCP can then interact with patients accordingly.

We believe that DocolaRx enables pharmaceutical brand teams to become an objective participant in the care continuum. Providing HCPs or pharma employed nurses, with a care communication platform that delivers information to and from patients. We believe that pharmaceutical, medical device, and biotechnology brand teams, as well as CROs can utilize DocolaRx to support new product launches, expand current therapeutic websites and forums with a patient centric digital environment, sales representative training, HCP education, wearable device connectivity, and virtual reality streaming.

We believe that the pharma industry is going through a major shift and must find new ways to meet the needs of a growing digital healthcare ecosystem. To adapt and succeed in this tech-driven market, we believe that pharmaceutical and medical device companies need the right tools to support a new patient-centric business model that combines connected devices and big data insights. DocolaRx offers content development, KPI measurement, and analysis using cutting edge machine learning and artificial intelligence technology.

With DocolaRx™, we offer both premium and white label options. The enterprise solution pricing is dependent upon the project scope and complexity. Integration levels, language, localization, and regulatory compliance are only some of the considerations that are taken into account. We work closely with our clients throughout the selection process as well as implementation. The pricing set forth below is a starting point for evaluation purposes and describes estimated fees associated with both our premium and white label options. The white label options enable organizations to create a complete custom user experience. The estimated fees are as follows:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; ***Type of Fee*** | &nbsp;&nbsp;***Premium*** | &nbsp;&nbsp;***White Label*** |
| &nbsp;&nbsp;Set Up Fee | &nbsp;&nbsp;$3000 | &nbsp;&nbsp;$60000 |
| &nbsp;&nbsp;Annual License Fee | &nbsp;&nbsp;$6000 | &nbsp;&nbsp;$125000 |
| &nbsp;&nbsp;Maintenance Fee | &nbsp;&nbsp;No Fee | &nbsp;&nbsp;$25000 |
| &nbsp;&nbsp;Training Webinars Fee | &nbsp;&nbsp;$3000 | &nbsp;&nbsp;$5000 |
| &nbsp;&nbsp;Custom Reports Fee | &nbsp;&nbsp;$3000 | &nbsp;&nbsp;$5000 |
| &nbsp;&nbsp;Custom Development Work Fee | &nbsp;&nbsp;Not available on Premium | &nbsp;&nbsp;$175 per hour |

---

**How it Works**

Our Platform offers a free care communication platform to connect clinicians and patients to deliver asynchronous patient education. Our Platform is free for healthcare providers, patients, and content providers. Our Platform aims to make it easy for healthcare providers to create their own library by:

&nbsp;&nbsp;&nbsp;&nbsp;· Easily uploading their own existing patient education;

&nbsp;&nbsp;&nbsp;&nbsp;· Importing free resources from the web;

&nbsp;&nbsp;&nbsp;&nbsp;· Using the tools in the Platform to create new videos, surveys;

&nbsp;&nbsp;&nbsp;&nbsp;· Or searching for and licensing resources from the marketplace

Then care teams can combine those resources into courses and ePrescribe them to patients. The Platform aims to be a growing clearinghouse of videos, decision aids, articles, checklists for patients, as well as clinician education. Some of the content is free, and some has licensing fees. This makes it easy for care teams to pick and choose the resources they want to use, versus the costs associated with buying a large content library. To ensure patients only see information that's right for them: they cannot search the Platform. They only see the information their care teams ePrescribe to them.

**Is our Platform Truly Free?**

The Platform is free to use as-is for all hospitals, clinics, healthcare providers, case managers, patient advocates, patients, and education and content providers. We do not display advertising information, nor do we sell or share user data. Some of the content is free, and some has licensing fees. The Company licenses a separate product, DocolaRx™, to research organizations and pharmaceutical and biotech companies.

There are no fees to use the Platform as is. Much of the patient and clinician education in the marketplace is free. Some of the third-party content has monthly or annual licensing fees, which are clearly labeled. This makes it easy to choose only the resources you want to use and save on the costs associated with buying a large content library. You only pay for what you use. No fees are ever passed on to patients. There are project fees associated with integrating the Platform into other systems such as electronic health records and telemedicine. Integrating our Platform into a third party health record solution is a project that requires the Company to provide project management personnel and resources, skilled web and database developer personnel and the utilization of a third party that provides linking into the electronic medical records. The foregoing can cost several thousands of dollars per year. Accordingly, we discuss these paid options with any prospective clients and inform them ahead of time if they would like to engage these paid services and provide them with a cost estimate if they wish to do so.

There is the option for users to create what we call a hands free account set up for a one-time fee of $499. Over the years clients have asked for additional help creating their account, uploading their educational resources, creating courses, and training their team members on using the Platform. This one time set up service includes 90 days of dedicated phone support for practice staff. There is also the option for users to elect for monthly account management for a monthly fee of $129. If a user would like ongoing help managing your practice's content, monthly usage, KPI reporting, and dedicated phone support for staff, they can select this option. There is also the option for users to engage in content licensing. Users can choose and license patient education and resources from a wide array of organizations and vendors on our content marketplace.

**Our Vision** 

Our vision is to be a social good organization with a free care communication platform that seeks to consolidate thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Our Platform was developed by a team of clinicians who know from experience that better communication is essential to better care, understanding, and outcomes. We believe that patient centricity, collaboration, and transparency is the best way to improve care. We believe that healthcare providers, hospitals, and clinics can utilize our Platform to find free and low-cost patient education and resources, or upload and

create their own, and deliver them to people before, between, and after visits on any web-enabled device. We are passionately committed to unifying the healthcare experience. We believe access to information and care should be available to everyone. We aim to make it possible for patients and families to receive the right information at the right time, so they can act on it. We believe that when we proactively meet people's informational needs, they understand why it's important, possible, and safe to participate in their own care. This also helps people think about their goals and preferences, in order to have better conversations.

**Competition and Competitive Advantages**

The market for our products and services is subject to rapid and significant change and competition. The market for technology-enabled services that empower healthcare consumers is characterized by rapid technological change, new product and service introductions, evolving industry standards, changing customer needs, existing competition and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to the rapidly evolving nature of the healthcare and technology industries and the substantial resources available to our existing and potential competitors. The market for technology-enabled services that empower healthcare consumers is relatively new and unproven, and it is uncertain whether this market will achieve and sustain high levels of demand and market adoption.

Our success depends to a substantial extent on the willingness of consumers to increase their use of technology platforms to manage their healthcare options, the ability of our Platform to increase consumer engagement, and our ability to demonstrate the value of our Platform to our potential users. If users do not recognize or acknowledge the benefits of our Platform or our Platform does not drive consumer engagement, then the market for our products and services might develop more slowly than we expect, which could adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business. We might make errors in predicting and reacting to relevant business, legal and regulatory trends, which could harm our business. If any of these events occur, it could materially adversely affect our business, financial condition or results of operations.

We believe that our primary direct competitors include Krames, Walter Kluwer and Salesforce and we believe that our primary indirect competitors are Teladoc, EPIC, Oracle Cerner, Nextgen and AMWELL, which competitors provide either patient education products, telehealth services and online healthcare website products that compete with the Company.

The following is a brief description of the foregoing companies which we see as our closest competitors, however it is possible that another company, that is not listed below, can potentially be a major competitor of the Company:

*Direct Competitors:*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Krames – is a private entity that provides patient education products and is one of the oldest
companies in the market of patient education and are widely used;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Walter Kluwer – is a publicly traded entity that provides Emmi® which is an end-to-end
technology suite for patient engagement and partnership; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Salesforce – is a publicly traded entity that provides a platform that aims to help patients
manage patient relationships from initial acquisition, service, care management, and ongoing engagement. and is one of the largest
customer relationship management providers on the market.

*Indirect Competitors:*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Teladoc – is a publicly traded entity that provides telehealth services that operates in
130 countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· EPIC – is a private entity that provides a software called MyChart® that holds patient
records with a focus on clinical management and patient engagement features;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Oracle Cerner – is an electronic health records company that was recently acquired by Oracle
Corporation, which is a publicly traded entity for over $28 billion, and offers patient engagement services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Nextgen – is a publicly traded entity that is an electronic health records company that offers
patient education which has a strong presence in the small to mid-size medical group market; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· AMWEL – is a publicly traded telemedicine company that connects patient to doctors over secure
video and is one of the leading telemedicine companies in the U.S.

Our competitors may have the ability to devote more financial and operational resources than we can to developing new technologies and services, including services that provide improved operating functionality, and adding features to their existing service offerings. If successful, their development efforts could render our services less desirable, resulting in the loss of our existing users or a reduction in the fees we earn from our products and services.

We believe that we have certain competitive advantages. For example, research shows when care teams curate and ePrescribe quality resources to patients before, after, and between visits, this can improve:

&nbsp;&nbsp;&nbsp;&nbsp;· Utilization

&nbsp;&nbsp;&nbsp;&nbsp;· Understanding

&nbsp;&nbsp;&nbsp;&nbsp;· Recall

&nbsp;&nbsp;&nbsp;&nbsp;· Health behaviors and outcomes

&nbsp;&nbsp;&nbsp;&nbsp;· Self-efficacy; and

&nbsp;&nbsp;&nbsp;&nbsp;· Patient-provider conversations and relationships.

Additionally, we believe that it has been shown that people feel safer honestly disclosing sensitive information about things like mental health, alcohol, drugs, abuse, or food security.

We believe that our competitive advantages are that our Platform enables:

&nbsp;&nbsp;&nbsp;&nbsp;· Better care communication and conversations (less need for Dr. Google)

&nbsp;&nbsp;&nbsp;&nbsp;· Improved patient and provider experience

&nbsp;&nbsp;&nbsp;&nbsp;· Value-based healthcare

&nbsp;&nbsp;&nbsp;&nbsp;· More effortless population health

&nbsp;&nbsp;&nbsp;&nbsp;· Virtual care

&nbsp;&nbsp;&nbsp;&nbsp;· Patient and family caregiver engagement; and

&nbsp;&nbsp;&nbsp;&nbsp;· Health literacy.

Unlike some of our competitors, our Platform provides more than just patient data, scheduling and record keeping, and also allows for informational courses, that are prescribed to support patients and families along the care continuum.

**Recent Developments**

*Issuance of Convertible Notes*

In July of 2022, the Company issued 2 convertible notes for proceeds of $50,000 each. The notes call for 6% simple interest and have a conversion feature whereby they will automatically convert into common stock upon consummation of an IPO at a 25% discount to the IPO price.

*SAFE Cancellation*

On November 15, 2022 the Company cancelled its previously issued Simple Agreements for Future Equity ("SAFE") and issued in exchange 1,379,377 shares of common stock. As a result of this corporate action, the SAFES are no longer outstanding.

*Increase in Authorized Shares and Forward Stock Split*

On December 13, 2022, the Company amended its Certificate of Incorporation to increase its authorized common shares to 250,000,000 and simultaneously effected a forward split of the existing common stock (on a ratio of 1:1,199.298126) resulting in 1,798,947 common shares outstanding on a post-stock split basis. The par value of the common stock was changed to $0.0001.

*Preferred Stock Authorization*

December 13, 2022, the Company authorized 20,000,000 shares of preferred stock, with a par value of $0.0001.

 

*Start-up Accelerator Stock Issuance*

In December of 2022 the Company issued, per its pre-existing contractual arrangement, 150,663 shares to a New York City-based start-up accelerator.

*Stock Issuance for Services*

 

On December 14, 2022, the Company issued 464,008 shares of common stock to professionals for services rendered.

On December 23, 2022, the Company issued 25,185 shares of common stock to a professional for services rendered.

**Facilities**

Our company headquarters are located at 801 W. Bay Drive, Suite 506, Largo, Florida 33770. We lease this space for $729 per month pursuant to a written lease agreement, dated May 7, 2015, and amended on July 22, 2015.

**Seasonality and Weather Patterns**

Our services and products are not subject to seasonal variability and weather patterns.

**Intellectual Property**

The Company currently holds the following trademarks in the following geographical areas:

U.S.A.: The Company holds a trademark in the U.S. under Trademark Registration number 4827657 registered on October 6, 2015, and expiring within 10 years from issuance, unless extended, which appears as follows:

![](dc001_s1img03.jpg)

China: The Company holds a trademark in China under Trademark Registration Certificate No. 17201243 registered on August 7, 2016 and expiring on August 6, 2026, which appears as follows:

![](dc001_s1img04.jpg)

Brazil: The Company holds a trademark in Brazil under Trademark Registration number 909519269 registered on October 17, 2017, and expiring on October 17, 2027, which appears as follows:

![](dc001_s1img05.jpg)

India: The Company holds a trademark in India under Trademark Registration number 2986103 registered on June 15, 2015, and expiring on June 15, 2025, which appears as follows:

![](dc001_s1img06.jpg)

**Material Agreements**

***License Agreement with Visual Health***

 

On September 1, 2019, the Company entered into a License Agreement (the "License Agreement") with Visual Health Solutions, Inc., a Colorado corporation (Visual Health). Pursuant to the License Agreement, the Company acquired a world-wide nonexclusive license to display, perform, exhibit, distribute or transmit Visual Health's animations, visual consults and other various products and services of Visual Health referred to together herein as the "Visual Intellectual Property" in the Company's products for the term of the License Agreement (the "License") in accordance with the terms of the License Agreement. The term of the License Agreement is initially for three (3) years from September 1, 2019, which will be automatically extended for two (2) successive one (1) year terms unless cancelled by written notice by either party to the other party note less than one-hundred twenty (120) days prior to the expiration of the term. Pursuant to the License Agreement, the Company agreed, to the extent possible, to provide attribution to Visual Health on the Company's products. Pursuant to the License Agreement, the Company agreed to forward to Visual Health a link to all of the Company's media that displays the Visual Intellectual Property within ten (10) business days of being made available to the general public. The License is not transferrable without the consent of Visual Health.

In exchange for the grant of the License under the License Agreement, the Company agreed to include Visual Intellectual Property in all of its product offerings and pay Visual Health a monthly fee equal to 70% of the provider-use fees collected by the Company (the "Monthly Fee"). The Monthly Fee is to be calculated by the Company reporting each month the number of providers paying fees to the Company for the use of the Company's Platform during the preceding month by the 5<sup>th</sup> of the month, together with the per-provider fees paid to the Company. Visual Health will invoice the Company the calculated fee based on the number of provider-users and the fees paid to the Company and payment of the invoice by the Company must be made within 30 days of receipt of such invoice.

The License Agreement can be terminated by either party by giving written notice to the other party in the event of a material breach of any term of the License Agreement which is not cured withing sixty (60) days following the written notice thereof. Additionally, after the first twelve (12) months following September 1, 2019, either party can terminate the License Agreement by giving the other party one hundred twenty (120) days' notice.

Further, Visual Health can terminate the License Agreement, by giving written notice to the Company to cure any of the following within 30 days and declare the total amount, or any portion thereof, due under the License Agreement payable immediately, (i) the Company fails to pay any amount due under the License Agreement within thirty (30) days of its due date or the Company or (ii) violates, breaches or details in performing any material requirement or obligation under the License Agreement or any representation in the License Agreement by the Company is inaccurate and such inaccuracy continues uncured for thirty (30) days after receiving notice thereof. The Company can terminate the License Agreement, any time if (i) the Company reasonably determines that the Visual Intellectual Property infringes on any copyright, rights of privacy or publicity of any third parties and such infringement is not cured within thirty (30) days after receiving notice thereof or (ii) Visual Health breaches any material terms of the License Agreement.

Pursuant to the License Agreement, the Company and Visual Health each agreed to indemnify the other party against all claims, liabilities and costs, including reasonable attorney's fees, incurred in defense of any claim brought against them by a third party alleging (1) that the Visual Health Intellectual Property infringes or misappropriates any patent, copyright, trademark, trade secret or other proprietary rights of any third party (2) resulting from a breach by a party of any of its representations and warranties under the License Agreement, provided that the party promptly notifies the other party in writing of any such claim and the indemnifying party is permitted to control fully the defense of such claim or (3) bodily injury, death of any person, or damage to real or tangible personal property resulting from a party's acts or omissions.

A copy of the License Agreement is filed as Exhibit 10.2 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

***License Agreement with Merck & Co.***

 

On September 30, 2020, the Company entered into a License Agreement (the "Merck License Agreement") with Merck & Co. ("Merck"), pursuant to which Merck agreed to grant the Company a non-exclusive license (the "Merck License") to use Merck's patent, copyright and other rights related to Merck's executable, object-code versions of certain software and/or content identified in the Merck License Agreement, together with all updates, corrections, and new versions thereof, and any users manuals or other materials that describe or explain the functionality and operability of the foregoing (referred to together as the "Merck Content"), to provide to the Company's North American based costumers web access to the Merck Content in conjunction with the Company's products.

Pursuant to the Merck License Agreement, the Company has sole and exclusive discretion concerning the marketing and distribution of the Merck Content so long as it is not monetized. Pursuant to the Merck License Agreement, the Company may use Merck's name, logos and proprietary images in an appropriate manner, in reference to Merck Content, until the termination of the Merck License Agreement. Additionally, pursuant to the Merck License Agreement, the Company is required to add a specific Merck proprietary rights notice, as set forth in the Merck License Agreement, when incorporating the Merck Content into its offerings. Pursuant to the Merck License Agreement, Merck must be notified of and approve all material before the Company releases any products incorporating the Merck Content and the Company agreed to provide Merck with user account access to the Company's website for review purposes.

As set forth in the Merck License Agreement, Merck is offering this free service of granting the License to the Company for the benefit of healthcare providers and patients and in exchange the Company will promote the "Merck Manual," which is part of the Merck Content as an offering to their users. A descriptive blurb of the Merck Manual (with the right of the Merck to adjust the description up to 4 times per calendar year) will be listed on the Company's website in the appropriate area to advertise that is it available. The Company agreed to at Merck's request, provide a quarterly report that includes usage statistics, plus the number of overall subscribers to Merck. The Company may not charge any of its customers for any Merck Content. If the Company imposes any charges related to the Merk Content, Merck can unilaterally terminate the Merck License Agreement.

The term of the Merck License Agreement is for two (2) years from September 30, 2020, and unless terminated, will be renewed for subsequent one (1) year periods upon written notice provided by Merck of its intention to renew the Merck License Agreement at least ninety (90) days prior to the termination date of the current term (including any renewals). The Merck License Agreement can be terminated any time by mutual agreement of the parties, and each party may terminate the Merck License Agreement immediately upon giving written notice of termination to the other party upon the occurrence of any of the following events: (i) the other party fails to cure a breach of the License Agreement committed by it within ninety days (90) after receiving written notice thereof, (ii) the other party institutes proceedings under bankruptcy or insolvency laws, for corporate reorganization, receivership, dissolution or similar proceedings, (iii) proceedings under bankruptcy or insolvency laws, for corporate reorganization, receivership, dissolution or similar proceedings are pending against the other party for more than ninety (90) days, (iv) the other party makes a general assignment for the benefit of creditors, (v) the other party becomes insolvent, or (vi) either party ceases to conduct business or to conduct the business relevant under the Merck License Agreement. Upon any termination of the Merck License Agreement, the Company must cease providing access to the Merck Content and incorporating the Merk Content into its products.

Additionally, pursuant to the Merck License Agreement, each the Company and Merck agreed to defend, indemnify and hold harmless the other party from and against any and all third-party claims, actions, causes of action, liabilities, damages, costs and expenses, including attorneys' fees, arising out of or related to any facts or alleged facts which, if true, would constitute a breach of such party's representations and warranties in the Merck License Agreement.

A copy of the Merck License Agreement is filed as Exhibit 10.3 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

 

***Non-exclusive License Agreement with the Regents of the University of California***

On August 16, 2021, the Company entered into a License Agreement (the "UCSF License Agreement") with the Regents of the University of California acting on behalf of the University of California San Francisco and through the Office of Technology Management & Advancement ("UCSF"), pursuant to which UCSF agreed to grant the Company a non-exclusive license (the "UCSF License") to use UCSF's websites and subdirectories designated as "PREPARE" on the Company's Platform, subject to the terms of the UCSF License Agreement, and additionally the UCSF License cannot be sub-licensed. Pursuant to the UCSF License Agreement, the Company agreed that the UCSF License can only be used to offer PREPARE as a patient content option for healthcare providers registered with the Company and the Company is not permitted to modify the source site specifications of PREPARE as set forth in the UCSF License Agreement, without the prior written consent of UCSF. The Company is also required to seek prior written approval from UCSF for any written descriptions of PREPARE appearing on the Company's websites and wherever the Company references PREPARE.

Pursuant to the UCSF License Agreement, the Company agreed to maintain its website in accordance with industry standards and to provide UCSF, on a quarterly basis with agreed upon metrics, such as, but not limited to, the number and organization type of all practice accounts that use PREPARE, the number and type of all clinician accounts that use PREPARE, the number of patients who are assigned/prescribed/utilize PREPARE per clinician and practice account, and any other available metrics and feedback regarding PREPARE that can be shared under applicable law. Additionally, pursuant to the UCSF License Agreement, the Company is required to add a specific UCSF proprietary rights notice, as set forth in the UCSF License Agreement, when using PREPARE.

Pursuant to the UCSF License Agreement, the Company agreed to pay UCSF earned royalties, of initially $20 per clinician account and practice account per month, subject to change by UCSF, with each clinician account and practice account being limited to 300 prescriptions of PREPARE per month (the "Earned Royalties"). Pursuant to the UCSF License Agreement, the Earned Royalties are nonrefundable and non-cancelable and are required to be paid by the Company to UCSF quarterly within sixty (60) days after the end of each calendar quarter and the Company is responsible for all bank or other transfer charges for such payment. If any amounts owed to UCSF under the UCSF License Agreement are not received when due, the Company will pay interest charges at a rate of ten percent (10%) per annum. For larger scale healthcare related organizations that require ongoing management by the Company, if there is a need for PREPARE materials, the Company will contact UCSF with prospective account information for specific pricing guidance.

The term of the UCSF License Agreement is for two (2) years from August 16, 2021. The UCSF License Agreement can be terminated at any time by either party by giving thirty (30) days prior written notice to the other party. The UCSF License Agreement can also be terminated by UCSF by giving the Company five (5) days written notice if the Company fails to perform or violates any term of covenant of the UCSF License Agreement.

 

Pursuant to the UCSF License Agreement, the Company agreed to indemnify and hold harmless and release and forever discharge, UCSF, by reason of any damage, or other consequences arising or resulting directly or indirectly from the UCSF License and occurring at any time subsequent to such grant of the UCSF license, including but not limited to, any use of PREPARE, that is not authorized under the UCSF License Agreement.

 ****

A copy of the License Agreement is filed as Exhibit 10.4 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

 ****

***Memorandum of Understanding with Patients for Patient Safety United States***

On December 17, 2021, the Company entered into a Memorandum of Understanding (the "MOU") with Patients for Patient Safety US ("PFPS"), which sets forth the preliminary understandings under which the Company and PFPS will work as organization partners to pursue the goals of PFPS, with the Company becoming an organization partner of PFPS. PFPS is a program of the World Health Organization (WHO) and is an international network of patient safety advocates established by the WHO in 2004 to raise awareness about avoidable harm in healthcare and advance the improvement of patient safety in every nation on earth. Pursuant to the MOU, the Company and PFPS, agreed to act in good faith in their cooperative dealings with one another in the pursuit of the PFPS's goals of raising awareness of avoidable harm in healthcare.

Pursuant to the MOU, PFPS agreed to consult the Company in the development of specific implementation positions, proposals or actions taken by PFPS. The MOU creates no obligation on the part of the Company to fund PFPS. Pursuant to the MOU, it is anticipated that PFPS work will be done by working groups that include people who work for or represent PFPS which will report on their work to PFPS, and the Company as an organizational partner of PFPS through email, conference calls, virtual meetings or in person meetings.

Pursuant to the MOU, the Company as an organization partner of PFPS, will be asked to allow the use of their organization's name and logo in PFPS materials, however, no logo will be used without receiving express written consent of the Company. The Term of the MOU is from December 17, 2021 until December 31, 2022 and is subject to renewal at that time by the parties. The Company is free to leave PEPS at any time as an organization partner.

A copy of the MOU is filed as Exhibit 10.5 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

 ****

***Master Services Agreement with AbbVie Corporation and Amendment Thereto***

On December 9, 2021, the Company entered into a Master Services Agreement (the "MSA") with AbbVie Corporation ("AbbVie") pursuant to which the AbbVie retained the Company to provide the Company's technology platform as a white labeled SAAS to AbbVie on a task-by-task basis and on the terms and conditions set forth in the MSA and in accordance with each applicable statement of work or purchase order under the MSA. The types of services to be provided by the Company to AbbVie under the MSA include the use of the Company's online Platform and development services as needed.

As compensation for the Company's services under the MSA, AbbVie agreed to pay the Company, in accordance with the budget described in each applicable statement of work or purchase order, which may be amended from time to time by both parties in writing. AbbVie will not be obligated to pay any broker's or booking commissions in connection with the services provided by the Company under the MSA. Under the MSA the Company will provide AbbVie with a detailed invoice setting forth services and expenses, and payment by AbbVie will be made within ninety (90) days of AbbVie's receipt of the invoice. AbbVie also agreed to pay for transportation expenses, as approved by AbbVie in advance, incurred by the Company while providing services under the MSA.

The term of the MSA is for an initial period of two (2) years from December 9, 2021, and automatically renews for a one (1) time renewal of two (2) years, unless AbbVie provides the Company with ninety (90) days written notice of its intent not to renew the MSA prior to the expiration of the initial term. Additionally, the Company and AbbVie can extend the term of the MSA by mutual written agreement. AbbVie can terminate the MSA at any time without cause by giving the Company thirty (30) days prior written notice. AbbVie can also suspend any of the deliverables associated with a statement of work or purchase order upon twenty four (24) hours prior written notice to the Company. AbbVie can terminate the MSA immediately by written notice to the Company, if AbbVie concludes, in its sole discretion, that (i) the Company materially breached certain sections of the MSA, or that such a breach is substantially likely to occur, (ii) the Company has provided any materially false or misleading information to AbbVie in connection with the MSA, (iii) the Company does not consent to an inspection and audit required by the MSA or fails to provide access or information to AbbVie's satisfaction or (iv) the Company declines to implement corrective or remedial action that AbbVie requires pursuant to the MSA.

The Company and AbbVie can terminate the MSA, or any purchase order or statement of work thereunder if either party defaults under the MSA (i) by giving written notice to the defaulting party of the default and if such default is not cured within thirty (30) days after the non-defaulting party provides notice reasonably detailing such failure, (ii) by giving written notice if the other party becomes the subject of a voluntary petition in bankruptcy or any similar proceeding that not dismissed within sixty (60) days of filing and (iii) immediately in the event of a statutory, judicial, regulatory or administrative ruling or interpretation by Health Canada or any other governmental or regulatory authority which makes it impossible or commercially impracticable to continue a statement of work or purchase order under the MSA, as determined in AbbVie's sole discretion. Any termination of expiration of the MSA will not affect any rights or obligations under the MSA which have accrued prior thereto. In the event of premature termination of the MSA, AbbVie shall pay the Company for services performed under the MSA on a prorated basis and for any and all reasonable expenses incurred by the Company through the date of termination, however, in no event will such amount exceed the amount that would have been payable to the Company, had the MSA not been terminated.

Pursuant to the MSA, the Company agreed to indemnify AbbVie against all breaches of the MSA by the Company and any other claims, actions, damages, liabilities, and expenses (including reasonable attorney's fees and costs) arising out the Company's negligence or willful misconduct in it performance of the services, or infringement of third party rights relating to AbbVie's use of the Company's Platform and AbbVie agreed to indemnify the Company against all breaches of the MSA by AbbVie and other claims, actions, damages, liabilities, and expenses (including reasonable attorney's fees and costs) arising out AbbVie's negligence or willful misconduct in the performance of its obligations under the MSA.

A copy of the MSA is filed as Exhibit 10.6 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

On March 4, 2022, the Company entered into an amendment (the "Amendment") to the MSA, pursuant to which the data classification category under the MSA was revised from "internal use" to "secret," with no other amendments to the MSA being made therein.

A copy of the Amendment is filed as Exhibit 10.7 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

***Collaborative Agreement with Sano Genetics Limited***

On August 2, 2022, the Company entered into a Collaborative Agreement (the "Collaborative Agreement") with Sano Genetics Limited ("Sano"), pursuant to which the Company and Sano agreed to work together to use one another's expertise to identify and screen individuals for clinical trial opportunities, and with the Company specifically agreeing to provide Sano with access to potential research participants (the "Services"). Pursuant to the Collaborative Agreement Sano will provide the Company with criteria for recruiting participants into the research project and provide the platform for analyzing participant genomic, medical, survey, or other data to check for potential eligibility.

Pursuant to the Collaborative Agreement, the Company will submit its invoices for fees and allowable expenses monthly in arrears for the Services it provides to Sano, and Sano will pay the Company's invoice within thirty (30) days after the date Sano receives payment from the subject client of the invoice (the "Fees"). The Fees are in respect of each participant introduced by the Company who meets all of the success criteria specified by Sano. If a participant does not meet the success criteria specified by Sano for a project in which the relevant participant was first introduced by the Company but does meet the success criteria specified by Sano of a subsequent project which the Company is working on for Sano under the Collaboration Agreement, Sano will pay the Fees to the Company for the subsequent project, so long as it was completed within two (2) years of the first project at issue.

Pursuant to the Collaborative Agreement, neither party will be liable for any loss of profits, loss of business, depletion of goodwill, or any special, indirect or consequential loss or damage and each party's total aggregate liability to the other under will be limited to the total Fees paid by Sano in respect of a certain project at issue.

There is no set term in the Collaborative Agreement, and no termination provisions included therein.

A copy of the Collaborative Agreement is filed as Exhibit 10.8 to the registration statement of which this prospectus forms a part and is incorporated by reference herein.

**Corporate Information**

Our principal executive offices are located at 801 W. Bay Drive, Suite 506, Largo, Florida 33770, and our telephone number is (888) 981-8111. Our website addresses are Https://www.doco.la and Https://www.docola.com. The information contained on our websites is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our websites as part of this prospectus or in deciding whether to purchase our securities.

**REGULATORY**

We are subject to various federal, state and local laws and regulations, compliance with which increases our operating costs, limits or restricts the services and products provided by us. Noncompliance with these laws and regulations can subject us to fines or various forms of civil or criminal prosecution, any of which could have a material adverse effect on our reputation, business, financial position, results of operations and cash flows.

**Regulatory Environment**

Participants in the healthcare industry are required to comply with extensive and complex laws and regulations in the United States at the federal and state levels as well as applicable international laws. Similarly, there are a number of legislative proposals in the Unites States, both at the federal and state level, which could impose new obligations in areas affecting our business. We have attempted to structure our operations to comply with applicable legal requirements, but there can be no assurance that our operations will not be challenged or impacted by enforcement initiatives.

**Healthcare Reform**

Our business could be affected by changes in healthcare laws, including without limitation, the Patient Protection and Affordable Care Act (the "ACA"), which was enacted in March 2010. The ACA has changed how healthcare services are covered, delivered and reimbursed through expanded coverage of individuals, changes in Medicare program spending and insurance market reforms. Ongoing government and legislative initiatives may bring about other changes.

While most of the provisions of the ACA and other healthcare reform legislation will not be directly applicable to us, they may affect the business of many of our users and customers, which may in turn affect our business. Although we are unable to predict with any reasonable certainty or otherwise quantify the likely impact of the ACA, any amendment or repeal of the ACA, or other healthcare reform on our business model, financial condition, or results of operations, negative changes in the business of our customers and the number of individuals they insure may negatively impact our business.

**Requirements Regarding the Privacy and Security of Personal Information**

***U.S.- HIPAA and Other Privacy and Security Requirements***

 ****

There are many U.S. federal and state laws and regulations related to the privacy and security of personal health information. In addition, under the Health Insurance Portability and Accountability Act of 1996 and its regulations (collectively, "HIPAA"), establishes privacy and security standards that limit the use and disclosure of protected health information and require the implementation of administrative, physical and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form. The healthcare providers who use our Platform are regulated under HIPAA. The Health Information Technology for Economic and Clinical Health Act ("HITECH"), which became effective on February 17, 2010, significantly expanded HIPAA's privacy and security requirements. Among other things, HITECH makes HIPAA's privacy and security standards directly applicable to "business associates," who are independent contractors or agents of covered entities that create, receive, maintain, or transmit protected health information in connection with providing a service for or on behalf of a covered entity. Under HIPAA and our contractual agreements with our users and customers, we are considered a "business associate" to our customers and thus are directly subject to HIPAA's privacy and security standards. In order to provide our covered entity customers with services that involve the use or disclosure of protected health information, HIPAA requires our customers to enter into business associate agreements with it. Such agreements must, among other things, require us to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·limit how we will use and disclose the protected health information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·implement reasonable administrative, physical and technical safeguards to protect such information from misuse;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·enter into similar agreements with our agents and subcontractors that have access to the information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·report security incidents, breaches and other inappropriate uses or disclosures of the information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·assist the customer in question with certain duties under the privacy standards.

In addition to HIPAA regulations, we may be subject to other state and federal privacy laws, including laws that prohibit unfair or deceptive practices and laws that place specific requirements on use of data. Such state laws can be similar to or even more protective than HIPAA, in which case we must comply with the more stringent law. As a result, it may be necessary to modify our planned operations in order to ensure we are in compliance with the stricter state laws.

***Data Protection and Breaches***

 

In recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of individuals' personal information. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals and state officials. In addition, under HIPAA, we must report breaches of unsecured protected health information to our contractual partners within 60 days of discovery of the breach. Notification must also be made to the U.S. Department of Health and Human Services ("HHS") and, in certain circumstances involving large breaches, to the media. Under the General Data Protection Regulation ("GDPR"), the data controller is required to report personal data breaches to the supervisory authority within 72 hours of discovery of the breach.

We have implemented and maintained physical, technical and administrative safeguards intended to protect all personal data,and have processes in place to assist it in complying with all applicable laws, regulations and contractual requirements regarding the protection of these data and properly responding to any security breaches or incidents. However, we cannot be sure that these safeguards are adequate to protect all personal data or to assist us in complying with all applicable laws and regulations regarding the privacy and security of personal data and responding to any security breaches or incidents. Furthermore, in many cases, applicable state laws, including breach notification requirements, are not preempted by the HIPAA privacy and security standards and are subject to interpretation by various courts and other governmental authorities, thereby complicating our compliance efforts. Additionally, state and federal laws regarding deceptive practices may apply to public assurances we give to individuals about the security of services we provide on behalf of our contractual customers.

***Other Healthcare Regulations***

In addition to data privacy laws, our operations and arrangements with healthcare professionals who use our Platform may subject us to various federal and state healthcare laws and regulations, including without limitation fraud and abuse laws, such as the federal Anti-Kickback Statute; civil and criminal false claims laws; physician transparency laws; and state laws regarding the corporate practice of medicine and fee-splitting prohibitions. These laws may impact, among other things, our sales and marketing operations, and our interactions with healthcare professionals. We continually monitor legislative, regulatory and judicial developments related to licensure and engagement arrangements with professionals; however, new agency interpretations, federal or state legislation or regulations, or judicial decisions could require us to change how we operate, may increase our costs of services and could have a material adverse impact on our business, results of operations or financial condition.

***Other Requirements***

In addition to HIPAA, numerous other U.S. state and federal laws govern the collection, dissemination, use, access to and confidentiality of individually identifiable health information and healthcare provider information. Some states also are considering new laws and regulations that further protect the confidentiality, privacy and security of medical records or other types of medical information. In many cases, these state laws are not preempted by the HIPAA privacy standards and may be subject to interpretation by various courts and other governmental authorities. Further, Congress and a number of states have considered or are considering prohibitions or limitations on the disclosure of medical or other information to individuals or entities located outside of the United States.

**Employees**

As of January 23, 2023, we have 1 full-time employee and 5 regular contractors.

**Legal Proceedings**

From time to time, we are involved in various legal proceedings arising from the normal course of business activities. We are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

**COVID-19**

A pandemic outbreak of novel strains of coronavirus (COVID-19) has occurred across the globe and efforts to mitigate the health impact of the pandemic have profoundly and adversely affected economic activity. National, state and local governments have taken actions to mitigate the impact of the COVID-19 pandemic in a variety of ways, including by declaring states of emergency, issuing stay-at-home orders and ordering certain businesses to close or limit their operations. Due to the digital/remote nature of the Company's business, COVID-19 has had, and is expected to have, only positive effects on the Company's operations since more patients and healthcare providers have switched to remote consultations and visits since the start of the COVID-19 pandemic, which lead to an increased use of the Company's Platform. Additionally, in the U.S., the Centers for Medicare and Medicaid Services ("CMS") has extended physicians' fees for telehealth use in certain specialties until December 2023. CMS has also amended rules and regulations to increase access to healthcare via remote services. We believe that this may present a potential opportunity for the Company to sign on new clients in these specific specialties. Notwithstanding the foregoing, the long-term financial impact of coronavirus on the Company cannot be reasonably estimated at this time and may ultimately have a material adverse impact on our business, financial condition, and results of operations.

The COVID-19 pandemic has also resulted in material adverse national and global economic conditions that. Such conditions may result in an economic recession or prolonged economic downturn, which could result in a material loss of business for the duration of the downturn. Actions taken to mitigate the pandemic and resulting economic conditions are likely to materially and adversely impact our business, financial condition, results of operations and cash flows. The COVID-19 pandemic has also resulted in severe disruption and volatility in the financial markets. Depending on the extent and duration of the COVID-19 pandemic, the price of our common stock may experience declines and volatility which may negatively impact our ability to raise capital through the equity markets if necessary to increase our liquidity.

**MANAGEMENT**

The following table sets forth the names, positions and ages of our directors and executive officers as of the date of this Offering Circular. Our directors are elected by our stockholders at an annual meeting of the stockholders and serve until their successors are elected and qualified. Officers are elected by our board of directors and their terms of office are at the discretion of our board.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Eran Kabakov | 48 | Chief Executive Officer, President and <br> Chairman of the Board of Directors |
| Itay Tsabari | 48 | Chief Financial Officer |
| Tomer Kabakov | 54 | Chief Operating Officer and Director |
| Jonathan Ascher | 52 | Chief Medical Officer |
| Geri Lynn Baumblatt | 52 | Chief Engagement Officer |
| Alexander Ellis | 36 | Chief Technology Officer |

---

***Eran Kabakov.*** Eran Kabakov, DPT, PT is the founder and CEO of Docola, and has served as the CEO, President and Chairman of the Board of Directors of the Company since September 5, 2013. Dr. Kabakov has also served as the Owner of, and a practicing physical therapist at Concierge Physical Therapy, Largo FL from 2016 to the present. Dr. Kabakov is a healthcare provider, digital health innovator, entrepreneur, and public speaker. From 2016 to present, Dr. Kabakov worked at Concierge Physical Therapy where he served as Owner and Physical Therapist. From January 2016 to September 2013, he worked at Info-Surge Inc. where he served as Founder and CEO. From October of 2004 to June of 2010, Dr. Kabakov worked at PhysAbility where he served as Owner and Physical Therapist. Early in his career Dr. Kabakov recognized a growing communication chasm between providers and patients. To solve this issue, Dr. Kabakov has been designing web-based care-communication platforms since 2001. Dr. Kabakov received a Paramedic Instructor certificate from the Israel Defense Force School of Medicine in 1993 and graduated with a degree in Massage Therapy in 1991. Dr. Kabakov graduated from the State University of New York at Buffalo with a Bachelor's Degree in Physical Therapy in May 2001. Dr. Kabakov graduated from the University of Montana with a Doctorate of Physical Therapy in May 2022. Dr. Kabakov brings knowledge and experience in the healthcare and Digital Health industries and we believe that his experience in the Digital Health market will help Docola to achieve market-product fit. Dr. Kabakov does not hold, and has not previously held, any directorships in any reporting companies.

The Company believes Mr. Kabakov's professional experience qualifies him to serve on its board of directors.

 ****

***Itay Tsabari.*** Itay Tsabari, CPA, has served as our Chief Financial Officer since January 1, 2022, and is a veteran financial professional. From September 2007 to March 2012, Mr. Tsabari worked at Motorola Mobility Israel, where he served as finance manager leading the integration of BitB and into Motorola Inc. post-acquisition. From October 2012 to July 2015, he worked at Mitrelli where he served as Commercial and Finance Manager. From February 2015 to January 2019, Mr. Tsabari served as the Chief Financial Officer of Zemingo LTD. From January 2019 to the present, Mr. Tsabari serves as the Chief Financial Officer of Copilot.Cx.<br>Mr. Tsabari received his Bachelor's Degree in Business Administration and Accounting in June 2001 from The College of Management in Tel-Aviv Israel and received his Master's Degree in Business Administration in June 2005 from Tel Aviv University. Mr. Tsabari also holds a license as a CPA from the Israel Auditors' Council (Israeli Ministry of Justice) which was issued in February of 2003 and has no expiration date.<br>Mr. Tsabari brings knowledge and experience in the business administration and finance industries and we believe that this experience in the financial market can help Docola with budgeting, financial reporting, and regulatory compliance.<br>Mr. Tsabari does not hold, and has not previously held, any directorships in any reporting companies.

 ****

***Tomer Kabakov.*** Tomer Kabakov has served as the Company's COO, Director and Chief Medical Officer since September 5, 2013. From 2014 to the present, Mr. Kabakov has served as the Founder of Tomer Ventures Ltd/. in Hibat Zion Israel where he manages the day to day activities and provides sales and marketing services. Additionally, from 2011 to the present, Mr. Kabakov serves as the Vice President of Sales, Marketing and Business Development at Advanced Semiconductor Technology where he has Overall responsibility for the company sales and marketing activities in Israel, Europe and USA. Mr. Kabakov is an experienced executive with over 25 years experience in sales, marketing, international business development with a focus on EMEA. Tomer has been involved in multiple start-ups in digital health and semiconductors market. Mr. Kabakov received a Bachelor's Degree in Business Administration from the Ruppin Academic Center in Emek-Hefer Israel in 2009. Additionally, Mr. Kabakov studied Software Engineering from at the College of Management in Haifa Israel in 1997 and Naturopathy at the Israeli College of Natural medicine in 1993. Mr. Kabakov is a graduate of Ruppn Academic Center with a B.A. in business administration in May 2008. Mr. Kabakov does not hold, and has not previously held, any directorships in any reporting companies

The Company believes Mr. Kabakov's professional experience qualifies him to serve on its board of directors.

***Geri Lynn Baumblatt.*** Geri Lynn Baumblatt, MA, has served as our Chief Engagement Officer since December 20, 2019. She brings over 20 years of experience working with patients, family caregivers, medical animators, behavioral and decision scientists, researchers, and clinicians to create a large range of print and multimedia resources for patient education, engagement, shared decision making, behavior change, care transitions, chronic condition management, and preventive care. These resources have been shown to reduce hospital readmissions, patient anxiety, procedure no-shows, procedure time, and length of stay, and improved patient understanding and engagement, The resources have also won Freddie Awards, the IHA Health Literacy Award, the Frank Netter Award, Clear Mark Plain Language Awards, and the 4th Annual Leonard G. Doak Health Literacy Innovator Award. From 2003 to 2017, Ms. Baumblatt worked at Emmi Solutions where she served in multiple roles, including senior writer and content developer, editorial director, and executive director of patient engagement, where she oversaw the research and development of all patient engagement content. She also frequently partners on and published patient engagement and health outcomes research. She was the sole multimedia expert on AHRQ's Patient Education Materials Assessment Tool, and currently serves on the Patient Centered Outcomes Research Institute's (PCORI) Patient Engagement Panel. From 2017 to the present, Ms. Baumblatt has been the principal at Atriculations Consulting, where she provides services around patient, family and clinician communication, engagement, health literacy, and interaction design. Ms. Baumblatt received her Bachelor's Degree in Literature from Wheaton College in May 1991 and her Master's Degree in Literature and Writing from the University of Denver in May 1995. Ms. Baumblatt brings knowledge and experience in the patient education and health tech industries. She's considered both an industry leader and patient advocate, has spoken at over 100 events, and has a large network. We believe her experience in the patient education and engagement market will help Docola develop business relationships as well as its patient education content library. Ms. Baumblatt does not hold, and has not previously held, any directorships in any reporting companies.

***Jonathan Ascher.***

Jonathan Ascher, MD, has served as our Chief Medical Officer since May 1, 2020. From 2008 to the present, Dr. Ascher has served as the President of East Manhattan Anesthesia Partners and as Director of the Anesthesia department at New York Eye and Ear Infirmary. Dr. Ascher received his Bachelor's Degree from Washington University in 1992 and then received his degree as a Medical Doctor from the University of Miami School of Medicine in 1998. He completed his Anesthesiology residency at Columbia University Medical Center. Dr. Ascher brings knowledge and experience in the healthcare industry and we believe that his experience in the healthcare market can help Docola to achieve market-product fit and regulatory compliance. Dr. Ascher does not hold, and has not previously held, any directorships in any reporting companies.

***Alexander Ellis***. Alexander Ellis has served as our Chief Technology Officer since January 11, 2019 and is an experienced computer programmer and web developer. Mr. Ellis previously served as the Company's Head of Development from 2016 to 2018. From 2014 to the present, Mr. Ellis serves as the Founder and Chief Executive Officer of Pineapple-Lab where he oversees and runs a web development studio. Mr. Ellis studied computer engineering at the Universidad O.R.T. Uruguay until September 2016. Mr. Ellis brings knowledge and experience in the IT and computer programming industries and we believe that his experience in the computer programming market can help Docola with research and development for the Platform. Mr. Ellis does not hold, and has not previously held, any directorships in any reporting companies.

  ****

<br> **Board Committees and Director Independence**

Prior to this offering, there has been no public market for our common stock. Our common stock is not currently listed on any national securities exchange market or quoted on the OTC Markets. We intend to apply to list our common stock on the Nasdaq Capital Market. In order to list our common stock on the Nasdaq Capital Market, we are required to comply with the Nasdaq Capital Market standards relating to corporate governance, requiring, among other things, that:

● A majority of our Board of Directors to consist of "independent directors" as defined by the applicable rules and regulations of the Nasdaq Capital Market;

● The compensation of our executive officers to be determined, or recommended to the Board of Directors for determination, by independent directors constituting a majority of the independent directors of the Board in a vote in which only independent directors participate or by a Compensation Committee comprised of at least two independent directors as well as composed entirely of independent directors;

● That director nominees to be selected, or recommended to the Board of Directors for selection, by independent directors constituting a majority of the independent directors of the Board in a vote in which only independent directors participate or by a nomination committee comprised of at least two independent directors as well as composed entirely of independent directors; and

● Establishment of an audit committee with at least three independent directors as well as composed entirely of independent directors, where at least one of the independent directors qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rules.

Under applicable rules of the Nasdaq Capital Market, a director will only qualify as an "independent director" if, in the opinion of the listed company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. For purposes of the audit committee composition requirements, we must have at least one independent director on our audit committee at the time of listing on the Nasdaq Capital Market, at least two independent directors within 90 days of listing on the Nasdaq Capital Market and at least three independent directors within one year of listing on the Nasdaq Capital Market, where at least one of the independent directors qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rule. In accordance with Rule 5615(b)(1), since we are listing in connection with our initial public offering, we are permitted to phase in our compliance with the independent committee requirements set forth in Rules 5605(d)(2) (for purposes of the compensation committee) and Rules 5605(e)(1)(B) (for purposes of the nominating committee) on the same schedule as we are permitted to phase in our compliance with the independent audit committee requirement pursuant to Rule 10A-3(b)(1)(iv)(A) under the Act. Accordingly, we are permitted to phase in the compensation committee and nominating committee composition requirements as follows: (1) one member must satisfy the independence requirement at the time of listing; (2) a majority of members must satisfy the independence requirement within 90 days of listing; and (3) all members must satisfy the independence requirement within one year of listing. Furthermore, a Company listing in connection with its initial public offering shall have twelve months from the date of listing to comply with the majority independent board requirement in Rule 5605(b). The foregoing is referred to herein as the "Independence Composition Requirements."

Our Board of Directors has affirmatively determined that we do not have any independent directors at this time. Prior to listing on the Nasdaq Capital Market, we will appoint three independent directors to the Board of Directors, including _______, ________ and _________ and the Board of Directors will appoint three independent directors to the audit committee, including ________, ________ and _________. Mr. ________ shall serve as the chair of the audit committee. Mr. ______ qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rules.

**Committees of the Board of Directors**

***Audit Committee*** 

We will establish an audit committee ("Audit Committee") prior to listing on the Nasdaq Capital Market, which shall consist of three independent directors, namely ________, ________ and _________. Mr. _____ shall serve as the chair of the Audit Committee. Mr. ______ qualifies as an audit committee financial expert under SEC rules and as a financially sophisticated audit committee member under the Nasdaq Capital Market rules. Our Audit Committee is expected to adopt a written charter, and following this offering, a copy of this charter will be posted on the Corporate Governance section of our website, at _________________________.

Our Audit Committee will be authorized to:

● approve and retain the independent auditors to conduct the annual audit of our financial statements;

● review the proposed scope and results of the audit;

● review and pre-approve audit and non-audit fees and services;

● review accounting and financial controls with the independent auditors and our financial and accounting staff;

● review and approve transactions between us and our directors, officers and affiliates;

● recognize and prevent prohibited non-audit services;

● establish procedures for complaints received by us regarding accounting matters; and

● oversee internal audit functions, if any.

  ****

***Compensation Committee***

We will establish a compensation committee prior to listing on the Nasdaq Capital Market, which shall consist of three directors who will be "independent" under the rules of the SEC, subject to the permitted "phase-in" period pursuant to the rules of the Nasdaq Capital Market.

This compensation committee would:

● review and determine the compensation arrangements for management;

● establish and review general compensation policies with the objective to attract and retain superior talent, to reward individual performance and to achieve our financial goals;

● administer our incentive compensation and benefit plans and purchase plans;

● oversee the evaluation of the Board of Directors and management; and

● review the independence of any compensation advisers.

Upon formation of a compensation committee, we would expect to adopt a compensation committee charter defining the committee's primary duties in a manner consistent with the rules of the SEC and Nasdaq Capital Market.

*Nominating and Corporate Governance Committee* 

We will establish a nominating and corporate governance committee prior to listing on the Nasdaq Capital Market, which shall consist of three directors who will be "independent" under the rules of the SEC, subject to the permitted "phase-in" period pursuant to the rules of the Nasdaq Capital Market.

The functions of the nominating and corporate governance committee, among other things, would include:

● identifying individuals qualified to become board members and recommending director;

● nominees and board members for committee membership;

● developing and recommending to our board corporate governance guidelines;

● review and determine the compensation arrangements for directors; and

● overseeing the evaluation of our board of directors and its committees and management.

Upon formation of a nominating and corporate governance committee, we would expect to adopt a nominating and corporate governance committee charter defining the committee's primary duties in a manner consistent with the rules of the SEC and the Nasdaq Capital Market.

Compensation Committee Interlocks and Insider Participation

None of our executive officers serve on the board of directors or compensation committee of a company that has an executive officer that serves on our board of directors. No member of our board is an executive officer of a company in which one of our executive officers serves as a member of the board of directors or compensation committee of that company.

**Code of Business Conduct and Ethics**

Prior to listing on the Nasdaq Capital Market, we will adopt a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The code of business conduct and ethics will be available at our website at www.doco.la. We expect that any amendments to the code, or any waivers of its requirement, will be disclosed on our website.

**Family Relationships**

Eran Kabakov, our Chief Executive Officer, President and Chairman of the Board, and Tomer Kabakov, our Chief Operating Officer and Director are brothers.

**Corporate Governance Guidelines**

Prior to listing on the Nasdaq Capital Market, our board of directors will adopt corporate governance guidelines in accordance with the corporate governance rules of the Nasdaq Capital Market. The corporate governance guidelines will be available at our website at www.doco.la. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities.

**Limitation on Liability and Indemnification of Officers and Directors**

Our certificate of incorporation, as amended, provides that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of any fiduciary duty as a director. If the General Corporation Law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware, as so amended.

Our bylaws, as amended, provides that the Company shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, suit, or proceeding, wherever brought, whether civil, criminal, administrative, or investigative (including an action by or in the right of the Company), by reason of such person's being or having been a Director, officer, member of a committee, employee, or agent of the Company, or by reason of such person's serving or having served at the request of the Company as a Director, officer, member of a committee, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys' fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit, or proceeding to the fullest extent allowable pursuant to and in accordance with the provisions of the Delaware General Corporation Law, as amended from time to time; provided, however, that in the event said Law shall be amended to increase or expand the permitted indemnification of persons provided for therein, the Company shall be deemed to have adopted such amendment as of its effective date and, provided further, that such indemnification shall be limited by other applicable law.

The effect of this provision of our certificate of incorporation, as amended, is to eliminate our rights and the rights of our stockholders (through stockholders' derivative suits on behalf of the Company) to recover damages against a director or officer for breach of the fiduciary duty of care as a director or officer (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined by statute. We believe that the indemnification provisions in our bylaws, as amended, are necessary to attract and retain qualified persons as directors and officers.

**The Board's Role in Risk Oversight**

Although our management is primarily responsible for managing our risk exposure on a daily basis, our board of directors oversees the risk management processes. Our board, as a whole, determines the appropriate level of risk for our Company, assesses the specific risks that we face, and reviews management's strategies for adequately mitigating and managing the identified risks. Although our board administers this risk management oversight function, our audit committee supports our board in discharging its oversight duties and addresses risks inherent in its area.

**EXECUTIVE COMPENSATION**

The following table summarizes all compensation recorded by us in the past two fiscal years ended December 31, 2022, for:

● our principal executive officer or other individual serving in a similar capacity, and

● our two most highly compensated executive officers, other than our principal executive officer, who received compensation exceeding $100,000 during the year ended December 31, 2022 and were serving as corporate officers as of December 31, 2022.

For definitional purposes, these individuals are sometimes referred to as the "named executive officers." No other executive officers received total compensation in excess of $100,000.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year <br> Ended** | **Salary**<br> **($)** | **Bonus**<br> **($)** | **Stock <br> Awards <br> ($)** | **Option**<br> **Awards**<br> **($) <sup>(1)</sup>** | **Plan <br> Compensation <br> ($)** | **All Other <br> Compensation <br> ($)** | **Total**<br> **($)** |
| Eran Kabakov <sup>(1)</sup> | 2022 |  | – |  | – |  |  |  |
| CEO | 2021 | 21340 | – |  | – |  |  | 21340 |
| Geri Lynn Baumblatt<sup>(2)</sup> | 2022 |  | – | 184062 | – |  | 21666 | 205728 |
| Chief Engagement Officer | 2021 |  | – |  | – |  | 119164 | 119164 |

---

(1) Eran Kabakov has served as the CEO, President and Chairman of the Board of Directors of the Company since September 5, 2013.

(2) Geri Lynn Baumblatt has served as the Company's Chief Engagement Officer since December 20, 2019.

**Outstanding Equity Awards at 2021 Fiscal Year-End**

None

**2021 Option Exercises and Stock Vested Table**

None

**Executive Officer and Director Compensation**

The Company intends to develop an executive compensation program that is consistent with its existing compensation policies and philosophies, which are designed to align compensation with our business objectives and the creation of stockholder value, while enabling us to attract, motivate and retain individuals who contribute to the long-term success of the Company.

Decisions on the executive compensation program will be made by the board of directors. The following discussion is based on the present expectations as to the executive compensation program to be adopted by the board of directors. The executive compensation program actually adopted will depend on the judgment of the members of the board of directors and may differ from that set forth in the following discussion.

We anticipate that decisions regarding executive compensation will reflect our belief that the executive compensation program must be competitive in order to attract and retain our executive officers. We anticipate that the compensation committee will seek to implement our compensation policies and philosophies by linking a significant portion of our executive officers' cash compensation to performance objectives and by providing a portion of their compensation as long-term incentive compensation in the form of equity awards.

We anticipate that compensation for our executive officers will have three primary components: base salary, an annual cash incentive bonus and long-term incentive compensation in the form of share-based awards, if any.

***Base Salary***

Our compensation committee will determine base salaries and manage the base salary review process, subject to existing employment agreements.

***Annual Bonuses***

We intend to use annual cash incentive bonuses for the executive officers to tie a portion of their compensation to financial and operational objectives achievable within the applicable fiscal year. We expect that, near the beginning of each year, the compensation committee will select the performance targets, target amounts, target award opportunities and other term and conditions of annual cash bonuses for the executive officers, subject to the terms of any employment agreement. Following the end of each year, the board of directors will determine the extent to which the performance targets were achieved and the amount of the award that is payable to the executive officers. No bonuses were awarded by the board of directors in 2022 or 2021.

***Stock-Based Awards***

We intend to use stock-based awards to reward long-term performance of the executive officers. We believe that providing a meaningful portion of the total compensation package in the form of stock-based awards will align the incentives of its executive officers with the interests of its stockholders and serve to motivate and retain the individual executive officers. Stock-based awards will be awarded under the Incentive Plan, which has been adopted by our Board of Directors and is being submitted to our shareholders for approval at the special meeting in lieu of an annual meeting.

**Executive Employment Agreements**

None.

**Director Compensation**

We did not pay any compensation or make any equity awards or non-equity awards to any of our directors during fiscal years ended 2022 and 2021. Directors may be reimbursed for travel and other expenses directly related to their activities as directors.

Prior to the effectiveness of the registration statement of which this prospectus forms a part, we did not have a formal policy to compensate our non-employee directors. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to implement a formal policy pursuant to which our non-employee directors will be eligible to receive the following cash retainers and equity awards.

Our policy will provide that each non-employee director elected to our board of directors after the effectiveness of this registration statement of which this prospectus forms a part, upon initial election to our board of directors, will be compensated as follows:

● Each director will be paid the sum of $______ annually for director's service as a director of the Company, to be paid $_________ each calendar quarter, payable within 5 business days of the end of each calendar quarter, and with such amount for any partial calendar quarter being appropriately prorated.

● Each director shall be paid $_____ annually for service as a member of the Audit Committee and an additional sum of $___________ annually for service as the Chairman of the Audit Committee, with each of these payments to be paid quarterly in equal portions, within 5 business days of the end of each calendar quarter, and with any amount for any partial calendar quarter being appropriately prorated.

The Company will reimburse the applicable director for all reasonable out-of-pocket expenses incurred by the applicable director in attending any in-person meetings, provided that the applicable director complies with the generally applicable policies, practices and procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as compared to out-of-pocket expenses of the applicable director in excess of $500.00) must be approved in advance by the Company.

**Equity Incentive Plans** 

***Docola, Inc. 2022 Equity Incentive Plan***

On December 22, 2022, our board of directors approved the Docola, Inc. 2022 Equity Incentive Plan (the "Plan"). Stockholders of the Corporation holding a majority of the voting power of the Corporation undertook an action by written consent in lieu of a meeting of stockholders to approve the Plan.

Our board of directors decided to adopt the Plan to provide the Corporation with additional flexibility to issue stock compensation in various forms to employees and advisors and consultants of the Corporation in an effort to attract and retain such persons as the Corporation grows, for the benefit of all stockholders.

<u>Authorized Shares</u>

The Plan reserves 502,000 shares of common stock for issuance under the Plan, via stock options, restricted stock, restricted stock units and other forms of awards. The shares may be authorized but unissued, or required common stock. If an award expires or becomes un-exercisable without having been exercised in full, is surrendered pursuant to an exchange program, or is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased shares which were subject thereto will generally become available for future grant or sale under this Plan, unless this Plan has terminated.

<u>Plan Administration</u>

The Plan will be administered by the board of directors or, upon the board's delegation, a committee thereof.

<u>Merger or Change in Control</u>

The Plan will provide that in the event of a merger or change in control, as defined under our Plan, each outstanding award will be treated as the administrator determines, except that if a successor corporation or its parent or subsidiary does not assume or substitute an equivalent award for any outstanding award, then such award will fully vest, all restrictions on such award will lapse, all performance goals or other vesting criteria applicable to such award will be deemed achieved at 100% of target levels and such award will become fully exercisable, if applicable, for a specified period prior to the transaction. The award will then terminate upon the expiration of the specified period of time. If the service of an outside director is terminated on or following a change of control, other than pursuant to a voluntary resignation, his or her awards will vest fully and become immediately exercisable and all performance goals or other vesting requirements will be deemed achieved at 100% of target levels.

**BENEFICIAL OWNERSHIP OF SECURITIES**

The following table sets forth the number of shares of and percent of the Company's common stock beneficially owned as of January 23, 2023, by all directors, our named executive officers, our directors and executive officers as a group, and persons or groups known by us to own beneficially 5% or more of our common stock, immediately prior to this Offering, and immediately after the closing of this offering, as adjusted to reflect the assumed sale of [●] units (which includes shares of our common stock and immediately exercisable warrants to purchase shares of our common stock) in this Offering and the exercise of the Representative's over-allotment option in full to purchase additional shares of common stock and warrants to purchase shares of common stock, but assumes the warrants forming part of the units and over-allotment option are not exercised.

The business address of each of the beneficial owners listed below is c/o Docola, Inc. 801 W. Bay Drive, Suite 506, Largo, Florida 33770.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of Beneficial Owner** | **Amount**<br> **and**<br> **Nature of Beneficial Ownership** | **Pre-**<br> **Closing Percentage of Class (1)** | **Post-**<br> **Closing Amount**<br> **and**<br> **Nature of Beneficial Ownership** | **Post- Closing Percentage of Class (1)** |
| **Directors and Executive Officers** | | | |  |
| Eran Kabakov, Chief Executive Officer | 1042190 | 27.30% | 1042190 | [●] |
| Itay Tsabari, Chief Financial Officer |  | \* |  | [●] |
| Tomer Kabakov, Chief Operating Officer | 816301 | 21.38% | 816301 | [●] |
| Jonathan Ascher, Chief Medical Officer | 223880 | 5.86% | 223880 | [●] |
| Geri Lynn Baumblatt, Chief Engagement Officer | 25185 | 0.5% | 25185 | [●] |
| Alexander Ellis, Chief Technology Officer | 31388 | 0.6% | 31388 | [●] |
| All directors and officers as a group (6 persons) | 2138944 | 55.64% | <br> 2138944 | [●] |
| **Principal Shareholders (more than 5%):** |  |  |  | [●] |
| Roger and Joelle Burnell | 384097 | 10.10% | 384097 | [●] |
| Fred Kaplan | 229904 | 6.02% | 229904 | [●] |

---

\* less than 1%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The pre-closing percentages in the table have been calculated on the basis of treating as outstanding for a particular person, all shares of our capital stock outstanding on January 23, 2023. The post-closing percentages in the table have been calculated on the basis of treating as outstanding for a particular person, all shares of our capital stock outstanding on January 23, 2023, plus the assumed sale of [●] units (which includes shares of our common stock and immediately exercisable warrants to purchase shares of our common stock) in this Offering and the exercise of the Representative's over-allotment option in full to purchase shares of common stock and warrants to purchase shares of common stock, but assumes the warrants forming part of the units and over-allotment option are not exercised. On January 23, 2023, there were 3,818,180 shares of our common stock outstanding. To calculate a stockholder's percentage of beneficial ownership, we include in the numerator and denominator the common stock outstanding and all shares of our common stock issuable to that person in the event of the exercise of outstanding options and other derivative securities owned by that person which are exercisable within 60 days of January 23, 2023. Common stock options and derivative securities held by other stockholders are disregarded in this calculation. Therefore, the denominator used in calculating beneficial ownership among our stockholders may differ. Unless we have indicated otherwise, each person named in the table has sole voting power and sole investment power for the shares listed opposite such person's name.

**CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS**

Once our audit committee is established, our audit committee will review and approve any related person transaction we propose to enter into. Our audit committee charter will detail the policies and procedures relating to transactions that may present actual, potential or perceived conflicts of interest and may raise questions as to whether such transactions are consistent with the best interest of our company and our stockholders. A summary of such policies and procedures is set forth below.

Any potential related party transaction that is brought to the audit committee's attention will be analyzed by the audit committee, in consultation with outside counsel or members of management, as appropriate, to determine whether the transaction or relationship does, in fact, constitute a related party transaction. At its meetings, the audit committee will be provided with the details of each new, existing or proposed related party transaction, including the terms of the transaction, the business purpose of the transaction and the benefits to us and to the relevant related party.

In determining whether to approve a related party transaction, the audit committee must consider, among other factors, the following factors to the extent relevant:

● whether the terms of the transaction are fair to us and on the same basis as would apply if the transaction did not involve a related party;

● whether there are business reasons for us to enter into the transaction;

● whether the transaction would impair the independence of an outside director; and

● whether the transaction would present an improper conflict of interest for any director or executive officer.

Any member of the audit committee who has an interest in the transaction under discussion must abstain from any voting regarding the transaction, but may, if so, requested by the chairman of the audit committee, participate in some or all of the audit committee's discussions of the transaction. Upon completion of its review of the transaction, the audit committee may determine to permit or to prohibit the transaction.

The CEO, Eran Kabakov, and COO, Tomer Kabakov have loaned the Company funds from time-to-time. The loans have no specific repayment terms and have an aggregate balance due of $57,397 and $21,373 as of December 31, 2021 and 2020, respectively.

Alexander Ellis who has served as our Chief Technology Officer since January 11, 2019, owns Pineapple-Lab, which has program developers that perform technological work for the Company such as exporting software services abroad and invoices the Company for such services. During the year ended December 31, 2021, invoices for such services totaled $108,100. During fiscal year ended December 31, 2022 and to date invoices for such services totaled $15,000.

**Director Independence**

For a description of director independence of our board members under Nasdaq Capital Market standards, see "Management— Board Committees and Director Independence" on page ____ of this prospectus.

**UNDERWRITING**

WallachBeth Capital LLC (the "Representatives") are acting as book-running manager of the offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, each underwriter named below has severally and not jointly agreed to purchase, and we have agreed to sell to that underwriter, the number of units, consisting of shares of common stock and warrants set forth opposite the underwriter's name.

---

| | |
|:---|:---|
| **Underwriter** | **Number of**<br> **Units** |
| WallachBeth Capital LLC | [●] |
| Total: | [●] |

---

The underwriting agreement provides that the obligations of the underwriters to purchase the shares of common stock and warrants included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all the shares of common stock and warrants (other than those covered by the over-allotment option described below) if they purchase any of the shares of common stock and warrants.

**Over-Allotment Option**

We have granted to the Representatives an option, exercisable no later than 45 calendar days after the closing of this offering, to purchase up to an additional [●] shares of common stock and/or additional warrants to purchase up to [●] shares of common stock (equal to 15% of the number of shares of common stock and/or warrants underlying the units sold in this offering), on one or more occasions and in any combination thereof, from us to cover over-allotments, if any. If the Representatives exercise all or any part of this option, they will purchase shares and/or warrants covered by the option at the public offering price per share and the public offering price per warrant, respectively, less the underwriting discount. If this option is exercised in full, the total offering price to the public will be $[●] and the total net proceeds, before expenses, to us will be $[●]. We will pay the expenses associated with the exercise of the over-allotment option.

**Underwriting discounts and commissions**

Shares of common stock and warrants sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any shares of common stock and warrants sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed $[●] per share and warrant. If all the shares of common stock and warrants are not sold at the initial offering price, the underwriters may change the offering price and the other selling terms.

The following table shows the public offering price, underwriting discounts and proceeds before expenses to us. The information assumes either no exercise or full exercise of the over-allotment option we granted to the Representatives.

---

| | | | |
|:---|:---|:---|:---|
|  | **Per Unit** | **Total Without<br> Over-Allotment <br> Option** | **Total With Full<br> Over-Allotment <br> Option** |
| Public offering price | $[●] | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[●] | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[●] |
| Underwriting discount (1) | $[●] | $[●] | $[●] |
| Proceeds, before expenses, to us | $[●] | $[●] | $[●] |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The underwriters will receive an underwriting discount equal to 8.0% on shares sold in this offering.

We have also agreed to reimburse the representative of the underwriters for non-accountable expenses of up to 1.5% of the gross offering proceeds. In addition, we have agreed to reimburse the representative of the underwriters for up to $145,000 for all of its agreed-upon, actual and out-of-pocket expenses, including but not limited to reasonable and documented travel, legal fees and other expenses, incurred in connection with the offering.

We estimate the total expenses of this offering which will be payable by us, excluding the underwriting discount and the underwriter's expenses payable by us, will be approximately $[●].

We have paid an expense deposit of $20,000 to the Representative, which will be applied against the accountable expenses that will be paid by us to the Representative in connection with this offering. The $20,000 expense deposit will be returned to us to the extent not actually incurred. The underwriting agreement also provides that in the event the offering is terminated, the $20,000 expense deposit paid to the Representative will be returned to us to the extent that offering expenses are not actually incurred by the Representative in accordance with Financial Industry Regulation Authority ("FINRA") Rule 5110.

**Representative's Warrant**

As additional compensation to the underwriters, upon consummation of this offering, we will issue to the Representative or its designees a non-redeemable Representative's Warrant to purchase an aggregate number of shares of our common stock equal to six and a half (6.5%) of the number of shares of common stock underlying the units issued in this offering, and the terms of the Representative's Warrant will be identical to the terms of the warrants being offered in this offering as part of the units. The Representative's Warrant and the underlying shares of common stock shall not be sold during the offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of six months immediately following the commencement of the sale of the public securities in accordance with FINRA Rule 5110(e)(1).

**Indemnification**

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make because of any of those liabilities.

**Right of First Refusal**

According to the terms of the underwriting agreement, the Representative shall have the right of first refusal for a period of twelve (12) months after the closing of this Offering to participate in each and every future public and private equity and debt offerings of the Company, or any successor to or any subsidiary of the Company. The right of first refusal granted hereunder may be terminated by us for "cause," which shall mean a material breach by the Representative of the underwriting agreement or a material failure by the Representative to provide the services as contemplated by the underwriting agreement in which case we will not be obligated to honor the right of first refusal.

**Tail Rights**

If the Company, within twelve (12) months after the termination of the engagement agreement with the Representative, effects a sale of any securities with a party introduced by the Representative, the Company shall pay to the Representative the cash discount and warrants set forth above upon the completion of such transaction, provided that such tail financing is by a party actually introduced to the Company in an offering in which the Company has direct knowledge of such party's participation. In compliance with FINRA Rule 5110(g)(5)(B), the "tail fee" will not be payable for greater than one year and our entire underwriting agreement with the Representative is terminable if the Representative materially breaches the engagement agreement or fails to materially perform the underwriting services contemplated in the underwriting agreement. The termination of such agreement will eliminate the obligation of the Company to pay the tail fee.

**Lock-up Agreements**

We, our executive officers and directors, and holders of 5% or more of our common stock have agreed to enter into lock-up agreements in connection with this offering. Under the lock-up agreements, subject to certain exceptions, we and each of these persons may not, without the prior written approval of the Underwriter, offer, sell, contract to sell, pledge, or otherwise dispose of, directly or indirectly, or hedge our common stock or securities convertible into or exchangeable or exercisable for our common stock. These restrictions remain in effect and will generally terminate on the six-month anniversary after the closing date ("lock-up period").

In connection with this offering, we agreed that we will not: (a) offer, sell, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company other than in a transaction pursuant to which such securities will be restricted under Rule 144 of the Securities Act and that no registration statement shall be filed as to such securities to remove such restriction prior to a six month holding period or (b) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company. Notwithstanding anything to the contrary, the Company may issue shares of its capital stock or any securities convertible into or exercisable or exchangeable for shares of its capital stock during the lock-up period so long as the capital stock or securities exercisable or exchangeable for shares of its capital stock are subject to the lock-up period.

**Offering Price Determination**

Prior to this offering, there has been no public market for our common stock or warrants (forming part of the units). In determining the initial public offering price, we and the underwriters have considered a number of factors including:

● the information set forth in this prospectus and otherwise available to the underwriters;

● our prospects and the history and prospects for the industry in which we compete;

● an assessment of our management;

● our prospects for future earnings;

● the general condition of the securities markets at the time of this offering;

● the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and

● other factors deemed relevant by the underwriters and us.

Neither we nor the underwriters can assure investors that an active trading market will develop for shares of our common stock or warrants (forming part of the units), or that the shares will trade in the public market at or above the initial public offering price.

The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters' obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers' certificates and legal opinions.

**Stabilization, Short Positions and Penalty Bids**

● Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.

● A short position involves a sale by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase in the offering, which creates the syndicate short position. This short position may be either a covered short position or a naked short position. In a covered short position, the number of shares involved in the sales made by the underwriters in excess of the number of shares they are obligated to purchase is not greater than the number of shares that they may purchase by exercising their option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in their option to purchase additional shares. The underwriters may close out any short position by either exercising their option to purchase additional shares and/or purchasing shares in the open market. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through their option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering.

● Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions.

● Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of the common stock. As a result, the price of the common stock may be higher than the price that might otherwise exist in the open market. These transactions may be affected on The Nasdaq Capital Market or otherwise and, if commenced, may be discontinued at any time.

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice.

**Electronic Distribution**

A prospectus in electronic format may be made available on the Internet sites or through other online services maintained by one or more of the underwriters and/or selling group members participating in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending upon the particular underwriter or selling group member, prospective investors may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the representatives on the same basis as other allocations.

Other than the prospectus in electronic format, the information on any underwriter's or selling group member's web site and any information contained in any other web site maintained by an underwriter or selling group member is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter or selling group member in its capacity as underwriter or selling group member and should not be relied upon by investors.

**Listing on The Nasdaq Capital Market**

Our common stock is not currently listed on any national securities exchange market or quoted on the OTC Markets. We intend to apply to list our common stock and warrants (forming part of the units offered hereby) on the Nasdaq Capital Market under the symbols "[●]" and "[●]W," respectively. There is no assurance that our listing application will be approved by the Nasdaq Capital Market. The approval of our listing on the Nasdaq Capital Market is a condition of closing this offering.

**Other Relationships**

The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for the issuer and its affiliates, for which they received or may in the future receive customary fees and expenses.

In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of the issuer or its affiliates. If the underwriters or their affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the shares of common stock offered hereby. Any such credit default swaps, or short positions could adversely affect future trading prices of the shares of common stock offered hereby. The underwriters and certain of their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

**Selling Restrictions**

This prospectus does not constitute an offer to sell to, or a solicitation of an offer to buy from, anyone in any country or jurisdiction (i) in which such an offer or solicitation is not authorized, (ii) in which any person making such offer or solicitation is not qualified to do so or (iii) in which any such offer or solicitation would otherwise be unlawful. No action has been taken that would, or is intended to, permit a public offer of the shares of common stock or possession or distribution of this prospectus or any other offering or publicity material relating to the shares of common stock in any country or jurisdiction (other than the United States) where any such action for that purpose is required. Accordingly, each underwriter has undertaken that it will not, directly or indirectly, offer or sell any shares of common stock or have in its possession, distribute or publish any prospectus, form of application, advertisement or other document or information in any country or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in compliance with any applicable laws and regulations and all offers and sales of shares of common stock by it will be made on the same terms.

***European Economic Area***

In relation to each Member State of the European Economic Area which has implemented the prospectus Directive (each, a "Relevant Member State") an offer to the public of any common stock which are the subject of the offering contemplated herein may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any common stock may be made at any time under the following exemptions under the prospectus Directive, if they have been implemented in that Relevant Member State:

● to legal entities which are qualified investors as defined under the prospectus Directive;

● by the underwriters to fewer than 100, or, if the Relevant Member State has implemented the relevant provisions of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the prospectus Directive), as permitted under the prospectus Directive, subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or

● in any other circumstances falling within Article 3(2) of the prospectus Directive, provided that no such offer of common stock shall result in a requirement for us or any underwriter to publish a prospectus pursuant to Article 3 of the prospectus Directive or supplement a prospectus pursuant to Article 16 of the prospectus Directive.

Each person in a Relevant Member State who receives any communication in respect of, or who acquires any common stock under, the offers contemplated here in this prospectus will be deemed to have represented, warranted and agreed to and with each underwriter and us that:

● it is a qualified investor as defined under the prospectus Directive; and

● in the case of any common stock acquired by it as a financial intermediary, as that term is used in Article 3(2) of the prospectus Directive, (i) the common stock acquired by it in the offering have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than qualified investors, as that term is defined in the prospectus Directive, or in the circumstances in which the prior consent of the representatives of the underwriters has been given to the offer or resale or (ii) where common stock have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of such common stock to it is not treated under the prospectus Directive as having been made to such persons.

For the purposes of this representation and the provision above, the expression an "offer of common stock to the public" in relation to any common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any common stock to be offered so as to enable an investor to decide to purchase or subscribe for the common stock, as the same may be varied in that Relevant Member State by any measure implementing the prospectus Directive in that Relevant Member State, the expression "prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in each Relevant Member State and the expression "2010 PD Amending Directive" means Directive 2010/73/EU.

***United Kingdom***

This prospectus has only been communicated or caused to have been communicated and will only be communicated or caused to be communicated as an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act of 2000 (the "FSMA")) as received in connection with the issue or sale of the common stock in circumstances in which Section 21(1) of the FSMA does not apply to us. All applicable provisions of the FSMA will be complied with in respect to anything done in relation to the common stock in, from or otherwise involving the United Kingdom.

***Notice to Residents of Canada***

The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

***France***

This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code monétaire et financier) and Articles 211-1, et seq. of the General Regulation of the French Autorité des marchés financiers ("AMF"). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.

This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.

Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifiés) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-1 to D.411-3, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint d'investisseurs non-qualifiés) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.

Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.

***Ireland***

The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the "Prospectus Regulations"). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.

***Israel***

The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the "ISA"), nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.

***Italy***

The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societá e la Borsa, "CONSOB") pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 ("Decree No. 58"), other than:

● to Italian qualified investors, as defined in Article 100 of Decree No. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 ("Regulation no. 11971") as amended ("Qualified Investors"); and

● in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971 as amended.

Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:

● made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and

● in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.

Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.

***Japan***

The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the "FIEL"), pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.

***New Zealand***

 ****

The securities offered hereby have not been offered or sold, and will not be offered or sold, directly or indirectly in New Zealand and no offering materials or advertisements have been or will be distributed in relation to any offer of shares in New Zealand, in each case other than:

● to persons whose principal business is the investment of money or who, in the course of and for the purposes of their business, habitually invest money;

● to persons who in all the circumstances can properly be regarded as having been selected otherwise than as members of the public;

● to persons who are each required to pay a minimum subscription price of at least NZ$500,000 for the shares before the allotment of those shares (disregarding any amounts payable, or paid, out of money lent by the issuer or any associated person of the issuer); or

● in other circumstances where there is no contravention of the Securities Act 1978 of New Zealand (or any statutory modification or reenactment of, or statutory substitution for, the Securities Act 1978 of New Zealand).

***Portugal***

This document is not being distributed in the context of a public offer of financial securities (oferta pública de valores mobiliários) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (Código dos Valores Mobiliários). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comissão do Mercado de Valores Mobiliários) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are "qualified investors" (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

***Sweden***

This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are "qualified investors" (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

***Switzerland***

The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange ("SIX") or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority.

This document is personal to the recipient only and not for general circulation in Switzerland.

***United Arab Emirates***

Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor have we received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by our Company.

No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.

**DESCRIPTION OF SECURITIES**

The following description of our capital stock is based upon our certificate of incorporation, as amended, our bylaws and applicable provisions of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its entirety by reference to our certificate of incorporation, as amended, and our bylaws, copies of which are filed with the SEC as exhibits to the registration statement of which this prospectus is a part.

**Authorized Capital Stock**

As of January 23, 2023, our authorized capital stock consists of (i) 250,000,000 shares of common stock, par value $0.0001per share, and (ii) 20,000,000 shares of preferred stock, par value $0.0001 per share. At January 23, 2023, we had 3,818,180 shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

As of January 23, 2023, there were 23 holders of record of our common stock and no holders of record of our preferred stock.

**Units Offered Hereby**

We are offering [●] units at a fixed price of $[●] per unit. Each unit shall consist of (a) one share of our common stock, and (b) one warrant to purchase one share of our common stock, with an exercise price of $[●] per share.

 ****

***Common Stock***

*Voting*

The holders of our common stock are entitled to one vote for each share held on all matters to be voted on by the Company's stockholders. There shall be no cumulative voting.

*Dividends*

The holders of shares of our common stock are entitled to dividends when and as declared by the Board from funds legally available therefor if, as and when determined by the Board of Directors of the Company in their sole discretion, subject to provisions of law, and any provision of the Company's Certificate of Incorporation, as amended from time to time. There are no preemptive, conversion or redemption privileges, nor sinking fund provisions with respect to the common stock.

*Liquidation*

In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities.

*Fully Paid and Non-assessable*

All outstanding shares of common stock are, and the common stock to be outstanding upon completion of this offering will be, duly authorized, validly issued, fully paid and non-assessable.

***Warrants Offered Hereby***

The warrants entitle the registered holder to purchase one share of our common stock at a price equal to $[●] per share (100% of the assumed public offering price), subject to adjustment as discussed below, at any time commencing on the date that is six-months from the consummation of this offering and terminating at 5:00 p.m., New York City time, on the fifth anniversary of the date of issuance (the "Issuance Date").

The warrants will be issued in registered form under a warrant agent agreement (the "Warrant Agent Agreement") between us and our warrant agent, Vstock Transfer, LLC (the "Warrant Agent"). The material provisions of the warrants are set forth herein and a copy of the Warrant Agent Agreement has been filed as an exhibit to the Registration Statement on Form S-1, of which this prospectus forms a part. The Company and the Warrant Agent may amend or supplement the Warrant Agent Agreement without the consent of any holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained therein or adding or changing any other provisions with respect to matters or questions arising under the Warrant Agent Agreement as the parties thereto may deem necessary or desirable and that the parties determine, in good faith, shall not adversely affect the interest of the holders. All other amendments and supplements shall require the vote or written consent of holders of at least 50.1%

The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances, including in the event of a stock dividend, extraordinary dividend on or recapitalization, reorganization, merger or consolidation.

The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, with the exercise form attached to the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

No warrants will be exercisable unless at the time of the exercise a prospectus or prospectus relating to common stock issuable upon exercise of the warrants is current and the common stock has been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of the Warrant Agent Agreement, we have agreed to use our best efforts to maintain a current prospectus or prospectus relating to common stock issuable upon exercise of the warrants until the expiration of the warrants. If we are unable to maintain the qualification or effectiveness of such registration statement until the expiration of the warrants, and therefore are unable to deliver registered shares of common stock, the warrants may become worthless. Such expiration would result in each holder paying the full unit purchase price solely for the shares of common stock underlying the units. Additionally, the market for the warrants may be limited if the prospectus or prospectus relating to the common stock issuable upon exercise of the warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of such warrants reside. In no event will the registered holders of a Warrant be entitled to receive a net-cash settlement, stock or other consideration in lieu of physical settlement in shares of our common stock.

No fractional shares of common stock will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of shares of common stock to be issued to the Warrant holder. If multiple warrants are exercised by the holder at the same time, we will aggregate the number of whole shares issuable upon exercise of all the warrants.

The price of the warrants has been arbitrarily established by us and the Underwriters after giving consideration to numerous factors, including but not limited to, the pricing of the units in this offering. No particular weighting was given to any one aspect of those factors considered. We have not performed any method of valuation of the warrants.

 ****

**Preferred Stock**

We are authorized to issue up to 20,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.

**Exclusive Forum Provision**

This choice of forum provision may limit a bondholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, a court could find these provisions of our certificate of incorporation and our bylaws to be inapplicable or unenforceable in respect of one or more of the specified types of actions or proceedings, which may require us to incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.

**Fee Shifting Provision**

Section 7.4 of our amended and restated bylaws provides that "[i]f any action is brought by any party against another party, relating to or arising out of these Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party reasonable attorneys' fees, costs and expenses incurred in connection with the prosecution or defense of such action, provided that the provisions of this sentence shall not apply with respect to "internal corporate claims" as defined in Section 109(b) of the DGCL."

Our amended and restated bylaws provide that for this section, the term "attorneys' fees" or "attorneys' fees and costs" means the fees and expenses of counsel to the Company and any other parties asserting a claim subject to Section 7.4 of the amended and restated bylaws, which may include printing, photocopying, duplicating and other expenses, air freight charges, and fees billed for law clerks, paralegals and other persons not admitted to the bar but performing services under the supervision of an attorney, and the costs and fees incurred in connection with the enforcement or collection of any judgment obtained in any such proceeding.

We adopted the fee-shifting provision to eliminate or decrease nuisance and frivolous litigation. We intend to apply the fee-shifting provision broadly to all actions except for claims brought under the Exchange Act and Securities Act.

There is no set level of recovery required to be met by a plaintiff to avoid payment under this provision. Instead, whoever is the prevailing party is entitled to recover the reasonable attorneys' fees, costs and expenses incurred in connection with the prosecution or defense of such action. Any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses, and other parties, are subject to this provision. Additionally, any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses, and other parties, would be able to recover fees under this provision.

In the event you initiate or assert a claim against us, in accordance with the dispute resolution provisions contained in our amended and restated bylaws, and you do not, in a judgment prevail, you will be obligated to reimburse us for all reasonable costs and expenses incurred in connection with such claim, including, but not limited to, reasonable attorney's fees and expenses and costs of appeal, if any. Additionally, this provision in Section 7.4 of our amended and restated bylaws could discourage shareholder lawsuits that might otherwise benefit the Company and its shareholders.

THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS IS NOT INTENDED TO BE DEEMED A WAIVER BY ANY HOLDER OF COMMON STOCK OF THE COMPANY'S COMPLIANCE WITH THE U.S. FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER. THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS DO NOT APPLY TO CLAIMS BROUGHT UNDER THE EXCHANGE ACT AND SECURITIES ACT.

**Certain Anti-Takeover Provisions of Delaware Law and our Certificate of Incorporation, as Amended, and Bylaws**

We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a "business combination" with:

● a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an "interested stockholder");

● an affiliate of an interested stockholder; or

● an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.

A "business combination" includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:

● our board of directors approves the transaction that made the stockholder an "interested stockholder," prior to the date of the transaction;

● after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of Common Stock; or

● on or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.

Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

**Special Meeting of Stockholders**

Our bylaws provide that special meeting of our stockholders other than a special meeting for the election of directors, may be called only by the Board of Directors.

**Classified Board of Directors**

We intend to adopt an amended and restated certificate of incorporation that will provide that, immediately after the completion of this offering, our board of directors will be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our current directors will be divided among the three classes as follows:

● Class I directors will be [__], and their terms will expire at the annual meeting of stockholders to be held in 2022;

● Class II directors will be [__], and their terms will expire at the annual meeting of stockholders to be held in 2023; and

● Class III directors will be [__], and their terms will expire at the annual meeting of stockholders to be held in 2024.

Each director's term will continue until the election and qualification of his successor, or his earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of our directors.

This classification of our board of directors may have the effect of delaying or preventing changes in control of our company.

**Removal of Directors**

Except as may otherwise be provided in connection with rights to elect additional directors under specified circumstances, which may be granted to the holders of any class or series of Preferred Stock, any director may be removed from office only by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the issued and outstanding stock entitled to vote. Other than with respect to any director(s) who are named by a class of preferred stock of the Company, which may be removed and replaced either for or without cause at any time solely by the holders of such class of preferred stock, any director(s) may be removed by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the issued and outstanding stock entitled to vote, at a special meeting of the stockholders called for that purpose and the vacancies thus created may be filled, at the meeting held for the purpose of removal, by the majority affirmative vote of the holders of all of the voting power of the issued and outstanding stock entitled to vote.

**Our Transfer Agent and Warrant Agent**

The transfer agent and registrar for our Common Stock and warrant agent for our Warrants is Vstock Transfer, LLC. The transfer agent and registrar's address is 18 Lafayette Place, Woodmere, NY 11598. and its telephone number is (212) 828-8436.

We have agreed to indemnify Vstock Transfer, LLC in its roles as transfer agent and warrant agent, its agents and each of its stockholders, directors, officers and employees against all liabilities, including judgments, costs and reasonable counsel fees that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity.

**MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK AND WARRANTS**

The following discussion describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock and warrants acquired in this Offering. This discussion is based on the current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury regulations promulgated thereunder, and administrative rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive effect. No ruling has been or will be sought from the Internal Revenue Service, or IRS, with respect to the matters discussed below, and there can be no assurance the IRS will not take a contrary position regarding the tax consequences of the acquisition, ownership or disposition of our common stock and warrants, or that any such contrary position would not be sustained by a court.

We assume in this discussion that the shares of our common stock and warrants will be held as capital assets (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxes, does not discuss the potential application of the Medicare contribution tax on net investment income or the alternative minimum tax and does not deal with state or local taxes, U.S. federal gift and estate tax laws, except as specifically provided below with respect to non-U.S. holders, or any non-U.S. tax consequences that may be relevant to holders in light of their particular circumstances. This discussion also does not address the special tax rules applicable to particular holders, such as

● financial institutions;

● brokers or dealers in securities or currencies, or traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;

● tax-exempt organizations;

● pension plans;

● regulated investment companies, real estate investment trusts;

● owners that hold our common stock or warrants as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;

● insurance companies;

● persons that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below);

● entities or arrangements treated as partnerships for U.S. federal income tax purposes and other pass-through entities (and partners or other investors therein);

● controlled foreign corporations, passive foreign investment companies, or corporations that accumulate earnings to avoid U.S. federal income tax;

● persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock or warrants being taken into account in an applicable financial statement;

● persons deemed to sell our common stock or warrants under the constructive sale provisions of the Code; and

● certain U.S. expatriates and certain former citizens or long-term residents of the United States.

In addition, this discussion does not address the tax treatment of partnerships or other pass-through entities or persons who hold our common stock or warrants through partnerships or other entities which are pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our common stock or warrants should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock or warrants through a partnership or other pass-through entity, as applicable.

**This discussion of U.S. federal income tax considerations is for general information purposes only and is not tax advice. Prospective investors should consult their own tax advisors regarding the U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding and disposing of our common stock and warrants.**

For the purposes of this discussion, a "U.S. Holder" means a beneficial owner of our common stock or warrants that is, for U.S. federal income tax purposes: (a) an individual who is a citizen or resident of the United States, (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d) a trust if it (1) is subject to the primary supervision of a court within the United States and one or more U.S. persons (within the meaning of Section 7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. A "Non-U.S. Holder" is, for U.S. federal income tax purposes, a beneficial owner of common stock or warrants that is not a U.S. Holder or an entity or arrangement treated as a partnership for U.S. federal income tax purposes.

*Allocation of Purchase Price*

For U.S. federal income tax purposes, the shares of common stock and warrants acquired in this Offering will be treated as an "investment unit" consisting of one share of common stock and a warrant to acquire of our common stock. The purchase price for each investment unit will be allocated between these two components in proportion to their relative fair market values at the time the unit is purchased by the holder. This allocation of the purchase price for each unit will establish the holder's initial tax basis for U.S. federal income tax purposes in the share of common stock and the warrant included in each unit. The separation of the share of common stock and the warrant included in each unit should not be a taxable event for U.S. federal income tax purposes. Each holder should consult his, her or its own tax advisor regarding the allocation of the purchase price for a unit.

**Tax Considerations Applicable to U.S. Holders**

*Exercise and Expiration of Warrants*

In general, a U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon exercise of a warrant. The U.S. Holder will take a tax basis in the shares acquired on the exercise of a warrant equal to the exercise price of the warrant, increased by the U.S. Holder's adjusted tax basis in the warrant exercised (as determined pursuant to the rules discussed above). The U.S. Holder's holding period in the shares of our common stock acquired on exercise of the warrant will begin on the date of exercise of the warrant, and will not include any period for which the U.S. Holder held the warrant.

In certain limited circumstances, a U.S. Holder may be permitted to undertake a cashless exercise of warrants into our common stock. The U.S. federal income tax treatment of a cashless exercise of warrants into our common stock is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a warrant described in the preceding paragraph. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of warrants.

The lapse or expiration of a warrant will be treated as if the U.S. Holder sold or exchanged the warrant and recognized a capital loss equal to the U.S. Holder's tax basis in the warrant. The deductibility of capital losses is subject to limitations.

*Certain Adjustments to and Distributions on Warrants*

Under Section 305 of the Code, an adjustment to the number of shares of common stock issued on the exercise of the warrants or an adjustment to the exercise price of the warrants may be treated as a constructive distribution to a U.S. Holder of the warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. Holder's proportionate interest in our "earnings and profits" or assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders). An adjustment made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution should generally not be considered to result in a constructive distribution. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property to the holders of warrants. In certain circumstances, if we were to make a distribution in cash or other property with respect to our common stock after the issuance of the warrants, then we may make a corresponding distribution to the holders of the warrants. The taxation of a distribution received with respect to a warrant is unclear. It is possible such a distribution would be treated as a distribution (or constructive distribution), although other treatments are possible. For more information regarding the U.S. federal income tax considerations related to distributions, see the discussion below regarding "—Distributions." U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to the warrants and any distributions with respect to the warrants.

*Distributions*

As discussed above, we currently anticipate that we will retain future earnings, if any, to finance the growth and development of our business and do not intend to pay cash dividends in respect of our common stock in the foreseeable future. In the event that we do make distributions on our common stock to a U.S. Holder, those distributions generally will constitute dividends for U.S. tax purposes to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a U.S. Holder's adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized on the sale or exchange of our common stock as described below under the section titled "– Disposition of Our Common Stock or Warrants." Under current law, if certain requirements are met, a preferential U.S. federal income tax rate will apply to any dividends paid to the beneficial owner of our common stock who is an individual U.S. Holder and meets certain holding period requirements.

Distributions constituting dividends for U.S. federal income tax purposes that are made to U.S. Holders that are corporate shareholders may qualify for the dividends received deduction, or DRD, which is generally available to corporate shareholders. No assurance can be given that we will have sufficient earnings and profits (as determined for U.S. federal income tax purposes) to cause any distributions to be eligible for a DRD. In addition, a DRD is available only if certain holding periods and other taxable income requirements are satisfied.

*Disposition of Our Common Stock or Warrants*

Upon a sale or other taxable disposition of our common stock or warrants, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder's adjusted tax basis in the common stock or warrants. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder's holding period for the common stock or warrants exceeds one year. The deductibility of capital losses is subject to certain limitations. U.S. Holders who recognize losses with respect to a disposition of our common stock or warrants should consult their own tax advisors regarding the tax treatment of such losses.

*Information Reporting and Backup Withholding*

Information reporting requirements generally will apply to payments of dividends (including constructive dividends) on the common stock and warrants and to the proceeds of a sale or other disposition of common stock and warrants paid by us to a U.S. Holder unless such U.S. Holder is an exempt recipient, such as a corporation. Backup withholding will apply to those payments if the U.S. Holder fails to provide the holder's taxpayer identification number, or certification of exempt status, or if the holder otherwise fails to comply with applicable requirements to establish an exemption.

Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against the U.S. Holder's U.S. federal income tax liability provided the required information is timely furnished to the IRS. U.S. Holders should consult their own tax advisors regarding their qualification for exemption from information reporting and backup withholding and the procedure for obtaining such exemption.

**Tax Considerations Applicable to Non-U.S. Holders**

*Exercise and Expiration of Warrants*

In general, a Non-U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon the exercise of warrants into shares of common stock. The U.S. federal income tax treatment of a cashless exercise of warrants into our common stock is unclear. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding the U.S. federal income tax consequences of a cashless exercise of warrants.

The expiration of a warrant will be treated as if the Non-U.S. Holder sold or exchanged the warrant and recognized a capital loss equal to the Non-U.S. Holder's tax basis in the warrant. However, a Non-U.S. Holder will not be able to utilize a loss recognized upon expiration of a warrant against the Non-U.S. Holder's U.S. federal income tax liability unless the loss is effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (and, if an income tax treaty applies, is attributable to a permanent establishment or fixed base in the United States) or is treated as a U.S.-source loss and the Non-U.S. Holder is present 183 days or more in the taxable year of disposition and certain other conditions are met.

*Certain Adjustments to and Distributions on Warrants*

As described under "—U.S. Holders –Certain Adjustments to and Distributions on Warrants," an adjustment to the warrants could result in a constructive distribution to a Non-U.S. Holder, which would be treated as described under "—Distributions" below, and the tax treatment of distributions on the warrants is unclear. Any resulting withholding tax attributable to deemed dividends would be collected from other amounts payable or distributable to the Non-U.S. Holder. Non-U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to and distributions on the warrants.

*Distributions*

As discussed above, we currently anticipate that we will retain future earnings, if any, to finance the growth and development of our business and do not intend to pay cash dividends in respect of our common stock in the foreseeable future. In the event that we do make distributions on our common stock to a Non-U.S. Holder, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as described in "—U.S. Holders – Distributions."

Any distribution (including constructive distributions) on our common stock that is treated as a dividend paid to a Non-U.S. Holder that is not effectively connected with the holder's conduct of a trade or business in the United States will generally be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and the Non-U.S. Holder's country of residence. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide the applicable withholding agent with a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate form, certifying the Non-U.S. Holder's entitlement to benefits under that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder's behalf, the holder will be required to provide appropriate documentation to such agent. The holder's agent may then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.

We generally are not required to withhold tax on dividends paid (or constructive dividends deemed paid) to a Non-U.S. Holder that are effectively connected with the holder's conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that the holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to the applicable withholding agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional "branch profits tax," which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder's effectively connected earnings and profits, subject to certain adjustments.

See also the sections below titled "—Backup Withholding and Information Reporting" and "—Foreign Accounts" for additional withholding rules that may apply to dividends paid to certain foreign financial institutions or non-financial foreign entities.

*Disposition of our Common Stock or Warrants*

Subject to the discussions below under the sections titled "—Backup Withholding and Information Reporting" and "—Foreign Accounts" a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain realized on a sale or other disposition of our common stock or warrants unless:

● the gain is effectively connected with the Non-U.S. Holder's conduct of a trade or business in the United States, and if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States; in these cases, the Non-U.S. Holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and if the Non-U.S. Holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income tax treaty, may also apply;

● the Non-U.S. Holder is a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other requirements are met, in which case the Non-U.S. Holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the Non-U.S. Holder, if any; or

● our common stock constitutes a U.S. real property interest because we are, or have been at any time during the five-year period preceding such disposition (or the Non-U.S. Holder's holding period for the common stock or warrants, if shorter), a "U.S. real property holding corporation," unless our common stock is regularly traded on an established securities market and the Non-U.S. Holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the Non-U.S. Holder held our common stock. Special rules may apply to the determination of the 5% threshold in the case of a holder of a warrant. Non-U.S. Holders are urged to consult their own tax advisors regarding the effect of holding our warrants on the calculation of such 5% threshold. Generally, a corporation is a "U.S. real property holding corporation" if the fair market value of its "U.S. real property interests" (as defined in the Code and applicable regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a "U.S. real property holding corporation" for U.S. federal income tax purposes. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. Non-U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax considerations that could result if we are, or become, a "U.S. real property holding corporation."

*Federal Estate Tax*

Common stock owned or treated as owned by an individual who is not a citizen or resident of the United States (as specially defined for U.S. federal estate tax purposes) at the time of death will be included in the individual's gross estate for U.S. federal estate tax purposes and, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. The foregoing may also apply to warrants. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding the U.S. federal estate tax consequences of the ownership or disposition of shares of our common stock and warrants.

*Backup Withholding and Information Reporting*

We must report annually to the IRS and to each Non-U.S. Holder the gross amount of the distributions (including constructive distributions) on our common stock or warrants paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. Holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate, currently 24%, with respect to dividends (or constructive dividends) on our common stock or warrants. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E (or other applicable IRS Form W-8) or otherwise meets documentary evidence requirements for establishing that it is a Non-U.S. Holder, or otherwise establishes an exemption. Dividends paid to Non-U.S. Holders subject to withholding of U.S. federal income tax, as described above under the heading "—Dividends," will generally be exempt from U.S. backup withholding.

Information reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock or warrants by a Non-U.S. Holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a Non-U.S. Holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. Holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.

Copies of information returns may be made available to the tax authorities of the country in which the Non-U.S. Holder resides or is incorporated under the provisions of a specific treaty or agreement.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a Non-U.S. Holder can be refunded or credited against the Non-U.S. Holder's U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.

*Foreign Accounts*

The Foreign Account Tax Compliance Act, or FATCA, generally imposes a 30% withholding tax on dividends (including constructive dividends) on, and gross proceeds from the sale or other disposition of, our common stock and warrants if paid to a non-U.S. entity unless (i) if the non-U.S. entity is a "foreign financial institution," the non-U.S. entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii) if the non-U.S. entity is a "non-financial foreign entity," the entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity, or (iii) the non-U.S. entity is otherwise exempt under FATCA.

Withholding under FATCA generally (1) applies to payments of dividends (including constructive dividends) on our common stock and warrants and (2) will apply to payments of gross proceeds from a sale or other disposition of our common stock and warrants made after December 31, 2018. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this section. Under certain circumstances, a holder may be eligible for refunds or credits of the tax. Holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in our common stock or warrants.

**The preceding discussion of material U.S. federal tax considerations is for information only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock or warrants, including the consequences of any proposed changes in applicable laws.**

**LEGAL MATTERS**

The validity of the securities offered by this prospectus will be passed upon for us by Anthony L.G., PLLC, 625 N. Flagler Drive, Suite 600, West Palm Beach, Florida 33401. Carmel, Milazzo & Feil LLP, New York, New York, is acting as counsel to the underwriters.

**EXPERTS**

Our balance sheets as of December 31, 2021 and December 31, 2020 and the related statement of operations, changes in stockholders' equity and cash flows for the year ended December 31, 2021 and December 31, 2020 included in this registration statement and prospectus have been audited by Sadler, Gibb & Associates, LLC, independent registered public accounting firm, as indicated in their report with respect thereto, and have been so included in reliance upon the report of such firm given on their authority as experts in accounting and auditing.

**DISCLOSURE OF COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES**

Our directors and officers are indemnified as provided by Delaware law, our certificate of incorporation, as amended, and our bylaws. We have agreed to indemnify each of our directors and certain officers against certain liabilities, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the provisions described above, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than our payment of expenses incurred or paid by our director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**WHERE YOU CAN FIND ADDITIONAL INFORMATION**

We have filed with the SEC the registration statement on Form S-1 under the Securities Act for the securities offered by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information in the registration statement and the exhibits filed with it, portions of which have been omitted as permitted by SEC rules and regulations. For further information concerning us and the securities offered by this prospectus, we refer to the registration statement and to the exhibits filed with it. Statements contained in this prospectus as to the content of any contract or other document referred to are not necessarily complete. In each instance, we refer you to the copy of the contracts and/or other documents filed as exhibits to the registration statement.

The registration statement on Form S-1, of which this prospectus forms a part, including exhibits, is available at the SEC's website at *http://www.sec.gov*. You may also read and copy any document we file with, or furnish to, the SEC at its public reference facilities:

<u> Public Reference Room Office 100 F Street, N.E. Room 1580 Washington, D.C. 20549</u> <br>

You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Callers in the United States can also call (202) 551-8090 for further information on the operations of the public reference facilities.

**Docola, Inc.**

**INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| [Report of Independent Registered Public Accounting Firm](#a_025) | [F-2](#a_025) |
| [Balance Sheets, as of December 31, 2021 and December 31, 2020 (Audited)](#a_026) | [F-3](#a_026) |
| [Statements of Operations, Fiscal Years Ended December 31, 2021 and December 31, 2020 (Audited)](#a_027) | [F-4](#a_027) |
| [Statements of Changes in Stockholders' Deficit, Fiscal Years Ended December 31, 2021 and December 31, 2020 (Audited)](#a_028) | [F-5](#a_028) |
| [Statements of Cash Flows, Fiscal Years Ended December 31, 2021 and December 31, 2020 (Audited)](#a_029) | [F-6](#a_029) |
| [Notes to Audited Financial Statements](#a_030) | [F-7](#a_030) |

---

**<u>Report of Independent Registered Public Accounting Firm</u>**

To the Board of Directors and Shareholders of Docola, Inc.:

<u>Opinion on the Financial Statements</u>

We have audited the accompanying balance sheets of Docola, Inc. ("the Company") as of December 31, 2021 and 2020, the related statements of operations, stockholders' deficit, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

<u>Explanatory Paragraph Regarding Going Concern</u>

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<u>Basis for Opinion</u>

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

*/s/ Sadler, Gibb & Associates, LLC* 

We have served as the Company's auditor since 2022

Draper, UT

January 23, 2023

**DOCOLA, INC.**

**BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2021** | **December 31,**<br>**2020** |
| **ASSETS** |  |  |
| **Current assets** |  |  |
| Cash and cash equivalents | $9527 | $39615 |
| Account receivable, net | 10000 | 4275 |
| Other current assets | 54470 |  |
| **Total current assets** | 73997 | 43890 |
| Property and equipment, net | 1230 | 2461 |
| **Total assets** | $75227 | $46351 |

---

**LIABILITIES AND STOCKHOLDERS' DEFICIT**

---

| | | |
|:---|:---|:---|
| **Current liabilities** | | |
| Simple Agreement for Future Equity liability | $6550440 | $2126360 |
| Other current liabilities | 13437 | $5362 |
| **Total current liabilities** | 6563877, | 2131722 |
| **Long-term liabilities** |  |  |
| Notes payable – related parties | 57397 | 21373 |
| **Total long-term liabilities** | 57397 | 21373 |
| **Total liabilities** | 6621274 | 2153095 |
| **Stockholders' deficit** |  |  |
| Common stock, $0.0001 par value, 250,000,000 shares authorized, 1,798,947 shares issued and outstanding as of December 31, 2021 and, 2020 | 180 | 180 |
| Accumulated deficit | (6546227) | (2106924) |
| **Total stockholders' deficit** | (6546047) | (2106744) |
| **Total liabilities and stockholders' deficit** | $75227 | $46351 |

---

See accompanying notes to the financial statements

**DOCOLA, INC.**

**STATEMENTS OF OPERATIONS** 

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2021** | **2020** |
| Revenue | $111318 | $137482 |
| Cost of revenue | 174839 | 192645 |
| **Gross loss** | (63521) | (55163) |
| **Operating expenses** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 5236 | 25009 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 302327 | 234789 |
| **Total operating expenses** | 307563 | 259798 |
| **Operating loss** | (371084) | (314961) |
| **Other income (expense)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant income | 10000 | 6000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of SAFE | (4102456) | (910120) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on debt forgiveness | 26215 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (1978) | (236) |
| **Total other income (expense)** | (4068219) | (904356) |
| **Income before benefit for income taxes** | (4439303) | (1219317) |
| **Benefit for income taxes** |  |  |
| **Net loss** | $(4439303) | $(1219317) |
| **Net loss per share of common stock:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $(2.47) | $(0.68) |
| Fully diluted | $(2.47) | $(0.68) |
| **Weighted average number of shares outstanding** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 1798947 | 1798947 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fully diluted | 1798947 | 1798947 |

---

See accompanying notes to the financial statements

**DOCOLA, INC.**

**STATEMENT OF STOCKHOLDERS' DEFICIT**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | | | |
|  | Shares | Amount | <br>Additional<br> Paid-in<br> Capital | <br>Accumulated <br> Deficit | <br>Total |
| **Balance, December 31, 2019** | 1798947 | $180 | $- | $(887607) | $(887427) |
| Net loss for the year ended December 31, 2020 | - | - | - | (1219317) | (1219317) |
| **Balance, December 31, 2020** | 1798947 | $180 | $- | $(2106924) | $(2106744) |
| Net loss for the year ended December 31, 2021 | - | - | - | (4439303) | (4439303) |
| **Balance, December 31, 2021** | 1798947 | $180 | $- | $(6546227) | $(6546047) |

---

See accompanying notes to the financial statements

**DOCOLA, INC.**

**STATEMENTS OF CASH FLOWS**

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2021** | **2020** |
| **Cash flows from operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(4439303) | $(1219317) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of SAFE agreements | 4102455 | 910120 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bad debt expense | 28750 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 1231 | 1230 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on debt forgiveness | (26215) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (34475) | (4275) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | (54470) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 8075 | 5362 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in operating activities** | (413952) | (306880) |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment |  | (3691) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in investing activities** | - | (3691) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from SAFE agreements | 321625 | 150000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of notes payable – related party | 51524 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from notes payable - PPP loan | 26215 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayments on notes payable – related party | (15500) | (453) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | 383864 | 149547 |
| **Net change in cash and cash equivalents** | (30088) | (161024) |
| **Cash and cash equivalents at the beginning of period** | 39615 | 200639 |
| **Cash and cash equivalents at the end of period** | $9527 | $39615 |
| **Supplemental disclosures of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $1978 | $236 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for taxes | $- | $- |

---

See accompanying notes to financial statements

**DOCOLA, INC.**

**NOTES TO FINANCIAL STATEMENTS**

**1.** **Nature of the business** 

Docola, Inc. ("the Company") was incorporated in the state of Delaware on September 5, 2013. Docola aims to be a social good organization offering a free care communication platform that seeks to consolidate thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one online marketplace called Docola at the following websites: Https://www.doco.la and Https://www.docola.com (the "Platform"). Additionally, our Platform allows users to easily create and upload their own resources. With the use of our Platform, clinicians and patient-facing professionals can ePrescribe personalized information to an individual patient or groups of patients. Patients can review the information and ask questions in the comfort of their own homes before, between, or after in-person or virtual visits. We aim to proactively meet people's informational needs, so they understand why it's important, possible, and safe to participate in their own medical care. We aim to save time both for the patient and provider and improve patient satisfaction and patient outcomes.

*Liquidity and Going Concern*

As of December 31, 2021, the Company had $9,527 of cash and cash equivalents. To date, the Company has primarily financed its operations through executing SAFE agreements (Simple Agreement for Future Equity) and loans from its founders. The Company has experienced significant negative cash flows from operations since inception, including net losses of $4,439,303 and $1,219,317 for the years ended December 31, 2021, and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of $6,546,227. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future.

The Company will need to obtain additional funding beyond the period that is 12 months from the date these financial statements were available to be issued in order to maintain operations. As a result, in the absence of such funding, substantial doubt exists about the Company's ability to operate as a going concern.

 ****

***Impact of COVID-19 Pandemic***

In March 2020, the World Health Organization declared the outbreak of a COVID-19 pandemic. The COVID-19 pandemic is evolving, and to date, has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures.

The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its operations and the operations of its customers, suppliers, vendors and business partners. The Company does not yet know the full extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or the global economy and it cannot presently predict the scope and severity of any potential business shutdowns or disruptions. The extent to which COVID-19 impacts its business, results of operation and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions to contain COVID-19 or treat its impact, among others. If the Company or any of the third parties with whom the Company engages, however, were to experience shutdowns or other business disruptions, its ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on its business, results of operation and financial condition.

The Company has not incurred impairment losses in the carrying values of its assets as a result of the COVID-19 pandemic and it is not aware of any specific related event or circumstance that would require to revise its estimates reflected in these financial statements.

**2.** **Summary of Significant Accounting Policies** 

 ****

***Basis of presentation and forward stock split.***

The accompanying financial statements were prepared using generally accepted accounting principles in the United States of America ("GAAP").

Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB").

In December of 2022, the Company effected a forward stock split at the ratio of 1199.298126:1 and its 1,500 shares of common stock were split into 1,798,947 shares of common stock. The financial statements presented herein, are presented as if the forward split occurred on the first day of the reporting period, or January 1, 2020.

 ****

***Segment information***

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer ("CEO"). The Company has determined that it operates as a single operating segment and has one reportable segment.

***Use of estimates***

The preparation of financial statements in accordance with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these financial statements include, but are not limited to, the estimated fair value of the Company's common stock and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, income tax valuation allowance and the accruals of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in facts and circumstances. Actual results may differ materially from those estimates or assumptions.

***Cash and cash equivalents***

The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The Company maintains its cash and cash equivalents with financial institutions, in which balances from time to time may exceed the U.S. federally insured limits. The objectives of the Company's cash management policy are to safeguard and preserve funds to maintain liquidity sufficient to meet the Company's cash flow requirements, and to attain a market rate of return.

***Concentration of credit risk***

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

For the years ended December 31, 2021 and 2020, one customer accounted for 84%, and 93% of revenue, respectively. At December 31, 2021 and 2020, one customer accounted for 100% of accounts receivable.

 ****

***Accounts receivable***

The Company's trade accounts receivable consist of amounts due from customers. The Company reserves against trade accounts receivable for estimated losses that may arise from a customer's inability to pay, and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. As of December 31, 2021 and 2020, the Company has recorded an allowance for bad debts against the trade accounts receivable of $28,750 and $0, respectively.

 ****

***Property and equipment***

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful life of the assets.

The estimated useful life of property and equipment is as follows:

---

| | |
|:---|:---|
|  | **Estimated**<br> **Useful Life** |
| Furniture & equipment | &nbsp;&nbsp;&nbsp;&nbsp;3 years |

---

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.

 ****

***Impairment of long-lived assets***

Long-lived assets, comprised of property and equipment, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets.

 ****

***Fair value measurements***

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1—Quoted prices in active markets that are identical assets or liabilities.

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company's ***Simple Agreement for Future Equity*** ("SAFE") are carried at fair value and are classified as Level 3 liabilities.

 ****

***Debt issuance costs***

The Company records debt issuance costs as a reduction to the carrying value of the debt. The debt discounts are amortized over the term of the debt using the effective interest method and recognized as interest expense in the accompanying statement of operations. The Company did not incur any debt issuance costs for the years ended December 31, 2021, 2020.

 ****

***Simple Agreement for Future Equity—SAFE***

The Company accounts for SAFEs at fair value in accordance with ASC 480. The SAFEs are subject to revaluation at the end of each reporting period, with changes in fair value recognized in the accompanying statements of operations.

 ****

***Revenue recognition***

The Company accounts for revenue in accordance with ASC Topic 606, *Revenue from Contracts With Customers* ("ASC 606"). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods or services. The Company applies ASC 606 to contracts with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.

The Company assesses the services promised within each contract and determines those that are performance obligations by evaluating whether each promised service is distinct. This assessment involves subjective determinations and requires management to make judgments about the individual promised services, the intended benefit of the contract and whether each service is separately identifiable from the other aspects of the contractual relationship. If a promised service is not distinct, an entity is required to combine that service with other promised services until it identifies a bundle of services that is distinct.

The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and, if over time, recognition is based on the use of an output or input method.

***Income taxes***

The Company accounts for income taxes according to the ASC 740, *Income Taxes* ("ASC 740") using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company's tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. In evaluating its ability to recover its deferred tax assets, the Company considers all available positive and negative evidence, including projected future taxable income, prudent and feasible tax planning strategies and recent financial operations.

The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. To the extent the Company determines that such tax provisions will not be sustained, the provision for income taxes would include the effects of any resulting income tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.

 ****

***Net loss per share***

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Diluted net loss is computed by adjusting net loss to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For purpose of this calculation, outstanding options, unvested restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive.

*Emerging growth company status*

The Company expects to qualify as an "emerging growth company" ("EGC"), as defined in the Jumpstart Our Business Startups Act ("JOBS Act"), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs.

 

*Recent Accounting Pronouncements*

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. Subsequently, the FASB issued ASU 2019-10 and then ASU 2020-05, both of which adjusted the effective date of ASU 2016-02 for non-public entities. The accounting standard is effective for non-public entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. A modified retrospective transition approach is required at the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has determined that the adoption of this standard has an immaterial impact on the financial statements presented herein.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): *Clarifying the Interaction between Topic 808 and Topic 606*, ("ASU 2018-18"). The amendments in this update clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. ASU 2018-18 is effective for the Company's annual reporting periods beginning after December 15, 2020. The Company has adopted this standard effective January 1, 2021.

In December 2019, the FASB issued ASU 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes* ("ASU 2019-12"), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective for the Company beginning January 1, 2021. The Company has adopted this standard effective January 1, 2021.

On August 5, 2020, the FASB issued ASU No. 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity's Own Equity (Subtopic 815-40)*. The amendments remove certain separation models for convertible debt instruments and convertible preferred stock that require the separation of a convertible debt instrument into a debt component and an equity or derivative component. The ASU also amends the derivative scope exception guidance for contracts in an entity's own equity. The amendments remove three settlement conditions that are required for equity contracts to qualify for the derivative scope exception. In addition to the above, the ASU expands disclosure requirements for convertible instruments and simplifies areas of the guidance for diluted earnings-per-share calculations that are impacted by the amendments. The new standard is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the potential impact this standard may have on its financial statements.

**3.** **Fair value measurements** 

The following tables present information about the Company's financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **December 31, 2020** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| SAFEs | $— | $— | $2126360 | $2126360 |
|  | $— | $— | $2126360 | $212630 |
| **December 31, 2021** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| SAFEs | $— | $— | $6550440 | $6550440 |
|  | $— | $— | $6550440 | $6550440 |

---

The value for the SAFE liability balances are based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.

During the years ended December 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.

 ****

***Simple agreement for future equity—SAFE***

During the years ended December 31, 2021 and 2020, the Company executed SAFE arrangements. The fair value of the SAFEs on the date of issuance was determined to equal the proceeds received by the Company.

The following table sets forth a summary of the activities of the SAFE arrangements which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs:

---

| | |
|:---|:---|
|  | **Amount** |
| Balance at December 31, 2019 | $1066240 |
| Issuance of SAFEs | 150000 |
| Change in fair value | 910120 |
| Balance at December 31, 2020 | $2126360 |

---

---

| | |
|:---|:---|
|  | **Amount** |
| Balance at December 31, 2020 | $2126360 |
| Issuance of SAFEs | 321625 |
| Change in fair value | 4102455 |
| Balance at December 31, 2021 | $6550440 |

---

**4.** **Prepaid Expenses and Other Current Assets** 

Prepaid expenses and other current assets consist of the following :

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2021** | **2020** |
| Accrued income | $54470 | $— |
|  | $54470 | $— |

---

Accrued income represents earned revenue that has not been invoiced to the customer.

**5.** **Property and equipment** 

Property and equipment, net consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2021** | **2020** |
| Furniture and equipment | $4687 | $4687 |
| Less: accumulated depreciation | (3457) | (2226) |
| Property and equipment, net | $1230 | $2461 |

---

Depreciation expense for the years ended December 31, 2021 and 2020 was $1,230 and $1,230, respectively.

**6.** **Other current liabilities** 

Accrued expenses and other current liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2021** | **2020** |
| Credit card payable | $13437 | $5362 |
|  | $13437 | $5362 |

---

**7.** **Notes payable with related parties** 

The principals of the Company have loaned the Company funds from time-to-time. The loans have no specific repayment terms and carried a balance due of $57,397 and $21,373 as of December 31, 2021 and 2020, respectively.

During the years ended December 31, 2021 and 2020, the Company recognized interest expense of $1,978 and $236, respectively, on the Related Notes.

**8.** **Note payable** 

 ****

***Note Payable—Paycheck Protection Program***

The Company applied for and received a loan, which is in the form of a note dated February 9, 2021, from Wells Fargo in the aggregate amount of $26,215 (the "PPP Loan"), pursuant to the Paycheck Protection Program ("PPP"). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act ("CARES Act"), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest may be forgiven if the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the covered period.

The PPP Loan was payable over five years at an interest rate of 1% per annum. The Paycheck Protection Flexibility Act of 2020 extended the deferral period for loan payments to either (1) the date that the Small Business Administration ("SBA") remits the borrower's loan forgiveness amount to the lender, or (2) if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower's loan forgiveness covered period.

On September 17, 2021 the PPP loan was forgiven in its entirety by the U.S. Small Business Administration and the full loan amount of $26,215 was recorded in other income for the year ended December 31, 2021.

**9.** **Simple Agreement for Future Equity—SAFEs** 

From 2014 through 2019, the Company executed 15 SAFE Agreements for proceeds of $1,158,000. During the years ended December 31, 2021the Company executed incremental SAFE Agreements for cash proceeds totaling $246,500, and services totaling $75,125 ($321,625 total),. In 2020 the Company executed SAFE Agreements for cash proceeds totaling $150,000.. The SAFEs are not mandatorily redeemable, nor do they require the Company to repurchase a fixed number of shares. The Company determined that the SAFEs contain a liquidity event provision that embodies an obligation indexed to the fair value of the Company's equity shares and could require the Company to settle the SAFE obligation by transferring assets or cash. For this reason, the Company records the SAFEs as a liability under ASC 480 and re-measures the fair value at the end of each reporting period, with changes in fair value reported in earnings. Upon conversion into common shares, the preferred shares are classified as temporary equity.

In 2022, the Company cancelled all SAFEs and exchanged the SAFEs for 1,379,377 common shares of stock.

**10.** **Common stock** 

The Company has authorized 250,000,000 shares of common stock with par value of $0.0001. As of December 31, 2021 and 2020 the Company had 1,798,947 and 1,798,947 shares of common stock issued and outstanding, respectively.

The holders of the Company's common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as the board from time to time may determine. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of shareholders.

**11.** **Income taxes** 

The Company is subject to U.S. federal income tax as well as income tax in Florida for financial reporting purposes. Loss before income taxes includes the following components:

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2021** | **2020** |
| United States | $- | $- |
| Florida | - |  |
| Total | $- | $- |

---

The income tax expense from continuing operations for the years ended December 31, 2021 and 2020 are as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2021** | **2020** |
| Current and deferred tax expense |  |  |
| &nbsp;&nbsp;&nbsp;United States | $— | $— |
| &nbsp;&nbsp;&nbsp;Florida |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total income tax expense | $— | $— |

---

A reconciliation of income taxes computed using the statutory federal tax rate to that reflected in the statements of operations is as follows:

---

| | | |
|:---|:---|:---|
|  | **Years Ended December 31,** | **Years Ended December 31,** |
|  | **2021** | **2020** |
| U.S. federal statutory income tax rate | 21.0% | 21.0% |
| &nbsp;&nbsp;&nbsp;State and local taxes, net of federal benefit | 4.458% | 4.458% |
| &nbsp;&nbsp;&nbsp;Change in valuation allowance | (25.458%) | (25.458%) |
| Effective income tax rate | 0.0% | 0.0% |

---

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows:

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2021** | **2020** |
| Deferred tax assets and (liabilities): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net operating loss carryforwards | $218072 | $138395 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other temporary differences | (9) | (19) |
| Gross deferred tax assets | 218063 | 138376 |
| Valuation allowance | (218063) | (138376) |
| Net deferred tax assets | $— | $— |

---

The Company has federal net operating loss carryforwards of $889,295 and $564,374 as of December 31, 2021 and 2020, respectively, which were generated from tax years beginning after January 1, 2018, and thus have no expiration date and can be carried forward indefinitely.

In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. Management has recorded a full valuation allowance against the net deferred tax assets as of December 31, 2021 and 2020. The valuation allowance increased by $79,677 during the year ended December 31, 2021 and $76,917 during the year ended December 31, 2020, primarily as a result of net operating losses generated during the periods. The Company reevaluates the positive and negative evidence at each reporting period.

Utilization of the NOL carry forwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code Sections 382 and 383 (the "Code"), as amended, and similar state provisions. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future. If the Company experienced an ownership change at any time since its formation, utilization of the NOL or tax credit carry forwards to offset future taxable income and taxes, respectively, would be subject to annual limitation under the Code. The annual limitation may result in the expiration of the NOL and credits before utilization. If impaired, the NOL and credit carry forwards would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.

On March 27, 2020, the President of the United States signed into law the CARES Act, which, along with earlier issued IRS guidance, contains numerous provisions that may benefit the Company, including the deferral of certain taxes. There is no material impact to the Company. The Company will continue to assess the effect of the CARES Act and ongoing government guidance related to COVID-19 as it is issued.

The Consolidated Appropriations Act, 2021, which was enacted on December 27, 2020, has expanded, extended, and clarified selected CARES Act provisions, specifically on Paycheck Protection Program loan and

Employee Retention Tax Credit, 100% deductibility of business meals as well as other tax extenders. The Consolidated Appropriations Act did not have a material impact on the Company's tax provision for the year ended December 31, 2020.

Generally, the statute of limitations for examination of the Company's U.S. federal and foreign income tax filings are open for the years ended December 31, 2019 and future periods.

**12.** **Net loss per share** 

The Company's unvested common shares have been excluded from the computation of basic net loss per share.

As of December 31, 2021 the Company had not issued any potentially dilutive securities.

In addition to the above, the Company has excluded common shares from the assumed conversion of the SAFEs outstanding at December 31, 2021 and 2020 from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect.

**13.** **Commitments and contingencies**

***Contractual Obligations***

 

***Lease agreements***

The Company has multiple operating lease agreements for office space that extend through March 2022. On January 1, 2019, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board ("FASB") on accounting for leases using the modified retrospective method. This new accounting standard requires a lessee to recognize an asset and liability for most leases on its balance sheet. The Company elected the optional transition method that allowed for a cumulative-effect adjustment to the opening balance of retained earnings recorded on January 1, 2019 and did not restate previously reported results in the comparative periods. The Company also elected the package of practical expedients, which among other things, allowed it to carry forward its historical lease classification. The new standard provides a number of optional practical expedients in transition. We elected the 'package of practical expedients', which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. We elected all of the new standard's available transition practical expedients that are applicable. The new standard also provides practical expedients for an entity's ongoing accounting. We elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, we will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. As all of the Company's leases were for less than 12 months, adoption of the lease standard did not have a material impact on the Company's financial statements or results of operations.

Rent expense for the years ended December 31, 2021 and 2020 was $8,754 and $8,820, respectively.

Minimum annual rent payments under this lease for the remaining term, excluding operating expenses and taxes which are not fixed for future periods as of December 31, 2021, are as follows:

---

| | |
|:---|:---|
| **Year Ended December 31,** | **Amount** |
| 2022 | $- |
| 2023 and thereafter | - |
|  | $- |

---

***Indemnification agreements***

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its financial statements as of December 31, 2020 or 2021.

 ****

***Legal proceedings***

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. As of December 31, 2021 and 2020, the Company was not a party to any material legal matters or claims.

**15.** **Subsequent events** 

The Company has evaluated subsequent events through January 23, 2023 and has concluded that no events or transactions have occurred that require disclosure in the accompanying financial statements, except as follows:

 ****

***Stock Split***

In December 2022, the Company increased its authorized shares and implemented an 1,199.298126-for-1 stock split to increase the number of common shares outstanding from 1,500 to 1,798,947. The financial statements herein have been presented as if the stock split occurred at the beginning of the reporting period, or January 1, 2020.

 ****

***Cancellation of SAFEs***

In 2022, the Company cancelled all SAFEs and issued 1,379,377 common shares of common stock to the SAFE holders.

 ****

***Issuance of Convertible Notes***

In July of 2022, the Company issued 2 convertible notes for proceeds of $50,000 each. The notes call for 6% simple interest and have a conversion feature whereby they will automatically convert into common stock upon and IPO at a 25% discount to the IPO price.

 ****

***Stock for Services***

In December of 2022 the Company issued 470,124 shares of common stock to four professionals for services rendered in 2022.

***Incubator Issuance***

In December of 2022 the Company issued, per its pre-existing contractual arrangement, 150,663 shares to Start-up Health, a New York City based incubator.

[●] **Units**

**Each Unit Consisting of One Share of Common Stock and**

**One Warrant to Purchase One Share of Common Stock**

![](dc001_s1img07.jpg)

**Docola, Inc.**

**PROSPECTUS**

*Book-Running Manager*

WallachBeth Capital LLC

**__________, 2023**

Through and including, 2023 (the 25<sup>th</sup> day after the date of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer's obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13.** **Other Expenses of Issuance and Distribution**

The following table sets forth all expenses to be paid by the registrant, other than estimated underwriting discounts, in connection with our public offering. All amounts shown are estimates except for the SEC registration fee, the Nasdaq Capital Market listing fee and the FINRA filing fee:

---

| | |
|:---|:---|
| Type | Amount |
| SEC Registration Fee | $|
| FINRA Filing Fee |  |
| Nasdaq Capital Market Listing Fee |  |
| Legal Fees and Expenses |  |
| Accounting Fees and Expenses |  |
| Transfer agent and registrar's fees and expenses |  |
| Printing and engraving expenses |  |
| Miscellaneous expense |  |
| Total Expenses | $|

---

**Item 14.** **Indemnification of Directors and Officers.**

Our certificate of incorporation, as amended, provides that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of any fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the General Corporation Law of the State of Delaware or (iv) for any transaction from which the director derives an improper personal benefit. If the General Corporation Law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware, as so amended.

Our bylaws, as amended, provides that the Company shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, suit, or proceeding, wherever brought, whether civil, criminal, administrative, or investigative (including an action by or in the right of the Company), by reason of such person's being or having been a Director, officer, member of a committee, employee, or agent of the Company, or by reason of such person's serving or having served at the request of the Company as a Director, officer, member of a committee, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys' fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit, or proceeding to the fullest extent allowable pursuant to and in accordance with the provisions of the Delaware General Corporation Law, as amended from time to time; provided, however, that in the event said Law shall be amended to increase or expand the permitted indemnification of persons provided for therein, the Company shall be deemed to have adopted such amendment as of its effective date and, provided further, that such indemnification shall be limited by other applicable law.

The effect of this provision of our certificate of incorporation, as amended, is to eliminate our rights and the rights of our stockholders (through stockholders' derivative suits on behalf of the Company) to recover damages against a director or officer for breach of the fiduciary duty of care as a director or officer (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined by statute. We believe that the indemnification provisions in our bylaws, as amended, are necessary to attract and retain qualified persons as directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**Item 15.** **Recent Sales of Unregistered Securities.**

On January 1, 2015, the Company issued 719,579 (600 pre-forward stock split) shares of its common stock to Eran Kabakov in exchange for total cash consideration of $6.00.

On January 1, 2015, the Company issued 719,579 (600 pre-forward stock split) shares of its common stock to Tomer Kabakov in exchange for total cash consideration of $6.00.

On January 1, 2015, the Company issued 359,789 (300 pre-forward stock split) shares of its common stock to Jonathan Cabin in exchange for total cash consideration of $3.00. In 2018, 269,842 (225 pre-forward stock split) of these shares were assumed by Eran Kabakov by mutual consent. On August 30, 2022 52,769 (44 pre-forward split) of the remaining 89,947 (75 pre-forward stock split) of these shares held by the Cabin Family Trust, were sold to Eran Kabakov for $2,500.

In July of 2022, we completed a convertible note offering, in which we sold $100,000 of unsecured convertible notes (the "Notes") to 2 investors, in exchange for proceeds of $100,000. The Notes are automatically convertible into shares of our common stock at a conversion price at a 25% discount to the IPO price and have a maturity date one year from the date of issuance.

From November 2014 through July 2021, the Company issued 22 Simple Agreement for Future Equity ("SAFE") to 15 investors for a total aggregate amount of $1,629,625. The SAFE granted each investor rights to receive certain preferred shares of the Company upon the consummation by the Company of an equity financing. On November 15, 2022, the Company cancelled its previously issued SAFES in exchange for 1,379,377 shares and as a result the SAFES are no longer outstanding.

In December of 2022 the Company issued, per its pre-existing contractual arrangement, 150,663 shares to a New York City-based start-up accelerator.

On December 14, 2022, the Company issued 464,008 shares of common stock to professionals for services rendered.

On December 23, 2022, the Company issued 25,185 shares of common stock to a professional for services rendered.

Other that the issuances made pursuant to the cancellation of the SAFES, which were made pursuant to the exemption from registration provided in Section 3(a)(9) of the Securities Act, the remainder of the above issuances/sales were made pursuant to an exemption from registration as set forth in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

**Item 16.** **Exhibits and Financial Statement Schedules**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Exhibits.* The list of exhibits preceding the signature page of this registration statement is incorporated herein by reference.

(b) *Financial Statements.* See page F-1 for an index to the financial statements and schedules included in the registration statement.

**Item 17.** **Undertakings**

Insofar as indemnification for liabilities arising under the Securities Act "may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Rule 415 Offering. The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers, or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(i) The undersigned Registrant hereby undertakes that it will:

(i) The undersigned Registrant hereby undertakes that it will:

a. for determining any liability under the Securities Act of 1933, treat the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1), or (4) or 497(h) under the Securities Act of 1933 as part of this registration statement as of the time the Commission declared it effective.

a. for determining any liability under the Securities Act of 1933, treat the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1), or (4) or 497(h) under the Securities Act of 1933 as part of this registration statement as of the time the Commission declared it effective.

b. for determining any liability under the Securities Act of 1933, treat each post-effective amendment that contains a form of prospectus as a new registration statement for the securities offered in the registration statement, and that offering of the securities at that time as the initial bona fide offering of those securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. for determining any liability under the Securities Act of 1933, treat each post-effective amendment that contains a form of prospectus as a new registration statement for the securities offered in the registration statement, and that offering of the securities at that time as the initial bona fide offering of those securities.

That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Exhibit** |
| 1.1 | Form of Underwriting Agreement\*\* |
| [3.1](dc001_ex3-1.htm) | [Amended and Restated Certificate of Incorporation of the Company dated December 13, 2022\*](dc001_ex3-1.htm) |
| [3.2](dc001_ex3-2.htm) | [Amended and Restated Bylaws\*](dc001_ex3-2.htm) |
| 4.1 | Form of Warrant (Annex C to the Form of Warrant Agent Agreement attached as Exhibit 4.5)\*\* |
| 4.2 | Form of Warrant Agent Agreement by and between the Company and Equiniti Trust Company\*\* |
| 4.3 | Form of Representative's Warrant (Exhibit E to the Form of Underwriting Agreement attached as Exhibit 1.1)\*\* |
| 5.1 | Opinion of Anthony L.G., PLLC\*\* |
| [10.1](dc001_ex10-1.htm) | [The Docola, Inc. 2022 Equity Incentive Plan \*†](dc001_ex10-1.htm) |
| [10.2](dc001_ex10-2.htm) | [License Agreement with Visual Health Solutions, Inc. dated September 1, 2019.\*](dc001_ex10-2.htm) |
| [10.3](dc001_ex10-3.htm) | [License Agreement with Merck & Co. dated September 30, 2020.\*](dc001_ex10-3.htm) |
| [10.4](dc001_ex10-4.htm) | [License Agreement with the Regents of the University of California acting on behalf of the University of California San Francisco and through the Office of Technology Management & Advancement dated August 16, 2021.\*](dc001_ex10-4.htm) |
| [10.5](dc001_ex10-5.htm) | [Memorandum of Understanding with Patients for Patient Safety US dated December 17, 2021.\*](dc001_ex10-5.htm) |
| [10.6](dc001_ex10-6.htm) | [Master Services Agreement with AbbVie Corporation dated December 9, 2021.\*#](dc001_ex10-6.htm) |
| [10.7](dc001_ex10-7.htm) | [Amendment dated March 4, 2022, to Master Services Agreement with AbbVie Corporation dated December 9, 2021.\*](dc001_ex10-7.htm) |
| [10.8](dc001_ex10-8.htm) | [Collaborative Agreement with Sano Genetics Limited dated August 2, 2022.\*](dc001_ex10-8.htm) |
| [10.9](dc001_ex10-9.htm) | [Master Services Agreement dated January 1, 2020 with Geri Lynn Baumblatt.\*†](dc001_ex10-9.htm) |
| 23.1 | Consent of Sadler, Gibb & Associates, LLC.\*\* |
| 23.2 | Consent of Anthony L.G., PLLC (included on Exhibit 5.1) \*\* |
| 24.1 | Power of Attorney (included on the signature page of the Form S-1)\*\* |

---

\* Filed herewith

\*\*To be filed by amendment

† Includes management contracts and compensation plans and arrangements

# Certain confidential portions (indicated by brackets and asterisks) of this exhibit have been omitted from this exhibit

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Largo, Florida, on [●].

---

| | |
|:---|:---|
| **DOCOLA, INC.** | **DOCOLA, INC.** |
| By: |  |
|  | Eran Kabakov |
|  | Chief Executive Officer and President<br> (Principal executive officer) |

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Eran Kabakov as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities held on [●], 2023.

---

| | | |
|:---|:---|:---|
| **Name** | **Position** | **Date** |
|  | Chief Executive Officer, President and | [●], 2023 |
| Eran Kabakov | Director (Principal Executive Officer) |  |
|  | Chief Financial Officer | [●], 2023 |
| Itay Tsabari | (Principal Financial and Accounting Officer) |  |
|  | Chief Operating Officer and Director | [●], 2023 |
| Tomer Kabakov |  |  |

---

## Exhibit 3.1

**Exhibit 3.1**

<u>Delaware</u> Page 1 <br> The First State

***I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF "DOCOLA, INC.", FILED IN THIS OFFICE ON THE THIRTEENTH DAY OF DECEMBER, A.D. 2022, AT 8:17 O`CLOCK A.M.***

---

| |
|:---|
| /s/ Jeffrey W. Bullock |
| Jeffrey W. Bullock, Secretary of State |

---

---

| | | |
|:---|:---|:---|
| 5394023 8100 | ![](dc001_ex3-1img01.jpg) | Authentication: 205084307 |
| SR# 20224246471 |  | Date: 12-13-22 |

---

You may verify this certificate online at corp.delaware.gov/authver.shtml

---

| |
|:---|
| State of Delaware |
| Secretary of State |
| Division of Corporations |
| Delivered 08:17AM 12/13/2022 |
| FILED 08:17AM 12/13/2022 |
| SR 20224246471 - FileNumber 5394023 |

---

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

docola, Inc.

docola, Inc. (hereinafter referred to as the "Corporation"), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:

FIRST: The date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware is September 5, 2015 (as amended to date, the "Certificate").

SECOND: This Amended and Restated Certificate of Incorporation amends and restates the Certificate in its entirety.

THIRD: This Amended and Restated Certificate of Incorporation has been duly approved and adopted by the Board of Directors of the Corporation and by the stockholders of the Corporation, in each case on December 7, 2022, in accordance with the provisions of Sections 141, 228, 242 and 245 of the General Corporation Law of the State of Delaware.

FOURTH: The Certificate is hereby amended and restated in its entirety to read as follows:

Section 1. <u>Name</u>. The name of the corporation is docola, Inc. (the "Corporation").

Section 2. <u>Registered Office and Agent</u>. The name and address of the registered agent of the Corporation in the State of Delaware is Corporate Creations Network Inc., 3411 Silverside Road Tatnall Building #104, Wilmington, DE 19810, New Castle County, or such other agent and address as the Board of Directors of the Corporation (the "Board") shall from time to time select.

Section 3. <u>Purpose and Business</u>. The purpose of the Corporation is to engage in any lawful act or activity for which corporations may now or hereafter be organized under the DGCL, including, but not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;(a) The Corporation may at any time exercise such rights, privileges, and powers, when not inconsistent with the purposes and object
for which this Corporation is organized.

&nbsp;&nbsp;&nbsp;&nbsp;(b) The Corporation shall have the power to have succession by its corporate name in perpetuity, or until dissolved and its affairs
wound up according to law.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The Corporation shall have the power to sue and be sued in any court of law or equity.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The Corporation shall have the power to make contracts.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The Corporation shall have the power to hold, purchase and convey real and personal estate and
to mortgage or lease any such real and personal estate with its franchises. The power to hold real and personal estate shall include
the power to take the same by devise or bequest in the State of Delaware, or in any other state, territory or country.

&nbsp;&nbsp;&nbsp;&nbsp;(f) The Corporation shall have the power to appoint such officers and agents as the affairs of the
Corporation shall require and allow them suitable compensation.

&nbsp;&nbsp;&nbsp;&nbsp;(g) The Corporation shall have the power to make bylaws not inconsistent with the constitution or laws
of the United States, or of the State of Delaware, for the management, regulation and government of its affairs and property, the
transfer of its stock, the transaction of its business and the calling and holding of meetings of stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;(h) The Corporation shall have the power to wind up and dissolve itself, or be wound up or dissolved.

&nbsp;&nbsp;&nbsp;&nbsp;(i) The Corporation shall have the power to adopt and use a common seal or stamp, or to not use such
seal or stamp and if one is used, to alter the same. The use of a seal or stamp by the Corporation on any corporate documents is
not necessary. The Corporation may use a seal or stamp, if it desires, but such use or non-use shall not in any way affect the
legality of the document.

&nbsp;&nbsp;&nbsp;&nbsp;(j) The Corporation shall have the power to borrow money and contract debts when necessary for the
transaction of its business, or for the exercise of its corporate rights, privileges or franchises, or for any other lawful purpose
of its incorporation; to issue bonds, promissory notes, bills of exchange, debentures and other obligations and evidence of indebtedness,
payable at a specified time or times, or payable upon the happening of a specified event or events, whether secured by mortgage,
pledge or otherwise, or unsecured, for money borrowed, or in payment for property purchased, or acquired, or for another lawful
object.

&nbsp;&nbsp;&nbsp;&nbsp;(k) The Corporation shall have the power to guarantee, purchase, hold, sell, assign, transfer, mortgage,
pledge or otherwise dispose of the shares of the capital stock of, or any bonds, securities or evidence in indebtedness created
by any other corporation or corporations in the State of Delaware, or any other state or government and, while the owner of such
stock, bonds, securities or evidence of indebtedness, to exercise all the rights, powers and privileges of ownership, including
the right to vote, if any.

&nbsp;&nbsp;&nbsp;&nbsp;(l) The Corporation shall have the power to purchase, hold, sell and transfer shares of its own capital
stock and use therefore its capital, capital surplus, surplus or other property or fund.

&nbsp;&nbsp;&nbsp;&nbsp;(m) The Corporation shall have the power to conduct business, have one or more offices and hold, purchase,
mortgage and convey real and personal property in the State of Delaware and in any of the several states, territories, possessions
and dependencies of the United States, the District of Columbia and in any foreign country.

&nbsp;&nbsp;&nbsp;&nbsp;(n) The Corporation shall have the power to do all and everything necessary
and proper for the accomplishment of the objects enumerated in its Certificate of Incorporation, or any amendments thereof, or
necessary or incidental to the protection and benefit of the Corporation and, in general, to carry on any lawful business necessary
or incidental to the attainment of the purposes of the Corporation, whether or not such business is similar in nature to
the purposes set forth in the Certificate of Incorporation of the Corporation, or any amendment thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(o) The Corporation shall have the power to make donations for the public welfare or for charitable, scientific or educational
purposes.

&nbsp;&nbsp;&nbsp;&nbsp;(p) The Corporation shall have the power to enter partnerships, general or limited, or joint ventures, in connection with any lawful
activities.

Section 4. <u>Capital Stock</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Classes and Number of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Total Shares</u>. The total number of shares of all classes of stock, which the Corporation
shall have authority to issue shall be Two Hundred and Fifty Million (250,000,000) shares of common stock, par value of $0.0001
per share (the "Common Stock") and Twenty Million (20,000,000) shares of preferred stock, par value of $0.0001 per
share (the "Preferred Stock").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Forward Split</u>. Upon the effectiveness of this Amended and Restated Certificate of Incorporation
(this "Certificate of Incorporation"), each share of the Common Stock then issued and outstanding (collectively, the
"Pre-Split Common Stock") shall automatically and without any action on the part of the holder thereof be reclassified
such that each one (1) share of the Common Stock shall become 1,199.298126 shares of Common Stock (the "Forward Stock Split").
Any certificate that immediately prior to the effectiveness of this Certificate of Incorporation represented shares of Pre-Split
Common Stock ("Old Certificates"), shall thereafter represent that number of shares of Common Stock into which the
shares of Common Stock represented by the Old Certificate shall have been reclassified, and changed as described above. The authorized
number of shares, and par value per share, of Common Stock shall not be affected by the Forward Stock Split.

&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Powers and Rights of Common Stock</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Preemptive Right</u>. No shareholders of the Corporation holding Common Stock shall have any
preemptive or other right to subscribe for any additional unissued or treasury shares of stock or for other securities of any class,
or for rights, warrants or options to purchase stock, or for scrip, or for securities of any kind convertible into stock or carrying
stock purchase warrants or privileges unless so authorized by the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Voting Rights and Powers</u>. With respect to all matters upon which stockholders are entitled
to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of the Common Stock shall
be entitled to cast thereon one (1) vote in person or by proxy for each share of the Common Stock standing in his/her name.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Dividends and Distributions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) <u>Cash Dividends</u>. Subject to the rights of holders of Preferred
Stock, holders of Common Stock shall be entitled to receive such cash dividends as may be declared thereon by the Board from time
to time out of assets or funds of the Corporation legally available therefore; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) <u>Other Dividends and Distributions</u>. The Board may issue shares of the Common Stock in the
form of a distribution or distributions pursuant to a stock dividend or split-up of the shares of the Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Other Rights</u>. Except as otherwise required by the DGCL and as may otherwise be provided
in this Certificate of Incorporation, each share of the Common Stock shall have identical powers, preferences and rights, including
rights in liquidation.

&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Classes of Preferred Stock</u>. The powers, preferences, rights, qualifications, limitations
and restrictions pertaining to the Preferred Stock, or any series thereof, shall be such as may be fixed, from time to time, by
the Board in its sole discretion, authority to do so being hereby expressly vested in the Board. The authority of the Board with
respect to each such series of Preferred Stock will include, without limiting the generality of the foregoing, the determination
of any or all of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The number of shares of any series and the designation to distinguish the shares of such series
from the shares of all other series;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the voting powers, if any, of the shares of such series and whether such voting powers are full
or limited;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the redemption provisions, if any, applicable to such series, including the redemption price or
prices to be paid;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) whether dividends, if any, will be cumulative or noncumulative, the dividend rate or rates of such
series and the dates and preferences of dividends on such series;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) the rights of such series upon the voluntary or involuntary dissolution of, or upon any distribution
of the assets of, the Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) the provisions, if any, pursuant to which the shares of such series are convertible into, or exchangeable
for, shares of any other class or classes or of any other series of the same or any other class or classes of stock, or any other
security, of the Corporation or any other corporation or other entity, and the rates or other determinants of conversion or exchange
applicable thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) the right, if any, to subscribe for or to purchase any securities of the Corporation or any other
corporation or other entity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) the provisions, if any, of a sinking fund applicable to such series; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) any other relative, participating, optional or other powers, preferences or rights, and any qualifications,
limitations or restrictions thereof, of such series.

&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Issuance of the Common Stock and the Preferred Stock</u>. The Board may from time to time authorize
by resolution the issuance of any or all shares of the Common Stock and the Preferred Stock herein authorized in accordance with
the terms and conditions set forth in this Certificate of Incorporation for such purposes, in such amounts, to such persons, corporations,
or entities, for such consideration and in the case of the Preferred Stock, in one or more series,
all as the Board in its discretion may determine and without any vote or other action by the stockholders, except as otherwise
required by law. The Board, from time to time, also may authorize, by resolution, options, warrants and other rights convertible
into Common or Preferred stock (collectively "securities"). The securities must be issued for such consideration, including
cash, property, or services, as the Board may deem appropriate, subject to the requirement that the value of such consideration
be no less than the par value of the shares issued. Any shares issued for which the consideration so fixed has been paid or delivered
shall be fully paid stock and the holder of such shares shall not be liable for any further call or assessment or any other payment
thereon, provided that the actual value of such consideration is not less that the par value of the shares so issued. The Board
may issue shares of the Common Stock in the form of a distribution or distributions pursuant to a stock dividend or split- up of
the shares of the Common Stock only to the then holders of the outstanding shares of the Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Cumulative Voting</u>. Except as otherwise required by applicable law, there shall be no cumulative
voting on any matter brought to a vote of stockholders of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>One Class</u>. Except as otherwise required by the DGCL, this Certificate of Incorporation,
or any designation for a class of Preferred Stock (which may provide that an alternate vote is required), (i) all shares of capital
stock of the Corporation shall vote together as one class on all matters submitted to a vote of the shareholders of the Corporation;
and (ii) the affirmative vote of
a majority of the voting power of all outstanding shares of voting stock entitled to vote in connection with the applicable matter
shall be required for approval of such matter.

&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Section 242(b)(2) Election</u>. For the avoidance of doubt, the intent of Section 4(f) is, and
the operation of Section 4(f) shall be, that, without limitation, (i) the number of authorized shares of Common Stock, may be increased
or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority
of the stock of the Corporation entitled to vote irrespective of Section 242(b)(2) of the DGCL, with no vote of any holders of
a particular class of stock, voting as a separate class, being required; and (ii) unless otherwise set forth in a certificate of
designations for the applicable class of Preferred Stock, the number of authorized shares of any class of Preferred Stock may be
increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of
a majority of the stock of the Corporation entitled to vote irrespective of Section 242(b)(2) of the DGCL, with no vote of any
holders of a particular class of stock, voting as a separate class, being required.

Section 5. <u>Adoption of Bylaws</u>. In the furtherance and not in limitation of the powers conferred by statute and subject to Section 6, the Board is expressly authorized to adopt, repeal, rescind, alter or amend in any respect the bylaws of the Corporation (the "Bylaws").

Section 6. <u>Shareholder Amendment of Bylaws</u>. Notwithstanding Section 5, the Bylaws may also be adopted, repealed, rescinded, altered or amended in any respect by the stockholders of the Corporation, but only by the affirmative vote of the holders of a majority of the voting power of all outstanding shares of voting stock, regardless of class and voting together as a single voting class.

Section 7. <u>Board of Directors</u>. The business and affairs of the Corporation shall be managed by and under the direction of the Board. Except as may otherwise be provided in connection with rights to elect additional directors under specified circumstances, which may be granted to the holders of any class or series of Preferred Stock, the number of directors of the Corporation may be amended from time to time as set forth in the Bylaws. The exact number of directors shall be fixed from time to time by the Board pursuant to a resolution adopted by a majority of the full Board. Directors need not be stockholders.

Section 8. <u>Powers of Board</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) In furtherance and not in limitation of the powers conferred by the laws of the DGCL, the Board
is expressly authorized and empowered:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To make, alter, amend, and repeal the Bylaws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Subject to the applicable provisions of the Bylaws then in effect, to determine, from time to time,
whether and to what extent, and at what times and places, and under what conditions and regulations, the accounts and books of
the Corporation, or any of them, shall be open to stockholder inspection, provided that no stockholder shall have any right to
inspect any of the accounts, books or documents of the Corporation, except as permitted by law, unless and until authorized to
do so by resolution of the Board or of the stockholders of the Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To authorize and issue, without stockholder consent, obligations of the Corporation, secured and
unsecured, under such terms and conditions as the Board, in its sole discretion, may determine, and to pledge or mortgage, as security
therefore, any real or personal property of the Corporation, including after-acquired property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) To determine whether any and, if so, what part of the earned surplus of the Corporation shall be
paid in dividends to the stockholders, and to direct and determine other use and disposition of any such earned surplus;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) To fix, from time to time, the amount of the profits of the Corporation to be reserved as working
capital or for any other lawful purpose;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) To establish bonus, profit-sharing, stock option, or other types of incentive compensation plans
for the employees, including officers and directors, of the Corporation, and to fix the amount of profits to be shared or distributed,
and to determine the persons to participate in any such plans and the amount of their respective participations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) to designate, by resolution or resolutions passed by a majority of the whole Board, one or more
committees, each consisting of two or more directors, which, to the extent permitted by law and authorized by the resolution or
the Bylaws, shall have and may exercise the powers of the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) To provide for the reasonable compensation of its own members by Bylaw, and to fix the terms and conditions upon which such
compensation will be paid.

&nbsp;&nbsp;&nbsp;&nbsp;(b) In addition to the powers and authority hereinbefore, or by statute, expressly conferred upon it,
the Board may exercise all such powers and do all such acts and things as may be exercised or done by the Corporation, subject,
nevertheless, to the provisions of the laws of the State of Delaware,
of this Certificate of Incorporation, and of the Bylaws of the Corporation.

Section 9. <u>Interested Directors</u>. No contract or transaction between this Corporation and any of its directors, or between this Corporation and any other corporation, firm, association, or other legal entity shall be invalidated by reason of the fact that the director of the Corporation has a direct or indirect interest, pecuniary or otherwise, in such corporation, firm, association, or legal entity, or because the interested director was present at the meeting of the Board which acted upon or in reference to such contract or transaction, or because he participated in such action, provided that: (1) the interest of each such director shall have been disclosed to or known by the Board and a disinterested majority of the Board shall have, nonetheless, ratified and approved such contract or transaction (such interested director or directors may be counted in determining whether a quorum is present for the meeting at which such ratification or approval is given); or (2) the conditions of DGCL Title 8, Section 144 are met.

Section 10. <u>Term of Board of Directors</u>. Except as otherwise required by applicable law, each director shall serve for a term ending on the first anniversary of their date of election, provided that, notwithstanding the foregoing provisions of this Section 10 each director shall serve until their successor is elected and qualified or until his or her death, resignation or removal. All directors shall have equal standing. Notwithstanding the foregoing provisions of this Section 10, no decrease in the authorized number of directors shall shorten the term of any incumbent director; and additional directors, elected in connection with rights to elect such additional directors under specified circumstances, which may be granted to the holders of any class or series of Preferred Stock, shall not be included in any class, but shall serve for such term or terms and pursuant to such other provisions as are specified in the resolution of the Board establishing such class or series.

Section 11. <u>Vacancies on Board of Directors</u>. Except as may otherwise be provided in connection with rights to elect additional directors under specified circumstances, which may be granted to the holders of any class or series of Preferred Stock, newly created directorships resulting from any increase in the number of directors, or any vacancies on the Board resulting from death, resignation, removal, or other causes, shall be filled solely by the quorum of the Board. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of directors in which the new directorship was created or the vacancy occurred and until such director's successor shall have been elected and qualified or until such director's death, resignation or removal, whichever first occurs.

Section 12. <u>Removal of Directors</u>. Except as may otherwise be provided in connection with rights to elect additional directors under specified circumstances, which may be granted to the holders of any class or series of Preferred Stock, any director may be removed from office only by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the issued and outstanding stock entitled to vote. Failure of an incumbent director to be nominated to serve an additional term of office shall not be deemed a removal from office requiring any stockholder vote.

Section 13. <u>Stockholder Action</u>. Any action required or permitted to be taken by the stockholders of the Corporation must be effective at a duly called annual meeting or at a special meeting of stockholders of the Corporation, unless such action requiring or permitting stockholder approval is approved by a majority of the directors, in which case such action may be authorized or taken by the written consent of the holders of outstanding shares of voting stock having not less than the minimum voting power that would be necessary to authorize or take such action at a meeting of stockholders at which all shares entitled to vote thereon were present and voted, provided all other requirements of applicable law and this Certificate of Incorporation have been satisfied.

Section 14. <u>Special Stockholder Meetings</u>. Special meetings of the stockholders of the Corporation for any purpose or purposes may be called at any time by a majority of the Board. Special meetings may not be called by any other person or persons. Each special meeting shall be held at such date and time as is requested by Board, within the limits fixed by law.

Section 15. <u>Location of Stockholder Meetings</u>. Meetings of stockholders of the Corporation may be held within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation may be kept (subject to any provision of the DGCL) outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws.

Section 16. <u>Private Property of Stockholders</u>. The private property of the stockholders shall not be subject to the payment of corporate debts to any extent whatever and the stockholders shall not be personally liable for the payment of the Corporation's debts.

Section 17. <u>Amendments</u>. The Corporation reserves the right to adopt, repeal, rescind, alter or amend in any respect any provision contained in this Certificate of Incorporation in the manner now or hereafter prescribed by applicable law and all rights conferred on stockholders herein granted subject to this reservation.

Section 18. <u>Term of Existence</u>. The Corporation is to have perpetual existence.

Section 19. <u>Liability of Directors</u>. No director of this Corporation shall have personal liability to the Corporation or any of its stockholders for monetary damages for breach of fiduciary duty as a director or officers involving any act or omission of any such director or officer. The foregoing provision shall not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or, which involve intentional misconduct or a knowing violation of law, (iii) under applicable sections of the DGCL, (iv) the payment of dividends in violation of the DGCL or, (v) for any transaction from which the director derived an improper personal benefit. Any repeal or modification of this Section 19 by the stockholders of the Corporation shall be prospective only and shall not adversely affect any limitation on the personal liability of a director or officer of the Corporation for acts or omissions prior to such repeal or modification.

Section 20. <u>Indemnification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Indemnification in Actions, Suits or Proceedings other than Those by or in the Right of the Corporation.* Subject to Section 20(c) and Section 20(j), the Corporation shall, to the fullest extent
permitted by the DGCL and applicable Delaware law as in effect at any time, indemnify, hold harmless and defend any person who:
(i) was or is a director or officer of the Corporation or was or is a director or officer of a direct or indirect wholly owned
subsidiary of the Corporation, and (ii) was or is a party or is threatened to be made a party to, or was or is otherwise directly
involved in (including as a witness), any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that such person
was or is a director or officer of the Corporation or any direct or indirect wholly owned subsidiary of the Corporation, or was
or is serving at the request of the Corporation as a director, officer, employee, partner, member or agent of another corporation,
partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise, whether the basis
of such proceeding is alleged action in an official capacity or in any other capacity, against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such
action, suit or proceeding if such person acted in good faith and in a manner such person reasonably
believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding,
had no reasonable cause to believe such person's conduct was unlawful. The termination of any action, suit or proceeding
by judgment, order, settlement, conviction, or upon a plea or nolo contendere or its equivalent, shall not, of itself, create a
presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed
to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe
that such person's conduct was unlawful.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Indemnification in Actions, Suits or Proceedings by or in the Right of the Corporation.* Subject
to Section 20(c) and Section 20(j), the Corporation shall indemnify, hold harmless and defend any person who: (i) was or is a director
or officer of the Corporation or was or is a director or officer of a direct or indirect wholly owned subsidiary of the Corporation,
and (ii) was or is a party or is threatened to be made a party to, or was or is otherwise directly involved in (including as a
witness), any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its
favor by reason of the fact that such person was or is a director or officer of the Corporation or any direct or indirect wholly
owned subsidiary of the Corporation, or was or is serving at the request of the Corporation as a director, officer, employee, partner,
member or agent of another corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or
other enterprise, and whether the basis of such action, suit or proceeding is alleged action in an official capacity or in any
other capacity, against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection
with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably
believed to be in or not opposed to the best interests of the Corporation; except that no indemnification shall be made in
respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and
only to the extent that the Courts in the State of Delaware or the court in which such action or suit was brought shall determine
upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly
and reasonably entitled to indemnity for such expenses which the Court in the State of Delaware or such other court shall deem
proper.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Authorization of Indemnification.* Any indemnification or defense
under this Section 20 (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon
a determination that indemnification of the director or officer is proper in the circumstances because such person has met the
applicable standard of conduct set forth in Section 20(a) or Section 20(b), as the case may be. Such determination shall be made,
with respect to a person who is a director or officer at the time of such determination: (i) by directors constituting a majority
of the Board and who are not parties to such action, suit or proceeding, even though less than a quorum (the "Board Voting
Majority"), or (ii) by a committee of such directors designated by the Board Voting Majority, even though less than a quorum,
or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion, or
(iv) by the stockholders. Such determination shall be made, with respect to former directors and officers, by any person or persons
having the authority to act on the matter on behalf of the Corporation. To the extent, however, that a present or former
director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding
set forth in Section 20(a) or Section 20(b) or in defense of any claim, issue or matter therein, such person shall be indemnified
against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith, without
the necessity of authorization in the specific case.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Good Faith Defined.* For purposes of any determination under Section 20(c), a person shall
be deemed to have acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests
of the Corporation, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe such person's
conduct was unlawful, if such person's action is based on good faith reliance on the records or books of account of the Corporation
or another enterprise, or on information supplied to such person by the officers of the Corporation or another enterprise in the
course of their duties, or on the advice of legal counsel for the Corporation or another enterprise or on information or records
given or reports made to the Corporation or another enterprise by an independent certified public accountant or by an appraiser
or other expert selected with reasonable care by the Corporation or another enterprise. The term "another enterprise"
as used in this Section 20(d) shall mean any other corporation or any partnership, limited liability company, joint venture, trust,
employee benefit plan or other enterprise of which such person was or is serving at the request of the Corporation as a director,
officer, employee, partner, member or agent. The provisions of this Section 20(d) shall not be deemed to be exclusive or to limit
in any way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth in Section
20(a) or Section 20(b), as the case may be.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Expenses Payable in Advance.* Expenses, including attorneys' fees, incurred by a current
or former director or officer in defending any action, suit or proceeding described in Section 20(a) or Section 20(b) shall be
paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by
or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled
to be indemnified by the Corporation as authorized in this Section 20.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Non-exclusivity of Indemnification and Advancement of Expenses.* The indemnification, defense
and advancement of expenses provided by or granted pursuant to this Section 20 shall not be deemed exclusive of any other rights
to which those seeking indemnification or advancement of expenses may be entitled under the Certificate, any agreement, vote of
stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as to action
in another capacity while holding such office, it being the policy of the Corporation that indemnification of the persons specified
in Section 20(a) or Section 20(b) shall be made to the fullest extent permitted by applicable law. The provisions of this Section
20 shall not be deemed to preclude the indemnification of, or advancement of expenses to, any person who is not specified in Section
20(a) or Section 20(b) but whom the Corporation has the power or obligation to indemnify under the provisions of the DGCL or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;(g) *Insurance.* The Corporation may purchase and maintain insurance
on behalf of any person who was or is a director, officer, employee or agent of the Corporation, or a direct or indirect wholly
owned subsidiary of the Corporation, or was or is serving at the request of the Corporation, as a director, officer, employee,
partner, member or agent of another corporation, partnership, limited liability company, joint venture, trust, employee benefit
plan or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or
arising out of such person's status as such, whether or not the Corporation would have the power or the obligation to indemnify,
hold harmless or defend such person against such liability under the provisions of this Section 20.

&nbsp;&nbsp;&nbsp;&nbsp;(h) *Certain Definitions.* For purposes of this Section 20 references to the "Corporation"
shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent)
absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify
its directors, officers, employees or agents so that any person who was or is a director, officer, employee or agent of such constituent
corporation, or was or is serving at the request of such constituent corporation as a director, officer, employee, partner, member
or agent of another corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise,
shall stand in the same position under the provisions of this Section 20 with respect to the resulting or surviving corporation
as such person would have with respect to such constituent corporation if its separate existence had continued. For purposes of
this Section 20, references to "fines" shall include any excise taxes assessed on a person with respect of any employee
benefit plan; and references to "serving at the request of the Corporation" shall include any service as a director,
officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee
or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith
and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit
plan shall be deemed to have acted in a manner "not opposed to the best interests of the Corporation" as referred to
in this Section 20.

&nbsp;&nbsp;&nbsp;&nbsp;(i) *Survival of Indemnification and Advancement of Expenses.* The indemnification, defense and
advancement of expenses provided by, or granted pursuant to, this Section 20 shall, unless otherwise provided when authorized or
ratified, continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors
and administrators of such a person.

&nbsp;&nbsp;&nbsp;&nbsp;(j) *Limitation on Indemnification; Attorneys' Fees.* Notwithstanding anything contained
in this Section 20 to the contrary, except for proceedings to enforce rights to indemnification and defense under this Section
20 (which shall be governed by Section 20(k)(ii)), the Corporation shall not be obligated under this Section 20 to indemnify, hold
harmless or defend any director, officer, employee or agent in connection with a proceeding (or part thereof) initiated by such
person unless such proceeding (or part thereof) was authorized by the Board. Notwithstanding anything contained in this Section
20 to the contrary, the prevailing party shall not be entitled to recover from the other party reasonable attorneys' fees,
costs and expenses incurred in connection with the prosecution or defense of such action to the extent that such fees, costs and
expenses relate to "internal corporate claims" as defined in Section 109(b) of the DGCL.

&nbsp;&nbsp;&nbsp;&nbsp;(k) *Contract Rights.* 

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The obligations of the Corporation under this Section 20 to indemnify, hold harmless and
defend a person who was or is a director or officer of the Corporation or was or is a director or officer of a direct or indirect
wholly owned subsidiary of the Corporation, including the duty to advance expenses, shall be considered a contract between the
Corporation and such person, and no modification or repeal of any provision of this Section 20 shall affect, to the detriment of
such person, such obligations of the Corporation in connection with a claim based on any act or failure to act occurring before
such modification or repeal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If a claim under Section 20(a), Section 20(b) or Section 20(e) is not paid in full by the Corporation
within 90 days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of
expenses, in which case the applicable period shall be 45 days, the person making such claim may at any time thereafter bring suit
against the Corporation to recover the unpaid amount of the claim. To the fullest extent permitted by applicable law, if successful
in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to
the terms of an undertaking, such person shall be entitled to be paid also the expense of prosecuting or defending such suit. In
(i) any suit brought by such person to enforce a right to indemnification hereunder (but not in a suit brought by such person to
enforce a right to an advancement of expenses) it shall be a defense, and (ii) in any suit brought by the Corporation to recover
an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses
upon a final adjudication that such person has not met any applicable standard for indemnification set forth in the DGCL. Neither
the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent
legal counsel or its Stockholders) to have made a determination prior to the commencement of such suit that indemnification of
such person is proper in the circumstances because such person has met the applicable standard of conduct set forth in the DGCL,
nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such
directors, independent legal counsel or its Stockholders) that such person has not met such applicable standard of conduct, shall
create a presumption that such person has not met the applicable standard of conduct or, in the case of such a suit brought by
such person, be a defense to such suit.

&nbsp;&nbsp;&nbsp;&nbsp;(l) *Indemnification Agreements.* Without limiting the generality of the foregoing, the Corporation
shall have the express authority to enter into such agreements as the Board deems appropriate for the indemnification of present
or future directors and officers of the Corporation in connection with their service to, or status with, the Corporation or any
other corporation, entity or enterprise with whom such person is serving at the express written request of the Corporation.

Section 22. <u>Headings</u>. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Incorporation and shall not be deemed to limit or affect any of the provisions hereof.

IN WITNESS WHEREOF, the undersigned has executed this Amended and Restated Certificate of Incorporation as of December 7, 2022.

---

| | |
|:---|:---|
| By: | /s/ Eran Kabakov |
| Eran Kabakov | Eran Kabakov |
| Chief Executive Officer | Chief Executive Officer |

---

## Exhibit 3.2

**Exhibit 3.2**

**Amended and Restated** 

**Bylaws**

**Of**

**docola, Inc.**

**a Delaware corporation**

Adopted December 7, 2022

1. *Offices*. docola, Inc. (the "Corporation") may have an office or offices, and keep the books and records
of the Corporation, except as may otherwise be required by applicable law, at such other place or places, either within or without
the State of Delaware, as the Board may from time to time determine or the business of the Corporation may require.

2. *Meetings of Stockholders*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. *Annual Meetings.* The annual meetings of stockholders for the election of directors and for such other business as may
be stated in the notice of the meeting shall be held at such time and date and place as the Board, by resolution, shall determine
and as set forth in the notice of the meeting and shall be held at such place, either within or without the State of Delaware.
If the date of the annual meeting shall fall upon a legal holiday, the meeting shall be held on the next succeeding business day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. *Deferred Meeting for Election of Directors, etc.* If the annual meeting of stockholders for the election of directors
and the transaction of other business is not held within the time specified in Section 2.1, the Board shall call a special meeting
of stockholders for the election of directors and the transaction of other business as soon thereafter as convenient.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. *Other Special Meetings.* A special meeting of stockholders (other than a special meeting for the election of directors),
unless otherwise prescribed by statute, may only be called by the Board and may be called at any time by the Board. At any special
meeting of stockholders, only such business may be transacted as is related to the purpose(s) of such meeting set forth in the
notice thereof given pursuant to Section 2.5 or in any waiver of notice thereof given pursuant to Section 2.6.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4. *Fixing Record Date.* For the purpose of determining the stockholders entitled to notice of or to vote at any meeting
of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or for the
purpose of determining stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights,
or entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful
action, the Board may fix, in advance, a date as of the record date for any such determination of stockholders. Such date shall
not be more than sixty (60) nor less than ten (10) days before the date of such meeting nor more than sixty (60) days prior to
any other action. If no such record date is fixed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The record date for the determination of stockholders entitled to notice of or to vote at a meeting of stockholders shall be
at the close of business on the day next preceding the day on which notice is given or, if no notice is given or if notice is waived,
at the close of business on the day next preceding the day on which the meeting is held;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The record date for determining stockholders entitled to express consent to corporate action in writing without a meeting,
when no prior action by the Board is necessary, shall be the day on which the first written consent is expressed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The record date for determining stockholders for any purpose other than those specified in Sections 2.4(a) and Section 2.4(b)
shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

When a determination of stockholders entitled to notice of, or to vote at, any meeting of stockholders has been made as provided in this Section 2.4, such determination shall apply to any adjournment thereof, unless the Board fixes a new record date for the adjourned meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5. *Notice of Meetings of Stockholders; Location.* Except as otherwise provided in Section 2.4 and Section 2.6, whenever
under any provision of the Delaware General Corporation Law (as the same may be amended and supplemented from time to time, and
including any successor provision thereto, the "DGCL"), the Certificate of Incorporation of the Corporation (as the
same may be amended, supplemented and/or restated from time to time, the "Certificate") or these Bylaws, stockholders
are required or permitted to take any action at a meeting, written notice shall be given stating the place, date and hour of the
meeting and, in the case of a special meeting, the purpose(s) for which the meeting is called. Except as otherwise provided by
any provision of the DGCL, a copy of the notice of any meeting shall be given, personally or by mail, not less than 10 nor more
than 60 days before the date of the meeting, to each stockholder entitled to notice of, or to vote at, such meeting. If mailed,
such notice shall be deemed to be given when deposited in the United States Mail, postage prepaid, directed to the stockholder
at his address as it appears on the records of the Corporation. An affidavit of the Secretary or an Assistant Secretary or of the
transfer agent of the Corporation that the notice required by this Section 2.5 has been given shall, in the absence of fraud, be
prima facie evidence of the facts stated therein. When a meeting is adjourned to another time or place, notice need not be given
of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken and, at the
adjourned meeting, any business may be transacted that might have been transacted at the meeting originally called. If, however,
the adjournment is for more than 60 days or if, after the adjournment, a new record date is fixed for the adjourned meeting, a
notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. The Board may designate
the place of meeting for any meeting of Stockholders. If no designation is made by the Board, the place of meeting shall be the
principal executive offices of the Corporation. The Board may, in its sole discretion, determine that the meeting shall not be
held at any place, but may instead be held solely by means of remote communication as authorized by the DGCL

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6. *Waivers of Notice.* Whenever notice is required to be given to the stockholders under any provision of the DGCL, or the
Certificate or these Bylaws, a written waiver thereof, signed by a stockholder entitled to notice, whether before or after the
time stated therein, shall be deemed equivalent to notice. Attendance of a stockholder at a meeting shall constitute a waiver of
notice of such meeting, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of
the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to
be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver
of notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7. *Quorum of Stockholders; Adjournment; Postponement.* The holders of a majority of the voting power, present,
in person or represented by proxy, shall be necessary and sufficient to constitute a quorum for the transaction of any business
at such meeting, except where otherwise provided by any provision of the DGCL. When a quorum is once present to organize a meeting
of stockholders, it is not broken by the subsequent withdrawal of any stockholders. The Chairman, or the holders of a majority
of the shares of stock present in person or represented by proxy at any meeting of stockholders, including an adjournment meeting,
whether or not a quorum is present, may adjourn such meeting to another time and place. Any previously scheduled meeting of stockholders
may be postponed, and any previously scheduled special meeting of Stockholders may be canceled, by the Board upon public notice
given prior to the time previously scheduled for such meeting of stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8. *Voting; Proxies.* 

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Unless otherwise provided in the Certificate, every stockholder of record shall be entitled at every meeting of stockholders
to one vote for each share of capital stock standing in his name on the record of stockholders determined in accordance with Section
2.4. If the Certificate provides for more or less than one vote for any share on any matter, every reference in these Bylaws or
any provision of the DGCL, to a majority or other proportion of stock shall refer to such majority or other proportion of the votes
of such stock. The provisions of the DGCL shall apply in determining whether any shares of capital stock may be voted and the persons,
if any entitled to vote such shares, but the Corporation shall be protected in treating the persons in whose names shares of capital
stock stand on the record of stockholders as owners thereof for all purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In any uncontested election of directors, each person receiving a majority of the votes cast shall be deemed elected. For purposes
of this paragraph, a 'majority of the votes cast' shall mean that the number of votes cast 'for' a director
must exceed the number of votes cast 'against' that director (with 'abstentions' and 'broker non-votes'
not counted as a vote cast with respect to that director). In any contested election of directors, the persons receiving a plurality
of the votes cast, up to the number of directors to be elected in such election, shall be deemed elected. The Board may, but need
not, establish policies and procedures regarding the nomination, election and resignation of directors, which policies and procedures
may: (i) include a condition to nomination by the Board for election or re-election as a director that an individual agree to tender,
if elected or re-elected, an irrevocable offer of resignation conditioned on: (A) failing to receive the required vote for re-election
at the next meeting at which such person would face re-election and (B) acceptance of the resignation by the Board, (ii) require:
(A) if one exists, the Corporation's nominating and governance committee or other committee designated by the Board (the
"Nominating and Governance Committee") to make a recommendation to the Board on whether to accept or reject the resignation,
or whether other action should be taken and (B) the Board to act on the Nominating and Governance Committee's recommendation
and publicly disclose its decision and the rationale behind it within 90 days, to the extent practicable, from the date of the
certification of the election results. A "contested election" is one in which: (i) the Secretary receives a notice
that a Stockholder has nominated a person for election to the Board in compliance with the advance notice requirements for stockholder
nominees for director set forth in Section and (ii) such nomination has
not been withdrawn by such stockholder on or before the 10<sup>th</sup> day before the Corporation first mails its notice of meeting
for such meeting to the stockholders. An "uncontested election" is any election other than a contested election. All
elections of directors shall be by written ballot unless otherwise provided in the Certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) As to each matter submitted to a vote of the stockholders (other than the election of directors), except as otherwise provided
by law or by the Certificate or by these Bylaws, such matter shall be decided by a majority of the votes cast on such matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) In voting on any other question on which a vote by ballot is required by law, the voting shall be by ballot. Each ballot shall
be signed by the stockholder voting or by his proxy and shall state the number of shares voted. Every stockholder entitled to vote
at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another
person(s) to act for him by proxy. Any proxy to be used at a meeting of stockholders must be delivered to the Secretary of the
Corporation or his or her representative at the principal executive offices of the Corporation at or before the time of the meeting.
The validity and enforceability of any proxy shall be determined in accordance with the provisions of the DGCL. The Chairman shall
fix and announce at the meeting the date and time of the opening and the closing of the polls for each matter upon which the stockholders
will vote at the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9. *Nomination of Directors.* Only persons who are nominated in accordance with the procedures set forth in these Bylaws
shall be eligible for election as directors. Nominations of persons for election to the Board may be made at a meeting of stockholders
at which directors are to be elected only (a) by or at the direction of the Board or (b) by any stockholder of the Corporation
entitled to vote for the election of directors at a meeting who complies with the notice procedures set forth in Section 2.10

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10. *Notices of Business or Nominations for Director.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) For director nominations or other business to be properly brought before an annual meeting of stockholders by a stockholder,
a stockholder's notice must include the following information and/or documents, as applicable: (A) the name and address of
the stockholder giving the notice, as they appear on the Corporation's books, and of the beneficial owner of stock of the
Corporation, if any, on whose behalf such nomination or proposal of other business is made (such beneficial owner, the "Beneficial
Owner"); (B) representations that, as of the date of delivery of such notice, such stockholder is a holder of record
of stock of the Corporation and is entitled to vote at such meeting and intends to appear in person or by proxy at such meeting
to propose and vote for such nomination and any such other business; (C) as to each person whom the stockholder proposes to
nominate for election or re-election as a director (a "Stockholder Nominee"): (1) all information relating to such
Stockholder Nominee that is required to be disclosed in solicitations of proxies for election of directors in an election contest,
or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934 (as amended from time
to time, the "Exchange Act") or any successor provision thereto, including such Stockholder Nominee's written
consent to being named in the proxy statement as a nominee and to serving as a director if elected and to being named in the Corporation's
proxy statement and form of proxy if the Corporation so determines, (2) a statement whether such Stockholder Nominee, if elected,
intends to tender, promptly following such Stockholder Nominee's election or re-election, an irrevocable offer of resignation
effective upon such Stockholder Nominee's failure to receive the required vote for re-election at the next meeting at which
such Stockholder Nominee would face re-election and upon acceptance of such resignation by the Board; and (3) such other information
as may be reasonably requested by the Corporation; (D) as to any other business that the stockholder proposes to bring before
the meeting: (1) a brief description of such business, (2) the text of the proposal (including the text of any resolutions proposed
for consideration and, if such business includes a proposal to amend these Bylaws, the text of the proposed amendment) and (3)
the reasons for conducting such business at the meeting; and (E) in all cases: (1) the name of each individual, firm, corporation,
limited liability company, partnership, trust or other entity (including any successor thereto, a "Person") with whom
the stockholder, any Beneficial Owner, any Stockholder Nominee and the respective affiliates and associates (as defined under Regulation
12B under the Exchange Act or any successor provision thereto) of such stockholder, Beneficial Owner and/or Stockholder Nominee
(each of the foregoing, including, for the avoidance of doubt, the Stockholder, Beneficial Owner and/or Stockholder Nominee, a
"Stockholder Group Member") either is acting in concert with respect to the Corporation or has any agreement, arrangement
or understanding (whether written or oral) for the purpose of acquiring, holding, voting (except pursuant to a revocable proxy
given to such Person in response to a public proxy solicitation made generally by such Person to all holders of common stock of
the Corporation) or disposing of any capital stock of the Corporation or to cooperate in obtaining, changing or influencing the
control of the Corporation (except independent financial, legal and other advisors acting in the ordinary course of their respective
businesses) (each Person described in this clause (1), including each Stockholder Group Member, a "Covered
Person"), and a description, and, if in writing, a copy, of each such agreement, arrangement or understanding, (2) a list
of the class, series and number of shares of capital stock of the Corporation that are beneficially owned or owned of record by
each Covered Person, together with documentary evidence of such record or beneficial ownership, (3) a list of all derivative securities
(as defined in Rule 16a-1 under the Exchange Act or any successor provision thereto) and other derivatives or similar arrangements
to which any Covered Person is a counterparty and relating to any shares of capital stock of the Corporation, a description of
all economic terms of all such derivative securities and other derivatives or similar arrangements and copies of all agreements
and other documents relating to each of such derivative securities and other derivatives or similar arrangements, (4) a list of
all transactions by any Covered Person involving any shares of capital stock of the Corporation or any derivative securities (as
defined under Rule 16a-1 under the Exchange Act or any successor provision thereto) or other derivatives or similar arrangements
related to any shares of capital stock of the Corporation entered into or consummated within 60 days prior to the date of such
notice, (5) details of all other material interests of each Covered Person in such nomination or proposal or shares of capital
stock of the Corporation (including any rights to dividends or performance-related fees based on any increase or decrease in the
value of such shares of capital stock) and (6) a representation as to whether any Covered Person intends or is part of a group
which intends to deliver a proxy statement and/or form of proxy to, in the case of a nomination or nominations, at least the percentage
of the Corporation's outstanding capital stock reasonably believed by the Covered Person to be sufficient to elect the nominee
or nominees proposed to be nominated by the stockholder and, in the case of a proposal, holders of at least the percentage of the
Corporation's outstanding capital stock required to elect any Stockholder Nominee or approve such proposal (such representation,
the "Solicitation Representation").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) A notice delivered by or on behalf of any Stockholder under this Section 2.10 shall be deemed to be not in compliance with
this Section 2.10 and not be effective if: (x) such notice does not include all of the information, documents and representations
required under this Section 2.10, (y) after delivery of such notice, any information or document required to be included in such
notice changes or is amended, modified or supplemented, as applicable, prior to the date of the relevant meeting and such information
and/or document is not delivered to the Corporation by way of a further written notice as promptly as practicable following the
event causing such change in information or amendment, modification or supplement, as applicable, and in any case where such event
occurs within 45 days of the date of the relevant meeting, within five business days after such event or (z) any Covered Person
does not act in accordance with the representation set forth in the Solicitation Representation; provided, however, that the
Board shall have the authority to waive any such non-compliance if the Board determines that such action is appropriate in the
exercise of its fiduciary duties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding Section 2.10(b), in the event that the number of directors to be elected to the Board is increased effective
at the next annual meeting and there is no Public Announcement (as defined below) specifying the size of the increased Board made
by the Corporation at least 100 days prior to the first anniversary of the preceding year's annual meeting, a stockholder's
notice required by this Section 2.10 shall also be considered timely, but only with respect to nominees for any new positions created
by such increase, if it is delivered to the Secretary at the principal executive offices of the Corporation not later than the
close of business on the 10<sup>th</sup> day following the day on which such Public Announcement is first made by the Corporation
and such notice otherwise complies with the requirements of this Section 2.10. To be timely, a stockholder's notice must
be delivered to the Secretary at the principal executive offices of the Corporation not less than 90 days nor more than 120 days
prior to the first anniversary of the preceding year's annual meeting; provided, however, that in the event that the
date of the annual meeting is advanced by more than 30 days, or delayed by more than 90 days, from such anniversary date, or if
no annual meeting was held in the preceding year, notice by a stockholder to be timely must be so delivered not earlier than the
120<sup>th</sup> day prior to such annual meeting and not later than the close of business on the later of the 90<sup>th</sup>
day prior to such annual meeting and the 10<sup>th</sup> day following the day on which the Public Announcement of the date of
such meeting is first made by the Corporation. In no event shall the Public Announcement of an adjournment or postponement of an
annual meeting commence a new time period for the giving of a Stockholder's notice as described in this Section 2.10.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) "Public Announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated
Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission
pursuant to Section 13, Section 14 or Section 15(d) of the Exchange Act or any document delivered to all Stockholders (including
any quarterly income statement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11. *Selection and Duties of Inspectors at Meeting of Stockholders.* The Board, in advance of any meeting of stockholders,
may appoint one or more inspectors to act at the meeting or any adjournment thereof. If inspectors are not so appointed, the person
presiding at such meeting may and, on the request of any stockholder entitled to vote thereat shall, appoint one or more inspectors.
In case any person appointed fails to appear or act, the vacancy may be filled by appointment made by the Board in advance of the
meeting or at the meeting by the person presiding thereat. Each inspector, before entering upon the discharge of his duties, shall
take and sign an oath faithfully to execute the duties of inspector at such meeting with strict impartiality and according to the
best of his ability. The inspector(s) shall determine the number of shares outstanding and the voting power of each, the shares
represented at the meeting, the existence of a quorum, the validity and effect of proxies, and shall receive votes, ballots or
consents, hear and determine all challenges and questions arising in connection with the right to vote, count and tabulate all
votes, ballots or consents, determine the result, and shall do such acts as are proper to conduct the election or vote with fairness
to all stockholders. On the request of the person presiding at the meeting or any stockholder entitled to vote thereat, the inspector(s)
shall make a report in writing of any challenge, question or matter determined by him or them and execute a certificate of any
fact found by him or them. Any report or certificate made by the inspector(s) shall be prima facie evidence of the facts stated
and of the vote as certified by him or them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12. *Organization.* At every meeting of stockholders, the Chief Executive Officer or, in the absence of the Chief Executive
Officer, a President or a Vice President, and in case more than one Vice President shall be present, that Vice President designated
by the Board (or in the absence of any such designation, the most senior Vice President, based on age, present) shall act as chairman
of the meeting. In case none of the officers above designated to act as chairman or secretary of the meeting, respectively, shall
be present, a chairman or a secretary of the meeting, as the case may be, may be chosen by a majority of the voting power present
at such meeting, which includes the voting power which is present in person or represented by proxy and entitled to vote at the
meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13. *Order of Business.* The order of business at all meetings of stockholders shall be as determined by the chairman of the
meeting, but the order of business to be followed at any meeting at which a quorum is present may be changed by a majority of the
votes cast at such meeting by the holders of shares of capital stock present, in person or represented by proxy and entitled to
vote at the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14. *Action Without Meeting.* Unless otherwise provided by the Certificate or these Bylaws,
 any action required to be taken at any annual or special meeting of stockholders, or any action which may be taken at any
 annual or special meeting, may be taken without a meeting, without prior notice and without a vote if a consent in writing
 setting forth the action so taken is signed by the stockholders holding at least a majority of the voting power, except that
 if a different proportion of voting power is required for such action at a meeting, then
that proportion of written consents is required. Every written consent shall bear the date of signature of each stockholder who
signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within 60
days of the date the earliest dated consent is delivered to the Corporation, a written consent or consents signed by a sufficient
number of holders to take action are delivered to the Corporation in the manner prescribed herein. An electronic transmission consenting
to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder
or proxyholder, shall be deemed to be written, signed and dated for the purposes of this Section 2.14
to the extent permitted by law. Any such consent shall be delivered in accordance with the DGCL. Prompt notice of the taking of
the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not
consented in writing or electronic transmission and who, if the action had been taken at a meeting, would have been entitled to
notice of the meeting if the record date of such meeting had been the date that written consents signed by a sufficient number
of stockholders or members to take the action were delivered to the Corporation as provided by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15. *Copies, Etc.* Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in
lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile
or other reproduction shall be a complete reproduction of the entire original writing

3. *Directors.* 

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1. *Number and Term.* Except as provided by any provision of the DGCL, the number of directors shall initially be one (1)
or such other number of persons as the majority of the full Board, by resolution, may from time to time determine. The directors
shall, except for filling vacancies (whether resulting from an increase in the number of directors, resignations, removals or otherwise),
be elected at the annual meeting of the stockholders and each director shall be elected to serve until his successor is elected
and qualifies. Directors need not be stockholders. No decrease in the number of directors constituting the Board shall shorten
the term of any incumbent director. The members of the Board may elect a chairman of the Board (the "Chairman") by
a vote of a majority vote of all directors (which may include the vote of the person so elected).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2. *Resignations.* Any director, member of a committee or other officer may resign at any time. Such resignation shall be
made in writing and shall take effect at the time specified therein and, if no time be specified, at the time of its receipt by
the Chief Executive Officer or Secretary. The acceptance of a resignation shall not be necessary to make it effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3. *Vacancies.* Except as may otherwise be provided in connection with rights to elect additional directors under specified
circumstances, which may be granted to the holders of any class or series of preferred stock, if the position of any director becomes
vacant (whether resulting from an increase in the number of directors, resignations, removals or otherwise), the remaining directors
in office, though less than a quorum, by a majority vote, may appoint any qualified person to fill such vacancy, who shall hold
office for the unexpired term and until his successor shall be duly chosen.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4. *Removal.* Other than with respect to any director(s) who are named by a class of preferred stock of the Corporation,
which may be removed and replaced either for or without cause at any time solely by the holders of such class of preferred stock,
any director(s) may be removed by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of
the issued and outstanding stock entitled to vote, at a special meeting of the stockholders called for that purpose and the vacancies
thus created may be filled, at the meeting held for the purpose of removal, by the majority affirmative vote of the holders of
all of the voting power of the issued and outstanding stock entitled to vote.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5. *Increase or Decrease of Number.* The number of directors may be increased or decreased only by the affirmative vote of
a majority of the directors, though less than a quorum. Any newly created directorships may be filled in the same manner as a vacancy.

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6. *Powers.* The business and affairs of the Corporation shall be managed by or under the direction of the Board, except
as otherwise provided by applicable law or by the Certificate. If any such provision is made in the Certificate, the powers and
duties imposed upon the Board by applicable law shall be exercised or performed to such extent and by such person or persons as
shall be provided in the Certificate. The Board shall exercise all of the powers of the Corporation except such as are by law,
or by the Certificate of the Corporation or by these Bylaws, conferred upon or reserved to the stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7. *Conference Call.* Members of the Board or any committee designated by such Board may participate in a meeting of the
Board or such committee by means of telephone conference or similar communication equipment by means of which all persons participating
in the meeting can hear each other and participation pursuant to this Section 3.7 shall constitute presence at such meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8. *Committees.* The Board may, by resolution(s) passed by a majority of the whole Board, designate one or more committees,
each committee to consist of one (1) or more of the directors of the Corporation. The Board may designate one or more directors
as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the
absence or disqualification of any member or such committee or committees, the member or members thereof present at any such meeting
and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the
Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided
in the resolution of the Board or in these Bylaws, shall have and may exercise all the powers and authority of the Board in the
management of the business and affairs of the Corporation, but no such committee shall have the power or authority in reference
to amending the Certificate, adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease
or exchange of all or substantially all of the Corporation's property and assets, recommending to the stockholders a dissolution
of the Corporation or a revocation of a dissolution, or amending these Bylaws of the Corporation and, unless the resolution, these
Bylaws or the Certificate expressly so provide, no such committee shall have the power or authority to declare a dividend or to
authorize the issuance of stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9. *Meetings.* Meetings of the Board, regular or special, may be held at any place within or without the State of Delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On the day when, and at the place where, the annual meeting of stockholders for the election of directors is held, and as soon
as practicable thereafter, the Board may hold its annual meeting, without notice of such meeting, for the purposes or organization,
election of officers and transaction of other business. The annual meeting of the Board may be held at any other time and place
specified in a notice given as provided in this Section 3.10 for special meetings of the Board or in a waiver of notice thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Regular meetings of the directors may be held without notice at such place and time as shall be determined from time to time
by resolution of the directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Special meetings of the Board may be called by the Chief Executive Officer or by the Secretary on the written request of any
two or more directors on at least five (5) days' notice to each director and shall be held at such place(s) as may be determined
by the directors, or as shall be stated in the call of the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Anything in these Bylaws or in any resolution adopted by the Board to the contrary notwithstanding, notice of any meeting of
the Board need not be given to any director who submits a signed waiver of such notice, whether before or after such meeting, or
who attends such meeting without protesting, prior thereto or at its commencement, the lack of notice to him.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10. *Quorum.* A majority of the directors in office from time to time shall constitute a quorum for the transaction of business.
If at any meeting of the Board there shall be less than a quorum present, a majority of those present may adjourn the meeting from
time to time until a quorum is obtained and no further notice thereof need be given, other than by announcement at the meeting
which shall be so adjourned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11. *Compensation.* Unless otherwise restricted by the Certificate, the Board shall have the authority to fix the compensation
of the directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board and may be paid
a fixed sum for attendance at each meeting of the Board or paid a stated salary or paid other compensation as director. No such
payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members
of special or standing committees may be allowed compensation for attending committee meetings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12. *Action Without Meeting.* Any action required or permitted to be taken at any meeting of the Board, or of any committee
thereof, may be taken without a meeting if a written consent thereto is signed by all members of the Board, or of such committee,
as the case may be, and such written consent is filed with the minutes of proceedings of the Board or committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13. *Telephone Meeting.* Any one or more members of the Board or any committee thereof may participate in a meeting of the
Board or such committee by means of a telephone conference or similar communications equipment allowing all persons participating
in the meeting to hear each other at the same time. Participation by such means shall constitute presence in person at such meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14. *Annual Report.* As soon as practicable after the close of each fiscal year, a report of the business and affairs of the
Corporation to the shareholders shall be made under the direction of the Board, unless the Board determines, in its reasonable
discretion, that such a report is not reasonably required.

4. *Officers*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. *Officers.* The Board may elect or appoint a Chief Executive Officer and such other officers as it may determine. The
Board may designate one or more Vice Presidents as Executive Vice Presidents and may use descriptive words or phrases to designate
the standing, seniority or area of special competence of the Vice Presidents elected or appointed by it. Each officer shall hold
his office until his successor is elected and qualified or until his earlier death, resignation or removal in the manner provided
in Section 4.2. Any two or more offices may be held by the same person. The Board may require any officer to give a bond or other
security for the faithful performance of his duties, in such amount and with such sureties as the Board may determine. All officers
as between themselves and the Corporation shall have such authority and perform such duties in the management of the Corporation
as may be provided in these Bylaws or as the Board may from time to time determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. *Removal of Officers.* Any officer elected or appointed by the Board may be removed by the Board with or without cause.
The removal of an officer without cause shall be without prejudice to his contract rights, if any. The election or appointment
of an officer shall not of itself create contract rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3. *Resignations.* Any officer may resign at any time by notifying the Board, the Chief Executive Officer or the Secretary
in writing. Such resignation shall take effect at the date of receipt of such notice or at such later time as is therein specified
and, unless otherwise specified, the acceptance of such resignation shall not be necessary to make it effective. The resignation
of an officer shall be without prejudice to the contract rights of the Corporation, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4. *Vacancies.* A vacancy in any office because of death, resignation, removal, disqualification or any other cause shall
be filled for the unexpired portion of the term in the manner prescribed in these Bylaws for the regular election or appointment
to such office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5. *Compensation.* Salaries or other compensation of the officers may be fixed from time to time by the Board. No officer
shall be prevented from receiving a salary or other compensation by reason of the fact that he is also a director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6. *Chief Executive Officer.* The Chief Executive Officer shall have general supervision and direction of the business and
affairs of the Corporation, subject to control of the Board, and shall report directly to the Board, and shall have supervisory
responsibility over officers operating and discharging their responsibilities. The Chief Executive Officer shall perform all such
other duties which are commonly incident to the capacity of Chief Executive Officer or which are delegated to him or her by the
Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7. *President.* The President shall have general supervision and direction of the business and affairs of the Corporation
as directed by the Chief Executive Officer. The President shall, if present, preside at all meetings of the stockholders. He may,
with the Secretary or the Treasurer or an Assistant Secretary or an Assistant Treasurer, sign certificates for shares of the Corporation.
He may sign and execute, in the name of the Corporation, deeds, mortgages, bonds, contracts and other instruments, except in cases
where the signing and execution thereof shall be expressly delegated by the Board or by these Bylaws to some other officer or agent
of the Corporation, or shall be required by law otherwise to be signed or executed,
and, in general, he shall perform all duties incident to the office of President and such other duties as from time to time may
be assigned to him by the Board. If there is no President, the Chief Executive Officer shall perform the President's functions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8. *Principal Financial Officer.* The Principal Financial Officer shall perform all the powers and duties of the office of
the principal financial officer and in general have overall supervision of the financial operations of the Corporation. The Principal
Financial Officer shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other
duties as he may agree with the Chief Executive Officer or as the Board may from time to time determine. If there is no Principal
Financial Officer, the Chief Executive Officer shall perform the Principal Financial Officer's functions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9. *Executive Vice Presidents.* At the request of the President or, in his absence, at the request of the Board, the Executive
Vice Presidents shall (in such order as may be designated by the Board or, in the absence of any such designation, in order of
seniority based on age) perform all of the duties of the President and, so acting, shall have all the powers of and be subject
to all restrictions upon the President. Any Executive Vice President may also, with the Secretary or the Treasurer or an Assistant
Secretary or an Assistant Treasurer, sign certificates for shares of the Corporation, may sign and execute in the name of the Corporation
deeds, mortgages, bonds, contracts or other instruments authorized by the Board, except in cases where the signing and execution
thereof shall be expressly delegated by the Board or by these Bylaws to some other officer or agent of the Corporation, or shall
be required by law otherwise to be signed or executed, and shall perform such other duties as from time to time may be assigned
to him by the Board or the President.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10. *Secretary.* The Secretary, if present, shall act as Secretary of all meetings of the stockholders and of the Board and
shall keep the minutes thereof in the proper book(s) to be provided for that purpose; he shall see that all notices required
to be given by the Corporation are duly given and served; he may, with the Chief Executive Officer or a Vice President, sign
certificates for shares of the Corporation; he shall be custodian of the seal of the Corporation, if any, and may seal with
the seal of the Corporation or a facsimile thereof, if any, all certificates for shares of capital stock of the Corporation and
all documents; he shall have charge of the stock ledger and also of the other books, records and papers of the Corporation
relating to its organization and management as a Corporation and shall see that the reports, statements and other documents required
by law are properly kept and filed; and shall, in general, perform all duties incident to the office of Secretary and such
other duties as from time to time may be assigned to him by the Board or the Chief Executive Officer. If there is no Secretary,
the Chief Executive Officer shall perform the Secretary's functions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.11. *Treasurer.* The Treasurer shall have charge and custody of, and be responsible for, all funds, securities and notes of
the Corporation; receive and give receipts for monies due and payable to the Corporation from any sources whatsoever;
deposit all such monies in the name of the Corporation in such banks, trust companies or other depositories as shall be selected
in accordance with these Bylaws; against proper vouchers, cause such funds to be disbursed by checks or drafts on the authorized
depositories of the Corporation signed in such manner as shall be determined in accordance with any provisions of these Bylaws,
and be responsible for the accuracy of the amounts of all monies to disbursed; regularly enter or cause to be entered in books
to be kept by him or under his direction full and adequate account of all monies received or paid by him for the account of the
Corporation; have the right to require, from time to time, reports or statements giving such information as he may desire
with respect to any and all financial transactions of the Corporation from the officers or agents transacting the same; render
to the Chief Executive Officer or the Board, whenever the Chief Executive Officer or the Board, respectively, shall require him
so to do, an account of the financial conditions of the Corporation and of all his transactions as Treasurer; exhibit at all
reasonable times his books of account and other records to any of the directors upon application at the office of the Corporation
where such books and records are kept; and, in general, perform all duties incident to the office of Treasurer and such other
duties as from time to time may be assigned to him by the Chief Executive Officer or the Board; and he may sign with the Chief
Executive Officer or a Vice President certificates for shares of the capital stock of the Corporation. If there is no Treasurer,
the Chief Executive Officer shall perform the Treasurer's functions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.12. *Assistant Secretaries and Assistant Treasurers.* Assistant Secretaries and Assistant Treasurers shall perform such duties
as shall be assigned to them by the Secretary or by the Treasurer, respectively, or by the Board or the Chief Executive Officer.
Assistant Secretaries and Assistant Treasurers may, with the Chief Executive Officer or a Vice President, sign certificates for
shares of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.13. *Additional Matters.* The Chief Executive Officer, the President and the Principal Financial Officer of the Corporation
shall have the authority to designate employees of the Corporation to have the title of Vice President, Assistant Vice President,
Assistant Treasurer, Assistant Controller or Assistant Secretary. Any employee so designated shall have the powers and duties determined
by the officer making such designation. The persons upon whom such titles are conferred shall not be deemed officers of the Corporation
unless elected by the Board.

5. *Contracts, Checks, Drafts, Bank Accounts, etc.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1. *Execution of Contracts.* The Board may authorize any officer, employee or agent, in the name and on behalf of the Corporation,
to enter into any contract or execute and satisfy any instrument, and any such authority may be general or confined to specific
instances, or otherwise limited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2. *Loans.* The Chief Executive Officer or any other officer, employee or agent authorized by these Bylaws or by the Board
may effect loans and advances at any time for the Corporation from any bank, trust company or other institutions or from any firm,
corporation or individual and for such loans and advances may make, execute and deliver promissory notes, bonds or other certificates
or evidence of indebtedness of the Corporation and, when authorized by the Board to do so, may pledge and hypothecate or transfer
any securities or the property of the Corporation as security for any such loans or advances. Such authority conferred by the Board
may be general or confined to specific instances or otherwise limited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3. *Checks, Drafts, etc.* All checks, drafts and other orders for the payment of money out of the funds of the Corporation
and all notes or other evidence of indebtedness of the Corporation shall be signed on behalf of the Corporation in such manner
as shall from time to time be determined by resolution of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4. *Deposits.* The funds of the Corporation not otherwise employed shall be deposited from time to time to the order of the
Corporation in such banks, trust companies or other depositories as the Board may select or as may be selected by an officer, employee
or agent of the Corporation to whom such power may from time to time be delegated by the Board.

6. *Stocks and Dividends.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1. *Certificates Representing Shares.* The shares of the Corporation shall not be certificated unless required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2. *Transfer of Shares.* Transfers of shares of capital stock of the Corporation shall be made only on the books of the Corporation
by the holder thereof or by his duly authorized attorney appointed by a power of attorney duly executed and filed with the Secretary
or a transfer agent of the Corporation and on surrender of any certificate(s) representing such shares of capital stock, if they
exist, properly endorsed for transfer and upon payment of all necessary transfer taxes and such other instruments of transfer as
requested by the Corporation. A person in whose name shares of capital stock shall stand on the books of the Corporation shall
be deemed the owner thereof to receive dividends, to vote as such owner and for all other purposes as respects the Corporation,
its stockholders and creditors for any purpose, except to render the transferee liable for the debts of the Corporation to the
extent provided by law, until such transfer shall have been entered on the books of the Corporation by an entry showing from and
to whom transferred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3. *Registered Stockholders and Addresses of Stockholders.* The Corporation shall be entitled to recognize the exclusive
right of a person registered on its records as the owner of shares of capital stock to receive dividends and to vote as such owner,
and shall not be bound to recognize any equitable or other claim to or interest in such share or shares of capital stock on the
part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by applicable
law. Each stockholder shall designate to the Secretary or transfer agent of the Corporation an address at which notices of meetings
and all other corporate notices may be given to such person, and, if any stockholder fails to designate such address, corporate
notices may be given to such person by mail directed to such person at such person's post office address, if any, as the
same appears on the stock record books of the Corporation or at such person's last known post office address or as otherwise
provided by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4. *Transfer and Registry Agents.* The Corporation may from time to time maintain one or more transfer offices or agents
and registry offices or agents at such place(s) as may be determined from time to time by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5. *Lost, Destroyed, Stolen and Mutilated Certificates.* The holder of any shares shall immediately notify the Corporation
of any loss, destruction, theft or mutilation of the certificate representing such shares and the Corporation may issue a new certificate
to replace the certificate alleged to have been lost, destroyed, stolen or mutilated. The Board may, in its discretion, as a condition
to the issue of any such new certificate, require the owner of the lost, destroyed, stolen or mutilated certificate, or his legal
representatives, to make proof satisfactory to the Board of such loss, destruction, theft or mutilation and to advertise such fact
in such manner as the Board may require, and to give the Corporation and its transfer agents and registrars, or such of them as
the Board may require, a bond in such form, in such sums and with such surety or sureties as the Board may direct, to indemnify
the Corporation and its transfer agents and registrars against any claim that may be made against any of them on account of the
continued existence of any such certificate so alleged to have been lost, destroyed, stolen or mutilated and against any expense
in connection with such claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6. *Regulations.* The Board may make rules and regulations as it may deem expedient, not inconsistent with these Bylaws or
with the Certificate, concerning the issue, transfer and registration of certificates representing shares of its capital stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7. *Restriction on Transfer of Stock.* A written restriction on the transfer or registration of transfer of capital stock
of the Corporation, if permitted by the provisions of the DGCL, and noted conspicuously on the certificate representing such capital
stock, if such certificate exists, may be enforced against the holder of the restricted capital stock of any successor or transferee
of the holder including an executor, administrator, trustee, guardian or other fiduciary entrusted with like responsibility for
the person or estate of the holder. Unless noted conspicuously on the certificate representing such capital stock, a restriction,
even though permitted by the provisions of the DGCL, as the same may be amended and supplements, shall be ineffective except against
a person with actual knowledge of the restriction. A restriction on the transfer or registration of transfer of capital stock of
the Corporation may be imposed either by the Certificate or by an agreement among any number of stockholders or among such stockholders
and the Corporation. No restriction so imposed shall be binding with respect to capital stock issued prior to the adoption of the
restriction unless the holders of such capital stock are parties to an agreement or voted in favor of the restriction. Except to
the extent that the Corporation has obtained an opinion of counsel acceptable to the Corporation that transfer restrictions are
not required under applicable securities laws, or has otherwise satisfied itself that such transfer restrictions are not required,
any certificates representing shares of the Corporation shall bear a legend on the face of the certificate, or on the reverse of
the certificate if a reference to the legend is contained on the face, which reads substantially as follows:

THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR APPLICABLE STATE SECURITIES LAWS, AND NO INTEREST MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS COVERING ANY SUCH TRANSACTION INVOLVING SAID SECURITIES, (B) THIS CORPORATION RECEIVES AN OPINION OF LEGAL COUNSEL FOR THE HOLDER OF THESE SECURITIES SATISFACTORY TO THIS CORPORATION STATING THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION, OR (C) THIS CORPORATION OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8. *Dividends, Surplus, etc.* Subject to the provisions of the Certificate and of law, the Board:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) may declare and pay dividends or make other distributions on the outstanding shares of capital stock in such amounts and at
such time to times as, in its discretion, the conditions of the affairs of the Corporation shall render advisable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) may use and apply, in its discretion, any of the surplus of the Corporation in purchasing or acquiring any shares of capital
stock of the Corporation, or purchase warrants therefor, in accordance with law, or any of its bonds, debentures, notes, scrip or other securities or evidence
of indebtedness; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) may set aside from time to time out of such surplus or net profits such sum(s) as, in its discretion, it may think proper,
as a reserve fund to meet contingencies, or for equalizing dividends or for the purpose of maintaining or increasing the property
or business of the Corporation, or for any other purpose it may think conducive to the best interests of the Corporation.

7. *Miscellaneous*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1. *Seal*. The Board shall have the power by resolution to adopt, make and use a corporate seal and to alter the form of
such seal from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2. *Fiscal Year.* The fiscal year of the Corporation shall be determined, and may be changed, by resolution of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3. *Books and Records.* The Corporation shall: (1) Keep as permanent records minutes of all meetings of its stockholders
and the Board, a record of all actions taken by the stockholders or the Board without a meeting, and a record of all actions taken
by a committee of the Board exercising the authority of the Board on behalf of the Corporation; (2) Maintain appropriate accounting
records; (3) Maintain a record of its stockholders, in a form that permits preparation of a list of the names and addresses
of all stockholders, in alphabetical order by class of shares showing the number and class of shares held by each; provided,
however, such record may be maintained by an agent of the Corporation; (4) Maintain its records in written form or in another
form capable of conversion into written form within a reasonable time; and (5) Keep a copy of the following records (subject
to any provision of the DGCL) outside the State of Delaware at such place or places as may be designated from time to time by the
Board: (a) the Certificate as currently in effect; (b) these Bylaws and all amendments thereto as currently in effect;
(c) the minutes of all meetings of stockholders and records of all action taken by stockholders; (d) the Corporation's
financial statements for the past three years; (e) all written communications to stockholders generally within the past three
years; (f) a list of the names and business addresses of the current Directors and officers; and (g) the most recent
annual report delivered to the Delaware Secretary of State.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4. *Forum Selection; Attorneys' Fees.* Unless the Corporation consents in writing to the selection of an alternative
forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any
action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the
Corporation or the Corporation's stockholders, (iii) an action asserting a claim arising pursuant to any provision of the
DGCL, or (iv) any action asserting a claim governed by the internal affairs doctrine shall be a state or federal court located
within the state of Delaware, in all cases subject to the court's having personal jurisdiction over the indispensable parties
named as defendants. If any action is brought by any party against another party, relating to or arising out of these Bylaws, or
the enforcement hereof, the prevailing party shall be entitled to recover from the other party reasonable attorneys' fees,
costs and expenses incurred in connection with the prosecution or defense of such action, provided that the provisions of this
sentence shall not apply with respect to "internal corporate claims" as defined in Section 109(b) of the DGCL. For
purposes of these Bylaws, the term "attorneys' fees" or "attorneys' fees and costs" shall mean
the fees and expenses of counsel to the Corporation and any other parties asserting a claim as set forth in the initial paragraph
of this Section 7.4, which may include printing, photocopying, duplicating and other expenses, air freight charges, and fees billed
for law clerks, paralegals and other persons not admitted to the bar but performing services under the supervision of an attorney, and the costs and fees
incurred in connection with the enforcement or collection of any judgment obtained in any such proceeding. The provisions of this
Section 7.4 shall survive the entry of any judgment, and shall not merge, or be deemed to have merged,
into any judgment. Notwithstanding the foregoing, the exclusive forum provision will not apply to suits brought to enforce any

courts have exclusive or concurrent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5. *Subject to Law and Certificate of Incorporation*. All powers, duties and responsibilities provided for in these Bylaws,
whether or not explicitly so qualified, are qualified by the provisions of the Certificate and applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6. *Facsimile Signatures.* In addition to the provisions for use of facsimile signatures elsewhere specifically authorized
in these Bylaws, facsimile signatures of any officer or officers of the Corporation may be used at any time unless otherwise restricted
by the Board or a committee thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7. *Time Periods.* In applying any provision of these Bylaws which requires that an act be done or not be done a specified
number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar
days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8. *Electronic Transmission.* For purposes of these Bylaws, "electronic transmission" means any form of communication,
not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed
by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.

8. *Indemnification.* The Corporation shall have the rights and obligations related to indemnification as set forth in the
Certificate.

9. *Amendments*. These Bylaws may be altered or repealed and Bylaws may be made at any annual meeting of the stockholders
or at any special meeting thereof, if notice of the proposed alteration or repeal of Bylaw or Bylaws to be made be contained in
the notice of such special meeting, by the affirmative vote of a majority of the voting power of the capital stock issued and outstanding
and entitled to vote thereat, or by the affirmative vote of a majority of the Board at any regular meeting of the Board, or at
any special meeting of the Board, if notice of the proposed alteration or repeal, or Bylaw or Bylaws to be made, be contained in
the notice of such meeting, or by a written consent in lieu of a meeting as set forth herein.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

## Exhibit 10.1

**Exhibit 10.1** 

**<u>docola, Inc.</u>**

**<u>2022 Equity Incentive Plan</u>**

**<u>**Table of Contents**</u>**

---

| | | |
|:---|:---|:---|
| **Article I. Purposes and Definitions** | **Article I. Purposes and Definitions** | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.01 | Purposes of this Plan; Structure. | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.02 | Definitions | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 1.03 | Additional Interpretations. | 6 |
| **Article II. Stock Subject to this Plan; Administration.** | **Article II. Stock Subject to this Plan; Administration.** | 7 |
| &nbsp;&nbsp;&nbsp;Section 2.01 | Stock Subject to this Plan | 7 |
| &nbsp;&nbsp;&nbsp;Section 2.02 | Administration of this Plan. | 8 |
| &nbsp;&nbsp;&nbsp;Section 2.03 | Eligibility | 9 |
| &nbsp;&nbsp;&nbsp;Section 2.04 | Indemnification. | 9 |
| **Article III. Awards.** | **Article III. Awards.** | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.01 | Stock Options. | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.02 | Stock Appreciation Rights. | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.03 | Restricted Stock | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.04 | Restricted Stock Units | 15 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.05 | Performance Units and Performance Shares. | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.06 | Cash-Based Awards and Other Stock-Based Awards | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 3.07 | Form of Award Agreements | 21 |
| **Article IV. Additional Provisions Applicable to this Plan and Awards** | **Article IV. Additional Provisions Applicable to this Plan and Awards** | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.01 | Outside Director Limitations | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.02 | Compliance With Code Section 409A. | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.03 | Leaves of Absence/Transfer Between Locations. | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.04 | Limited Transferability of Awards | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.05 | Adjustments; Dissolution, Merger, Etc. | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.06 | Tax Withholding. | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.07 | Compliance with Securities Laws. | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.08 | Tax Withholding. | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.09 | No Effect on Employment or Service. | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.10 | Repurchase Rights | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.11 | Fractional Shares. | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.12 | Forfeiture Events. | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.13 | Date of Grant | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.14 | Term of Plan | 27 |

---

(i) ---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.15 | Amendment and Termination of this Plan. | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.16 | Conditions Upon Issuance of Shares | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.17 | Inability to Obtain Authority | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.18 | Shareholder Approval. | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.19 | Retirement and Welfare Plans | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.20 | Beneficiary Designation | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.21 | Severability | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.22 | No Constraint on Corporate Action. | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.23 | Unfunded Obligation | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 4.24 | Choice of Law. | 29 |

---

<u>Exhibits</u>

---

| | |
|:---|:---|
| Exhibit A | Form of Award Agreement for Options |
| Exhibit B | Form of Award Agreement for Stock Appreciation Rights |
| Exhibit C | Form of Award Agreement for Restricted Stock |
| Exhibit D | Form of Award Agreement for Restricted Stock Units |

---

(ii) **docola, Inc.**

**2022 Equity Incentive Plan**

**Article I. <u>Purposes and Definitions</u>**

**Section 1.01 <u>Purposes of this Plan; Structure.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) The purposes of this Plan are (i) to attract and retain the best available personnel for positions
of substantial responsibility, (ii) to provide additional incentive to Employees, Directors and Consultants, and (ii) to promote
the success of the Company's business.

&nbsp;&nbsp;&nbsp;&nbsp;(b) This Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation
Rights, Restricted Stock, Restricted Stock Units, Performance Awards, Cash-Based Awards and Other Stock-Based Awards.

**Section 1.02 <u>Definitions.</u> As used herein, the following definitions will apply:**

&nbsp;&nbsp;&nbsp;&nbsp;(a) "Administrator" means the Board or any of its Committees as will be administering this
Plan, in accordance with ‎Section 2.02.

&nbsp;&nbsp;&nbsp;&nbsp;(b) "Affiliate" means, with respect to any Person, any other Person directly or indirectly
Controlling, Controlled by, or under common Control with such Person.

&nbsp;&nbsp;&nbsp;&nbsp;(c) "Applicable Laws" means the legal and regulatory requirements relating to the administration
of equity-based awards, including but not limited to the related issuance of shares of Common Stock, including but not limited
to under U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation
system on which the Common Stock is listed or quoted and the applicable laws of any non-U.S. country or jurisdiction where Awards
are, or will be, granted under this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(d) "Award" means, individually or collectively, a grant under this Plan of Options, Stock
Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, or Cash-Based Award or
Other Stock-Based Award granted under this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(e) "Award Agreement" means the written or electronic agreement setting forth the terms
and provisions applicable to each Award granted under this Plan, which Award Agreement shall be is subject to the terms and conditions
of this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(f) "Board" means the Board of Directors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(g) "Cash-Based Award" means an Award denominated in cash and granted pursuant to ‎Section
3.06. 1

&nbsp;&nbsp;&nbsp;&nbsp;(h) "Cause" means, unless such term or an equivalent term is otherwise defined by the applicable
Award Agreement or other written agreement between a Participant and the Company or its Affiliates applicable to an Award, any
of the following: (i) the Participant's theft, dishonesty, willful misconduct,
breach of fiduciary duty for personal profit, or falsification of documents or records of the Company or any of its Affiliates;
(ii) the Participant's material failure to abide by the Company's or any Affiliate's code of conduct or other
policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct); (iii) the Participant's
unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset or corporate opportunity of the
Company or any of its Affiliates (including, without limitation, the Participant's improper use or disclosure of the Company's
or any of its Affiliate's confidential or proprietary information); (iv) any intentional act by the Participant which has
a material detrimental effect on the Company's or any of its Affiliate's reputation or business; (v) the Participant's
repeated failure to perform any reasonable assigned duties after written notice from the Company or any of its Affiliates, and
a reasonable opportunity to cure, such failure; (vi) any material breach by the Participant of any employment, service, non-disclosure,
non-competition, non-solicitation or other similar agreement between the Participant and the Company or any of its Affiliates which
breach is not cured pursuant to the terms of such agreement; or (vii) the Participant's conviction (including any plea of
guilty or nolo contendere) of any criminal act involving fraud, dishonesty, misappropriation or moral turpitude, or which impairs
the Participant's ability to perform his or her duties with the Company or any of its Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;(i) "Change in Control" means the occurrence of any of the following events, subject to
the provisions of ‎Section 1.03:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Change in Ownership of the Company</u>. A change in the ownership of the Company which occurs
on the date that any one person, or more than one person acting as a group ("Person"), acquires ownership of the stock
of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting
power of the stock of the Company; provided, however, that for purposes of this ‎Section 1.02(i)(i), the acquisition of additional
stock by any one Person, who is considered to own more than fifty percent (50%) of the total voting power of the stock of
the Company will not be considered a Change in Control. Further, if the shareholders of the Company immediately before such change
in ownership continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership
of shares of the Company's voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership
of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company,
such event shall not be considered a Change in Control under this ‎Section 1.02(i)(i). For this purpose, indirect beneficial
ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations
or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary corporations
or other business entities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Change in Effective Control of the Company</u>. A change in the effective control of the Company
which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose
appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.
For purposes of this ‎Section 1.02(i)(ii), if any Person is considered to be in effective control of the Company, the acquisition
of additional control of the Company
by the same Person will not be considered a Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Change in Ownership of a Substantial Portion of the Company's Assets</u>. A change in
the ownership of a substantial portion of the Company's assets which occurs on the date that any Person acquires (or has
acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets
from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair
market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that
for purposes of this ‎Section 1.02(i)(iii), the following will not constitute a change in the ownership of a substantial
portion of the Company's assets: (A) a transfer to an entity that is controlled by the Company's shareholders
immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a shareholder of the Company (immediately
before the asset transfer) in exchange for or with respect to the Company's stock, (2) an entity, fifty percent
(50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person,
that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock
of the Company, or (4) an entity, at least fifty percent (50%) of the total value or voting power of which is owned,
directly or indirectly, by a Person described in clause (B)(3) of this ‎Section 1.02(i)(iii). For purposes of this ‎Section
1.02(i)(iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of,
determined without regard to any liabilities associated with such assets.

&nbsp;&nbsp;&nbsp;&nbsp;(j) "Code" means the Internal Revenue Code of 1986, as amended, and reference to a specific
section of the Code or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such
section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section
or regulation.

&nbsp;&nbsp;&nbsp;&nbsp;(k) "Committee" means a committee of Directors or of other individuals satisfying Applicable
Laws appointed by the Board, or by a duly authorized committee of the Board, in accordance with ‎Section 2.02.

&nbsp;&nbsp;&nbsp;&nbsp;(l) "Common Stock" means the common stock, par value $0.0001 per share, of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(m) "Company" means docola, Inc., a Delaware corporation, or any successor thereto.

&nbsp;&nbsp;&nbsp;&nbsp;(n) "Consultant" means any natural person, including an advisor, engaged by the Company
or a Parent or Subsidiary to render bona fide services to such entity, provided the services (i) are not in connection with
the offer or sale of securities in a capital-raising transaction, and (ii) do not directly promote or maintain a market for
the Company's securities, in each case, within the meaning of Form S-8 promulgated under the Securities Act, and provided
further, that a Consultant will include only those persons to whom the issuance of Shares may be registered under Form S-8 promulgated
under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;(o) "Control" of a Person means the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities,
by contract, or otherwise." Controlled", "Controlling" and "under common Control with" have
correlative meanings. Without limiting the foregoing a Person (the "Controlled Person") shall be deemed Controlled
by (a) any other Person (the "10% Owner") (i) owning beneficially, as meant in Rule 13d-3 under the Exchange Act, securities
entitling such Person to cast 10% or more of the votes for election of directors or equivalent governing authority of the Controlled
Person or (ii) entitled to be allocated or receive 10% or more of the profits, losses, or distributions of the Controlled Person;
(b) an officer, director, general partner, partner (other than a limited partner), manager, or member (other than a member having
no management authority that is not a 10% Owner) of the Controlled Person; or (c) a spouse, parent, lineal descendant, sibling,
aunt, uncle, niece, nephew, mother-in-law, father-in-law, sister-in-law, or brother-in-law of an Affiliate of the Controlled Person
or a trust for the benefit of an Affiliate of the Controlled Person or of which an Affiliate of the Controlled Person is a trustee.

&nbsp;&nbsp;&nbsp;&nbsp;(p) "Director" means a member of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;(q) "Disability" means total and permanent disability as defined in Code Section 22(e)(3),
provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether
a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator
from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;(r) "Dividend Equivalent Right" means the right of a Participant, granted at the discretion
of the Administrator or as otherwise provided by this Plan, to receive a credit for the account of such Participant in an amount
equal to the cash dividends paid on one Share for each Share represented by an Award held by such Participant.

&nbsp;&nbsp;&nbsp;&nbsp;(s) "Employee" means any person, including Officers and Directors, employed by the Company
or any Parent or Subsidiary of the Company, provided that neither service as a Director nor payment of a director's fee by
the Company will be sufficient to constitute "employment" by the Company or any Parent or Subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(t) "Exchange Act" means the Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;(u) "Exchange Program" means a program under which (i) outstanding Awards are surrendered
or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards
of a different type, and/or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial
institution or other person or entity selected by the Administrator, and/or (iii) the exercise price of an outstanding Award is
reduced or increased. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;(v) "Fair Market Value" means, as of any date, the value of Common Stock determined as
follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If the Common Stock is listed on any established stock exchange or a national market system (other
than an over-the counter market, which will not be considered an established stock exchange of
national market system for the purposes of this definition), including without limitation the New York Stock Exchange, the Nasdaq
Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market of The Nasdaq Stock Market, its Fair Market Value will
be the closing sales price for such stock (or, if no closing sales price was reported on that date, as applicable, on the last
trading date such closing sales price was reported) as quoted on such exchange or system on the day of determination, as reported
in The Wall Street Journal or such other source as the Administrator deems reliable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are
not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for the Common Stock
on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids
and asks were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) In the absence of an established market for the Common Stock, the Fair Market Value will be determined
in good faith by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;(w) "Fiscal Year" means the fiscal year of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(x) "Incentive Stock Option" means an Option that by its terms qualifies and is otherwise
intended to qualify as an incentive stock option within the meaning of Code Section 422 and the regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;(y) "Nonstatutory Stock Option" means an Option that by its terms does not qualify or is
not intended to qualify as an Incentive Stock Option.

&nbsp;&nbsp;&nbsp;&nbsp;(z) "Officer" means a person who is an officer of the Company within the meaning of Section
16 of the Exchange Act and the rules and regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;(aa) "Option" means a stock option granted pursuant to this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(bb) "Outside Director" means a Director who is not an Employee.

&nbsp;&nbsp;&nbsp;&nbsp;(cc) "Other Stock-Based Award" means an Award denominated in Shares and granted pursuant
to ‎Section 3.06.

&nbsp;&nbsp;&nbsp;&nbsp;(dd) "Parent" means a "parent corporation," whether now or hereafter existing,
as defined in Code Section 424(e).

&nbsp;&nbsp;&nbsp;&nbsp;(ee) "Participant" means the holder of an outstanding Award.

&nbsp;&nbsp;&nbsp;&nbsp;(ff) "Performance Award" means an Award of Performance Shares or Performance Units.

&nbsp;&nbsp;&nbsp;&nbsp;(gg) "Performance Award Formula" means, for any Performance Award, a formula or table established
by the Administrator pursuant to ‎Section 3.05 which provides the basis for computing the value of a Performance Award at
one or more levels of attainment of the applicable Performance Goal(s) measured as of the end of the applicable Performance Period.

&nbsp;&nbsp;&nbsp;&nbsp;(hh) "Performance Share" means an Award denominated in Shares which may be earned in whole
or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine pursuant to ‎Section
3.05. &nbsp;&nbsp;&nbsp;&nbsp;(ii) "Performance Unit" means an Award which may be earned in whole or in part upon attainment
of performance goals or other vesting criteria as the Administrator may determine and which may be settled for cash, Shares or
other securities or a combination of the foregoing pursuant to ‎Section 3.05.

&nbsp;&nbsp;&nbsp;&nbsp;(jj) "Period of Restriction" means the period during which the transfer of Shares of Restricted
Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions
may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined
by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;(kk) "Person" means an individual, corporation, partnership (including a general partnership,
limited partnership or limited liability partnership), limited liability company, association, trust or other entity or organization,
including a government, domestic or foreign, or political subdivision thereof, or an agency or instrumentality thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(ll) "Plan" means this 2022 Equity Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(mm) "Restricted Stock" means Shares issued pursuant to an Award of Restricted Stock under
‎Section 3.03, or issued pursuant to the early exercise of an Option.

&nbsp;&nbsp;&nbsp;&nbsp;(nn) "Restricted Stock Unit" means a bookkeeping entry representing an amount equal to the
Fair Market Value of one Share, granted pursuant to ‎Section 3.04. Each Restricted Stock Unit represents an unfunded and
unsecured obligation of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(oo) "Rule 16b-3" means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as
in effect when discretion is being exercised with respect to this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(pp) "Section 16(b)" means Section 16(b) of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;(qq) "Securities Act" means the Securities Act of 1933, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;(rr) "Service Provider" means an Employee, Director or Consultant.

&nbsp;&nbsp;&nbsp;&nbsp;(ss) "Share" means a share of the Common Stock, as adjusted in accordance with ‎Section
4.05. &nbsp;&nbsp;&nbsp;&nbsp;(tt) "Stock Appreciation Right" means an Award, granted alone or in connection with an Option,
that pursuant to ‎Section 3.02 is designated as a Stock Appreciation Right.

&nbsp;&nbsp;&nbsp;&nbsp;(uu) "Subsidiary" means a "subsidiary corporation," whether now or hereafter
existing, as defined in Code Section 424(f).

**Section 1.03 <u>Additional Interpretations.</u> For purposes of ‎Section 1.02(i), persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time. Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i) its sole purpose is to change the jurisdiction of the Company's incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transaction.**

**Article II.** **<u>Stock Subject to this Plan; Administration.</u>**

**Section 2.01 <u>Stock Subject to this Plan.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to the provisions of ‎Section 2.01(a) and ‎Section 4.05, the maximum aggregate
number of Shares that may be subject to Awards and sold under this Plan is 502,000 Shares. The Shares may be authorized but unissued,
or reacquired Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(b) If an Award expires or becomes un-exercisable without having been exercised in full, is surrendered
pursuant to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance
Shares, is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased Shares (or for Awards other than
Options or Stock Appreciation Rights the forfeited or repurchased Shares) which were subject thereto will become available for
future grant or sale under this Plan (unless this Plan has terminated). With respect to Stock Appreciation Rights, only Shares
actually issued pursuant to a Stock Appreciation Right will cease to be available under this Plan; all remaining Shares under Stock
Appreciation Rights will remain available for future grant or sale under this Plan (unless this Plan has terminated). Shares that
have actually been issued under this Plan under any Award will not be returned to this Plan and will not become available for future
distribution under this Plan; provided, however, that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock
Units, Performance Shares or Performance Units are repurchased by the Company or are forfeited to the Company due to the failure
to vest, such Shares will become available for future grant under this Plan. Shares used to pay the exercise price of an Award
or to satisfy the tax withholdings related to an Award will become available for future grant or sale under this Plan. To the extent
an Award under this Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares
available for issuance under this Plan. Notwithstanding the foregoing and, subject to adjustment as provided in ‎Section
4.05, the maximum number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share
number stated in ‎Section 2.01(a), plus, to the extent allowable under Code Section 422 and the Treasury Regulations promulgated
thereunder, any Shares that become available for issuance under this Plan pursuant to ‎Section 2.01(b) and ‎Section
2.01(c).

&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company, during the term of this Plan, will at all times reserve and keep available such number
of Shares as will be sufficient to satisfy the requirements of this Plan.

**Section 2.02 <u>Administration of this Plan.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) Procedure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) *Multiple Administrative Bodies*. Different Committees with respect to different groups of
Service Providers may administer this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) *Rule 16b-3*. To the extent desirable to qualify transactions hereunder as exempt under Rule
16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) *Other Administration*. Other than as provided above, this Plan will be administered by (A) the
Board or (B) a Committee, which Committee will be constituted to satisfy Applicable Laws.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Powers of the Administrator*. Subject to the provisions of this Plan, and in the case of
a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority,
in its discretion:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to determine the Fair Market Value;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to select the Service Providers to whom Awards may be granted hereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) to determine the number of Shares to be covered by each Award granted hereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) to approve forms of Award Agreements for use under this Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) to determine the terms and conditions, not inconsistent with the terms of this Plan, of any Award
granted hereunder, with such terms and conditions including, but not being limited to, the exercise price, the time or times when
Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions,
and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the
Administrator will determine;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) to determine whether an Award will be settled in Shares, cash, other property or in any combination
thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) to institute and determine the terms and conditions of an Exchange Program;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) to construe and interpret the terms of this Plan and Awards granted pursuant to this Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) to prescribe, amend and rescind rules and regulations relating to this Plan, including rules and
regulations relating to sub-plans established for the purpose of satisfying applicable non-U.S. laws or for qualifying for favorable
tax treatment under applicable non-U.S. laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) to modify or amend each Award (subject to ‎Section 4.15(c)), including but not limited to
the discretionary authority to extend the post-termination exercisability period of Awards; provided, however, that in no case
will an Option or Stock Appreciation Right be extended beyond its original maximum term;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) to allow Participants to satisfy tax withholding obligations in a manner prescribed in ‎Section
4.05(d);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) to authorize any person to execute on behalf of the Company any instrument required to effect the
grant of an Award previously granted by the Administrator;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that
otherwise would be due to such Participant under an Award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) to prescribe, amend or rescind rules, guidelines and policies relating to this Plan, or to adopt
sub-plans or supplements to, or alternative versions of, this Plan, including, without limitation, as the Administrator deems necessary
or desirable to comply with the laws of, or to accommodate the tax policy, accounting principles or custom of, foreign jurisdictions
whose residents may be granted Awards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) to correct any defect, supply any omission or reconcile any inconsistency in this Plan or any Award
Agreement and to make all other determinations and take such other actions with respect to this Plan or any Award as the Administrator
may deem advisable to the extent not inconsistent with the provisions of this Plan or applicable law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) to make all other determinations deemed necessary or advisable for administering this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Option or Stock Appreciation Right Repricing*. The Administrator shall have the authority,
without additional approval by the shareholders of the Company, to approve a program providing for either (a) the cancellation
of outstanding Options or Stock Appreciation Rights having exercise prices per share greater than the then Fair Market Value of
a Share ("Underwater Awards") and the grant in substitution therefor of new Options or Stock Appreciation Rights covering
the same or a different number of shares but with an exercise price per share equal to the Fair Market Value per share on the new
grant date or payments in cash, or (b) the amendment of outstanding Underwater Awards to reduce the exercise price thereof to the
Fair Market Value per share on the date of amendment.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Effect of Administrator's Decision*. The Administrator's decisions, determinations
and interpretations will be final and binding on all Participants and any other holders of Awards and will be given the maximum
deference permitted by Applicable Laws

**Section 2.03 <u>Eligibility.</u> Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees.**

**Section 2.04 <u>Indemnification.</u> In addition to such other rights of indemnification as they may have as members of the Board or the Administrator or as officers or employees of the Company or any of its Affiliates, to the extent permitted by applicable law, members of the Board or the Administrator and any officers or employees of the Company or any of its Affiliates to whom authority to act for the Board, the Administrator or the Company is delegated shall be indemnified by the Company against all reasonable expenses, including attorneys' fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with this Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the institution of such action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense to handle and defend the same.**

**Article III.** **<u>Awards</u>.**

**Section 3.01 <u>Stock Options.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Grant of Options*. Subject to the terms and provisions of this Plan, the Administrator, at
any time and from time to time, may grant Options in such amounts as the Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Option Agreement*. Each Award of an Option will be evidenced by an Award Agreement that will
specify the exercise price, the term of the Option, the number of Shares subject to the Option, the exercise restrictions, if any,
applicable to the Option, and such other terms and conditions as the Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Limitations*. Each Option will be designated in the Award Agreement as either an Incentive
Stock Option or a Nonstatutory Stock Option. Notwithstanding such designation, however, to the extent that the aggregate Fair Market
Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during
any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000),
such Options will be treated as Nonstatutory Stock Options. For purposes of this ‎Section 3.01(c), Incentive Stock Options
will be taken into account in the order in which they were granted, the Fair Market Value of the Shares will be determined as of
the time the Option with respect to such Shares is granted, and the calculation will be performed in accordance with Code Section 422
and Treasury Regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Term of Option*. The term of each Option will be stated in the Award Agreement. In the case
of an Incentive Stock Option, the term will be no more than ten (10) years from the date of grant thereof. In the case of an Incentive
Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than
ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term
of the Incentive Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in the Award
Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Option Exercise Price and Consideration*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Exercise Price</u>. The per Share exercise price for the Shares to be issued pursuant to the
exercise of an Option will be determined by the Administrator, subject to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) In the case of an Incentive Stock Option:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing
more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share
exercise price will be no less than one hundred ten percent (110%) of the Fair Market Value per Share (or the fair market value
per Share as determined in accordance with Treas. Reg. 1.409A-1(b)(5)(iv)(A)) on the date of grant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) granted to any Employee other than an Employee described in paragraph ‎(1) immediately above,
the per Share exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of
grant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) In the case of a Nonstatutory Stock Option, the per Share exercise price will be no less than one
hundred percent (100%) of the Fair Market Value per Share on the date of grant (or the fair market value per Share as determined
in accordance with Treas. Reg. 1.409A-1(b)(5)(iv)(A)).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Notwithstanding the foregoing provisions of this ‎Section 3.01(e), Options may be granted
with a per Share exercise price of less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant
pursuant to a transaction described in, and in a manner consistent with, Code Section 424(a).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Waiting Period and Exercise Dates</u>. At the time an Option is granted, the Administrator will
fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option
may be exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Form of Consideration</u>. The Administrator will determine the acceptable form of
 consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the
 Administrator will determine the acceptable form of consideration at the time of grant. Such consideration may consist
 entirely of: (1) cash; (2) check; (3) promissory note, to the extent permitted by Applicable Laws; (4) other Shares, provided
 that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to
 which such Option will be exercised and provided further that accepting such Shares will not result in any adverse accounting
 consequences to the Company, as the Administrator determines in its sole discretion; (5) consideration received by the
 Company under a broker assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented by
 the Company in connection with this Plan; (6) by net exercise; (7) such other consideration and method of payment for the
 issuance of Shares to the extent permitted by Applicable Laws; or (8) any combination of the foregoing methods
of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance
of such consideration may be reasonably expected to benefit the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Exercise of Option*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Procedure for Exercise; Rights as a Shareholder</u>. Any Option granted hereunder will be exercisable
according to the terms of this Plan and at such times and under such conditions as determined by the Administrator and set forth
in the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company
receives: (i) notice of exercise (in such form as the Administrator may specify from time to time) from the person entitled
to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised (together with
applicable tax withholding). Full payment may consist of any consideration and method of payment authorized by the Administrator
and permitted by the Award Agreement and this Plan. Shares issued upon exercise of an Option will be issued in the name of the
Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. Until the Shares are issued
(as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right
to vote or receive dividends or any other rights as a shareholder will exist with respect to the Shares subject to an Option, notwithstanding
the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised.
No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued,
except as provided in ‎Section 4.05. Exercising an Option in any manner will decrease the number of Shares thereafter available,
both for purposes of this Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Termination of Relationship as a Service Provider</u>. If a Participant ceases to be a Service
Provider, other than upon the Participant's termination as the result of the Participant's death or Disability, the
Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that
the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth
in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three
(3) months following the Participant's termination. Unless otherwise provided by the Administrator, if on the date of
termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option
will revert to this Plan. If after termination the Participant does not exercise his or her Option within the time specified by
the Administrator, the Option will terminate, and the Shares covered by such Option will revert to this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Disability of Participant</u>. If a Participant ceases to be a Service Provider as a result
of the Participant's Disability, the Participant may exercise his or her Option within such period of time as is specified
in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration
of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement,
the Option will remain exercisable for twelve (12) months following the Participant's termination. Unless otherwise
provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the
Shares covered by the unvested portion of the Option will revert to this Plan. If after termination the Participant does not exercise
his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert
to this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Death of Participant</u>. If a Participant dies while a Service Provider, the Option may be
exercised following the Participant's death within such period of time as is specified in the Award Agreement to the extent
that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term
of such Option as set forth in the Award Agreement), by the Participant's designated beneficiary, provided such beneficiary
has been designated prior to Participant's death in a form acceptable to the Administrator. If no such beneficiary has been
designated by the Participant, then such Option may be exercised by the personal representative of the Participant's estate
or by the person(s) to whom the Option is transferred pursuant to the Participant's will or in accordance with the laws of
descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve
(12) months following Participant's death. Unless otherwise provided by the Administrator, if at the time of death Participant
is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert
to this Plan. If the Option is not so exercised within the time specified herein, the Option will terminate, and the Shares covered
by such Option will revert to this Plan.

**Section 3.02 <u>Stock Appreciation Rights.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Grant of Stock Appreciation Rights*. Subject to the terms and conditions of this Plan, a
Stock Appreciation Right may be granted to Service Providers at any time and from time to time as will be determined by the Administrator,
in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Number of Shares*. The Administrator will have complete discretion to determine the number
of Shares subject to any Award of Stock Appreciation Rights.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Exercise Price and Other Terms*. The per Share exercise price for the Shares that will determine
the amount of the payment to be received upon exercise of a Stock Appreciation Right as set forth in ‎Section 3.02(f) will
be determined by the Administrator and will be no less than one hundred percent (100%) of the Fair Market Value per Share on the
date of grant. Otherwise, the Administrator, subject to the provisions of this Plan, will have complete discretion to determine
the terms and conditions of Stock Appreciation Rights granted under this Plan. Stock Appreciation Rights which have become exercisable
may be exercised by delivery of written or electronic notice of exercise to the Company in accordance with the terms of the Award
Agreement, specifying the number of Stock Appreciation Rights to be exercised and the date on which such Stock Appreciation Rights
were awarded and vested.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Stock Appreciation Right Agreement*. Each Stock Appreciation Right grant will be evidenced
by an Award Agreement that will specify the exercise price, the term of the Stock Appreciation Right, the
conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Expiration of Stock Appreciation Rights*. A Stock Appreciation Right granted under this Plan
will expire upon the date determined by the Administrator, in its sole discretion, and set forth in the Award Agreement. Notwithstanding
the foregoing, the rules of ‎Section 3.01(d) relating to the maximum term and ‎Section 3.01(f) relating to exercise
also will apply to Stock Appreciation Rights.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Payment of Stock Appreciation Right Amount*. Upon exercise of a Stock Appreciation Right,
a Participant will be entitled to receive payment from the Company in an amount determined by multiplying (i) the difference between
the Fair Market Value of a Share on the date of exercise over the exercise price; and (ii) the number of Shares with respect to
which the Stock Appreciation Right is exercised. At the discretion of the Administrator, the payment upon Stock Appreciation Right
exercise may be in cash, in Shares of equivalent value, or in some combination thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(g) *Deemed Exercise of Stock Appreciation Rights*. If, on the date on which a Stock Appreciation
Rights would otherwise terminate or expire, the Stock Appreciation Right by its terms remains exercisable immediately prior to
such termination or expiration and, if so exercised, would result in a payment to the holder of such Stock Appreciation Right,
then any portion of such Stock Appreciation Right which has not previously been exercised shall automatically be deemed to be exercised
as of such date with respect to such portion.

**Section 3.03 <u>Restricted Stock.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Grant of Restricted Stock*. Subject to the terms and provisions of this Plan, the Administrator,
at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator,
in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Restricted Stock Agreement*. Each Award of Restricted Stock will be evidenced by an Award
Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the
Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, the Company as escrow agent
will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Transferability*. Except as provided in this ‎Section 3.03 or as the Administrator
determines, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated
until the end of the applicable Period of Restriction.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Other Restrictions*. The Administrator, in its sole discretion, may impose such other restrictions
on Shares of Restricted Stock as it may deem advisable or appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Removal of Restrictions*. Except as otherwise provided in this ‎Section 3.03, Shares
of Restricted Stock covered by each Restricted Stock grant made under this Plan will be released from escrow as soon as practicable
after the last day of the Period of Restriction or at such other time as the Administrator may determine. The Administrator, in
its discretion, may accelerate the time at which any restrictions will lapse or be removed.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Voting Rights*. During the Period of Restriction, Service Providers holding Shares of Restricted
Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;(g) *Dividends and Other Distributions*. During the Period of Restriction, Service Providers holding
Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares,
unless the Administrator provides otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject
to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were
paid.

&nbsp;&nbsp;&nbsp;&nbsp;(h) *Return of Restricted Stock to Company*. On the date set forth in the Award Agreement, the
Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under
this Plan.

**Section 3.04 <u>Restricted Stock Units.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Grant*. Restricted Stock Units may be granted at any time and from time to time as determined
by the Administrator. After the Administrator determines that it will grant Restricted Stock Units under this Plan, it will advise
the Participant in an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of
Restricted Stock Units.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Vesting Criteria and Other Terms*. The Administrator will set vesting criteria in its discretion,
which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be
paid out to the Participant. The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional,
business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state
securities laws, or any other basis determined by the Administrator in its discretion.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Earning Restricted Stock Units*. Upon meeting the applicable vesting criteria, the Participant
will be entitled to receive a payout as determined by the Administrator or as set forth in the applicable Award Agreement. Notwithstanding
the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or
waive any vesting criteria that must be met to receive a payout.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Form and Timing of Payment*. Payment of earned Restricted Stock Units will be made as soon
as practicable after the date(s) determined by the Administrator and set forth in the Award Agreement. The Administrator, in its
sole discretion, may settle earned Restricted Stock Units in cash, Shares, or a combination of both.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Voting Rights, Dividend Equivalent Rights and Distributions*. Participants shall have
 no voting rights with respect to Shares represented by Restricted Stock Units until the date of the issuance of such shares
 (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).
 However, the Administrator, in its discretion, may provide in the Award Agreement evidencing any Restricted Stock Unit Award
 that the Participant shall be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Stock
 during the period beginning on the date such Award is granted
and ending, with respect to each share subject to the Award, on the earlier of the date the Award is settled or the date on which
it is terminated. Dividend Equivalent Rights, if any, shall be paid by crediting the Participant with a cash amount or with additional
whole Restricted Stock Units as of the date of payment of such cash dividends on Stock, as determined by the Administrator. The
number of additional Restricted Stock Units (rounded to the nearest whole number), if any, to be credited shall be determined by
dividing (a) the amount of cash dividends paid on the dividend payment date with respect to the number of Shares represented by
the Restricted Stock Units previously credited to the Participant by (b) the Fair Market Value per Share on such date. Such cash
amount or additional Restricted Stock Units shall be subject to the same terms and conditions and shall be settled in the same
manner and at the same time as the Restricted Stock Units originally subject to the Restricted Stock Unit Award. In the event of
a dividend or distribution paid in Shares or other property or any other adjustment made upon a change in the capital structure
of the Company as described in ‎Section 4.05, appropriate adjustments shall be made in the Participant's Restricted
Stock Unit Award so that it represents the right to receive upon settlement any and all new, substituted or additional securities
or other property (other than regular, periodic cash dividends) to which the Participant would be entitled by reason of the Shares
issuable upon settlement of the Award, and all such new, substituted or additional securities or other property shall be immediately
subject to the same vesting conditions as are applicable to the Award.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Cancellation*. On the date set forth in the Award Agreement, all unearned Restricted Stock
Units will be forfeited to the Company.

**Section 3.05 <u>Performance Units and Performance Shares.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Issuance*. Performance Awards may be granted to Service Providers at any time and from time
to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in
determining the number of Performance Units and Performance Shares granted to each Participant.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Value of Performance Units/Shares*. Each Performance Unit will have an initial value that
is established by the Administrator on or before the date of grant. Each Performance Share will have an initial value equal to
the Fair Market Value of a Share on the date of grant.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Performance Objectives and Other Terms*. The Administrator will set performance objectives
or other vesting provisions (including, without limitation, continued status as a Service Provider) in its discretion which,
depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid
out to the Service Providers. The time period during which the performance objectives or other vesting provisions must be met will
be called the "Performance Period." Each Performance Awards will be evidenced by an Award Agreement that will specify
the Performance Period, and such other terms and conditions as the Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Performance Targets and Goals*. The Administrator may set performance objectives based
 upon the achievement of Company-wide, divisional, business unit or individual goals (including, but not limited to, continued
 employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator in
 its discretion ("Performance Goals").
Performance Goals shall be established by the Administrator on the basis of targets to be attained ("Performance Targets")
with respect to one or more measures of business or financial performance (each, a "Performance Measure"), subject
to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Performance Measures</u>  *.*** Performance Measures shall be calculated in accordance
with the Company's financial statements, or, if such measures are not reported in the Company's financial statements,
they shall be calculated in accordance with generally accepted accounting principles, a method used generally in the Company's
industry, or in accordance with a methodology established by the Administrator prior to the grant of the Performance Award. As
specified by the Administrator, Performance Measures may be calculated with respect to the Company and its Subsidiaries consolidated
therewith for financial reporting purposes, one or more Subsidiaries or such division or other business unit of any of them selected
by the Administrator. Unless otherwise determined by the Administrator prior to the grant of the Performance Award, the Performance
Measures applicable to the Performance Award shall be calculated prior to the accrual of expense for any Performance Award for
the same Performance Period and excluding the effect (whether positive or negative) on the Performance Measures of any change in
accounting standards or any unusual or infrequently occurring event or transaction, as determined by the Administrator, occurring
after the establishment of the Performance Goals applicable to the Performance Award. Each such adjustment, if any, shall be made
solely for the purpose of providing a consistent basis from period to period for the calculation of Performance Measures in order
to prevent the dilution or enlargement of the Participant's rights with respect to a Performance Award. Performance Measures
may be based upon one or more of the following, as determined by the Administrator: (1) revenue; (2) sales; (3) expenses; (4) operating
income; (5) gross margin; (6) operating margin; (7) earnings before any one or more of: stock-based compensation expense, interest,
taxes, depreciation and amortization; (8) pre-tax profit; (9) net operating income; (10) net income; (11) economic value added;
(12) free cash flow; (13) operating cash flow; (14) balance of cash, cash equivalents and marketable securities; (15) stock price;
(16) earnings per share; (17) return on shareholder equity; (18) return on capital; (19) return on assets; (20) return on investment;
(21) total shareholder return; (22) employee satisfaction; (23) employee retention; (24) market share; (25) customer satisfaction;
(26) product development; (27) research and development expenses; (28) completion of an identified special project; and (29) completion
of a joint venture or other corporate transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Performance Targets.</u> Performance Targets may include a minimum, maximum, target level and
intermediate levels of performance, with the final value of a Performance Award determined under the applicable Performance Award
Formula by the Performance Target level attained during the applicable Performance Period. A Performance Target may be stated as
an absolute value, an increase or decrease in a value, or as a value determined relative to an index, budget or other standard
selected by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Earning of Performance Units/Shares*. After the applicable Performance Period has ended,
the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned
by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance
objectives or other vesting provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its
sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Form and Timing of Payment of Performance Units/Shares*. Payment of earned Performance Units
or Performance Shares will be made as soon as practicable after the expiration of the applicable Performance Period. The Administrator,
in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market
Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a
combination thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(g) *Cancellation of Performance Units/Shares*. On the date set forth in the Award Agreement,
all unearned or unvested Performance Units or Performance Shares will be forfeited to the Company, and again will be available
for grant under this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(h) *Qualified Performance-Based Awards.* Restricted Stock and Restricted Stock Units granted
to officers and Employees of the Company or any Parent or Subsidiary of the Company (within the meaning of Code Section 424) may
be granted with the intent that the award satisfy the "Performance-Based Exception" (any such award intended to satisfy
the Performance-Based Exception, a "Qualified Performance-Based Award"). The grant, vesting, or payment of a Qualified
Performance-Based Awards may depend on the degree of achievement of one or more performance goals relative to a pre-established
targeted level or levels using one or more performance targets as determined by the Administrator (on an absolute or relative (including,
without limitation, relative to the performance of one or more other companies or upon comparisons of any of the indicators of
performance relative to one or more other companies) basis, any of which may also be expressed as a growth or decline measure relative
to an amount or performance for a prior date or period) for the Company on a consolidated basis or for one or more of the Company's
Subsidiaries, segments, divisions, or business or operational units, or any combination of the foregoing. The performance period
applicable to any Performance Units or Performance Shares may not be less than three (3) months nor more than ten (10) years. To
satisfy the Performance-Based Exception, the performance measure(s) applicable to the Qualified Performance-Based Award and specific
performance formula, goal or goals ("targets"), including must be established and approved by the Administrator during
the first ninety (90) days of the applicable Performance Period (and, in the case of Performance Periods of less than one year,
in no event after 25% or more of the Performance Period has elapsed) and while performance relating to such target(s) remains substantially
uncertain within the meaning of Section 162(m) of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;(i) *Voting Rights; Dividend Equivalent Rights and Distributions*. Participants shall have no
voting rights with respect to Shares represented by Performance Share Awards until the date of the issuance of such Shares, if
any (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).
However, the Administrator, in its discretion, may provide in the Award Agreement evidencing any Performance Share Award that the
Participant shall be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Stock during the period
beginning on the date the Award is granted and ending, with respect to each share subject to the Award, on the earlier of the
date on which the Performance Shares are settled or the date on which they are forfeited. Such Dividend Equivalent Rights, if any,
shall be credited to the Participant either in cash or in the form of additional whole Performance Shares as of the date of payment
of such cash dividends on Stock, as determined by the Administrator. The number of additional Performance Shares (rounded to the
nearest whole number), if any, to be so credited shall be determined by dividing (a) the amount of cash dividends paid on the dividend
payment date with respect to the number of Shares represented by the Performance Shares previously credited to the Participant
by (b) the Fair Market Value per Share on such date. Dividend Equivalent Rights, if any, shall be accumulated and paid to the extent
that the related Performance Shares become nonforfeitable. Settlement of Dividend Equivalent Rights may be made in cash, Shares,
or a combination thereof as determined by the Administrator, and may be paid on the same basis as settlement of the related Performance
Share as provided in ‎Section 3.05(e). Dividend Equivalent Rights shall not be paid with respect to Performance Units. In
the event of a dividend or distribution paid in Shares or other property or any other adjustment made upon a change in the capital
structure of the Company as described in ‎Section 4.05, appropriate adjustments shall be made in the Participant's
Performance Share Award so that it represents the right to receive upon settlement any and all new, substituted or additional securities
or other property (other than regular, periodic cash dividends) to which the Participant would be entitled by reason of the Shares
issuable upon settlement of the Performance Share Award, and all such new, substituted or additional securities or other property
shall be immediately subject to the same Performance Goals as are applicable to the Award.

**Section 3.06 <u>Cash-Based Awards and Other Stock-Based Awards.</u> Cash-Based Awards and Other Stock-Based Awards shall be evidenced by Award Agreements in such form as the Administrator shall establish. Such Award Agreements may incorporate all or any of the terms of this Plan by reference and shall comply with and be subject to the following terms and conditions.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Grant of Cash-Based Awards.* Subject to the provisions of this Plan, the Administrator, at
any time and from time to time, may grant Cash-Based Awards to Participants in such amounts and upon such terms and conditions,
including the achievement of performance criteria, as the Administrator may determine.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Grant of Other Stock-Based Awards.* The Administrator may grant other types of equity-based
or equity-related Awards not otherwise described by the terms of this Plan (including the grant or offer for sale of unrestricted
securities, stock-equivalent units, stock appreciation units, securities or debentures convertible into common stock or other forms
determined by the Administrator) in such amounts and subject to such terms and conditions as the Administrator shall determine.
Other Stock-Based Awards may be made available as a form of payment in the settlement of other Awards or as payment in lieu of
compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may involve the transfer of actual Shares to
Participants, or payment in cash or otherwise of amounts based on the value of a Share and may include, without limitation, Awards
designed to comply with or take advantage of the applicable local laws of jurisdictions other than the United States.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Value of Cash-Based and Other Stock-Based Awards.* Each Cash-Based Award shall specify a
monetary payment amount or payment range as determined by the Administrator. Each Other Stock-Based Award shall be expressed in
terms of Shares or units based on such Shares, as determined by the Administrator. The Administrator may require the satisfaction
of such Service requirements, conditions, restrictions or performance criteria, including, without limitation, Performance Goals
as described in ‎Section 3.05, as shall be established by the Administrator and set forth in the Award Agreement evidencing
such Award. If the Administrator exercises its discretion to establish performance criteria, the final value of Cash-Based Awards
or Other Stock-Based Awards that will be paid to the Participant will depend on the extent to which the performance criteria are
met. The establishment of performance criteria with respect to the grant or vesting of any Cash-Based Award or Other Stock-Based
Award intended to result in Performance-Based Compensation shall follow procedures substantially equivalent to those applicable
to Performance Awards set forth in ‎Section 3.05.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Payment or Settlement of Cash-Based Awards and Other Stock-Based Awards.* Payment or settlement,
if any, with respect to a Cash-Based Award or an Other Stock-Based Award shall be made in accordance with the terms of the Award,
in cash, Shares or other securities or any combination thereof as the Administrator determines. The determination and certification
of the final value with respect to any Cash-Based Award or Other Stock-Based Award intended to result in Performance-Based Compensation
shall comply with the requirements applicable to Performance Awards set forth in ‎Section 3.05. To the extent applicable,
payment or settlement with respect to each Cash-Based Award and Other Stock-Based Award shall be made in compliance with the requirements
of Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;(e) *Voting Rights; Dividend Equivalent Rights and Distributions.* Participants shall have no
voting rights with respect to Shares represented by Other Stock-Based Awards until the date of the issuance of such Shares (as
evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), if any,
in settlement of such Award. However, the Administrator, in its discretion, may provide in the Award Agreement evidencing any Other
Stock-Based Award that the Participant shall be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends
on Stock during the period beginning on the date such Award is granted and ending, with respect to each share subject to the Award,
on the earlier of the date the Award is settled or the date on which it is terminated. Such Dividend Equivalent Rights, if any,
shall be paid in accordance with the provisions set forth in ‎Section 3.04(e). Dividend Equivalent Rights shall not be granted
with respect to Cash-Based Awards. In the event of a dividend or distribution paid in Shares or other property or any other adjustment
made upon a change in the capital structure of the Company as described in ‎Section 4.05, appropriate adjustments shall be
made in the Participant's Other Stock-Based Award so that it represents the right to receive upon settlement any and all
new, substituted or additional securities or other property (other than regular, periodic cash dividends) to which the Participant
would be entitled by reason of the Shares issuable upon settlement of such Award, and all such new, substituted or additional securities
or other property shall be immediately subject to the same vesting conditions and performance criteria, if any, as are applicable
to the Award.

&nbsp;&nbsp;&nbsp;&nbsp;(f) *Nontransferability of Cash-Based Awards and Other Stock-Based Awards.* Prior to the payment
or settlement of a Cash-Based Award or Other Stock-Based Award, the Award shall not be subject in any manner
to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Participant
or the Participant's beneficiary, except transfer by will or by the laws of descent and distribution. The Administrator may
impose such additional restrictions on any Shares issued in settlement of Cash-Based Awards and Other Stock-Based Awards as it
may deem advisable, including, without limitation, minimum holding period requirements, restrictions under applicable federal securities
laws, under the requirements of any stock exchange or market upon which such Shares are then listed and/or traded, or under any
state securities laws or foreign law applicable to such Shares.

**Section 3.07 <u>Form of Award Agreements.</u> A form of Award Agreement for a grant of Options is attached hereto as Exhibit A, a form of Award Agreement for a grant of Stock Appreciation Rights is attached hereto as Exhibit B, a form of Award Agreement for a grant of Restricted Stock is attached hereto as Exhibit C; and a form of Award Agreement for a grant of Restricted Stock Units is attached hereto as Exhibit D, provided that the Administrator shall have the discretion to modify such forms and to replace such forms with any other agreement as determined by the Administrator. In the event of a conflict between the terms of any Award Agreement and the provisions in the body of this Plan, the terms of the Award Agreement shall control.**

**Article IV. <u>Additional Provisions Applicable to this Plan and Awards</u>**

**Section 4.01 <u>Outside Director Limitations.</u> No Outside Director may be granted, in any Fiscal Year, Awards with a grant date fair value (computed as of the date of grant in accordance with U.S. generally accepted accounting principles) of more than $300,000. Any Awards granted to an individual while he or she was an Employee, or while he or she was a Consultant but not an Outside Director, will not count for purposes of the limitations under this ‎Section 4.01.**

**Section 4.02 <u>Compliance With Code Section 409A.</u> Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Code Section 409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A, except as otherwise determined in the sole discretion of the Administrator. This Plan and each Award Agreement under this Plan is intended to meet the requirements of Code Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A. In no event will the Company have any obligation under the terms of this Plan to reimburse a Participant for any taxes or other costs that may be imposed on Participant as a result of Section 409A.**

**Section 4.03 <u>Leaves of Absence/Transfer Between Locations.</u> Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6) months following the first (1<sup>st</sup>) day of such leave, any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.**

**Section 4.04 <u>Limited Transferability of Awards.</u> Unless determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, or otherwise transferred in any manner other than by will or by the laws of descent and distribution, and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate.**

**Section 4.05 <u>Adjustments; Dissolution, Merger, Etc.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Adjustments*. In the event that any dividend or other distribution (whether in the form of
cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger,
consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other
change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution
or enlargement of the benefits or potential benefits intended to be made available under this Plan, will adjust the number and
class of shares of stock that may be delivered under this Plan and/or the number, class, and price of shares of stock covered by
each outstanding Award, and the numerical Share limits of ‎Section 2.01.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Dissolution or Liquidation*. In the event of the proposed dissolution or liquidation of the
Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction.
To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed
action.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Change in Control*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In the event of a merger of the Company with or into another corporation or other entity or a Change
in Control, each outstanding Award will be treated as the Administrator determines (subject to the provisions of the following
paragraph) without a Participant's consent, including, without limitation, that (i) Awards will be assumed, or substantially
equivalent awards will be substituted, by the acquiring or succeeding corporation (or an Affiliate thereof) with appropriate adjustments
as to the number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant's Awards
will terminate upon or immediately prior to the consummation of such merger or Change in Control; (iii) outstanding Awards
will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part
prior to or upon consummation of such merger or Change in Control, and, to the
extent the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or Change in Control;
(iv) (A) the termination of an Award in exchange for an amount of cash and/or property, if any, equal to the amount that would
have been attained upon the exercise of such Award or realization of the Participant's rights as of the date of the occurrence
of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Administrator determines
in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant's
rights, then such Award may be terminated by the Company without payment), or (B) the replacement of such Award with other
rights or property selected by the Administrator in its sole discretion; or (v) any combination of the foregoing. In taking any
of the actions permitted under this ‎Section 4.05(c), the Administrator will not be obligated to treat all Awards, all Awards
held by a Participant, or all Awards of the same type, similarly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In the event that the successor corporation does not assume or substitute for the Award (or portion
thereof), the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation
Rights, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock
and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other
vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met,
in all cases, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the
Participant and the Company or any of its Subsidiaries or Parents, as applicable. In addition, if an Option or Stock Appreciation
Right is not assumed or substituted in the event of a merger or Change in Control, the Administrator will notify the Participant
in writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by
the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of such
period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) For the purposes of this ‎Section 4.05(c) and ‎Section 4.05(d), an Award will be considered
assumed if, following the merger or Change in Control, the Award confers the right to purchase or receive, for each Share subject
to the Award immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other securities
or property) received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date of
the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority
of the outstanding Shares); provided, however, that if such consideration received in the merger or Change in Control is not solely
common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation,
provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a
Restricted Stock Unit, Performance Unit, or Performance Share, for each Share subject to such Award, to be solely common stock
of the successor corporation or its Parent equal in fair market value to the per share consideration received by
holders of Common Stock in the merger or Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Notwithstanding anything in this ‎Section 4.05(c) to the contrary, an Award that vests, is
earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its
successor modifies any of such performance goals without the Participant's consent, in all cases, unless specifically provided
otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any of its
Subsidiaries or Parents, as applicable; provided, however, a modification to such performance goals only to reflect the successor
corporation's post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Notwithstanding anything in this ‎Section 4.05(c) to the contrary, and unless otherwise provided
in an Award Agreement, if an Award that vests, is earned or paid-out under an Award Agreement is subject to Code Section 409A and
if the change in control definition contained in the Award Agreement does not comply with the definition of "change of control"
for purposes of a distribution under Code Section 409A, then any payment of an amount that is otherwise accelerated under this
‎Section 4.05(c) will be delayed until the earliest time that such payment would be permissible under Code Section 409A without
triggering any penalties applicable under Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) The Administrator may, without affecting the number of Shares reserved or available hereunder,
authorize the issuance or assumption of benefits under this Plan in connection with any merger, consolidation, acquisition of property
or stock, or reorganization upon such terms and conditions as it may deem appropriate, subject to compliance with Section 409A
and any other applicable provisions of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Outside Director Awards*. In the event of a Change in Control, with respect to Awards granted
to an Outside Director, the Outside Directors will fully vest in and have the right to exercise Options and/or Stock Appreciation
Rights as to all of the Shares underlying such Award, including those Shares which would not otherwise be vested or exercisable,
all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based
vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels
and all other terms and conditions met, unless specifically provided otherwise under the applicable Award Agreement or other written
agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable.

**Section 4.06 <u>Tax Withholding.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Withholding Requirements*. Prior to the delivery of any Shares or cash pursuant to an
 Award (or exercise thereof) or such earlier time as any tax withholding obligation is due, the Company will have the power
 and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy
 federal, state, local, non-U.S. or other taxes (including
the Participant's FICA obligation) required to be withheld with respect to such Award (or exercise thereof).

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Withholding Arrangements*. The Administrator, in its sole discretion and pursuant to such
procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or
in part by such methods as the Administrator shall determine, including, without limitation, (i) paying cash, (ii) electing
to have the Company withhold otherwise deliverable cash or Shares having a fair market value equal to the minimum statutory amount
required to be withheld or such greater amount as the Administrator may determine if such amount would not have adverse accounting
consequences, as the Administrator determines in its sole discretion, (iii) delivering to the Company already-owned Shares having
a fair market value equal to the minimum statutory amount required to be withheld or such greater amount as the Administrator may
determine, in each case, provided the delivery of such Shares will not result in any adverse accounting consequences, as the Administrator
determines in its sole discretion, (iv) selling a sufficient number of Shares otherwise deliverable to the Participant through
such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount
required to be withheld, or (v) any combination of the foregoing methods of payment. The amount of the withholding requirement
will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed
the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with
respect to the Award on the date that the amount of tax to be withheld is to be determined or such greater amount as the Administrator
may determine if such amount would not have adverse accounting consequences, as the Administrator determines in its sole discretion.
The fair market value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to
be withheld.

**Section 4.07 <u>Compliance with Securities Laws.</u> The grant of Awards and the issuance of Shares pursuant to any Award shall be subject to compliance with all applicable requirements of federal, state and foreign law with respect to such securities and the requirements of any stock exchange or market system upon which the Stock may then be listed. In addition, no Award may be exercised or shares issued pursuant to an Award unless (a) a registration statement under the Securities Act shall at the time of such exercise or issuance be in effect with respect to the shares issuable pursuant to the Award, or (b) in the opinion of legal counsel to the Company, the shares issuable pursuant to the Award may be issued in accordance with the terms of an applicable exemption from the registration requirements of the Securities Act. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company's legal counsel to be necessary to the lawful issuance and sale of any shares under this Plan shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been obtained. As a condition to issuance of any Stock, the Company may require the Participant to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company.**

**Section 4.08 <u>Tax Withholding.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Tax Withholding in General.* The Company shall have the right to deduct from any and all
payments made under this Plan, or to require the Participant, through payroll withholding, cash payment or otherwise, to make adequate
provision for, the federal, state, local and foreign taxes (including social insurance), if any, required by law to be withheld
by the Company or any of its Affiliates with respect to an Award or the Shares acquired pursuant thereto. The Company shall have
no obligation to deliver Shares, to release Shares from an escrow established pursuant to an Award Agreement, or to make any payment
in cash under this Plan until the Company or its Affiliate's, as applicable, withholding obligations have been satisfied
by the Participant.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Withholding in or Directed Sale of Shares.* The Company shall have the right, but not the
obligation, to deduct from the Shares issuable to a Participant upon the exercise or settlement of an Award, or to accept from
the Participant the tender of, a number of whole Shares having a Fair Market Value, as determined by the Administrator, equal to
all or any part of the tax withholding obligations of any the Company or its Affiliates, as applicable. The Fair Market Value of
any Shares withheld or tendered to satisfy any such tax withholding obligations shall not exceed the amount determined by the applicable
minimum statutory withholding rates. The Administrator may require a Participant to direct a broker, upon the vesting, exercise
or settlement of an Award, to sell a portion of the shares subject to the Award determined by the Administrator in its discretion
to be sufficient to cover the tax withholding obligations of the Company or its Affiliates, as applicable, and to remit an amount
equal to such tax withholding obligations to the Company or its Affiliates, as applicable ,in cash.

**Section 4.09 <u>No Effect on Employment or Service.</u> Neither this Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant's relationship as a Service Provider with the Company or its Subsidiaries or Parents, as applicable, nor will they interfere in any way with the Participant's right or the right of the Company and its Subsidiaries or Parents, as applicable to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.**

**Section 4.10 <u>Repurchase Rights.</u> Shares issued under this Plan may be subject to one or more repurchase options, or other conditions and restrictions as determined by the Administrator in its discretion at the time the Award is granted. The Company shall have the right to assign at any time any repurchase right it may have, whether or not such right is then exercisable, to one or more persons as may be selected by the Company. Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of Shares hereunder and shall promptly present to the Company any and all certificates representing Shares acquired hereunder for the placement on such certificates of appropriate legends evidencing any such transfer restrictions.**

**Section 4.11 <u>Fractional Shares.</u>**

The Company shall not be required to issue fractional shares upon the exercise or settlement of any Award.

**Section 4.12 <u>Forfeiture Events.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) All Awards under this Plan will be subject to recoupment under any clawback policy that the Company
is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company's
securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable
Laws. In addition, the Administrator may impose such other clawback, recovery or recoupment provisions in an Award Agreement as
the Administrator determines necessary or appropriate, including but not limited to a reacquisition right regarding previously
acquired Shares or other cash or property. Unless this ‎Section 4.12 is specifically mentioned and waived in an Award Agreement
or other document, no recovery of compensation under a clawback policy or otherwise will be an event that triggers or contributes
to any right of a Participant to resign for "good reason" or "constructive termination" (or similar term)
under any agreement with the Company or a Subsidiary or Parent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Notwithstanding any other provision of this Plan, if the Participant's service to the Company
or any of its Affiliates as a Service Provider is terminated for Cause, then any Award which has no vested as of such time in accordance
with its terms shall automatically be forfeited and cancelled and shall cease to vest, be exercisable or otherwise provide any
benefit to Participant, provided that such provision may be amended in any Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The Administrator may specify in an Award Agreement that the Participant's rights, payments,
and benefits with respect to an Award will be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence
additional of specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events
may include, but will not be limited to, termination of such Participant's status as Service Provider for Cause or any specified
action or inaction by a Participant, whether before or after such termination of service, that would constitute Cause for termination
of such Participant's status as a Service Provider.

**Section 4.13 <u>Date of Grant.</u> The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.**

**Section 4.14 <u>Term of Plan.</u> This Plan will become effective upon its adoption by the Board. It will continue in effect for a term of ten (10) years from the date adopted by the Board, unless terminated earlier under ‎Section 4.15.**

**Section 4.15 <u>Amendment and Termination of this Plan.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Amendment and Termination*. The Administrator may at any time amend, alter, suspend or terminate
this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Shareholder Approval*. The Company will obtain shareholder approval of any Plan amendment
to the extent necessary and desirable to comply with Applicable Laws.

&nbsp;&nbsp;&nbsp;&nbsp;(c) *Effect of Amendment or Termination*. No amendment, alteration, suspension or termination
of this Plan will impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator,
which agreement must be in writing and signed by the Participant and the Company. Termination of this Plan will not affect the
Administrator's ability to exercise the powers granted to it hereunder with respect to Awards granted under this Plan prior
to the date of such termination.

**Section 4.16 <u>Conditions Upon Issuance of Shares.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Legal Compliance*. Shares will not be issued pursuant to the exercise of an Award unless
the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject
to the approval of counsel for the Company with respect to such compliance.

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Investment Representations*. As a condition to the exercise of an Award, the Company may
require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased
only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company,
such a representation is required.

**Section 4.17 <u>Inability to Obtain Authority.</u> The inability of the Company to obtain authority from any regulatory body having jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal or non-U.S. law or under the rules and regulations of the Securities and Exchange Commission, the stock exchange on which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company's counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been obtained.**

**Section 4.18 <u>Shareholder Approval.</u> This Plan will be presented for approval by the shareholders of the Company within twelve (12) months after the date this Plan is adopted by the Board. Such shareholder approval will be obtained in the manner and to the degree required under Applicable Laws. No Option granted under this Plan may be treated as an Incentive Stock Option if this Plan is not approved by shareholders of the Company within twelve (12) months after the date this Plan is adopted by the Board.**

**Section 4.19 <u>Retirement and Welfare Plans.</u> Neither Awards made under this Plan nor Shares or cash paid pursuant to such Awards may be included as "compensation" for purposes of computing the benefits payable to any Participant under the Company's or any of its Affiliates' retirement plans (both qualified and non-qualified) or welfare benefit plans unless such other plan expressly provides that such compensation shall be taken into account in computing a Participant's benefit.**

**Section 4.20 <u>Beneficiary Designation.</u> Subject to local laws and procedures, each Participant may file with the Company a written designation of a beneficiary who is to receive any benefit under this Plan to which the Participant is entitled in the event of such Participant's death before he or she receives any or all of such benefit. Each designation will revoke all prior designations by the same Participant, shall be in a form prescribed by the Company, and will be effective only when filed by the Participant in writing with the Company during the Participant's lifetime. If a married Participant designates a beneficiary other than the Participant's spouse, the effectiveness of such designation may be subject to the consent of the Participant's spouse. If a Participant dies without an effective designation of a beneficiary who is living at the time of the Participant's death, the Company will pay any remaining unpaid benefits to the Participant's legal representative.**

**Section 4.21 <u>Severability.</u> If any one or more of the provisions (or any part thereof) of this Plan shall be held invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of this Plan shall not in any way be affected or impaired thereby.**

**Section 4.22 <u>No Constraint on Corporate Action.</u> Nothing in this Plan shall be construed to: (a) limit, impair, or otherwise affect the Company's or any of its Affiliate's right or power to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure, or to merge or consolidate, or dissolve, liquidate, sell, or transfer all or any part of its business or assets; or (b) limit the right or power of the Company any of its Affiliates to take any action which such entity deems to be necessary or appropriate.**

**Section 4.23 <u>Unfunded Obligation.</u> Participants shall have the status of general unsecured creditors of the Company. Any amounts payable to Participants pursuant to this Plan shall be considered unfunded and unsecured obligations for all purposes, including, without limitation, Title I of the Employee Retirement Income Security Act of 1974. Neither the Company nor any of its Affiliates shall be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations. The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder. Any investments or the creation or maintenance of any trust or any Participant account shall not create or constitute a trust or fiduciary relationship between the Administrator, the Company or any of its Affiliates and a Participant, or otherwise create any vested or beneficial interest in any Participant or the Participant's creditors in any assets of the Company or any of its Affiliates. The Participants shall have no claim against the Company or any of its Affiliates for any changes in the value of any assets which may be invested or reinvested by the Company with respect to this Plan.**

**Section 4.24 <u>Choice of Law.</u> Except to the extent governed by applicable federal law, the validity, interpretation, construction and performance of this Plan and each Award Agreement shall be governed by the laws of the State of Delaware, without regard to its conflict of law rules.**

\*\*\*

**Exhibit A**

**Form of Option Award Agreement**

**docola, Inc.**

**Option Award Agreement**

This grant of an Award to purchase Shares ("Grant") is made as of [_______________] (the "Effective Date") by docola, Inc., a Delaware corporation (the "Company") under the docola, Inc. 2022 Equity Incentive Plan (the "Plan"), to [__________________] (the "Participant"). Under applicable provisions of the Internal Revenue Code of 1986, as amended, the Option is treated as *[an incentive option][a non-qualified option]*.

***By signing this cover sheet, you hereby accept the Option (as defined below) and agree to all of the terms and conditions described herein and in this Plan.***

Participant Name:   <br>Signature:  

---

| |
|:---|
| docola, Inc. |
| By: |
| Name: |
| Title: |

---

 ****

***This is not a stock certificate or a negotiable instrument. This grant of Option is a voluntary, revocable grant from the Company and Participant hereby acknowledges that the Company has no obligation to make additional grants in the future.***

**UPON RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING**

**ENTRY WILL BE ENTERED INTO THE COMPANY'S BOOKS AND RECORDS**

**TO EVIDENCE THE OPTIONS GRANTED TO YOU.**

**\*\*\***

1. <u>Grant</u>. As of the Effective Date, the Company grants to the Participant an option (the "Option")
to purchase on the terms and conditions hereinafter set forth all or any part of an aggregate of [________________] shares of the
Company's Common Stock, par value $0.0001 per share, (the "Option Shares"), at the purchase price of $[____________]
per share (the "Option Price"). The Participant shall have the cumulative right to exercise the Option, and the Option
is only exercisable, with respect to the following number of Option Shares on or after the following dates:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Date** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Number of Options Vested and Shares Which**<br> **May be Acquired** |

---

The Administrator may, in its sole discretion, accelerate the date on which the Participant may purchase Option Shares.

2. <u>Term</u>. The Option granted hereunder shall expire in all events at 5:00 p.m., Eastern time
on [______________], unless sooner terminated as provided in in this Section 2.

3. <u>Change in Accounting Treatment</u>. If the Administrator finds that a change in the financial
accounting treatment for options granted under this Plan adversely affects the Company or, in the determination of the Administrator,
may adversely affect the Company in the foreseeable future, the Administrator may, in its discretion, set an accelerated termination
date for the Option. In such event, the Administrator may take whatever other action, including acceleration of any exercise provisions,
it deems necessary.

4. <u>Blackout Periods</u>. The Administrator reserves the right to suspend or limit the Participant's
rights to exercise and sell Shares acquired through the exercise of Options to comply with Applicable Requirements and any Company's
insider trading policy, any Applicable Law, or at any other times that it deems appropriate.

5. <u>Transfers</u>. Except as otherwise provided herein or in any separate provisions applicable
to this Option, the Option is transferable by the Participant only by will or pursuant to the laws of descent and distribution
in the event of the Participant's death, in which event the Option may be exercised by the heirs or legal representatives
of the Participant as set forth in this Plan. Any attempt at assignment, transfer, pledge or disposition of the Option contrary
to the provisions hereof or the levy of any execution, attachment or similar process upon the Option shall be null and void and
without effect. Any exercise of the Option by a Person other than the Participant shall be accompanied by appropriate proofs of
the right of such person to exercise the Option.

6. <u>Adjustments on Changes in Common Stock</u>. In the event that, prior to the delivery by the
Company of all of the Option Shares in respect of which the Option is granted, there shall be an increase or decrease in the number
of issued shares of Common Stock of the Company as a result of a subdivision or consolidation of Shares or other capital adjustment,
or the payment of a stock dividend or other increase or decrease in such Shares, effected without receipt of consideration by the
Company, the remaining number of Option Shares still subject to the Option and the Option Price therefor shall be adjusted in a
manner determined by the Administrator so that the adjusted number of Option Shares and the adjusted Option Price shall be the
substantial equivalent of the remaining number of Option Shares still subject to the Option and the Option Price
thereof prior to such change. For purposes of this Section 7 no adjustment shall be made as a result of the issuance of Common
Stock upon the conversion of other securities of the Company which are convertible into Shares.

7. <u>Legal Requirements</u>. If the listing, registration or qualification of the Option Shares upon
any securities exchange or under any federal or state law, or the consent or approval of any governmental regulatory body is necessary
as a condition of or in connection with the purchase of such Option Shares, the Company shall not be obligated to issue or deliver
the certificates representing the Option Shares as to which the Option has been exercised unless and until such listing, registration,
qualification, consent or approval shall have been effected or obtained. If registration is considered unnecessary by the Company
or its counsel, the Company may cause a legend to be placed on the Option Shares being issued calling attention to the fact that
they have been acquired for investment and have not been registered.

8. <u>Administration</u>. The Option has been granted pursuant to, and is subject to the terms and
provisions of, this Plan. All questions of interpretation and application of this Plan and the Option shall be determined by the
Administrator, and such determination shall be final, binding and conclusive. The Option shall not be treated as an incentive stock
option (as such term is defined in section 422(b) of the Code) for federal income tax purposes unless expressly indicated as same
hereupon.

9. <u>Severability</u>. Should a court of competent jurisdiction deem any of the provisions in this
Agreement to be unenforceable in any respect, it is the intention of the parties to this Agreement that this Agreement be deemed,
without further action on the part of the parties hereto, modified, amended and limited to the extent necessary to render the same
valid and enforceable. It is further the parties' intent that all provisions not deemed to be overbroad shall be given their
full force and effect. You acknowledge that you are freely, knowingly and voluntarily entering into this Agreement after having
an opportunity for consultation with your own independent counsel.

10. <u>Notices</u>. Any notice to be given to the Company shall be addressed to the Administrator at
its principal executive office, and any notice to be given to the Participant shall be addressed to the Participant at the address
then appearing on the personnel or other records of the Company, or at such other address as either party hereafter may designate
in writing to the other. Any such notice shall be deemed to have been duly given when deposited in the United States mail, addressed
as aforesaid, registered or certified mail, and with proper postage and registration or certification fees prepaid.

11. <u>Reservation of Right to Terminate</u>. Nothing herein contained shall affect the right of the
Company or any Affiliate to terminate the Participant in its applicable capacity as a Service Provider at any time for any reason
whatsoever.

12. <u>Choice of Law; Jurisdiction</u>. This Grant shall be governed by and construed and interpreted
in accordance with the substantive laws of the State of Delaware, without giving effect to any conflicts of law rule or principle
that might require the application of the laws of another jurisdiction. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR
BASED UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED
STATES, IN EACH CASE LOCATED IN PINELLAS COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH
COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.

13. <u>Taxes</u>. You agree to comply with the appropriate procedures established by the Company, from
time to time, to provide for payment or withholding of such income or other taxes as may be required by law to be paid or withheld
in connection with the Options and exercise thereof.

\*\*\*

**Exhibit B**

**Form of Stock Appreciation Right Award Agreement**

**docola, Inc.**

**Stock Appreciation Rights Award Agreement**

---

| | | |
|:---|:---|:---|
| **Number of SARs** | **Grant Date** | **Vesting Schedule** |

---

 **Exercise Price: $_______________ per share of Common Stock**

docola, Inc., a Delaware corporation (the "Company"), hereby grants to [_________] (the "Participant", also referred to as "you") Stock Appreciation Rights (the "SAR"), pursuant to the terms of the attached Stock Appreciation Rights Award Agreement and the docola, Inc. 2022 Equity Incentive Plan (the "Plan").

 ****

***By signing this cover sheet, you agree to all of the terms and conditions described in the attached Stock Appreciation Rights Award Agreement and this Plan.***

---

| |
|:---|
| Participant: |
| Signature: |
| docola, Inc. |
| By: |
| Name: |
| Title: |

---

 ****

***This is not a stock certificate or a negotiable instrument. This grant of SAR is a voluntary, revocable grant from the Company and Participant hereby acknowledges that the Company has no obligation to make additional grants in the future.***

**UPON RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY**

**WILL BE ENTERED INTO THE COMPANY'S BOOKS AND RECORDS**

**TO EVIDENCE THE SAR GRANTED TO YOU.**

**docola, Inc.** 

**STOCK APPRECIATION RIGHTS AWARD AGREEMENT**

1. <u>SAR/Nontransferability</u>. This Stock Appreciation Rights Award Agreement (this "Agreement")
evidences the grant to you on the Grant Date set forth on the cover page of this Agreement the Stock Appreciation Right as set
forth therein (the "SAR") under the docola, Inc. 2022 Equity Incentive Plan (the "Plan"). These SARs represent
the right to receive, upon exercise thereof, an amount in cash as set forth in this Plan. This SAR will NOT be credited with dividends
to the extent dividends are paid on the Common Stock of the Company. Your SAR may not be transferred, assigned, pledged or hypothecated,
whether by operation of law or otherwise, nor may the SAR be made subject to execution, attachment or similar process. Any capitalized,
but undefined, term used in this Agreement shall have the meaning ascribed to it in this Plan.

2. <u>The Plan</u>. The SAR is issued in accordance with and is subject to and conditioned upon all
of the terms and conditions of this Agreement and this Plan as amended from time to time; provided, however, that no future amendment
or termination of this Plan shall, without your consent, alter or impair any of your rights or obligations under this Plan, all
of which are incorporated by reference in this Agreement as if fully set forth herein.

3. <u>Cash Value Determination upon Vesting and Exercise</u>. Subject to the terms and conditions
set forth in this Agreement, the SARs covered by this grant shall vest on the vesting date set forth on the cover page of this
Agreement, provided the Participant is a Service Provider of the Company on the Date of Vesting. The payment of the value of the
SARs shall be made no later than ten (10) days following exercise. The payment of amounts with respect to the SARs is subject
to the provisions of this Plan and to interpretations, regulations and determinations concerning this Plan as established from
time to time by the Administrator in accordance with the provisions of this Plan, including, but not limited to, provisions relating
to (i) rights and obligations with respect to withholding taxes, (ii) capital or other changes of the Company and (iii) other
requirements of applicable law.

4. <u>No Shareholder Rights</u>. SARs are not Shares. Neither the Participant, nor any Person entitled
to exercise the Participant's rights in the event of the Participant's death, shall have any of the rights and privileges
of a holder of Shares.

5. <u>Severability</u>. Should a court of competent jurisdiction deem any of the provisions in this
Agreement to be unenforceable in any respect, it is the intention of the parties to this Agreement that this Agreement be deemed,
without further action on the part of the parties hereto, modified, amended and limited to the extent necessary to render the same
valid and enforceable. It is further the parties' intent that all provisions not deemed to be overbroad shall be given their
full force and effect. You acknowledge that you are freely, knowingly and voluntarily entering into this Agreement after having
an opportunity for consultation with your own independent counsel.

6. <u>Notices</u>. Any notice to be given to the Company shall be addressed to the Administrator at
its principal executive office, and any notice to be given to the Participant shall be addressed to the Participant at the address
then appearing on the personnel or other records of the Company, or at such other address as either party hereafter may designate
in writing to the other. Any such notice shall be deemed to have been duly given when deposited in the United States mail, addressed
as aforesaid, registered or certified mail, and with proper postage and registration or certification fees prepaid.

7. <u>Reservation of Right to Terminate</u>. Nothing herein contained shall affect the right of the
Company or any Affiliate to terminate the Participant in its applicable capacity as a Service Provider at any time for any reason
whatsoever.

8. <u>Choice of Law; Jurisdiction</u>. This Grant shall be governed by and construed and interpreted
in accordance with the substantive laws of the State of Delaware, without giving effect to any conflicts of law rule or principle
that might require the application of the laws of another jurisdiction. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR
BASED UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED
STATES, IN EACH CASE LOCATED IN PINELLAS COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH
COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.

9. <u>Taxes</u>. You agree to comply with the appropriate procedures established by the Company, from
time to time, to provide for payment or withholding of such income or other taxes as may be required by law to be paid or withheld
in connection with the SARs.

\*\*\*

**Exhibit C**

**Form of Restricted Stock Award Agreement**

**docola, Inc.** 

**Restricted Stock Award Agreement**

---

| | | |
|:---|:---|:---|
| **Number of Shares** | **Grant Date** | **Vesting Schedule** |

---

docola, Inc., a Delaware corporation (the "Company"), hereby grants to [_________] (the "Participant", also referred to as "you") shares of Restricted Stock (the "Shares"), pursuant to the terms of the attached Restricted Stock Award Agreement and the docola, Inc. 2022 Equity Incentive Plan (the "Plan").

 **

***By signing this cover sheet, you agree to all of the terms and conditions described in the attached Restricted Stock Award Agreement and this Plan.***

 **

---

| |
|:---|
| Participant: |
| Signature: |
| docola, Inc. |
| By: |
| Name: |
| Title: |

---

 ****

***This is not a stock certificate or a negotiable instrument. This grant of Shares is a***

***voluntary, revocable grant from the Company and Participant hereby acknowledges that the***

***Company has no obligation to make additional grants in the future.***

**UPON RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY**

**WILL BE ENTERED INTO THE COMPANY'S BOOKS AND RECORDS**

**TO EVIDENCE THE SHARES GRANTED TO YOU.**

**docola, Inc.** 

**RESTRICTED STOCK AWARD AGREEMENT**

1. <u>Award</u>. This Restricted Stock Award Agreement (this "Agreement") evidences the
grant to Participant on the Grant Date set forth on the cover page of this Agreement the shares of Restricted Stock as set forth
therein (the "Shares") under the docola, Inc. 2022 Equity Incentive Plan (the "Plan"). Any capitalized,
but undefined, term used in this Agreement shall have the meaning ascribed to it in this Plan.

2. <u>Non-Transferability of the Shares</u>. Your Shares may not be transferred, assigned, pledged
or hypothecated, whether by operation of law or otherwise, nor may the Shares be made subject to execution, attachment or similar
process. Except as may be required by federal income tax withholding provisions or by the tax laws of any state, your interests
(and the interests of your beneficiaries, if any) under this Agreement are not subject to the claims of your creditors and may
not be voluntarily or involuntarily sold, transferred, alienated, assigned, pledged, anticipated, or encumbered. Any attempt to
sell, transfer, alienate, assign, pledge, anticipate, encumber, charge or otherwise dispose of any right to benefits payable hereunder
shall be void. Your rights to your Shares are no greater than that of other general, unsecured creditors of the Company.

3. <u>Vesting</u>. Subject to the terms and conditions set forth in this Agreement, the Shares covered
by this grant shall vest on the vesting date set forth on the cover page of this Agreement, provided the Participant is a Service
Provider of the Company or a member of the Company Group on the Date of Vesting.

4. <u>Delivery of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Vesting</u>. Shares that vest (together with any payment due pursuant to the terms herein in
respect of such Shares) shall be delivered to Participant (or the person to whom ownership rights may have passed by will or the
laws of descent and distribution), on or as soon as administratively practicable after, the date of such vesting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Certain Limitations</u>. Notwithstanding the foregoing provisions of this Section ‎3,
delivery of Shares, if any, by reason of Participant's termination of employment shall be delayed until the six (6) month
anniversary of the date of Participant's termination of employment to the extent necessary to comply with Code Section 409A(a)(B)(i),
and the determination of whether or not there has been a termination of Participant's employment with the Company shall be
made by the Administrator consistent with the definition of "separation from service" (as that phrase is used for purposes
of Code Section 409A, and as set forth in Treasury Regulation Section 1.409A-1(h)).

5. <u>Withholding Taxes</u>. Participant shall be responsible to pay to the Company the amount of
withholding taxes as determined by the Company with respect to the date the Shares are delivered. If Participant does not arrange
for payment of the applicable withholding taxes by providing such amount to the Company in cash prior to the date established by
the Company as the deadline for such payment, Participant shall be treated as having elected to relinquish to the Company a portion
of the Shares that would otherwise have been transferred to Participant having a fair market value, based on the Fair Market Value
of the Common Stock on the business day immediately preceding the date of delivery of the Shares, equal to the amount of such applicable
withholding taxes, in lieu of paying such amount to the Company in cash. Participant authorizes the Company to withhold in accordance
with applicable law from any compensation payable to him or her any taxes required to be
withheld for federal, state or local law in connection with this Agreement.

6. <u>Legal Requirements</u>. If the listing, registration or qualification of Shares deliverable
in respect of an Shares upon any securities exchange or under any federal or state law, or the consent or approval of any governmental
regulatory body is necessary as a condition of or in connection with the issuance of such Shares, the Company shall not be obligated
to issue or deliver such Shares unless and until such listing, registration, qualification, consent or approval shall have been
effected or obtained. If registration is considered unnecessary by the Company or its counsel, the Company may cause a legend to
be placed on any Shares being issued calling attention to the fact that they have been acquired for investment and have not been
registered. The Administrator may from time to time impose any other conditions on the Shares it deems necessary or advisable to
ensure that Shares are issued and resold in compliance with the Securities Act of 1933, as amended.

7. <u>Severability</u>. Should a court of competent jurisdiction deem any of the provisions in this
Agreement to be unenforceable in any respect, it is the intention of the parties to this Agreement that this Agreement be deemed,
without further action on the part of the parties hereto, modified, amended and limited to the extent necessary to render the same
valid and enforceable. It is further the parties' intent that all provisions not deemed to be overbroad shall be given their
full force and effect. You acknowledge that you are freely, knowingly and voluntarily entering into this Agreement after having
an opportunity for consultation with your own independent counsel.

8. <u>Notices</u>. Any notice to be given to the Company shall be addressed to the Administrator at
its principal executive office, and any notice to be given to the Participant shall be addressed to the Participant at the address
then appearing on the personnel or other records of the Company, or at such other address as either party hereafter may designate
in writing to the other. Any such notice shall be deemed to have been duly given when deposited in the United States mail, addressed
as aforesaid, registered or certified mail, and with proper postage and registration or certification fees prepaid.

9. <u>Reservation of Right to Terminate</u>. Nothing herein contained shall affect the right of the
Company or any Affiliate to terminate the Participant in its applicable capacity as a Service Provider at any time for any reason
whatsoever.

10. <u>Choice of Law; Jurisdiction</u>. This Grant shall be governed by and construed and interpreted
in accordance with the substantive laws of the State of Delaware, without giving effect to any conflicts of law rule or principle
that might require the application of the laws of another jurisdiction. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR
BASED UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED
STATES, IN EACH CASE LOCATED IN PINELLAS COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH
COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.

11. <u>Taxes</u>. You agree to comply with the appropriate procedures established by the Company, from
time to time, to provide for payment or withholding of such income or other taxes as may be required by law to be paid or withheld
in connection with the Restricted Stock.

\*\*\*

**Exhibit D**

**Form of Restricted Unit Award Agreement**

**docola, Inc.** 

**Restricted Unit Award Agreement**

---

| | | |
|:---|:---|:---|
| **Number of**<br> **Restricted Stock**<br> **Units** | **Grant Date** | **Vesting Schedule/Performance**<br> **Period/Performance Vesting Requirements** |

---

docola, Inc., a Delaware corporation (the "Company"), hereby grants to [_________] (the "Participant", also referred to as "you") the Restricted Stock Units (the "Restricted Stock Units" or "RSUs"), pursuant to the terms of the attached Restricted Unit Award Agreement and the docola, Inc. 2022 Equity Incentive Plan (the "Plan").

 ****

***By signing this cover sheet, you agree to all of the terms and conditions described in the attached Restricted Unit Award Agreement and this Plan.***

---

| |
|:---|
| Participant: |
| Signature: |
| docola, Inc. |
| By: |
| Name: |
| Title: |

---

 ****

***This is not a stock certificate or a negotiable instrument. This grant of RSUs is a***

***voluntary, revocable grant from the Company and Participant hereby acknowledges that the***

***Company has no obligation to make additional grants in the future.***

**UPON RECEIPT OF YOUR SIGNED AGREEMENT, A BOOKKEEPING ENTRY**

**WILL BE ENTERED INTO THE COMPANY'S BOOKS AND RECORDS**

**TO EVIDENCE THE RSUs GRANTED TO YOU.**

**docola, Inc.** 

**RESTRICTED UNIT AWARD AGREEMENT**

1. <u>Award</u>. This Restricted Unit Award Agreement (this "Agreement") evidences the
grant to Participant on the Grant Date set forth on the cover page of this Agreement the Restricted Stock Units as set forth therein
(the "Restricted Stock Units" or "RSUs") under the docola, Inc. 2022 Equity Incentive Plan (the "Plan").
As used herein, the term "Restricted Stock Unit" or "RSU" shall mean a non-voting unit of measurement which
is deemed for bookkeeping purposes to be equivalent to one outstanding Share solely for purposes of this Plan and this Agreement.
The Restricted Stock Units shall be used solely as a device for the determination of the payment to eventually be made to the Participant
if such Restricted Stock Units vest pursuant to this Award Agreement. The Restricted Stock Units shall not be treated as property
or as a trust fund of any kind. Any capitalized, but undefined, term used in this Agreement shall have the meaning ascribed to
it in this Plan.

2. <u>Non-Transferability of the RSUs</u>. Your RSUs may not be transferred, assigned, pledged or
hypothecated, whether by operation of law or otherwise, nor may the RSUs be made subject to execution, attachment or similar process.
Except as may be required by federal income tax withholding provisions or by the tax laws of any state, your interests (and the
interests of your beneficiaries, if any) under this Agreement are not subject to the claims of your creditors and may not be voluntarily
or involuntarily sold, transferred, alienated, assigned, pledged, anticipated, or encumbered. Any attempt to sell, transfer, alienate,
assign, pledge, anticipate, encumber, charge or otherwise dispose of any right to benefits payable hereunder shall be void. Your
rights to your RSUs are no greater than that of other general, unsecured creditors of the Company.

3. <u>Vesting</u>. Subject to the terms and conditions set forth in this Agreement, the RSUs covered
by this grant shall vest on the vesting date set forth on the cover page of this Agreement and subject to the satisfaction or attainment
of the performance criteria set forth therein, if any, provided the Participant is employed by the Company on the date of vesting.
The Administrator may not accelerate vesting of Restricted Stock Units for any reason.

4. <u>Dividends</u>. Participant shall not be entitled to any cash, securities or property that would
have been paid or distributed as dividends with respect to the RSUs subject to this Agreement prior to the date the RSUs are delivered
to Participant; provided, however, that the Company shall keep a hypothetical account in which any such items shall be recorded,
and shall pay to Participant the amount of such dividends (in cash or in kind as determined by the Company) on the same date that
the RSUs to which such payments or distributions relate are required to be delivered under this Agreement.

5. <u>Timing and Manner of Payment on RSUs</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On or as soon as administratively practical following the vesting event pursuant to this Agreement
(and in all events not later than two and one-half (2½) months after such vesting event), the Company shall deliver to the
Participant a number of Shares (either by delivering one or more certificates for such Shares or by entering such Shares in book
entry form, as determined by the Company in its discretion) equal to the number of Shares subject to the RSU that vest on the Vesting
Date, less any withholding or expenses as set forth herein, or may settle the RSU in cash or other payment as provided in this
Plan, as determined by the Administrator. The Company's obligation to deliver Shares or otherwise make payment with respect
to vested RSUs is subject to the condition precedent that the Participant or other person entitled under this Plan to receive any
Shares or payment with respect
to the vested RSUs deliver to the Company any representations or other documents or assurances required pursuant to this Plan.
The Participant shall have no further rights with respect to any RSUs that are paid or that terminate pursuant to this Agreement
or this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Certain Limitations</u>. Notwithstanding the foregoing provisions of this Section ‎3,
delivery of Shares or other payment, if any, with respect to RSUs by reason of Participant's termination of employment shall
be delayed until the six (6) month anniversary of the date of Participant's termination of employment to the extent necessary
to comply with Code Section 409A(a)(B)(i), and the determination of whether or not there has been a termination of Participant's
employment with the Company shall be made by the Administrator consistent with the definition of "separation from service"
(as that phrase is used for purposes of Code Section 409A, and as set forth in Treasury Regulation Section 1.409A-1(h)).

6. <u>Rights of Participant</u>. Participant shall have none of the rights of a shareholder at any
time prior to the delivery of any Shares pursuant to the RSUs subject to this Agreement, except as expressly set forth in this
Plan or herein.

7. <u>Withholding Taxes</u>. Participant shall be responsible to pay to the Company the amount of
withholding taxes as determined by the Company with respect to the date the RSUs are settled. If Participant does not arrange for
payment of the applicable withholding taxes by providing such amount to the Company in cash prior to the date established by the
Company as the deadline for such payment, Participant shall be treated as having elected to relinquish to the Company a portion
of the Shares that would otherwise have been transferred to Participant having a fair market value, based on the Fair Market Value
of the Common Stock on the business day immediately preceding the date of delivery of the Shares, equal to the amount of such applicable
withholding taxes, in lieu of paying such amount to the Company in cash, or an amount in cash if the RSU is settled in cash. Participant
authorizes the Company to withhold in accordance with applicable law from any compensation payable to him or her any taxes required
to be withheld for federal, state or local law in connection with this Agreement.

8. <u>Legal Requirements</u>. If the listing, registration or qualification of Shares deliverable
in respect of an RSU upon any Securities Exchange or any Applicable Requirement, or the consent or approval of any governmental
regulatory body is necessary as a condition of or in connection with the issuance of such Shares, the Company shall not be obligated
to issue or deliver such Shares unless and until such Applicable Requirements shall have been effected or obtained. If registration
is considered unnecessary by the Company or its counsel, the Company may cause a legend to be placed on any Shares being issued
calling attention to the fact that they have been acquired for investment and have not been registered. The Administrator may from
time to time impose any other conditions on the Shares it deems necessary or advisable to ensure that Shares are issued and resold
in compliance with the Securities Act of 1933, as amended.

9. <u>Severability</u>. Should a court of competent jurisdiction deem any of the provisions in this
Agreement to be unenforceable in any respect, it is the intention of the parties to this Agreement that this Agreement be deemed,
without further action on the part of the parties hereto, modified, amended and limited to the extent necessary to render the same
valid and enforceable. It is further the parties' intent that all provisions not deemed to be overbroad shall be given their
full force and effect. You acknowledge that you are freely, knowingly and voluntarily entering into this Agreement after having
an opportunity for consultation with your own independent counsel.

10. <u>Notices</u>. Any notice to be given to the Company shall be addressed to the Administrator at
its principal executive office, and any notice to be given to the Participant shall be addressed to the Participant at the address
then appearing on the personnel or other records of the Company, or at such other address as either party hereafter may designate
in writing to the other. Any such notice shall be deemed to have been duly given when deposited in the United States mail, addressed
as aforesaid, registered or certified mail, and with proper postage and registration or certification fees prepaid.

11. <u>Reservation of Right to Terminate</u>. Nothing herein contained shall affect the right of the
Company or any Affiliate to terminate the Participant in its applicable capacity as a Service Provider at any time for any reason
whatsoever.

12. <u>Choice of Law; Jurisdiction</u>. This Grant shall be governed by and construed and interpreted
in accordance with the substantive laws of the State of Delaware, without giving effect to any conflicts of law rule or principle
that might require the application of the laws of another jurisdiction. ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR
BASED UPON THIS AGREEMENT SHALL BE INSTITUTED SOLELY IN THE COURTS OF THE STATE OF FLORIDA OR THE FEDERAL COURTS OF THE UNITED
STATES, IN EACH CASE LOCATED IN PINELLAS COUNTY, FLORIDA, AND EACH PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH
COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.

13. <u>Taxes</u>. You agree to comply with the appropriate procedures established by the Company, from
time to time, to provide for payment or withholding of such income or other taxes as may be required by law to be paid or withheld
in connection with the RSUs.

\*\*\*

## Exhibit 10.2

**Exhibit 10.2**

**LICENSE AGREEMENT**

This Commercial Use License Agreement, including the Schedules (hereinafter referred to as "Agreement"), is effective this 1<sup>st</sup> day of September, 2019 ("Effective Date"), by and between Visual Health Solutions, Inc., a Colorado corporation having a primary place of business at 300 Boardwalk Dr., Suite 4B, Fort Collins, Colorado 80525, (hereinafter referred to as "Licensor" or "Visual"), and Docola, Inc. with offices located at 801 West Bay Dr. #506, Largo, FL 33770 (hereinafter referred to as "Licensee" or Doc.la).

**WITNESSETH:**

**WHEREAS,** Visual is engaged in the business of creating animations and multimedia content;

**WHEREAS,** DOC.LA is a developer and distributor of certain digital medical care, healthcare education and patient engagement technology, products, and related services ("DOC.LA Product(s)");

**WHEREAS,** the Licensee desires to acquire a license to use Visual's animations, Visual Consults and other various products/services ("Visual Intellectual Property"), as listed in Schedule A attached, on its platform; and

**NOW THEREFORE,** in consideration of the mutual promises and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

**1. Grant of License.** Visual grants Licensee, subject to the terms and conditions contained herein, a world-wide, nonexclusive license, subject to 2.3 below, to display, perform, exhibit, distribute, or transmit the Visual Intellectual Property in DOC.LA Products for the Term. To the extent possible, the Licensee will provide attribution to the Licensor on the DOC.LA Products. The license granted herein ("Licensed Rights") is not transferable without the consent of Visual. Licensee may not use, copy, display, modify (except as agreed to for this use), produce derivative works or distribute the Visual Intellectual Property except in strict accordance with this Agreement.

**2. Intellectual Property**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 Reservation of Rights.** All rights with respect to the Visual Intellectual Property (and any reproductions or derivative works thereof), whether now existing or which may hereafter come into existence which are not expressly granted to Licensee herein, including but not limited to print publication, electronic publication in all media and formats, and video, movie, and audio rights, are reserved to Visual. Without limiting the foregoing, and except as provided herein, Visual specifically reserves all rights, whether now existing or which hereafter may come into existence, to: make any derivative works of the Visual Intellectual Property or derivative works thereof; combine the Visual Intellectual Property or derivative works thereof, in whole or in part, with any other materials; transmit or download the Visual Intellectual Property or derivative works thereof through electronic, telephonic, optical or any other means; alter or modify in any way the Visual Intellectual Property or any derivative works thereof or publicly perform or display in any way the Visual Intellectual Property of any derivative works thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 Use of Trademarks and Trade-names**. The Parties may grant to each other non-exclusive and immediately terminable right to use the other party's name and other trademarks during the term of this Agreement solely in connection with the marketing, licensing and support of the Pilot Programs in accordance with the terms of this Agreement. Upon termination of this Agreement, each Party will purge such name or marks from all materials, letterheads, signs and any other media in which a trademark or trade-name is displayed. A Party shall notify the other Party of any infringement or appropriation of its names or marks it becomes aware of during the term of this Agreement.

**3. Approvals and Samples.** Licensee agrees to forward to Visual a link to all Licensee's Media, displaying Visual's Visual Intellectual Property within ten (10) business days of being made available to the general public.

**4. Payment-Compensation.** In consideration of the rights granted by Visual to Licensee under this Agreement, Licensee agrees to pay Visual the sums specified in the Schedule B.

**5. Term/Termination.** This Agreement shall have an initial term of three (3) years from the Effective Date ("Initial Term"), which shall be automatically renewed for two successive one (1) year terms unless canceled by written notice by either Party to the other not less than one-hundred and twenty (120) days prior to the expiration of the stated term ("Renewal Term(s)" together with the Initial Term as the "Term"). This Agreement shall also be terminable by either Party by written notice to the other Party in the event of a material breach of any term hereof which is not cured within sixty (60) days following written notice thereof. Notwithstanding the foregoing, after the first twelve (12) months following the Effective Date, either Party may terminate this Agreement by providing the other party one hundred twenty (120) days' notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1** Without prejudice to any other rights Visual may have pursuant to this Agreement or otherwise, Visual will have the right to terminate this Agreement and the Licensed Rights in the event of any of the following events of default (hereinafter referred to as "Default(s)"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Licensee fails to pay any amount due under the License Agreement between Visual and Licensee within thirty (30) days of its
due date; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Licensee violates, breaches or defaults in performing any other material requirement or obligation under this Agreement, or
any representation in this Agreement, any document furnished in connection with this Agreement, and such failure or inaccuracy
continues uncured for thirty (30) days after notice thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.2** Without prejudice to any other rights Licensee may have pursuant to this Agreement or otherwise, Licensee will have the right to terminate this Agreement in the event of any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Licensee reasonably determines that the Visual Intellectual Property infringes any copyright or other Visual Intellectual Property
rights, or rights of privacy or publicity of any third parties, and such infringement continues uncured for thirty (30) days after
notice hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Visual commits a breach of any material term of this agreement.

**6. Remedies of the Parties.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.1** Upon the occurrence of a Default and at any time thereafter, Visual may, in its sole discretion, take any one or more of the following actions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Upon written notice to Licensee and the opportunity to cure within 30 days, terminate this Agreement and the Licensed Rights.
Termination of this Agreement and the Licensed Rights will not terminate any liability arising out of conduct before the date of
termination. In the event of such termination of this Agreement and the Licensed Rights, (i) neither Licensee nor its receivers,
representatives, trustees, agents, administrators, successors and/or assigns will have any right to use the Visual Intellectual
Property or to sell, exploit, or in any way deal with or in any Visual Intellectual Property which in any manner contains any Licensed
Rights or the name of the Licensor; and (ii) upon Visual's request, either return or, if requested by Visual, destroy all
copies of the Visual Intellectual Property.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Declare the total amount or any portion thereof of amounts due hereunder immediately due and payable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.2** Upon the termination of the Agreement by Licensee pursuant to Section 5.2 above, Visual shall immediately return to Licensee any fees paid by Licensee within the last month for the Licensed Rights.

**7. Confidentiality.** For purposes of the Agreement, "confidential information" shall be and remain the sole property of the party disclosing such confidential information and is defined to include, among other things, all information obtained by either party (in such context, a "Receiving Party") from the other party (the "Disclosing Party") that relates to the Disclosing Party's past, present and future research, development and business activities as well as all information, conclusions, drafts and associated materials and final work product resulting from either party's performance under this Agreement, that is either identified as being confidential by the Disclosing Party, with the exception of information (a) previously known to the Receiving Party prior to its receipt from the Disclosing Party or (b) publicly disclosed by the Disclosing Party or (c) lawfully disclosed by any third party either prior to or subsequent to the Receiving Party's receipt of such information or (d) which is required to be disclosed pursuant to any statutory or regulatory authority, provided the Disclosing Party is given prompt notice of such requirement and the scope of disclosure is limited to the extent possible, or (e) which is required to be disclosed by a court order, provided the Disclosing Party is given prompt notice of such order and provided the opportunity to contest it. The Receiving Party will hold all confidential information in trust and confidence for the Disclosing Party and will take all necessary precautions to protect such confidential information including, without limitation, all precautions the Receiving Party employs with respect to its own confidential materials. The Receiving Party will not use any confidential information except as authorized under this Agreement and will not disclose any confidential information to any persons except on a need to know basis for purposes contemplated under this Agreement and under a written obligation of confidentiality. Further, the Receiving Party will not remove or export any confidential information from the country in which it is located except as may be allowed by applicable export laws. Upon termination or expiration of this Agreement, the Receiving Party will return to the Disclosing Party or destroy all written or descriptive materials including, but not limited to, drawings, descriptions, drafts, manuscripts and other papers and documents that contain confidential information.

**8. Warranties.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.1** Visual warrants that the Visual Intellectual Property (a) will perform in accordance with the stated purpose and the operating documentation supplied; and (b) is original to Visual or Visual has full and sufficient rights to grant to Licensee the rights and licenses granted hereunder, without the necessity of payment or attribution of any type to any third party. EXCEPT AS SPECIFIED IN THIS SECTION, THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND THE VISUAL INTELLECTUAL PROPERTY IS PROVIDED "AS IS."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.2** EXCEPT FOR THE PARTIES' (A) INDEMNIFICATION OBLIGATIONS HEREIN; (B) BREACHES OF CONFIDENTIALITY; (C) REPRESENTATIONS RELATING TO INTELLECTUAL PROPERTY; AND (D) REPRESENTATIONS RELATING TO EXCLUSIVITY, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INDIRECT, PUNITIVE, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES ARISING FROM ANY BREACH OF ANY REPRESENTATION OR WARRANTY OR THE RESPECTIVE PARTY'S OBLIGATIONS CONTAINED IN THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND EXCEPT AS STATED IN SUBSECTIONS A THROUGH D OF THIS PARAGRAPH, IN NO EVENT SHALL EITHER PARTY'S TOTAL LIABILITY EXCEED THE AMOUNT LICENSEE PAID IN LICENSE FEES FOR THE RIGHT TO USE THE VISUAL INTELLECTUAL PROPERTY.

**9. Representations and Warranties.** Each of the parties represents and warrants to the other that it has the full right, power, and authority to enter into this Agreement.

**10. No Partnership, Etc.** The relationship of Visual and Licensee is that of independent contractors and each is not and shall not be considered a joint venture, employee or agent of each other. It is understood and agreed that except as expressly stated, nothing in this Agreement authorizes either party to make any contract, agreement, warranty or representation on behalf of the other party, or to incur debt or other obligations in the name of the other party, and that neither party shall in any event assume liability for, or be deemed liable hereunder as a result of any action by the other party.

**11. Applicable Law.** This Agreement and the rights and obligations of the parties shall be governed by and interpreted in accordance with the internal law of the State of Colorado without giving effect to the principles of conflict of laws.

**12. Jurisdiction and Venue.** The parties acknowledge that the execution of, and substantial performance under, this Agreement has occurred or will occur in the State of Colorado. Without limiting the right of the parties to pursue their rights and remedies under this Agreement (or under any judgment obtained in respect thereof) in any appropriate jurisdiction, the parties hereby irrevocably consent to the jurisdiction and venue of the courts of the State of Colorado or any United States Court of competent jurisdiction situate therein, to adjudicate any legal action commenced by a party and waive any objections they may at any time have to such jurisdiction and venue.

**13. Notices.** Any notice, demand, or communication required or permitted to be given by any provision of this Agreement shall be deemed to have been sufficiently given or served for all purposes: (i) if delivered personally to the party or to an executive officer of the party to whom the same is directed; (ii) if sent by registered or certified mail, postage and charges prepaid, or by a recognized overnight courier service, addressed to the party's address set forth below; or (iii) upon facsimile transmissions to the party's facsimile number shown below with a copy of said notice given by one of the other methods set forth in this Section. Except as otherwise provided herein, any such notice shall be deemed to be given under clause (i) upon delivery; under clause (ii) two business days after mailing or one business day after delivery by overnight delivery service; or under clause (iii) upon completion of the facsimile transmission.

---

| | |
|:---|:---|
| If to Visual: | Visual Health Solutions, Inc |
|  | 1300 Riverside Ave., Suite 101 |
|  | Fort Collins, Colorado 80524 |
|  | ATTN: Paul M. Baker |
|  | EMAIL: pbaker@visiblep.com |
| If to Licensee: | Docola, Inc. |
|  | 801 West Bay Dr. #506 |
|  | Largo, FL 33770 |
|  | ATTN: Eran Kabakov |
|  | EMAIL: eran@doco.la |

---

**14. Assignment.** This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the parties hereto.

**15.** Intentionally Deleted.

**16. Descriptive Headings.** The descriptive headings of the separate sections or paragraphs of this Agreement are inserted for convenience of reference only and do not form a part hereof and in no way modify, interpret, or construe the meaning of the parties.

**17. Waiver.** A party's failure to exercise any of its rights hereunder or insist on compliance or enforcement of any provision of this Agreement, shall not affect the validity or enforceability or constitute a waiver of future enforcement of that provision or any other provision of this Agreement by that party or any other party.

**18. Email Transmissions.** This Agreement may be executed and delivered by a party by an email attachment, which transmission copies shall be considered an original, and shall be binding and enforceable against such party.

**19. Entire Agreement.** Except for the Confidentiality Agreement executed either prior to or contemporaneously herewith, this Agreement supersedes any prior agreements or understandings between the parties with respect to the matters set forth herein, and constitutes the entire understanding of the parties as to the matters set forth herein. No modification of this Agreement shall be valid or binding unless executed in writing by each of the parties on or after the date hereof. None of the parties shall be bound by any representations, warranties, promises, statements, or information as to the matters which are the topic of this Agreement, unless such are specifically set forth herein.

**20. Acknowledgment.** The parties agree that in entering into this Agreement, they are relying upon their own judgment, belief and knowledge as to all phases of their claims and further acknowledge that no promise, inducement or agreement or any representations and warranties not specifically expressed herein have been made to procure their agreement hereto. The parties further acknowledge that this Agreement is contractual and not merely recital, and that they have read, understood and fully agree to the terms of this Agreement.

**21. Severability.** The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, which shall remain in full force and effect. If any covenant or provision of this Agreement is determined to be unenforceable by reason of its extent, duration, scope, or otherwise, then the parties contemplate that the court making such determination shall reduce such extent, duration, scope, or other provision and enforce them in their reduced form for all purposes contemplated by this Agreement.

**22. Survivability.** Where the context of this Agreement requires such an interpretation, this Agreement shall survive the termination of the Licensed Rights. Notwithstanding the above, Visual retains the right to use the Product in its own promotional materials and in presentations.

**23. Indemnification.** Each party agrees to indemnify, defend and hold harmless the other party, and its affiliates and their respective directors, officers, employees and agents (each, an "Indemnified Party") against all claims, liabilities and costs, including reasonable attorneys' fees, incurred in the defense of any claim brought against any Indemnified Party by a third party (i) alleging that the Visual Intellectual Property, with respect to Visual, or Licensee's Media, with respect to Licensee, infringes or misappropriates any patent, copyright, trademark, trade secret, trade dress, or other Visual Intellectual Property or proprietary rights of any third party, (ii) resulting from a breach by such party of any of its representations or warranties hereunder, provided that the Indemnified Party promptly notifies the indemnifying party in writing of any such claim and the indemnifying party is permitted to control fully the defense of such claim, or (iii) bodily injury, death of any person, or damage to real or tangible personal property resulting from a party's acts or omissions.

**24. Excluded Providers.** Visual represents and warrants that it is not presently under exclusion from, nor has it ever been excluded from, participation in Medicare, Medicaid or any other federally funded health care program pursuant to 42 U.S.C. §1320a-7b, or any similar federal, state or local statute or regulation, nor does it presently employ or contract with any individual or entity that is or has been so excluded, or convicted of a criminal offense related to the provision of healthcare services. If at any time during the term of this agreement Visual is excluded from participation in any federally funded health care program, such exclusion shall cause this agreement to terminate immediately and without notice. Furthermore, both parties agree to use their best commercially reasonable efforts to comply with any and all requirements imposed on Visual and Licensee, respectively, under 42 U.S.C. § 1320a 7b(b)(3)(A) and the "safe harbor" regulations regarding discounts or other reductions in price set forth in 42 C.F.R. § 1001.952(h).

**IN WITNESS WHEREOF**, the parties hereto have executed this Agreement as of the date hereof.

---

| | | | |
|:---|:---|:---|:---|
| **VISUAL HEALTH SOLUTIONS, Inc.** | **VISUAL HEALTH SOLUTIONS, Inc.** | **Docola Inc.** | **Docola Inc.** |
| By: |  | By: |  |
|  | Paul M. Baker |  | Eran Kabakov |
| Title: | CEO | Title: | CEO |
| Date: | 9/1/19 | Date: |  |

---

**SCHEDULE A**

&nbsp;&nbsp;&nbsp;&nbsp;· Visual Intellectual Property includes all:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Illustrations, animations and associated "programs"
 displayed on <u>www.visualhealthsolutions.com</u> or otherwise available ("Visual
 Content");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Visual Consults either existing or added during the Term of this Agreement ("Visual Consults"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Any new illustrations or animations added to its web site.

&nbsp;&nbsp;&nbsp;&nbsp;· Visual agrees to provide the Visual Intellectual Property and related
functionality in a format acceptable to Licensee, including those required for DOC.LA's fixed and mobile products. Notwithstanding,
the Visual Consults will be provided to work on PCs using the Windows 7 or Windows 10 platforms and iPads.

&nbsp;&nbsp;&nbsp;&nbsp;· Visual shall have the right to initially approve, in its absolute
discretion, the specific placement, appearance, size, format, positioning, and all other aspects relating to the display of the
Visual Intellectual Property on the DOC.LA products. Visual shall have the right to review and approve, in its absolute discretion,
material changes to the display of the Visual Intellectual Property.

**SCHEDULE B:** 

&nbsp;&nbsp;&nbsp;&nbsp;· Licensee may format the Visual Intellectual Property in accordance
with Licensee's product requirements, provided that the Visual Intellectual Property may not be edited or modified in a material
way. Licensee is not under any obligation to display any particular content item, and may decide not to display, or to remove,
individual content items in their entirety at their sole and absolute discretion.

&nbsp;&nbsp;&nbsp;&nbsp;· Licensee agrees to include the Visual Intellectual Property into all
of its offerings and pay Licensor a monthly fee equal to 70% of the provider-user fees collected by DOC.LA (the "Monthly
Fee").

&nbsp;&nbsp;&nbsp;&nbsp;· The Monthly Fee will be calculated as follows: Licensee will report
each month the number of providers paying fees to DOC.LA for the use of the DOC.LA platform during the preceding month by the 5<sup>th</sup>
of the month, together with the per-provider fees paid to DOC.LA. Licensor will invoice the Licensee the calculated Licensor fee
based on the number of provider-users and the fees paid to DOC.LA. Payment shall be made within 30 days.

&nbsp;&nbsp;&nbsp;&nbsp;· DOC.LA can utilize images for a mobile platform in cases where mobile
complements the exam room offering in a hospital, health system or physician office at no cost, provided DOC.LA isn't receiving
fees from the mobile use.

## Exhibit 10.3

**Exhibit 10.3**

**LICENSE AGREEMENT**

THIS AGREEMENT ("Agreement") is effective this 29th day of September 2020 ("Effective Date") by and between Docola Inc. ("Docola"), having a place of business at 801 W Bay Dr #560, Largo, FL 33770 and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey,

U.S.A. ("Merck").

WHEREAS, Merck is the holder of proprietary rights in and to certain software and/or content ("Merck Content" as defined below and as more specifically identified in Exhibit A); and

WHEREAS, Docola desires to obtain a license from Merck to incorporate Merck Content into Docola's products below and as more specifically identified in Exhibit B; and

WHEREAS, Merck is willing to grant such a license to Docola subject to the terms and conditions set forth herein;

NOW, THEREFORE, IT IS AGREED by and between the parties as follows:

1. DEFINITIONS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1 "Merck Content"** as used in this Agreement shall mean executable, object-code versions of the software and/or content identified in Exhibit A, together with all updates, corrections, and new versions thereof, and any users manuals or other materials that describe or explain the functionality and operability of Merck Content.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2 "Docola offering"** as used in this Agreement means Docola's products offerings identified in Exhibit B. All right, title and interest, including all copyrights, in and to Docola (but excluding any Merck Content incorporated therein) is and shall remain the property of Docola.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3 "Docola Customer"** means an entity that has licensed the right to use the Docola content and/or Merck Content as an end user directly from the Docola offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.4 "Proprietary Rights"** means all patent, copyright, and other rights related to the Merck Content.

2. LICENSE, COMMERCIALIZATION

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 <u>License</u>.** In accordance with Merck guidelines set forth in section 3.1 herein, Merck hereby grants to Docola a non-exclusive license of its Proprietary Rights to provide to Docola's North American based customers web access to the Merck Content in conjunction with Docola's offerings. If used outside the North America restrictions apply and are detailed in section 3.1 and Exhibit A.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

![](dc001_ex10-3img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 <u>Commercialization</u>.** Docola shall have sole and exclusive discretion concerning the marketing and distribution of Merck Content so long as it is not monetized including, but not limited to, decisions concerning terms and conditions of sale or licensure of such Docola offerings to end users, pricing, advertising, channels of distribution, and whether (and when) to discontinue the marketing and distribution of any particular Docola offerings. The Docola team may use Merck's name, logos and proprietary images in an appropriate manner, in reference to Merck Content, provided, however, that Docola shall cease all use of Merck's name, logos and proprietary images upon termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3 <u>Attribution Right</u>.** All of Docola's offerings that incorporate the Merck Content, in whole or in part, shall include the following proprietary rights notice in addition to a Docola proprietary rights notice: "Copyright© 2020 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4 <u>Competitive Products</u>.** Nothing in this Agreement shall restrict in any way either party's right or ability to develop, have developed, market or distribute any product or service that directly or indirectly competes with the products or services of the other party, including those covered by this Agreement.

3. OTHER RESPONSIBILITIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 **<u>Marketing.</u>** Merck is offering this free service for the benefit of HCPs and patients to Docola. Docola will promote the Merck Manual content as an offering to their users. A descriptive blurb of the Merck Manuals professional and consumer versions (with the right of the Merck to adjust the description up to 4 times per calendar year) will be listed a) on the partner page and b) on the Welcome page or appropriate area to advertise that is it available. The Docola team at Merck's request will provide a quarterly report that includes usage statistics, plus the number of overall subscribers. With respect to Docola Customers, Docola shall not charge for any Merck content. The Merck offering will be included as part of the base subscription price and cannot be monetized in any way. If Docola imposes any charges related to the offerings of the Merck product Merck shall have the unilateral right to terminate this contract.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2 <u>Taxes and Duties</u>.** Docola shall be solely responsible for and shall pay all taxes, duties, import deposits, assessments and other governmental charges, however designated, which are now or hereafter imposed by any governmental authority or agency resulting from this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.3 <u>Expenses</u>.** Each party has full responsibility for its own costs and expenses incurred in carrying out its obligations under this Agreement.

4. REPRESENTATIONS, WARRANTIES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1 <u>Docola Warranties and Indemnification</u>.** Docola makes the following representations and warranties to Merck:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that Docola has and shall have full power and authority to enter into this Agreement and to perform hereunder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that Docola offerings do not and shall not violate any patent, copyright, trade secret or other right of any third party, or create any liability to any third party including, but not limited to personal injury or property damage; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) that Docola shall defend, indemnify and hold harmless Merck from and against any and all third-party claims, actions, causes of action, liabilities, damages, costs and expenses, including attorneys' fees, arising out of or related to any facts or alleged facts which, if true, would constitute a breach of such representations and warranties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2 <u>Merck Warranties and Indemnification</u>.** Merck makes the following representations and warranties to Docola, which Docola may pass through to Docola customers:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that Merck has and shall have full power and authority to enter into this Agreement and to perform hereunder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that the Merck Content does not and shall not violate any patent, copyright, trade secret or other right of any third party, or create any liability to any third party including, but not limited to personal injury or property damage; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) that Merck shall defend, indemnify and hold harmless Docola from and against any and all third-party claims, actions, causes of action, liabilities, damages, costs and expenses, including attorneys' fees, arising out of or related to any facts or alleged facts which, if true, would constitute a breach of such representations and warranties.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

![](dc001_ex10-3img01.jpg)

5. CONFIDENTIALITY OBLIGATION

All Confidential Information shall be deemed confidential and proprietary to the party disclosing such information hereunder. Each party may use the Confidential Information of the other party during the term of this Agreement only as permitted or reasonably required for the receiving party's performance hereunder. The receiving party shall not disclose or provide any Confidential Information to any third party, and shall exercise the same degree of care to protect the disclosing party's Confidential Information as the receiving party exercises to protect its own Confidential Information, but never less than a reasonable degree of care.

6. TERM AND TERMINATION

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.1 <u>Term</u>.** This Agreement shall become effective upon the Effective Date and shall remain in force for two years ("Initial Term"), unless otherwise terminated in accordance with the terms contained herein. Thereafter, this Agreement shall be renewed for subsequent one year periods upon written notice provided by Merck of its intention to renew this Agreement at least ninety days prior to the termination date of the current term (including any renewals).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.2 <u>Termination</u>.** This Agreement may be terminated by mutual agreement of the parties, and either party <u>may</u> terminate this Agreement with respect to any, or all, Merck Content immediately upon giving written notice of termination to the other party upon the occurrence of any of the following events: (i) the other party fails to cure a breach hereof committed by it within ninety days after receiving written notice thereof, (ii) the other party institutes proceedings under bankruptcy or insolvency laws, for corporate reorganization, receivership, dissolution or similar proceedings, (iii) proceedings under bankruptcy or insolvency laws, for corporate reorganization, receivership, dissolution or similar proceedings are pending against the other party for more than ninety days, (iv) the other party makes a general assignment for the benefit of creditors, (v) the other party becomes insolvent, or (vi) either party ceases to conduct business or to conduct the business relevant hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.3 <u>Obligations Upon Termination</u>.** Upon any termination of this Agreement, Docola shall cease providing access to the Merck Content and incorporating Merck Content into Docola offerings. A party's decision to terminate this Agreement shall not affect its ability to enforce its rights hereunder.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

![](dc001_ex10-3img01.jpg)

7. EXCUSED PERFORMANCE

Each party's performance is subject to interruption and delay due to causes beyond its reasonable control such as acts of God, acts of any government, war or other hostility, fire, explosion, power failure, equipment failure, industrial or labor dispute, inability to obtain necessary supplies and the like.

8. RELATIONSHIP OF THE PARTIES

The parties shall be independent contractors hereunder, and except as specifically provided herein, each party shall bear its own costs and expenses. This Agreement is not intended to constitute or create a joint venture, partnership or other formal business organization of any kind.

9. LIMITATIONS OF LIABILITY AND CLAIMS

Neither party shall be liable to the other party hereunder for any profits lost by the other party or for any consequential, exemplary, incidental, indirect or special damages suffered by the other party, even if a party has been advised of the possibility of such damages. No claim, regardless of form, which in any way arises out of this Agreement or the parties' performance of this Agreement may be made, nor action based upon such a claim brought, by either party more than one year after the basis for the claim becomes known to the party desiring to assert it. The terms of Sections 4, 5, 6, 12 and this Section 9 shall survive any termination of the Agreement.

10. NOTICES

The parties shall each appoint a representative from their organization to accept all written notices which are required, or may be given, hereunder.

Docola representative shall be:

Eran Kabakov

Docola Inc.

801 W Bay Dr #560

Largo, FL 33770

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

![](dc001_ex10-3img01.jpg)

Merck's representative shall be:

Melissa Adams

Merck Sharp & Dohme Corp.

PO Box 2000, RY34-A426

Rahway, NJ 07065

Ph: (732) 594-0715

or such other person or address as Merck may provide Docola in writing.

11. WAIVER AND MODIFICATION

Failure or delay by either party to enforce any provision of this Agreement shall not constitute or be construed as a waiver of such provision or of the right to enforce such provision. No part of this Agreement may be waived, modified, or supplemented in any manner whatsoever (including a course of dealing or of performance or usage of trade) except by a written amendment signed by authorized representatives of both parties.

12. GOVERNING LAW, DISPUTE RESOLUTION

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.1 <u>Governing Law</u>.** This Agreement, including its making, interpretation, performance, termination and enforcement shall be governed by the laws of the State of New Jersey, excluding its choice of law rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.2 <u>Dispute Resolution</u>.** The parties shall attempt in good faith to amicably resolve between themselves any controversy, claim or dispute (cumulatively, "Dispute") arising out of this Agreement. Any Dispute not resolved within thirty (30) days of written notice of the Dispute shall undergo mediation in accordance with the Center for Public Resources Model Procedures using a mediator having a background in the industry and subject matter of the Dispute. Mediator costs shall be equally shared. If the Dispute has not been resolved by the mediation process within thirty (30) days after commencement of the process (which occurs with the first conference or telephone conference mediated by the mediator), any party may initiate litigation upon ten (10) days notice to the other party. Except where disclosure is required by law or regulation, the parties agree to hold all Disputes in confidence until the first pleading arising from any litigation that has been filed with the court. The procedures herein are exclusive and shall be fully exhausted prior to the initiation of litigation; provided, however, that nothing herein shall preclude a party from taking any action necessary to prevent imminent and irreparable harm.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

13. EFFECT OF AGREEMENT

This Agreement embodies the entire understanding between the parties and supersedes any and all prior agreements, if any, whether written or oral, between the parties with respect to the subject matter of this Agreement. Should any provision of this Agreement be held to be void, invalid, unenforceable, or illegal by a court, the validity and enforceability of the other provisions of this Agreement shall not be affected thereby. The headings and captions contained in this Agreement are for convenience only and shall not constitute a part hereof.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their authorized representatives.

---

| | | | |
|:---|:---|:---|:---|
| **Docola Inc.** | **Docola Inc.** | **Merck Sharp & Dohme Corp.** | **Merck Sharp & Dohme Corp.** |
| By | Eran Kabakov | By | /s/ Melissa Adams |
| Title | CEO | Title | Publisher |
| Date | 9/29/2020 | Date | September 30, 2020 |

---

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

**EXHIBIT A - Merck Content**

The Merck Content shall include the following:

1) *The Merck Manual Consumer and Professional Editions –* Residing Online at www.merckmanuals.com (in US and Canada) and www.msdmanuals.com (outside of North America), including web access to its written information and content, HTML code, infobutton functionality, images, navigation, and programming.

**Note -**

Docola shall not remove any citations or copyright information unless specifically agreed to in writing by Merck.

Merck acknowledges and agrees that Docola may distribute the Merck content by the infobutton API or website link which will make the call directly to the Merckmanuals.com or msdmanuals.com content web site.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

**EXHIBIT B – Docola Offerings**

Offerings that access the Merck content shall include the following:

1) Infobutton access following HL7 standards within Docola offering

2) Website link access if needed within Docola offering.

3) Access to both offerings on the consumer and professional side whether it be for clinical decision support or for patient education

**Note -**

Docola acknowledges and agrees that Merck must be notified of and approve all material before Docola releases any Docola offerings incorporating MM content. Docola agrees to provide Merck with user account access to the Docola web site for review purposes.

---

| | |
|:---|:---|
| ![](dc001_ex10-3img02.jpg) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., based in Kenilworth, New Jersey, U.S.A. Merck, known as MSD outside the United States and Canada, is an innovative, global healthcare leader that is committed to improving health and well-being around the world. |

---

## Exhibit 10.4

**Exhibit 10.4**

**UC Technology Reference Number – SF2013-168**

**NONEXCLUSIVE LICENSE AGREEMENT**

This Nonexclusive License Agreement ("Agreement") is made and entered into this 16th day of August, 2021 ("Effective Date"), by and between **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA**, a California constitutional corporation ("The Regents"), acting on behalf of the University of California San Francisco ("UCSF"), and through the Office of Technology Management & Advancement, University of California San Francisco, 600 16<sup>th</sup> Street, Suite S-272, San Francisco, California, 94143, and **DOCOLA, INC., 801 West bay Drive, #506, Largo, FL 33770** called "Licensee".

Whereas, The Regents is the proprietor of all of the content, including, without limitation, text, graphics and video, on the websites designated as <u>www.prepareforyourcare.org</u> and subdirectories thereof ("PREPARE");

Whereas, Licensee is the proprietor of a software platform that enables healthcare providers to share healthcare information with their patients; and

Whereas Licensee and The Regents would like to make PREPARE available to healthcare providers and patients through Licensee's platform.

NOW, THEREFORE, in consideration of the mutual covenants, conditions, and terms hereinafter set forth, and for other good and valuable consideration, the parties hereto hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. Licensee will provide to UCSF a list of domains from which Licensee would like to link to PREPARE.

&nbsp;&nbsp;&nbsp;&nbsp;2. Within seven days of the receipt of the list of domains from Licensee, UCSF will provide to
Licensee a link to PREPARE ("Link" respectively) and will make technical changes required to allow Licensee-provided
domains to show PREPARE in an I-frame on websites hosted within those domains.

&nbsp;&nbsp;&nbsp;&nbsp;3. The Regents grants to Licensee the nonexclusive right, without the right to sublicense, to display
and provide PREPARE through an I-Frame on web pages owned by Licensee ("Source Site") as long as (i) the specifications
of Exhibit A of this Agreement are met and (ii) Licensee maintains the integrity of the Link. Licensee's use of the I-Frame
shall be solely to offer PREPARE as a patient content option for healthcare providers registered with Licensee. Licensee shall
not modify the Source Site specifications in Exhibit A without the prior written consent of The Regents. Licensee shall seek prior
written approval from The Regents for any written descriptions of PREPARE appearing on Licensee's websites, or wherever Licensee
references, links, or I-Frames PREPARE.

&nbsp;&nbsp;&nbsp;&nbsp;4. Licensee will maintain its website, including the Source Site, in accordance with industry standards.
Licensee will not make any changes to the I-Frame without prior written approval of The Regents. Licensee
agrees to use the I-Frame and Link in compliance with this Agreement, and all applicable statutes and regulations.

**UC Technology Reference Number – SF2013-168**

&nbsp;&nbsp;&nbsp;&nbsp;5. Licensee will provide UCSF with agreed upon metrics, such as, but not limited to, the number
and organization type of all Practice Accounts, as defined in Exhibit B, that use PREPARE, the number and type of all Clinician
Accounts, as defined in Exhibit B, that use PREPARE, the number of patients who are assigned/prescribed/utilize PREPARE per Clinician
and Practice Account, and any other available metrics and feedback regarding PREPARE that can be shared under applicable law (e.g.,
this may include demographics of the sites and users). This information will be provided to UCSF quarterly with the paid Earned
Royalties.

&nbsp;&nbsp;&nbsp;&nbsp;6. Licensee shall pay to The Regents earned royalties in accordance with Exhibit B of this Agreement
("Earned Royalties"). These Earned Royalties are non- refundable and non-cancelable. Earned Royalties accruing to The
Regents will be paid to The Regents quarterly within sixty (60) days after the end of each calendar quarter. All consideration
due The Regents will be payable and will be made in United States dollars by check payable to "The Regents of the University
of California" or by wire transfer to an account designated by The Regents below. The Licensee is responsible for all bank
or other transfer charges.

Checks shall be mailed to:

UCOP Knowledge Transfer Office

Attn: Accounts Receivable

1111 Franklin Street, 5th Floor

Oakland, CA 94607-5200

Bank Information for Wire Transfers:

Bank of America

1655 Grant Street

Concord, CA 94520

Attn: OTI Depository Account No. 12337-17062

ABA Transit Routing No. 121000358

Beneficiary Name: Regents of the University of California

Wire ABA: 026009593 (within U.S. only)

Wire SWIFT: BOFAUS3N

Fax your remittance advice to: (510) 835-3705

University of California, Knowledge Transfer Office

**UC Technology Reference Number – SF2013-168**

**NOTE: To ensure that funds are properly credited to Licensee's account, reference UC case number <u>SF2013-168</u> on all checks and wire transfers.**

<u>Late Payments</u>. If monies owed to The Regents under this Agreement are not received by The Regents when due, Licensee will pay to The Regents interest charges at a rate of ten percent (10%) per annum. Such interest will be calculated from the date payment was due until actually received by The Regents. Such accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of The Regents related to such late payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. OWNERSHIP: As between The Regents and Licensee, all right, title, and interest in and to PREPARE
shall at all times remain with The Regents. Licensee acknowledges that PREPARE is a copyrighted work and as such is protected by
the copyright laws of the United States and by international treaties. Licensee shall not copy, distribute, modify, or publicly
display, nor permit any of its personnel to copy, distribute, modify, or publicly display the same for any purpose that is not
specifically authorized under this Agreement. Nothing in this Agreement grants by implication, estoppel, or otherwise any rights
to the intellectual property of The Regents except as explicitly set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. LICENSEE UNDERSTANDS THAT THE REGENTS MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY
KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE,
OR THAT THE USE OF THE AUTHORED WORK WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS. NOTHING IN THIS AGREEMENT
SHALL BE CONSTRUED AS AN OBLIGATION OF THE REGENTS TO FURNISH ANY TECHNICAL INFOMRATION OR ASSISTANCE TO LICENSEE RELATING TO PREPRE.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Licensee hereby agrees to indemnify and hold harmless and release and forever discharge The Regents,
its agents, officers, assistants, and employees thereof, either in their individual capacities or by reason of their relationship
to The Regents and successors, from any or all of the above mentioned persons or their successors, by reason of any damage, or
other consequences arising or resulting directly or indirectly from the license herein and hereby granted and occurring at any
time subsequent to such grant of license, including but not limited to, any use of PREPARE, that is not authorized under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. USE OF NAME: Nothing in this Agreement shall be construed as conferring rights to use in
 advertising, publicity or otherwise any trademark, trade name, service mark or the name of "University
 of California" or "The Regents of the University of California" or any abbreviation thereof. However, the use
 of The Regents' name as associated with the copyright
notice for PREPARE shall not be restricted.

**UC Technology Reference Number – SF2013-168**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. In all uses of PREPARE to be made pursuant to this License, Licensee shall include the following
notice:

Copyright© 2012-2020 The Regents of the University of California. All rights reserved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Life of the Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will remain in effect for two (2) years from the Effective Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. This Agreement may be terminated by either party at any time upon the giving of thirty (30) days prior written notice to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. If the Licensee fails to perform or violates any term or covenant of this Agreement, then The Regents will have the right to terminate this Agreement by providing five (5) days written notice of termination to Licensee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Any termination or expiration of this Agreement will not affect the rights and obligations set forth in Articles 6, 7, 8, 9,10, and 11.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. This Agreement embodies the entire understanding of the parties and supersedes all previous communications,
representations, or understandings, either oral or written, between the parties relating to the subject matter hereof. No amendment
of modification of this Agreement is valid or binding on the parties unless made in writing and signed on behalf of each party.

IN WITNESS WHEREOF, the parties hereto have executed this License Agreement on the date and year first written above.

---

| | | | |
|:---|:---|:---|:---|
| THE REGENTS OF | THE REGENTS OF | DOCOLA, INC. | DOCOLA, INC. |
| THE UNIVERSITY OF CALIFORNIA | THE UNIVERSITY OF CALIFORNIA |  |  |
| By: | /s/ Gonzalo Barrera-Hernandez | By: | /s/ Eran Kabakov |
| Name: | Gonzalo Barrera-Hernandez | Name: | Eran Kabakov |
| Title: | Director, Business Affairs & Strategic Partnerships, OTMA | Title: | CEO |
| Date: | &nbsp;&nbsp;&nbsp;8/18/2021 | Date: | 8/17/2021 |

---

**UC Technology Reference Number – SF2013-168**

**EXHIBIT A**

**SOURCE SITE SPECIFICATIONS**

The text at the Source Site that includes the Link will read as follows:

PLEASE use this easy-to-read description of the PREPARE program for patients/clients:

*PREPARE is a step-by-step program with video stories to help you:*

&nbsp;&nbsp;&nbsp;&nbsp;· *Have a voice in YOUR medical care* 

&nbsp;&nbsp;&nbsp;&nbsp;· *Talk with your doctors* 

&nbsp;&nbsp;&nbsp;&nbsp;· *Fill out an advance directive form to put your wishes in writing.* 

 

PLEASE use this description of the PREPARE program for other purposes:

*"PREPARE for Your Care is an online resource that helps people learn about and prepare for medical decision making. It is evidenced-based and includes video stories in English and Spanish that guides users as they explore their wishes and learn how to discuss them with family, friends, and medical providers. The website also offers PREPARE written pamphlets and Toolkits to put on PREPARE Group Movie Events. These Movie Events can be used in group medical visits or in the community. PREPARE also offers easy-to-read, legally-valid advance directives for all 50 states in English and Spanish. Check out PREPARE here: www.prepareforyourcare.org."*

 

**UC Technology Reference Number – SF2013-168**

**EXHIBIT B**

**Earned Royalties**

The Earned Royalty amount due The Regents per Clinician Account and Practice Account shall initially be $20.00 per month. Subsequently, The PREPARE team at UCSF shall have the ability to change the Earned Royalty amount at any time. Each Clinician Account and Practice Account shall be limited to 300 prescriptions of PREPARE per month.

"Clinician Account" is defined by the technical permission to aggregate information (multi media) and prescribe to patient accounts. A clinician can be any person who is patient facing as part of their profession. These can include, but not limited to physicians, nurses, social workers, physical/occupational/speech therapists, psychologists, dentists, patient advocates, case managers, peer support group leaders etc. A Clinician Account is not limited in the number of patients it can invite into Docola, however, a "flagging" system is utilized that triggers at 500 new patients per individual month. If a Clinician Account is flagged, Docola will contact the account to ensure that the account is being used appropriately.

"Practice Account" is exactly the same as Clinician Account with one exception: multiple clinicians can manage the content and patients of the Practice Account. A practice account is meant to be used by a single clinic, practice, or service line within a larger organization. It is not to be used for a large healthcare organization. Practice account enables gold standard utilization practice for maintaining privacy and security of account information. The first 5 clinicians on a practice account can be added at no cost. Any additional clinician carries a charge of $9 USD/month. Docola reserves the right to change pricing at any time.

For larger scale health care related organizations that require ongoing management by Docola, (resulting in Enterprise Accounts) if there is a need for PREPARE materials, Docola will contact the PREPARE team with prospective account information for specific pricing guidance.

## Exhibit 10.5

**Exhibit 10.5**

**<u>Memorandum of Understanding Between Docola and Patients for Patient Safety United States</u>**

1. <u>Parties and Definitions</u>: This Memorandum of Understanding (MOU) reflects the preliminary agreement between Docola and
Patients for Patient Safety US (PFPS US) working together to pursue goals of PFPS US. The purpose of this MOU is to set forth the
understandings under which PFPS US and Docola will work as Organizational Partners. Attachment A lists current PFPS US Organizational
Partners.

2. <u>Background</u>: Avoidable harm in healthcare includes death or injury caused by human error, process or protocol failures,
missed or delayed diagnoses of medical conditions, medication errors, technology or medical equipment failures, gaps in communication
or coordination among healthcare providers or with patients, and health equity problems such as bias or discrimination, among other
causes.

Although estimates vary from country to country, avoidable harm in healthcare is now recognized as a one of the leading causes of avoidable death and therefore a serious global public health challenge. Many more people who do not die, but survive avoidable harm in healthcare, experience serious bodily injury, disability, emotional or psychological harm such as trauma or depression, or financial harm.

3. <u>Patients for Patient Safety, a Program of the World Health Organization (WHO)</u>: Patients for Patient Safety is an international
network of patient safety advocates established by WHO in 2004 to raise awareness about avoidable harm in healthcare and advance
the improvement of patient safety in every nation on earth.

PFPS was organized and is led by patients who have experienced avoidable harm themselves or close family members who are their advocates. Membership in PFPS is open to any person who:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Agrees to supports WHO patient safety goals,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Agrees to support the PFPS London Declaration (Attachment B), developed in 2005 as the PFPS pledge of partnership,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Completes an orientation to WHO patient safety objectives and programs and PFPS's role in advancing them, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Agrees to abide by WHO rules of engagement.

People who meet these criteria are designated PFPS "Champions" and added to an international roster of members maintained by WHO. PFPS Champions are volunteers. We receive no compensation from WHO, are not agents of WHO, and cannot present ourselves as representatives of WHO.

PFPS US is a branch of the PFPS international network, established in 2021 by patient safety advocates with the mission of advancing the WHO Global Patient Safety Action Plan 2021-2030 (GPSAP) (Attachment C) in the United States.

In addition to individual PFPS Champions, the PFPS US network includes Organizational Partners interested in working with patients and their advocates to achieve one or more of the WHO GPSAP strategic objectives, in whole or in part. Organizational partners include government entities, educational institutions, nonprofit organizations, and for-profit organizations who are stakeholders in improving patient safety. These organizations have expressed a willingness to cooperate with PFPS Champions to improve patient safety.

4. <u>Strategic Objectives</u>:

PFPS US will be active in pursuing the seven Strategic Objectives set forth in the GPSAP (Attachment C), pages 16-68.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 1. Policies to eliminate avoidable harm in health care

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 2. High-reliability systems

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 3. Safety of clinical processes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 4. Patient and family engagement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 5. Health worker education, skills and safety

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 6. Information, research and risk management

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪ Strategic objective 7. Synergy, partnership and solidarity

PFPS Organizational Partners are asked to actively support implementation of at least one of these Strategic Objectives, in whole or in part. <u>By joining PFPS US as an Organizational Partner, Docola is not required to support every strategy set forth in the GPSAP</u>.

Organizational Partners will be consulted in the development of specific implementation positions, proposals or actions taken by PFPS US, but not required to support or endorse any specific position, proposal or action pursued by PFPS US.

5. <u>Additional Organizational Partners</u> **:** As PFPS US grows it will partner with additional organizations that support
the PFPS US Goal, Mission and Pledge of Partnership beyond those listed in Attachment A. Entities that produce, distribute or earn
revenue from the distribution of firearm or tobacco products will not be eligible to participate as PFPS US Organizational Partners.

6. <u>PFPS US Funding</u>: This MOU creates no obligation on the part of Organizational
Partners to fund PFPS US. Budgets for activities that implement all or part of PFPS US activity will be managed with the agencies
or organizations contributing that funding or though agreements distinct from this MOU.

7. <u>Description of Cooperative Work</u>: It is anticipated that PFPS US work will be done by working groups that include people
who work for or represent PFPS US Organizational Partners. Working groups will report on their work to PFPS US Organizational Partners
through email, conference calls, virtual meetings or in person meetings. Regular virtual meetings open to participation by PFPS
US Organizational Partner representatives will be scheduled to coordinate this cooperative work.

8. <u>Use of Names on PFPS US Work Product</u>: Each PFPS US Organizational Partner will be asked to allow the use of their organization's
name and logo in PFPS US materials, but logo use is not required. No Organizational Partner logo will be used without receiving
express written consent.

9. <u>Duration and Amendment</u>: The MOU will be effective from the date signed through December 31, 2022. It may be renewed
at that time.

10. <u>Withdrawal</u>: Any Organizational Partner is free to leave the PFPS US at any time. An Organizational Partner's name
will be removed from the list of partners (Attachment A) upon receipt by mail or fax of a written notice to do so.

11. <u>Good Faith Decision-making</u>: All parties to the MOU agree to act in good faith in their cooperative dealings with one
another in the pursuit of the PFPS US Goal, Mission and Pledge of Partnership. We agree to strive, through discussion and good
faith negotiation, to reach consensus whenever possible.

12. <u>Confidentiality</u>: All parties agree to respect the confidentiality of documents explicitly designated as such or the
embargo on unreleased documents that may be shared by PFPS US Organizational Partners from time to time.

13. <u>Letters of Invitation</u>: Organizations wishing to participate as a PFPS US Organizational Partner have the option of doing
so by requesting a letter of invitation in lieu of or in addition to signing this MOU. Letters of invitation may be requested and
must be accepted in writing.

14. <u>Notices</u>: All official notices on any matter pertaining
to the commitments made in this MOU shall be sent mail email or fax to:

Contact Person: Martin Hatlie Contact Person: Eran Kabakov <br> PFPS US Docola <br> 620 N LaSalle Street Chicago, IL 60654 Email: mhatlie@p4ps.net 801 W Bay Dr #506 Largo, FL 33770 eran@doco.la

All official notices from PFPS US will be sent to the designated contact person for the PFPS US Organizational Partner who signed the MOU or accepted a letter of invitation.

15. <u>Approval</u>: By signing below, our organization agrees to the provisions of this MOU.

**<u>Agreement</u>**

---

| | | |
|:---|:---|:---|
| **Organization:** |  |  |
| **Docola** |  |  |
|  | /s/ Martin J Hatlie | /s/ Martin J Hatlie |
|  | **Signature** | **Signature** |
| /s/ Eran Kabakov | Martin J Hatlie | Martin J Hatlie |
| **Signature** | **Printed Name of Signer** | **Printed Name of Signer** |
| **Eran Kabakov** | Founder | Founder |
| **Printed Name of Signer** | **Title** |  |
| CEO |  |  |
| **Title:** | **Date**: | December 17, 2021 |

---

**Date**: December 17, 2021

**Organization:**

**Patients for Patient Safety US** 

**<u>ATTACHMENT A</u>**

**<u>Patients for Patient Safety US (PFPS US)</u>**

**<u>Organizational Partners</u>**

Collaborative for Accountability and Improvement

GeaCom, Inc.

Healthcare Patient Partnership Institute

Institute for Safe Medication Practices/ECRI

Jewish Healthcare Foundation

Lucian Leape Institute & Institute for Healthcare Improvement

National Association for Healthcare Quality

Patient Safety Movement Foundation

Project Patient Care

Safe Care Campaign

**ATTACHMENT B** 

**LONDON DECLARATION** 

**Available at:**

**https://www.who.int/patientsafety/patients_for_patient/pfps_london_declaration_2010_en.pdf**

**<u>ATTACHMENT C</u>**

**Available at:** 

**<u>https://www.who.int/teams/integrated-health-services/patientsafety/policy/global-patient-safety-action-plan</u>**

## Exhibit 10.6

**Exhibit 10.6**

![](dc001_ex10-6img01.jpg)

**CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED**

**AND REPLACED WITH "[\*\*\*]". SUCH IDENTIFIED INFORMATION HAS BEEN**

**EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND**

**(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

**MASTER SERVICES AGREEMENT**

DOCOLA INC

801 WEST BAY DR LARGO, FL

33770-3220

This Agreement is effective as of December 9, 2021 by and between AbbVie Corporation, a corporation under the laws of Canada and having its principal place of business at 8401 Trans- Canada Highway, St-Laurent, Quebec, Canada H4S 1Z1 ("**AbbVie**") and Docola Inc., having a mailing address of 801 West Bay Dr, Largo, FL, 33770-3220 ("**Service Provider**", collectively with AbbVie, the "**Parties**" or individually a "**Party**").

AbbVie desires to retain Service Provider to provide Services (defined below) based upon the following terms and conditions:

**1. Definitions.** Unless otherwise defined, capitalized terms have the meaning set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;1.1 "**AbbVie Data**" means data which, regardless
of medium (e.g., paper, electronic), AbbVie controls by determining how it is collected, processed, transmitted, viewed, accessed, or
stored, including through third parties such as Service Provider. AbbVie Data includes AbbVie Personal Information (defined below) and
AbbVie's Confidential Information (defined below).

&nbsp;&nbsp;&nbsp;&nbsp;1.2 "**AbbVie IP**" means all Deliverables, innovations,
inventions, and discoveries (whether or not patentable or copyrightable) conceived, reduced to practice, made, or developed by Service
Provider (or Services Personnel (defined below)) solely or jointly with others in connection with Service Provider's (or any Services
Personnel's) (i) performance of the Services, (ii) use of AbbVie's Confidential Information or any AbbVie-Provided Item (defined
below) that no longer falls within the definition of Confidential Information, or (iii) use of any Intellectual Property Rights owned
or licensed by AbbVie or any of its Affiliates (including any modifications, enhancements or derivatives of any of the foregoing in clauses
(i) through (iii)) shall be collectively referred to herein as "**AbbVie IP** ".

&nbsp;&nbsp;&nbsp;&nbsp;1.3 "**AbbVie-Provided Items**" means items AbbVie
may in its discretion supply to Service Provider or allow Service Provider to have access to, for use by Service Provider in connection
with the provision of Services, such as information, data, materials, equipment or other items (collectively, "**AbbVie-Provided Items** ").

&nbsp;&nbsp;&nbsp;&nbsp;1.4 "**Affiliate**" means any entity, which controls,
is controlled by, or is under common control with such entity. An entity will be deemed to control another entity if it owns or controls,
directly or indirectly, more than fifty percent (50%) of the voting equity (or other comparable ownership interest for an entity other
than a company) of such other entity.

Page 1 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;1.5 "**Confidential Information**" means any and
all information (i) provided by either Party (or its Affiliates or any of the foregoing's employees, representatives, contractors
or agents) (collectively, the "**Disclosing Party**") to the other Party (or to its Affiliates or to any of the foregoing's
employees, representatives, contractors or agents) (collectively, the "**Receiving Party**") or (ii) to which the Receiving
Party otherwise gains access (whether in writing, orally, visually, through observation, or otherwise) in connection with this Agreement,
or any Services or SOW, which is labeled or otherwise identified as being confidential or which would be regarded as confidential by
a reasonable business person in the Disclosing Party's position under circumstances substantially similar to those at the time
of disclosure. Without limiting the generality of the foregoing, Confidential Information shall include product plans, designs, schematics,
specifications, development, know-how, trade secrets, techniques, processes, procedures, results, algorithms, formulae, costs, prices,
finances, marketing plans, business opportunities, research contracts, customer information (and, in the case of Deliverables (defined
below), AbbVie IP, AbbVie-Provided Items, AbbVie Data and AbbVie Personal Information (defined below)), and any modifications, enhancements,
or derivatives of any of the foregoing and any information, data, or materials developed using any Confidential Information. Notwithstanding
the foregoing, Confidential Information (other than Personal Information (defined below)) shall not include materials, data, or information
which (A) was in the public domain at the time it was disclosed or falls within the public domain after it was disclosed, other than
through the fault of the Receiving Party, (B) was known to the Receiving Party (without an obligation of confidentiality with respect
thereto) at the time of disclosure by the Disclosing Party, as evidenced by the Receiving Party's written records, (C) becomes
known to the Receiving Party (without an obligation of confidentiality with respect thereto) from a source other than the Disclosing
Party who had the right to make such disclosure or (D) is independently developed by or for Receiving Party without use of Confidential
Information of the Disclosing Party, as evidenced by Receiving Party's written records.

&nbsp;&nbsp;&nbsp;&nbsp;1.6 "**Deliverables**" means, collectively, all data,
reports, communications, material, deliverables, work product (inclusive of the result of all design, development, testing, integration,
implementation, or other work included in or arising from the Services) made or prepared by Service Provider in performance of the Services
including any items specified in the applicable SOW. Service Provider shall provide all Deliverables to AbbVie as provided in the applicable
SOW or otherwise upon AbbVie's written request.

&nbsp;&nbsp;&nbsp;&nbsp;1.7 "**Disclosing Party**" has the meaning defined
in Section 1.5.

&nbsp;&nbsp;&nbsp;&nbsp;1.8 "**Engagement**" means an event, presentation,
engagement, speaking requirement, task, or any other Service to be provided by Service Provider as described in each applicable SOW or
PO.

&nbsp;&nbsp;&nbsp;&nbsp;1.9 "**Intellectual Property**" includes everything
that can be protected by Intellectual Property Rights, including without limitation inventions, data, and works.

&nbsp;&nbsp;&nbsp;&nbsp;1.10 "**Intellectual Property Rights**" means all
rights, titles, and interests granted, conferred, or recognized by any law (whether Canadian or foreign) relating to, without limitation,
works, inventions (whether patentable or not), discoveries, improvements, trade secrets, know-how, scientific formulae, data, information,
images, reports, results, analysis, software, models, research and development, information, technical information, prototypes, specifications,
patterns, drawings, algorithms, products, compositions, processes and protocols, methods, tests, devices, computer programs, trademarks,
and any and all proprietary rights provided under patent law, copyright law, trademark law, design patent or industrial design law, semi-conductor
chip or mask work law, or any other statutory provision or civil or common law principle applicable to the protection of intangible proprietary
information or rights, including trade secret law, which may provide a right in any of the foregoing, as well as any and all applications,
registrations, or other evidence of a right in any of the foregoing, whether this right is currently granted, conferred, or recognized,
or becomes so in the future.

Page 2 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;1.11 **"Personal Information**" means any information,
or set of information, including personal health information, about an identifiable individual or that could reasonably be used to identify
such person, regardless of the medium in which such information is displayed, as more particularly defined in applicable federal and
provincial legislation relating to privacy and personal information. "**AbbVie Personal Information**" shall refer to
Personal Information that is Processed (defined below) for or on behalf of AbbVie and for which AbbVie is the data controller (or similar
term under applicable law) as defined under applicable data protection laws.

&nbsp;&nbsp;&nbsp;&nbsp;1.12 "**Processing**" (and its conjugates, including
without limitation "**Process**") means any operation or set of operations that is performed upon Personal Information,
including without limitation collecting, selling, renting, leasing, disseminating, making available, recording, retaining, altering,
using, disclosing, accessing, transferring, or destroying.

&nbsp;&nbsp;&nbsp;&nbsp;1.13 "**Purchase Order**" or "**PO** "
means a document submitted by AbbVie to Service Provider from time to time in writing, which provides details on the nature and price
of the Services. During the term of this Agreement, AbbVie may issue one or more POs. Upon issuance of the PO, such PO shall be incorporated
herein and made a part of this Agreement by reference.

&nbsp;&nbsp;&nbsp;&nbsp;1.14 "**Receiving Party**" has the meaning defined
in Section 1.5.

&nbsp;&nbsp;&nbsp;&nbsp;1.15 "**Services**" means the services made available
to AbbVie by Service Provider and shall include all services and other activities as set forth in an agreement, SOW (as may be amended
or modified from time to time), PO, or other work instruction executed by the Parties (collectively, the "**Services** ").

&nbsp;&nbsp;&nbsp;&nbsp;1.16 "**Services Personnel**" means all persons (including
employees, directors, officers, agents, consultants, and authorized subcontractors, entities, and individuals, and may include Affiliates
of Service Provider) providing Services or otherwise performing any of Service Provider's obligations hereunder or under an SOW
or PO.

&nbsp;&nbsp;&nbsp;&nbsp;1.17 **"Statement of Work**" or "**SOW** "
means a statement of work submitted by Service Provider to AbbVie from time to time and as may be amended from time to time in writing
by the Parties. Such Statement of Work shall describe the Services and Deliverables to be provided, Service Provider's compensation,
additional terms and conditions, if any, and such other details as AbbVie and Service Provider deem appropriate. Upon execution of a
SOW by both Parties, such SOW shall be incorporated herein and made a part of this Agreement by reference.

&nbsp;&nbsp;&nbsp;&nbsp;1.18 "**Work Product**" means, any and all Deliverables
(whether copyrightable or not), inventions, discoveries and innovations, documents, materials, software (including source code), and
information, directly and/or proximately conceived or developed by Service Provider in connection with Service Provider's Deliverables
hereunder and any improved, updated, upgraded, modified, customized or additional parts thereof, and all Intellectual Property rights
embodied therein.

Page 3 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

**2. Services.** AbbVie agrees to retain Service Provider to perform the Services, on a task-by-task basis and Service Provider agrees to perform the Services on the terms and conditions set forth in this Agreement and in accordance with each applicable SOW or PO.

3. Compensation.

&nbsp;&nbsp;&nbsp;&nbsp;3.1 In consideration for Service Provider's preparation and
performance of the Services hereunder, AbbVie shall pay Service Provider in accordance with the budget described in each applicable SOW
or PO, which may be amended from time to time by both Parties in writing. AbbVie shall not be obligated to pay any broker's or
booking commissions in connection with Services. Service Provider agrees that in the event that an Engagement is cancelled by either
Service Provider or AbbVie, or if an SOW or this Agreement is subject to premature termination, Service Provider will not be compensated
except for expenses incurred by Service Provider or work performed by Service Provider prior to the date of such cancellation or termination.
Service Provider further agrees that AbbVie shall only pay Service Provider upon completion of each Engagement. AbbVie shall not be obligated
to pay to Service Provider more than the total amount of fees as set forth in the SOW or PO, under any circumstances.

&nbsp;&nbsp;&nbsp;&nbsp;3.2 Service Provider shall supply AbbVie with a detailed invoice
setting forth Services, expenses, sales tax, and sales tax registration numbers, as applicable. Payment will be made within ninety (90)
days of AbbVie's receipt of such complete, accurate and otherwise undisputed invoice.

&nbsp;&nbsp;&nbsp;&nbsp;3.3 If the SOW or PO indicates that AbbVie shall cover Service Provider's
out-of-pocket expenses relating to the performance of the Service, AbbVie shall pay Service Provider for all such reasonable expenses
upon presentation of appropriate receipts incurred by Service Provider, provided that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) In the case of expenses relating to travel and accommodations
or any other expenses exceeding fifty Canadian dollars (CAD 50), such expenses have been pre-approved in writing by AbbVie; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) In no event shall the expenses exceed the amount as indicated
in the SOW or PO.

&nbsp;&nbsp;&nbsp;&nbsp;3.4 Without limiting the foregoing, in connection with any travel
required by Service Provider to provide the Services, AbbVie will pay for transportation, coach air fare, and reasonable hotel accommodations
(including reasonable meals), provided such expenses are approved by AbbVie in advance and Service Provider submits supporting documentation
for such expenses.

&nbsp;&nbsp;&nbsp;&nbsp;3.5 The amount of any payment invoiced by Service Provider represents
the fair market value for the Services that Service Provider has agreed to render and has not been determined in any manner that takes
into account the volume or value of any referrals or business otherwise generated between Service Provider and AbbVie.

Page 4 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;3.6 AbbVie shall be entitled to deduct from any payments to Service
Provider the amount of any withholding taxes with respect to such amounts payable, or any other taxes, in each case required to be withheld
by AbbVie, to the extent that AbbVie pays to the appropriate governmental authority on behalf of Service Provider such taxes, levies,
or charges. Upon the request of Service Provider, AbbVie shall deliver proof of payment of all such taxes, levies, and other charges
and any documentation within its control that is necessary to obtain any applicable tax credit.

4. Contacts. AbbVie's contact during the term of the Agreement will be [\*\*\*], Senior Brand Manager, Lupron PCa, <u>[\*\*\*]@abbvie.com</u>, or whomever AbbVie may designate (the "**AbbVie Contact**"). Service Provider's contact during the term of the Agreement will be [\*\*\*], CEO, [\*\*\*]doco.la.

**5. Review and Delivery of Reports.** Service Provider shall submit written reports on the progress of the Services as reasonably requested by AbbVie and be available for telephone and/or in- person consultation to AbbVie as is reasonable and necessary to keep AbbVie advised of the progress of the Services.

6. Term and Termination.

&nbsp;&nbsp;&nbsp;&nbsp;6.1 This Agreement shall be effective as of December 9, 2021 and
continue for a period of two (2) years ()"**Initial Term** "). At the expiration of the Initial Term, this Agreement will
automatically renew for a one (1) time renewal of two (2) years ()"**Renewal Term** "), unless AbbVie provides Service Provider
with ninety (90) days written notice of its intent not to renew the Agreement prior to the expiration of the Initial Term.

&nbsp;&nbsp;&nbsp;&nbsp;6.2 The Parties may extend this Agreement by mutual written agreement.

&nbsp;&nbsp;&nbsp;&nbsp;6.3 AbbVie may terminate this Agreement without cause upon giving
thirty (30) days prior written notice to Service Provider.

&nbsp;&nbsp;&nbsp;&nbsp;6.4 AbbVie may suspend all or any portion of the Deliverables associated
with an SOW or PO without cause, upon twenty-four (24) hours prior written notice to Service Provider. Service Provider will resume the
suspended work within three (3) days of receipt of written notice that the suspension has been lifted by AbbVie.

&nbsp;&nbsp;&nbsp;&nbsp;6.5 Notwithstanding anything else in this Agreement, AbbVie may
terminate this Agreement immediately by written notice to Service Provider if it concludes, in its sole discretion, that (a) Service
Provider has breached any part of Section 14 or that such a breach is substantially likely to occur; (b) Service Provider has provided
any materially false or misleading information to AbbVie in connection with this Agreement or Service Provider's performance under
this Agreement; (c) Service Provider does not consent to an inspection and audit required by Section 15.4 or fails to provide access
or information to AbbVie's satisfaction; or (d) Service Provider declines to implement corrective or remedial action that AbbVie
requires pursuant to Section 9.2, Section 14, or Section 15.4.

Page 5 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;6.6 Either Party may terminate this Agreement, any SOW or PO, or
any part thereof, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) upon written notice to the defaulting Party, if the defaulting
Party fails to perform any material term of this Agreement and does not cure such failure within thirty (30) days after the non-defaulting
Party provides notice reasonably detailing such failure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) upon written notice if the other Party becomes the subject of
a voluntary petition in bankruptcy or any similar proceeding relating to insolvency, receivership, or reorganization and if such petition
or proceeding is not dismissed within sixty (60) days of filing. If such proceeding is involuntary and is contested in good faith, this
Agreement shall terminate only after the passage of one hundred twenty (120) days without the dismissal of such proceeding;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) immediately in the event of a statutory, judicial, regulatory
or administrative ruling or interpretation by Health Canada or any other governmental or regulatory authority which makes it impossible
or commercially impracticable to continue a SOW or PO, as determined in AbbVie's sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;6.7 If the term of any SOW or PO extends beyond the termination
or expiration date of this Agreement, the applicable terms and conditions of this Agreement shall extend automatically for such SOW or
PO until such SOW or PO's termination or expiration date.

&nbsp;&nbsp;&nbsp;&nbsp;6.8 Termination or expiration of this Agreement shall not affect
any rights or obligations which have accrued prior thereto.

&nbsp;&nbsp;&nbsp;&nbsp;6.9 In the event of premature termination of the Agreement, AbbVie
shall pay Service Provider for Services performed on a prorated basis and for any and all reasonable expenses incurred by Service Provider
through the date of termination, subject to the requirements and limitation set out in Section 3. In no event shall such amount exceed
the amount that would have been payable to Service Provider, had this Agreement and/or the applicable SOW(s) or PO(s) not been terminated.

&nbsp;&nbsp;&nbsp;&nbsp;6.10 Notwithstanding the expiration or termination of this Agreement
for any reason, any obligation that by its nature should survive such termination or expiration, including without limitation any assignment,
license, waiver, authorization, declaration, confidentiality obligation or other rights and obligations stipulated in sections 7, 10,
and 17 of this Agreement, shall remain in force.

7. Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;7.1 During the term of this Agreement and for a period of ten (10)
years thereafter, Service Provider shall not disclose or use AbbVie's Confidential Information except as permitted in this Agreement
or in writing by AbbVie. Service Provider undertakes to have all of Services Personnel having access to the Confidential Information
under this Agreement shall abide by the confidentiality obligations set forth in this Agreement.

Page 6 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;7.2 Confidential Information shall include all information concerning
AbbVie and the Services disclosed to Service Provider by AbbVie, or developed as a result of Service Provider's Services hereunder,
except any portion thereof which:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) is known to Service Provider on a non-confidential basis before
receipt thereof under this Agreement, as evidenced by Service Provider's written records;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) is disclosed to Service Provider after acceptance of this Agreement
by a third party who has a right to make such disclosure in non-confidential manner; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) is or becomes part of the public domain through no fault of
Service Provider.

&nbsp;&nbsp;&nbsp;&nbsp;7.3 Upon completion of the Services hereunder, or the termination
or expiration of this Agreement, Service Provider shall return to AbbVie all Confidential Information, data, and materials provided to
Service Provider by AbbVie, or developed by Service Provider as a result of Service Provider Services hereunder, as requested by AbbVie.

&nbsp;&nbsp;&nbsp;&nbsp;7.4 Service Provider shall not (a) disclose to AbbVie any information
which is confidential and/or proprietary to a third party without first obtaining the written consent of both such third party and AbbVie
and (b) use Confidential Information for any purpose other than that indicated in this Agreement without AbbVie's prior written approval.

8. Data Protection and Privacy.

&nbsp;&nbsp;&nbsp;&nbsp;8.1 <u>Description of AbbVie Personal Information</u>. The type
of AbbVie Personal Information and categories of data subjects with respect to such AbbVie Personal Information processed pursuant to
this Agreement are described, each to the extent applicable, in the description of Services, an applicable SOW, PO or schedule, or as
documented in the AbbVie data classification tool.

&nbsp;&nbsp;&nbsp;&nbsp;8.2 <u>Limitation of Use</u>. As between the Parties, AbbVie is
the sole controller of AbbVie Personal Information. Service Provider shall Process AbbVie Personal Information solely on behalf of AbbVie
in compliance with all applicable laws including data protection laws and solely for the purpose of providing the Services in accordance
with this Agreement and any applicable Services, SOW or PO and shall not Process AbbVie Personal Information for any other purpose. Service
Provider shall immediately notify AbbVie if Service Provider believes that any Processing of AbbVie Personal Information required by
Service Provider in the performance of the Services or other instructions by AbbVie violates applicable data protection law. Service
Provider shall not create or maintain data derived from Processing AbbVie Personal Information, except where permitted for providing
the Services in accordance with this Agreement and any applicable SOW or PO.

&nbsp;&nbsp;&nbsp;&nbsp;8.3 <u>Transmission of Personal Information</u>. In the event this
Agreement or applicable Services, SOW or PO requires Service Provider to transmit to AbbVie any Personal Information that was not Processed
by Service Provider exclusively for or on behalf of AbbVie, Service Provider represents and warrants that the Processing and transmission
of such Personal Information was and is compliant with all applicable laws, Service Provider's own applicable terms of use and
privacy policy(ies), and the notices provided to and consents obtained from the individuals whose Personal Information is being transmitted.

Page 7 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;8.4 <u>Receipt of Inquiries</u>. Service Provider shall ensure that
AbbVie is notified immediately and in any event no later than seven (7) calendar days from receipt of any communication from: (i) any
individual relating to that individual's rights to access, amend, transfer, restrict, delete, or exercise any other right or request
with respect to such individual's AbbVie Personal Information; or (ii) any third-party (including, but not limited to, any legal
or regulatory authority) relating to the Processing of any AbbVie Personal Information by Service Provider for or on behalf of AbbVie.
Service Provider shall not respond to any such communications without the consent of AbbVie and shall further provide all reasonable
assistance to AbbVie and shall comply with all reasonable instructions of AbbVie in responding to such communications.

&nbsp;&nbsp;&nbsp;&nbsp;8.5 <u>Cardholder Data</u>. In the event Service Provider is Processing
credit or debit card account numbers or related information provided by AbbVie or collected for or on behalf of AbbVie, then Service
Provider shall, at all times, maintain compliance with the applicable Payment Card Industry Data Security Standard.

&nbsp;&nbsp;&nbsp;&nbsp;8.6 <u>International Data Transfers</u> AbbVie Personal Information
shall not be transferred between AbbVie and Service Provider across international borders unless such transfer is necessary for Service
Provider to perform Services and the transfer is described in this Agreement or any attached schedules. Where applicable law requires
AbbVie or Service Provider to implement additional measures to effectuate international data transfers, then Service Provider will, at
AbbVie's request, promptly implement such measures.

&nbsp;&nbsp;&nbsp;&nbsp;8.7 <u>Data Protection Assistance</u>. Service Provider shall provide
full and prompt cooperation with and assistance to AbbVie with respect to any data protection and privacy obligations required for the
Processing of AbbVie Personal Information under this Agreement. Such cooperation and assistance shall include but is not limited to completing
data protection impact assessments and/or prior consultations that may be required in respect of any Processing carried out under this
Agreement, data subject rights requests provided by AbbVie with respect to AbbVie Personal Information, securely deleting AbbVie Personal
Information and/or providing AbbVie with a list of AbbVie Personal Information categories or specific elements about a particular individual
maintained by Service Provider on AbbVie's behalf. Service Provider shall respond to such requests within the timeframes requested
by AbbVie; provided, however, Service Provider shall complete any data subject rights requests provided by AbbVie within fifteen (15)
days of receiving such request.

&nbsp;&nbsp;&nbsp;&nbsp;8.8 <u>Retention</u>. Service Provider agrees to retain AbbVie Personal
Information for only so long as necessary to conduct the Services or as may otherwise be required under applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;8.9 <u>Notice of AbbVie Privacy Practices</u>. To the extent AbbVie
Processes Personal Information of Services Personnel, notification of AbbVie's privacy practices, including but not limited to
a description of the categories of Personal Information collected, the purposes of Processing, data subject rights, and cross-border
transfers, are described at <u>https://www.abbvie.ca/en/privacy.html</u>. Service Provider represents and warrants that, to the extent
it discloses or makes available Personal Information about Services Personnel to AbbVie, Service Provider shall make such Services Personnel
aware of the AbbVie privacy notice referenced in this Section 8.9.

Page 8 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;8.10 <u>Certification</u>. Service Provider certifies that it understands
and will comply with applicable data protection laws and the requirements with respect to the Processing AbbVie Personal Information
set forth in this Agreement. Service Provider shall immediately notify AbbVie if makes the determination that it has not, or can no longer
meet, its obligations under this Agreement with respect to the Processing of AbbVie Personal Information. Upon such notice, AbbVie may
require Service Provider to cease and/or remediate such unauthorized Processing of AbbVie Personal Data, or otherwise terminate this
Agreement for cause.

&nbsp;&nbsp;&nbsp;&nbsp;8.11 <u>Records</u>. Service Provider shall maintain a written record
of all AbbVie Personal Information Processing activities carried out on behalf of AbbVie under this Agreement and any Service, SOW or
PO. Such record shall contain, at a minimum:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) the name and contact details of AbbVie as controller, Service
Provider as processor, and any subcontractors / subprocessors of Service Provider;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) the name and contact details of the respective data protection
officers of AbbVie, Service Provider, and Service Provider's subcontractors / subprocessors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) the categories of Processing carried out;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) transfers to third countries or international organizations
and documentation of the suitable safeguards employed; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) a written agreement to apply the security controls that may
be applicable under Schedule A (AbbVie Third Party Security Controls) hereto.

Service Provider shall provide such written record to AbbVie promptly upon request and agrees that such written record may be submitted by AbbVie in its discretion to any third- party data controller (where applicable) and to relevant government authorities.

9. Data Security.

&nbsp;&nbsp;&nbsp;&nbsp;9.1 <u>Data Security Program</u>. Service Provider shall maintain
a documented security program that has reasonable administrative, technical, and physical safeguards that are commensurate with the laws
and industry standards relevant to Service Provider's business activities and protects AbbVie Data according to its sensitivity.
The minimum standards for Service Provider's security controls that shall apply to the Services are set forth in Schedule A (AbbVie
Third Party Security Controls).

Page 9 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;9.2 <u>Data Security Incident</u>. In the event of any actual or
suspected security incident affecting AbbVie Data Processed by Service Provider (a "**Data Security Incident** "), Service
Provider shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) immediately, and in any event no later than twenty-four (24)
hours following discovery of such Data Security Incident, send written notice of the incident via e- mail to <u>csirt@abbvie.com</u>;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) not make any statements or notifications about the Data Security
Incident to any individual affected by the incident, the public or any third-party without AbbVie's prior written approval;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) immediately take steps to investigate and mitigate the Data
Security Incident, including all such steps reasonably requested by AbbVie and, in conducting such investigation and mitigation, Service
Provider shall reasonably cooperate with AbbVie, including by providing access to Service Provider's premises, books, logs and
records to the extent necessary to investigate and mitigate the Data Security Incident;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) take all remediation efforts required by applicable law or reasonably
directed by AbbVie; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) if requested by AbbVie, provide AbbVie within five (5) business
days after the request a report that describes: (A) the nature and extent of the Data Security Incident; (B) the AbbVie Data (including
separate identification of AbbVie Personal Information) affected unless otherwise provided herein; (C) supporting evidence, including
system, network and application logs related to the incident; (D) the investigative, corrective and remedial actions completed, and planned
to be completed (and the dates by which such actions will be completed) by Service Provider; and (E) an assessment of the security impact
to AbbVie.

&nbsp;&nbsp;&nbsp;&nbsp;9.3 <u>Location of Primary and Backup Data Centers</u>. Service
Provider will store AbbVie Data at only the data centers specified in Schedule B (AbbVie Approved Third Party Data Centers). Service
Provider may not store AbbVie Data at any other data centers without notifying AbbVie in writing in advance.

&nbsp;&nbsp;&nbsp;&nbsp;9.4 <u>Return/Destruction</u>. Within sixty (60) days following
the earlier to occur of (i) termination of the Services or (ii) AbbVie's written request, Service Provider shall, in accordance
with AbbVie's written direction, securely transfer to AbbVie (or to a third party designated by AbbVie), or destroy, all AbbVie
Data received or created in the course of providing the Services, to the extent permitted by law, subject to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all transfers of AbbVie Data in accordance with the foregoing
shall occur in a structured and widely used format, or such other format as mutually agreed by the Parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Service Provider shall promptly notify AbbVie of any inability
to securely return or destroy AbbVie Data in accordance with the terms hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) as soon as is feasible following the transfer of any AbbVie
Data to AbbVie or a third party designated by AbbVie, Service Provider shall destroy all copies of such data in its possession except
for copies it is required to maintain by law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Service Provider agrees that all AbbVie Data retained by Service
Provider as required by law shall remain subject to the requirements of this Agreement or any Service.

Page 10 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

10. Intellectual Property Rights, Information Technology, Deliverables, and Work Product.

&nbsp;&nbsp;&nbsp;&nbsp;10.1 All data, reports, communications, material, information, innovations,
inventions, or discoveries (whether or not patentable or copyrightable), Deliverables, or Work Product conceived, reduced to practice,
made or developed by Service Provider solely or jointly with others in connection with the performance of the Services, and all Intellectual
Property Rights embodied therein, shall be promptly disclosed to and be the sole property of AbbVie, and Service Provider hereby assigns
to AbbVie all right, title, and interest therein without any obligation on AbbVie to pay royalties or other remuneration therefore. To
the extent Service Provider cannot assign to AbbVie any right, title, and interest in and to any Work Product or Deliverable, Service
Provider grants to AbbVie an exclusive, perpetual, royalty-free, transferable, irrevocable, worldwide licence (with rights to sublicense),
or the broadest licence that Service Provider is legally capable of granting, to utilize, copy, reproduce, modify, create derivative
works, perform, or publicly display such non-assignable rights, title, and interest. To the extent Service Provider cannot assign or
licence to AbbVie any such right, title, or interest, Service Provider irrevocably waives and agrees never to assert a claim against
AbbVie for or in connection with such non-assignable and non-licensable rights (including moral rights), title, and interest. Service
Provider shall not permit any employee or other person to contribute to the production of the Deliverables or Work Product or perform
any portion of the Services under this Agreement unless such employee or other person expressly and irrevocably, in writing, assigns
all right, title, and interest in the Deliverables or Work Product to Service Provider and waives in favour of Service Provider any moral
rights in the Deliverables or Work Product. At AbbVie's request and expense, Service Provider shall execute such documents and
take such other actions as AbbVie deems necessary or appropriate to obtain, record, or enforce patents, copyrights, or assignments thereof
in AbbVie's name. AbbVie's rights to ownership are limited to the content it uploads and utilizes on the Service Provider's
platform, and to the exclusion of Service Provider's ownership as described in the following paragraph. AbbVie's rights are
limited to said content, even if AbbVie, through work it has paid Service Provider for, provides ideas, suggestions, and or any modifications
to the technology Platform.

Notwithstanding the foregoing, AbbVie shall not acquire ownership of any materials, information, know-how, tools, models, methodologies, techniques, software, documents and/or other Intellectual Property Rights owned by Service Provider prior to the performance of Services under this Agreement or after the performance of same, or that is licensed by Service Provider from any third party (all of the foregoing, "**Pre-existing Intellectual Property Rights**"). Service Provider retains all rights to its platform, including rights that may have been performed on behalf of AbbVie, paid for by AbbVie, but does not include the rights to AbbVie's content as descried in the previous paragraph. Service Provider hereby grants to AbbVie a non-exclusive, irrevocable, royalty-free worldwide licence to use, modify, and enhance such Pre-existing Intellectual Property Rights (including the right to sublicense) to the extent that such licence is required to enable AbbVie to make use of the Services hereunder, including without limitation any Deliverables and Work Product.

Page 11 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;10.2 All application and system development shall follow industry
best practices and processes for secure programming. Service Provider shall be responsible for verifying that all software developers
working on application and system development under this Agreement have been trained on and are knowledgeable and proficient on secure
programming techniques and able to deal with all current application vulnerabilities, including, but not limited to (a) open web application
security project's top ten web code vulnerabilities ()"**OWASP Top 10** "), (b) web application security consortium
threat classification version 2 ()"**WASC TCv2**") and (c) the common weakness enumeration top 25 most dangerous ()"**CWE-25** ").
Service Provider shall perform an application security assessment on all applications, and any modifications, updates, new versions or
releases, or any other changes to such applications prior to delivery to AbbVie or installation on any AbbVie or third-party system.
The application security assessments shall include, at a minimum, penetration tests, source code reviews, and other tests and assessments
necessary to identify security vulnerabilities as identified by industry recognized organization, i.e. OWASP Top 10, CWE-25, SANS vulnerabilities,
etc. Upon AbbVie request, Service Provider shall furnish AbbVie with a summary and/or copies of the reports generated by the scanning
products/services. AbbVie reserves the right to perform scans, either directly or via a third-party service, if it applies.

**11.** **Representations and Warranties.** Service Provider represents
and warrants that Service Provider shall perform all Services and Deliverables in a good and workmanlike manner using reasonable skill
and care and that such Deliverables will materially conform to the requirements set forth in the specific SOW or PO. Service Provider
represents and warrants that the Deliverables provided hereunder shall not violate or infringe upon any patent, copyright, trademark,
trade secret, or other Intellectual Property Right of any third party.

**12.** **Presentations and Publications.** Service Provider shall
not present or publish, nor submit for publication, any work resulting from Service Provider's Services provided hereunder without
AbbVie's prior written approval.

**13.** **Public Announcements.** Service Provider shall not use
the name of AbbVie in any publicity, advertising, announcement or for any other commercial purpose without the prior written approval
of AbbVie.

**14.** **Compliance.** In the performance of the Services hereunder,
Service Provider shall comply with all applicable federal, provincial, and local laws, regulations, industry codes of practice, and guidelines.
Service Provider shall also comply with AbbVie policies while on AbbVie's premises or performing Services. Without limiting the
generality of the foregoing, Service Provider represents, warrants, and undertakes that Service Provider is and will continue to be in
compliance with all applicable anti-bribery and anti-corruption laws, and that neither Service Provider, nor its employees or agents,
has either given or offered to give, and will not give or offer to give, directly or indirectly, money, property, services, or anything
else of value to any government official, government entity, or private person to secure a business advantage, to obtain or retain business,
or to direct business to any person/entity or away from any person/entity.

Page 12 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

15. Audit/Inspection/Regulatory Communications.

&nbsp;&nbsp;&nbsp;&nbsp;15.1 Service Provider shall, throughout the term, at its own cost,
maintain adequate and accurate written management-approved practices and procedures ()"**SOPs**") that describe in detail
how Service Provider shall perform specific tasks, services, and functions related to the Services to be performed, and shall make them
accessible to AbbVie, upon AbbVie's request. If Service Provider, during the term, intends to modify its SOPs relevant to thet conduct
of the Services, Service Provider shall, at least thirty (30) days prior to implementation of such modifications, provide notification
of such proposed modifications to the AbbVie Contact.

&nbsp;&nbsp;&nbsp;&nbsp;15.2 Service Provider shall, at its own cost, maintain adequate and
accurate books and records that in reasonable detail accurately and fairly reflect transactions and asset disposals with respect to Service
Provider's performance of its obligations under this Agreement, including without limitation records of payments made by or to,
and expenses incurred by Service Provider as a result of this Agreement, and Service Provider shall retain these records until the later
of (a) five (5) years after expiry or termination of this Agreement, or (b) as required by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;15.3 In performance of the Services, Service Provider shall follow
its SOPs (unless in conflict with the terms hereof or of any SOW) and shall have initial training and retraining as necessary on all
applicable SOPs for all Services Personnel.

&nbsp;&nbsp;&nbsp;&nbsp;15.4 Service Provider shall, upon request by AbbVie with reasonable
advance notice, cause AbbVie (including its employees, representatives and authorized agents) to have access, at reasonable business
hours, to (i) inspect all facilities, equipment, procedures, and practices being employed by Service Provider or any Services Personnel
in the provision of the Services under this Agreement, and (ii) examine and audit all records, files, notebooks, relevant operating procedures,
and data relating to the Services and/or Deliverables provided, in order to assure the true and accurate recording of data and confirm
Service Provider's compliance with the terms of this Agreement. Any significant non-compliance issues identified during any such
inspection or audit will be communicated to Service Provider and Service Provider shall provide a corrective action plan in writing to
AbbVie within fifteen (15) days of receipt of a corrective action request letter from AbbVie. AbbVie may, at its sole discretion, prohibit
Service Provider from further performance of any Services until resolution of all such non-compliance issues is complete to AbbVie's
reasonable satisfaction. If Service Provider does not consent to the audit or fails to provide access or information to AbbVie's
satisfaction or disagrees with the recommended remediation or fails to implement it, AbbVie may (but is not obliged to) terminate this
Agreement by written notice to Service Provider. In the event resolution cannot be reached within a reasonable period of time following
AbbVie's communication to Service Provider of the significant non-compliance issues, AbbVie may terminate this Agreement for cause.

Page 13 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;15.5 Upon request by any properly authorized officer or employee
of any regulatory authority, Service Provider shall permit such officer or employee, at reasonable times, to interview key Service Provider
personnel and key Services Personnel, have access to, copy, and verify documents in Service Provider's or any Services Personnel's
possession or under their control, related to the Services and/or Deliverables, and that are required to be maintained under applicable
laws and regulations, and shall submit such documents (or copies thereof) to such regulatory authorities when it is required. Service
Provider shall (i) notify AbbVie immediately upon receiving from any regulatory authority any such requests and (ii) immediately provide
AbbVie with a copy of any documents received from or provided to any regulatory authority, to the extent relating to the Services as
well as any findings by a regulatory authority as they become available. Notwithstanding the foregoing, Service Provider shall, within
three (3) days of receipt of any regulatory citation or notice, which relates to the Services, provide AbbVie with an explanation of
(A) the issues identified by the regulatory authority, (B) Service Provider's proposed response thereto, and (C) the applicability
thereof to the Services. The provisions of this paragraph shall survive for a period of one (1) year after termination of the Services.

&nbsp;&nbsp;&nbsp;&nbsp;15.6 Notwithstanding anything to the contrary herein, AbbVie may,
as the result of an action by an applicable regulator, in its discretion and without penalty suspend all or any portion of the Services
associated with this Agreement or any SOW upon twenty-four (24) hours' prior written notice to Service Provider. In such cases,
Service Provider shall use commercially reasonable efforts to resume the suspended work promptly upon its receipt of written notice that
AbbVie has lifted the suspension.

**16.** **Adverse Event and Product Quality Complaint Reporting.** If
necessary, as determined in AbbVie's sole discretion, the Parties shall enter into a Pharmacovigilance Agreement prior to the performance
of the Services for the purposes of facilitating accurate, timely exchange of Adverse Events and Product Quality Complaints and each
Party's compliance with regulatory reporting requirements.

**17.** **Indemnity.** Service Provider shall hold AbbVie harmless
from and against all breaches of this Agreement by Service Provider and other claims, actions, damages, liabilities, and expenses (including
reasonable attorney's fees and costs) arising out Service Provider's negligence or willful misconduct in it performance of
the Services, or infringement of third party rights relating to AbbVie's use of Service Provider's platform, Deliverables
or Work Product. AbbVie shall hold Service Provider harmless from and against all breaches of this Agreement by AbbVie and other claims,
actions, damages, liabilities, and expenses (including reasonable attorney's fees and costs) arising out AbbVie's negligence
or willful misconduct in the performance of its obligations under this Agreement.

**18.** **No Restrictions.** Service Provider represents and warrants
that the terms of this Agreement are not inconsistent with any other contractual or legal obligations Service Provider may have or with
the policies of any institution with which Service Provider is employed or associated.

**19.** **Non-debarment.** Service Provider represents and warrants
that neither Service Provider, nor any of Service Provider's employees or agents providing services or products under this Agreement,
has ever been is currently, or is the subject of a proceeding that could lead to that party becoming, as applicable, a Debarred Individual
or Debarred Entity. A "**Debarred Individual**" is an individual who has been debarred by the U.S. Food and Drug Administration
(" **FDA**") pursuant to Title 21 United States Code § 335a (a) or (b) or by any other competent regulatory authority
from providing services in any capacity to a person that has an approved or pending drug product application. A "**Debarred Entity** "
is a corporation, partnership or association that has been debarred by FDA pursuant to Title 21 United States Code § 335a (a) or
(b) or by any other competent regulatory authority, from submitting or assisting in the submission of any drug application, or a subsidiary
or affiliate of such a corporation, partnership, or association. Service Provider further covenants, represents, and warrants that if,
during the term of this Agreement, Service Provider, or any of Service Provider's employees or agents providing services or products
under this Agreement, becomes or is the subject of a proceeding that could lead to that party becoming, as applicable, a Debarred Individual
or Debarred Entity, Service Provider shall immediately notify AbbVie, and AbbVie shall have the right to immediately terminate this Agreement.
This provision shall survive termination or expiration of this Agreement.

Page 14 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

**20.** **Independent Contractor.** Service Provider's status
under this Agreement is that of an independent contractor. Service Provider shall not be deemed an employee, agent, partner, or joint
venture of AbbVie for any purpose whatsoever, and Service Provider shall have no authority to bind or act on behalf of AbbVie. This Agreement
shall not entitle Service Provider to participate in any benefit plan or program of AbbVie. Service Provider shall be responsible for
and agree to comply with obligation under federal and provincial tax laws for payment of income and, if applicable, self-employment tax.
Service Provider is not entitled to worker's compensation coverage by AbbVie, and Service Provider hereby waives any and all rights
Service Provider may have to coverage under AbbVie's worker's compensation policies.

**21.** **No Endorsement.** This Agreement has not been made in exchange
for any explicit or implicit agreement that Service Provider purchase, recommend or otherwise arrange for the use of AbbVie products.

**22.** **Waiver.** No waiver of any term or condition of this Agreement
in any instance shall be deemed to be or construed as a further or continuing waiver of such term of condition or of any other term of
condition of this Agreement.

**23.** **Assignment/Subcontracting/Subprocessing.** 

&nbsp;&nbsp;&nbsp;&nbsp;23.1 <u>Assignment</u>. Except as provided below, the rights and
obligations under this Agreement shall not be assigned, subcontracted, or delegated to third parties by Service Provider without the
prior written consent of AbbVie, which consent may be granted or withheld by AbbVie in its sole discretion and subject to such conditions
as AbbVie may determine. Either Party may assign this Agreement or delegate some or all of its rights and obligations under this Agreement
to one or more of its Affiliates without the consent of the other Party, however any such assignment will not relieve the assignor of
any of its obligations under this Agreement. In the event any assignment, subcontracting, or delegation is approved in accordance with
this provision, Service Provider shall and hereby does assume responsibility for ensuring compliance and adherence to all terms and provisions
of this Agreement by the approved party assuming obligations under this Agreement, and Service Provider shall be liable for any breach
by such party.

Page 15 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;23.2 <u>Subcontracting/Subprocessing</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) AbbVie grants general authorization to the subprocessing of
AbbVie Data if Service Provider provides AbbVie with a list of subprocessors. Otherwise, Service Provider shall not subcontract/subprocess
(including to an Affiliate) the Processing of AbbVie Data to any party other than Service Provider without AbbVie's prior written
consent (which shall not be unreasonably withheld). AbbVie shall have the right to review any contract (redacted to remove any confidential
or proprietary information) between Service Provider and the proposed subcontractor/subprocessor relating to the Services. Services Provider
represents and warrants that any contract with a subcontractor/subprocessor contains the same or similar obligations regarding data privacy
and security, confidential information, Intellectual Property, and auditing to those to which Service Provider is bound hereunder. Service
Provider shall maintain a copy of such executed subcontract for the purpose of AbbVie's review for no less than the duration of
the Services. For the avoidance of doubt, AbbVie's general authorization to a subcontracting/subprocessing arrangement in no way
limits Service Provider's obligations hereunder to (A) cause Services Personnel to comply with the provisions herein and (B) be
liable for all acts and omissions of its subcontractors/subprocessors to the same extent as if they were the acts and/or omissions of
Service Provider.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) If the use of such subcontractor/subprocessor in the reasonable
determination of AbbVie results in unreasonable delay, continuing inadequacy of Services or Deliverables, actual damages, opportunity
costs, or significant financial/legal risks to AbbVie, AbbVie shall have the right in its sole discretion to require the prompt removal
and/or replacement of such subcontractor/subprocessor by Service Provider and payment of actual damages incurred by AbbVie. Such remedies
shall be implemented only following a meeting and review of any such alleged non-performance by the appropriate managers from each Party
responsible for the performance or acceptance of the relevant Services or Deliverables. Nothing in the foregoing shall limit or impair
any rights or remedies that either Party may have under law, equity, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Service Provider shall (A) cause all Services Personnel to comply
with Service Provider's obligations hereunder or under an applicable SOW or PO, applicable to the portion of the Services or Deliverables
being performed by such Services Personnel (which, for the avoidance of doubt, shall always include all of Service Provider's obligations
with respect to data privacy and security, confidential information, Intellectual Property and compliance with laws) and (B) be liable
hereunder for the acts and omissions of Services Personnel to the same extent as if they were the acts or omissions of Service Provider.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Service Provider shall conduct appropriate due diligence on
all Services Personnel to ensure they have capabilities to comply with the obligations in this Agreement.

24. Entire Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;24.1 This Agreement and its schedules contain the complete understanding
of the Parties with respect to the subject matters of this Agreement and supersede all prior agreements relating to the same subject
matter. This Agreement may be modified only by written agreement signed by the Parties. It is specifically agreed that no printed (including
standard terms) that may appear on any documents including any quotations, orders, acceptance notes, or invoices relating to the Services
or products in this Agreement shall have any effect. Except as specifically set forth or referred to in this Agreement, and any applicable
SOW or PO, there are no other Agreements between the Parties.

Page 16 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;24.2 In the event of an inconsistency between the terms and conditions
of a SOW and the terms and conditions of this Agreement, the terms and conditions of the SOW shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;24.3 In the event of an inconsistency between the terms and conditions
of a PO or quote, and terms and conditions of this Agreement, the terms and conditions of this Agreement shall prevail.

&nbsp;&nbsp;&nbsp;&nbsp;24.4 For purposes of this Agreement, all use of the word "including"
should be defined to mean "including, but not limited to".

**25.** **Severability.** If and to the extent that any court of
competent jurisdiction holds any provision of this Agreement to be invalid or unenforceable in a final non-appealable order, such holding
shall in no way affect the validity of the remainder of this Agreement.

**26.** **Governing Law.** This Agreement shall be governed by and
construed in accordance with the laws of the Province of Quebec, excluding its conflicts of laws provisions. Service Provider agrees
that any suit, action or proceeding arising out of or relating to this Agreement may be brought in any court in the Province of Quebec
having jurisdiction over the subject matter of any such suit, action or proceeding, and Service Provider hereby irrevocably and unconditionally
attorns and submits to the jurisdiction of such courts.

**27.** **Language.** The Parties have required this Agreement, as
well as all related documents to be drawn in the English language. *Les Parties aux présentes ont convenu que cette entente ainsi que tous les documents qui s'y rattachent soient rédigés en anglais*.

**28.** **Counterparts.** This Agreement may be executed in separate
counterparts (including by electronic signature or by facsimile or other electronic transmission), each of which shall be an original
document, with the same effect as if the signatures were upon the same instrument.

*[signature page follows]*

Page 17 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

If the foregoing terms and conditions are acceptable, please have an authorized representative sign and date, and return a copy to the AbbVie Contact set forth in Section 4 above, at AbbVie Corporation, 8401 Trans-Canada Highway, St-Laurent (Quebec) H4S 1Z1. AbbVie shall countersign and provide a fully executed copy of this Agreement to the person set forth in Section 4 above.

---

| | | | |
|:---|:---|:---|:---|
| **ACCEPTED:** | **ACCEPTED:** | **ACCEPTED:** | **ACCEPTED:** |
| **ABBVIE CORPORATION** | **ABBVIE CORPORATION** | **DOCOLA INC** | **DOCOLA INC** |
|  | /s/ Michael Reny |  | /s/ Eran Kabakov |
| Name: | Michael Reny | Name: | Eran Kabakov |
| Title: | Senior Brand Manager, Lupron PCa | Title: | CEO |
| Date: | 2022-01-05 | Date: | 12/22/2021 |

---

Page 18 of 19

This information is confidential to AbbVie.

![](dc001_ex10-6img01.jpg)

**Schedule A**

**AbbVie Third Party Security Controls**

Pursuant to Sections 8, 9, and 10, Service Provider shall implement and maintain the security activities listed below for the selected Data Classification category below:

Data Classification (select one): ◻ Public ⌧ Internal Use ◻ Restricted ◻ Secret

For purposes of this Schedule A:

[\*\*\*]

Page 19 of 19

This information is confidential to AbbVie.

## Exhibit 10.7

**Exhibit 10.7**

![](dc001_ex10-7img01.jpg)

**AMENDMENT TO**

**MASTER SERVICES AGREEMENT**

This first amendment ("**Amendment**") is dated as of March 4, 2022 (the "**Effective Date**") by and between **ABBVIE CORPORATION**, a corporation under the laws of Canada and having its principal place of business at 8401 Trans-Canada Highway, St-Laurent, Quebec, Canada H4S 1Z1 ("**AbbVie**") and **DOCOLA INC**., having a mailing address of 801 West Bay Dr, Largo, FL, 337703220 ("Service Provider", collectively with AbbVie, the "Parties" or individually a "Party").

WHEREAS AbbVie and Service Provider have previously entered into a Master Services Agreement, effective December 9, 2021 (the "**Agreement**"); and

WHEREAS Allergan and Service Provider desire to amend the terms of the Agreement as set forth below.

NOW, THEREFORE, in consideration of the foregoing and respective representations, warranties, covenants, and agreements set forth in the Agreement and this Amendment, the Parties hereto agree as follows:

**1.** DATA CLASSIFICATION. The Data Classification category set forth in Schedule A is revised from "Internal Use" to "Secret".

**2.** NO OTHER AMENDMENTS. Except as expressly provided in this Amendment, all other terms, conditions, and provisions of the Agreement shall apply and remain in full force and effect. The addition of capitalized and/or defined terms, as set forth in this Amendment, shall be incorporated into the Agreement, and any lower case and/or undefined terms shall have the meaning as set forth in this Amendment. To the extent there are any inconsistencies or ambiguities between the terms of this Amendment and the Agreement, the terms of this Amendment shall supersede and prevail.

**3.** COUNTERPARTS. This Amendment may be executed in two counterparts each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument. Signatures to this Amendment transmitted by email, portable document format (.pdf) or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Amendment shall have the same effect as the physical delivery of the paper document bearing the original signatures.

IN WITNESS WHEREOF, this Amendment has been executed by the Parties hereto through their duly authorized representatives as of the Effective Date.

*(Signatures on following page)*

 

Corporation AbbVie/AbbVie Corporation Tél./Tel. : 514-906-9700 <br> C.P./P.O. Box 120, Pointe-Claire/Dorval Téléc./Fax : 514-906-9701 <br> Pointe-Claire (QC) H9R 4N5 abbvie.ca

Page **1** of **2**

This information is confidential to AbbVie.

---

| | | | |
|:---|:---|:---|:---|
| **ABBVIE CORPORATION** | **ABBVIE CORPORATION** | **DOCOLA INC.** | **DOCOLA INC.** |
| By: | /s/ Yves Lorion | By: | /s/ Eran Kabakov |
| Name: | Yves Lorion | Name: | Eran Kabakov |
| Title: | Business Unit Manager | Title: | CEO |
|  | 2022-03-05 |  | 2022-03-04 |

---

Page **2** of **2**

This information is confidential to AbbVie.

## Exhibit 10.8

**Exhibit 10.8**

**COLLABORATIVE AGREEMENT SANO GENETICS AND DOCOLA INC.**

This collaborative agreement ("Agreement") dated 2<sup>nd</sup> of August 2022, is between Sano Genetics Limited ("Sano Genetics") with a company number of 10636359 and a registered address of Salisbury House, Station Rd, Cambridge CB1 2LA, and Docola Inc. ("Partner"), with a company tax identification number of 46-3626795 and a permanent address of 801 W Bay Dr. STE 506, Largo FL 33770.

Whereas Sano is a biotech company whose mission it is to connect individuals with precision medicine, and

Whereas Partner is digital health company whose mission it is to optimize patient-clinician asynchronous communication, and

Whereas Sano and Partner wish to use one another's expertise to identify and screen individuals for clinical trial opportunities, the definitions and covenants below specify the terms of the Parties collaboration in this shared vision.

1. DEFINITIONS

1.1. "**Data Protection Legislation**" means the European Union's General Data Protection
Regulation (2016/679), the Privacy and Electronic Communications (EC Directive) Regulations 2003 (SI 2003/2426) and all applicable
laws and regulations relating to the processing of personal data and privacy as amended, re-enacted, replaced or superseded from
time to time, including where applicable the mandatory guidance and codes of practice issued by the United Kingdom's Information
Commissioner.

1.2. "**Intellectual Property Rights**" means all patents, trade marks, service marks,
designs, applications for any of the foregoing and the right to apply for any of the foregoing in any part of the world, copyright,
design right, database rights, inventions, know-how and any other similar right anywhere in the world.

1.3. "**Partner**" means the company identified in the Project Schedule as providing Sano
Genetics with access to potential research participants.

**2.** **FEES AND PAYMENT** 

2.1. Unless otherwise stated in the Project Schedule, Partner shall submit its invoices for fees and
allowable expenses monthly in arrears. The fees do not include VAT which shall be payable in addition if applicable. Sano Genetics
shall pay Partner's invoices within 30 days after the date Sano Genetics receives payment from the client, unless otherwise
specified in the Project Schedule (Appendix 1).

2.2. Fees shall be payable in respect of each participant introduced by Partner who meets all of the
success criteria specified in the Project Schedule. If a participant does not meet the success criteria of the Project Schedule
in which the relevant participant was first introduced by Partner, but does meet the success criteria of a subsequent Project Schedule
entered into by the parties, Sano Genetics shall pay the fee specified in such subsequent Project Schedule PROVIDED THAT such subsequent
Project Schedule was executed within two years of the start date of the first Project Schedule.

3. INTELLECTUAL PROPERTY RIGHTS

3.1. All Intellectual Property Rights of each party in existence at the date of the Project Schedule,

4. CONFIDENTIALITY

4.1. Each party agrees to keep all confidential information and trade secrets disclosed to it by or
on behalf of the other party confidential, and not at any time for any reason to disclose or permit such confidential information
or trade secrets to be disclosed to any third party without the disclosing party's prior written consent.

5. LIABILITY

5.1. Neither party shall be liable for any loss of profits; loss of business; depletion of goodwill;
or any special, indirect or consequential loss or damage.

5.2. Each party's total aggregate liability to the other under the Project Schedule shall be limited
to the total fees paid by Sano Genetics to Partner in respect of that Project.

5.3. Each party's liability for death or personal injury caused by negligence, and liability for fraud
or fraudulent misrepresentation, shall be unlimited.

6. PUBLICITY

6.1. The contents, but not the existence, of the Project Schedule shall constitute confidential information
for each party. Either party shall be entitled to publish on its website, in its marketing literature and in press releases information
confirming the existence of the parties' commercial relationship, and may incorporate the other party's house-mark or logo into
such publicity material. The text of any such publicity material shall be agreed prior to publication and neither party shall unreasonably
withhold or delay its agreement to any text proposed by the other party.

7. GENERAL

7.1. The parties agree to comply with all Data Protection Legislation to the extent applicable to their
activities under the Project Schedule.

7.2. No person other than Sano Genetics and Partner shall have any rights under or in connection with
the Project Schedule.

7.3. Nothing in the Project Schedule shall operate to create a formal partnership between the parties.

7.4. The Project Schedule constitutes the entire and only agreement between the parties in relation
to its subject matter. Each of the parties acknowledges that they are not relying on any statements, warranties or representations
given or made by any of them, save those expressly set out in the Project Schedule.

7.5. The Project Schedule is governed by the laws of England. The parties irrevocably agree that the
courts of England have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with the Project
Schedule.

(remainder of page intentionally left blank)

**AS WITNESS** the duly authorised representatives of each of the parties the day and year first before written.

---

| | |
|:---|:---|
| **SIGNED** by Patrick Short, CEO) |  |
| for and on behalf of) | /s/ Patrick Short |
| **SANO GENETICS LIMITED)** |  |
| **SIGNED** by Eran Kabakov, CEO) |  |
| for and on behalf of) | /s/ Eran Kabakov |
| **Docola Inc**) |  |

---

**Appendix 1:**

**Project Schedule**

---

| | |
|:---|:---|
| **Project title** | Title |
| **Start date** | Date |
| **Term** | Weeks/months/years |
| **Definitions** | **Partner** – Docola Inc.<br>**Sano** – Sano Genetics Limited |

---

 **Project Structure** 

● Platform for analysing participant genomic, medical, survey, or other data to check for potential eligibility.

 **Project Financials** 

---

| | | |
|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Supplementary Terms** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Supplementary Terms** |
|  | No additional terms necessary | No additional terms necessary |
| **Authorisation** | **AS WITNESS** the duly authorised representatives of each of the parties the day and year first before written. | **AS WITNESS** the duly authorised representatives of each of the parties the day and year first before written. |
|  | **SIGNED** by Patrick Short, CEO | **)** |
|  | for and on behalf of | **)** |
|  | **SANO GENETICS LIMITED** | **)** |
|  | **SIGNED** by Eran Kabakov,CEO | **)** |
|  | for and on behalf of | **)** |
|  | /s/ Eran Kabakov |  |
|  | Docola Inc. | **)** |

---

## Exhibit 10.9

**Exhibit 10.9**

**MASTER SERVICES AGREEMENT**

This is an Agreement executed this 1<sup>st</sup> day of January 2020 ("Effective Date"), by and between:

Docola, Inc. ("Company"), a Delaware Corporation, whose principal place of business is located at 801 West Bay Drive #506, Largo FL 33770, and

Geri Lynn Baumblatt working as Articulations Consulting DBA Hyperjeff Inc ("Consultant"), whose principal place of business is located at ██████████████ Chicago, IL █████.

Company is engaged in the business of enabling a content management marketplace between content providers and healthcare providers.

Consultant is engaged in the business of providing business development, content design services in connection with third party and general administration.

Company desires to acquire, or has acquired and will continue to acquire, from Consultant, and Consultant desires to provide, or has provided and will continue to provide, Company, the services described below in accordance with all of the terms and conditions hereof.

**<u>AGREEMENT</u>**

**NOW, THEREFORE**, in consideration of the foregoing and the mutual covenants and conditions herein contained, the parties hereto agree as follows:

1. Scope
 of Work .

Consultant agrees to provide to Company, on a timely basis during the period of consultancy as defined herein. Company and Consultant may add to, amend, or change the scope, nature and amount of work by a writing signed by both parties. Any such Additional Statement of Work shall be deemed an amendment to this Agreement and all other terms of this Agreement shall apply.

2. Term
 and Duration .

Certain parts of this Agreement remain in effect post the Consultant delivering agreed to work(s) to the Company and post receiving payment for same. Specifically, the mutual obligations to maintain Trade Secrets and Confidential Information, as described herein, are in effect in perpetuity, or as long as allowed by applicable law. The term of this Agreement shall commence on the date that both parties have signed and shall continue through and including completion of the work.

![](dc001_ex10-9img01.jpg)

3. Compensation .

&nbsp;&nbsp;&nbsp;&nbsp;3.1. <u>Terms</u>:
 Company shall pay Consultant for services provided in full under this Agreement in accordance
 with the terms set forth herein. Consultant will receive no royalty or other remuneration
 on the production or distribution of any products or services (collectively "Product")
 developed by Company in connection with, or based upon, the work provided hereunder. Company
 agrees that development work will be done on Consultant's computer and Company will
 provide access to tools for remote team work as needed. .

&nbsp;&nbsp;&nbsp;&nbsp;3.2. <u>Cost and Expenses</u>: In addition to all other compensation provided herein, Company shall reimburse
 Consultant for reasonable out-of-pocket business expenses incurred by Consultant in the performance
 of the work provided hereunder, but  ***only*** when preapproved by the Company. All
 such expenses will be documented to the Company with appropriate receipts. In the case wherein
 such costs and expenses relate to the licensing of third party intellectual property, the
 Consultant will also provide Company the third party licensing agreement, if any.

&nbsp;&nbsp;&nbsp;&nbsp;3.3. <u>Payment of Fees</u>: Fees are to be paid unless otherwise agreed to in writing by the parties. The
 Company will utilize a third party service to make payments for work performed. Payment is
 due upon receipt of invoice. If full payment is not received within fifteen (15) days of
 invoice date, the Consultant reserves the right to stop work until payment is received and
 Company's accounts are current. This may cause project completion dates or repairs
 to problems to be delayed past completion date. Thirty (30) days after the invoice date,
 bills will be considered delinquent and a late fee at the rate of 1.5% APR above the then
 current Wall Street Journal prime rate will be assessed on the unpaid balance. Payment will
 be made to Consultant at the address specified as its principal place of business herein.

4. Warranties.

Consultant warrants that the work provided hereunder shall be performed in a reasonable and professional manner. Consultant agrees that it will make reasonable efforts to repair or replace work that contains inconsistencies resulting from Consultant's work. Consultant agrees to provide Company access to work under development so that Company can assess said work as provided for herein.

5. Time
 is of the Essence .

In order to complete the work on time, questions, directions and materials must be received from Company in a timely manner.

6. Conflict
 of Interest .

The Consultant agrees to inform the Company of all the Consultant's interests, if any, which may be, or which the Consultant has reason to believe may be, incompatible with the interests of the Company, or the Company's customers. In addition to the foregoing, the Consultant agrees not to make improper use of any information that comes to Consultant or to Consultant's agents or representatives, in the performance of work under this Agreement.

![](dc001_ex10-9img01.jpg)

7. Confidentiality .

Either party to this Agreement may, in the course of fulfilling its terms, need to disclose information to the other party that is proprietary or confidential. When such disclosure is undertaken, the following provisions apply:

&nbsp;&nbsp;&nbsp;&nbsp;7.1. <u>The Parties</u>: The term "Disclosing Party," as used in this Agreement, means the
 party providing Confidential Information. The "Receiving Party" is the party
 receiving the information.

&nbsp;&nbsp;&nbsp;&nbsp;7.2. <u>Confidential Information</u>: The term "Confidential Information," as used in this Agreement,
 means any oral, written, or documentary information or information that is stored by electronic
 means which (i) relates to this Agreement, (ii) is received by one of the parties from the
 other, and, in the case of written information, (iii) is marked "Confidential,"
 "Proprietary" or bears a marking of like import or which the Disclosing Party
 states in writing at the time of transmittal to, or receipt by, the Receiving Party is to
 be considered confidential. Orally disclosed information shall be considered confidential
 if identified as such at the time of disclosure and if followed up in writing within ten
 (10) calendar days, with the information identified and marked as confidential.

&nbsp;&nbsp;&nbsp;&nbsp;7.3. <u>Business Relationship</u>: The term "Business Relationship," as used in this Agreement,
 means the contractual arrangement between Company and Consultant as defined herein, including
 any Addendums that may hereafter be incorporated into this Agreement, and any oral or written
 communications between Company and Consultant regarding same. Consultant agrees not to publish
 information, in any medium, that acknowledges the Business Relationship, without the express
 written consent of Company, unless required to do so by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;7.4. <u>Trade Secret:</u> The term "Trade Secret," as used in this Agreement, means any oral,
 written, or documentary information or information that is stored by electronic means that:
 (i) derives economic value, actual or potential, from not being generally known to, and not
 being readily ascertainable by proper means, by other persons who can obtain economic value
 from its disclosure or use; and (ii) is the subject of efforts that are reasonable under
 the circumstances to maintain its secrecy.

&nbsp;&nbsp;&nbsp;&nbsp;7.5. <u>Exclusions:</u> The terms "Confidential Information" and "Trade Secrets" do not
 include information that: (i) is already known to the Receiving Party as evidenced by prior
 documentation thereof; or (ii) is or becomes publicly known through no wrongful act of the
 Receiving Party; or (iii) is rightfully received by the Receiving Party from a third party
 without restriction and without breach of this Agreement or any other agreement; or (iv)
 is approved for release by written authorization of the Disclosing Party.

![](dc001_ex10-9img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;7.6. <u>Duties of Receiving Party:</u> The Receiving Party shall not disclose to others, or use for any
 purpose of its own, any Confidential Information, financial or business data, technical data,
 or other confidential or proprietary information obtained from the Disclosing Party, or from
 an affiliated entity of the Disclosing Party, as a result of work done pursuant to this Agreement,
 or generated or developed in the performance of work under this Agreement. With respect to
 Trade Secrets, the Receiving Party agrees not to use for any purpose whatsoever or to disclose
 Trade Secrets at any time during or after the term of this Agreement or until such Trade
 Secrets lose their status as such by becoming generally available to the public by independent
 discovery, development, or publication. Furthermore, the Receiving Party shall not display
 for any purpose any drawing, letter, report, other document, or any copy or reproduction
 thereof belonging to or pertaining to the Disclosing Party, or to an affiliated entity of
 the Disclosing Party, unless such drawing, letter, report, or other document has been previously
 published by the Disclosing Party. Publication shall not include publication to an affiliated
 entity of the Disclosing Party. Upon termination of this Agreement, the Receiving Party agrees
 to return all Confidential Information to the Disclosing Party.

&nbsp;&nbsp;&nbsp;&nbsp;7.7. <u>Application of Covenants:</u> The covenants regarding Confidential Information and Trade Secrets will
 apply to any Confidential Information or Trade Secrets disclosed to the Receiving Party by
 the Disclosing Party before or after the date of this Agreement.

8. Protected
 Works, Intellectual Property Rights, and Confidentiality of Consultant's Employees
 or Agents .

&nbsp;&nbsp;&nbsp;&nbsp;8.1. <u>Protected Works</u>: The term "Protected Works," as used in this Agreement, includes any
 and all works of authorship and design delivered by the Consultant to the Company under this
 Agreement before or after the date of this Agreement, or conceived, developed or produced
 by the Consultant, whether alone or jointly with others, in connection with or pursuant to
 the Consultant's performance under this Agreement, except as detailed in Sections 9.2 and
 9.3.

&nbsp;&nbsp;&nbsp;&nbsp;8.2. <u>Reusable Components:</u> The term "Reusable Components," as used within this Agreement,
 shall mean all tools, designs, descriptions ,documentation and written work that is or reasonably
 may be useable in other work, projects or applications, by Consultant, and which were developed
 prior to the Effective Date of this Agreement, and incorporated in the Company's Product.
 However, any such components developed hereunder, shall not be deemed to be Reusable Components,
 and shall be treated as a Work for Hire as defined herein, with Company owning all right,
 title and interest to same. Consultant grants to Company a permanent, irrevocable, non-exclusive
 license to use, market, copy, distribute and reproduce the Reusable Components for Company's
 own business use in its own operations and subsequent sale, licensing and/or distribution
 of its Product, which incorporates the Reusable Components. Company is licensed to edit or
 modify the Reusable Components for such use. Company may accomplish such modifications by
 itself or by the use of such consultants as it may choose. Consultant agrees that the license
 granted to Company by Consultant regarding Reusable Components, including the ability to
 make modifications to same, is also granted to Company's successors, assigns, and licensees.

![](dc001_ex10-9img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;8.3. <u>Licensed Components:</u> The term "Licensed Components," as used within this Agreement,
 shall refer to those commercial, Creative Commons, open source, or otherwise licensed third
 party components or applications which are used by Consultant as part of the work delivered
 to Company hereunder, and upon which a license is being enforced by said third party, whether
 or not such enforcement is apparent to Consultant. Consultant hereby agrees to adhere by
 the terms and conditions of all licensed components and further agrees to indemnify Company
 for any violation of said terms and conditions, caused either directly, or indirectly, by
 Consultant.

&nbsp;&nbsp;&nbsp;&nbsp;8.4. <u>Exclusions:</u> The term "Protected Works," as used in this Agreement, shall not include
 Reusable Components and Licensed Components. These are and will remain the property of Consultant
 and/or the respective licensors of said components, even though they may be used in, or made
 a part of, the work performed under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;8.5. <u>Intellectual Property Rights</u>: The term "Intellectual Property Rights," as used in this
 Agreement, includes all rights of design and authorship, all copyrights, all trademark and
 service mark rights, all rights in trade secret and proprietary information, all rights of
 attribution and integrity and other moral rights, and all other intellectual property rights
 of any type.

&nbsp;&nbsp;&nbsp;&nbsp;8.6. <u>Work for Hire</u>: The Consultant agrees that all Protected Works shall be deemed a "work
 for hire" under the United States Copyright Act and owned exclusively by the Company.
 To the extent that any Protected Work cannot be deemed a work for hire, the Consultant agrees
 to assign and hereby does assign to the Company all right, title, and interest in and to
 all Protected Works and all Intellectual Property Rights in and to the Protected Works. The
 Consultant agrees to execute any documents reasonably required by the Company to evidence
 the Company's exclusive ownership of the Protected Works, and all Intellectual Property Rights
 therein, as contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;8.7. <u>Moral Rights Waiver:</u> The term "Moral Rights," as used in this Agreement, means
 any right to claim authorship of a work, any right to object to any distortion or other modification
 of a work, and any similar right, existing under the law of any country in the world, or
 under any treaty. Consultant hereby irrevocably transfers and assigns to Company any and
 all Moral Rights that Consultant may have in any Protected Works, in deliverables resulting
 from Consultant's work hereunder and incorporated in any Company Product or derivatives
 therefrom. Consultant also hereby forever agrees never to assert against Company, its successors,
 assigns or licensees, any and all Moral Rights Consultant may have in any Company Product,
 or Protected Works, or derivatives thereof, delivered hereunder, even after expiration or
 termination of this Agreement. Nothing in this Agreement, however, shall affect any rights
 or grant of rights existing or created apart from this Agreement.

![](dc001_ex10-9img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;8.8. <u>Consultant Confidentiality Agreement of Its Employees and Agents</u>: Consultant will ensure that Consultant
 and each of its employees or agents who will have access to the Protected Works or Confidential
 Information of Company executes an agreement, the form of which has been approved by Company
 (the "Confidentiality Agreement"), acknowledging Company's exclusive ownership
 and control of the Protected Works, obligating the employee to keep all Confidential Information
 confidential and not to use the Protected Works or Confidential Information in any way, commercially
 or otherwise, except in performing the work as defined hereunder, and transferring to Company
 and waiving any and all Moral Rights and Intellectual Property Rights in the Protected Works.
 Likewise Consultant will ensure that none of its employees or agents publishes information,
 in any medium, that acknowledges the Business Relationship, without the express written consent
 of Company, unless required to do so by applicable law. Company agrees to submit a proposed
 form for such a Confidentiality Agreement in conformity with this Agreement.

9. Modifications
 to Protected Works.

Unless otherwise agreed to in writing by the parties, the Consultant is not responsible for any changes made to the Protected Works by any other party, except for a subcontractor of Consultant. Any modification by any party not authorized by Consultant (including Company) voids any warranties or obligations to support as defined herein. The fixed nature (e.g. price) of any project bid is also void, if applicable. If Company or any other person, other than Consultant or subcontractor of Consultant, attempts to update the Protected Works, or otherwise makes modifications to same.

10. Company
 Intellectual Property Provided to Consultant.

Company represents to Consultant and unconditionally guarantees that any elements of text, graphics, photos, designs, trademarks, or other artwork furnished to the Consultant for inclusion in the Protected Works are owned by the Company, or that the Company has permission from the rightful owner to use each of these elements, and will hold harmless, protect, and defend the use of such elements furnished by the Company to the extent that Consultant is using them within the scope of this Agreement. Consultant acknowledges that Company is the owner of certain Company names, trademarks, service marks, names and symbols which may be used in the Protected Works (collectively the "Marks"). Company hereby grants Consultant a nonexclusive right to use the Marks, in accordance with the terms and conditions of this Agreement. Consultant agrees to comply with the quality guidelines provided by Company to Consultant from time to time regarding usage of the Marks. This right to use granted shall be expressly limited to the purpose of this Agreement and Consultant shall make no other use of the Marks without the written consent of the Company.

11. Indemnification
 of Claims by Third Parties.

Consultant will indemnify Company and hold it harmless from and against all claims, damages, losses and expenses, including court costs and reasonable fees and expenses of attorneys, expert witnesses and other professionals, arising out of or resulting from any final and non appealable adjudication by a third party against Company, holding that any Protected Works delivered to Company by Consultant or deliverables resulting from work of Consultant that is incorporated in the Protected Works under this Agreement, infringes a copyright, violates a trade secret, or violates any other Intellectual Property Right of a third party.

12. Limitations
 of Liability.

Except as specified herein, each party shall indemnify, defend and hold harmless the other party, its parents, subsidiaries, affiliates, and their respective officers, directors, members, employees and agents from and against any and all third party demands for losses, claims, actions, damages, liabilities, costs and expenses, including reasonable attorney fees, directly related to or arising from injuries to persons, tangible, intangible or real property to the extent caused **by the negligence or willful misconduct of a party**. A party's indemnity and hold harmless obligations as to any claim or suit within the scope of this clause shall be reduced to the extent of any concurrent fault, failure to mitigate damages or negligence by the other party. Other than as specified herein, the Consultant provides no warranty and is not liable for any consulting advice. Although Consultant, based upon experience, will attempt to assist the Company, Consultant is not liable for any such assistance unrelated to services rendered.. If such claim is made, the Indemnifying Party, at its expense shall defend against and pay any and all costs, expenses, including reasonable fees of attorneys and other retained professionals or consultants and damages of any kind arising out of such claim, whether or not that claim is successful, provided that the indemnified party: (a) gives the Indemnifying Party prompt written notice of such claim, and (b) cooperates with the Indemnifying Party, at the Indemnifying party's expense, in the defense of such claim. The Indemnifying party shall not be responsible for any settlement made by the Indemnified party without the Indemnifying party's prior written consent. The maximum liability of Consultant is the amount paid for the specific work done or not done which was billed in the preceding sixty days. No punitive damages shall be awarded against either party.

13. Attorneys'
 Fees.

In any action to enforce this Agreement, the prevailing party shall be entitled to recover all court costs and expenses and reasonable attorneys' fees, in addition to any other relief to which it may be entitled.

14. Notices.

All notices hereunder (other than payment) shall be in writing and delivered personally or sent via facsimile, by certified mail, return receipt requested, email (return receipt requested), or by a reputable courier service to the addresses shown above or to such other addresses as may be designated in the future via an Addendum to this Agreement.

![](dc001_ex10-9img01.jpg)

15. Entire
 Agreement.

This Agreement constitutes the entire agreement between Company and Consultant with respect to the transactions contemplated herein and supersedes any and all prior or contemporaneous oral or written communications relating to the subject matter hereof. This Agreement shall not be amended except by a writing executed by both parties. No waiver of any provision of this Agreement or any rights or obligations of either party hereunder shall be effective, except pursuant to a written instrument signed by the party or parties waiving compliance, and any such waiver shall be effective only in the specific instance and for the specific purpose stated in such writing. No remedy made available to Company by any of the provisions of this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity.

16. Laws,
 Taxes, and Tariffs.

Various governments enact laws and levy taxes and tariffs affecting Internet electronic commerce. Company agrees that it is solely responsible for complying with such laws, taxes, and tariffs, and will hold harmless, protect and defend the Consultant and its subcontractors from any claim, suit, penalty, tax or tariff arising from the Company's exercise of Internet electronic commerce.

17. Governing
 Law and Venue.

This Agreement and the rights of the parties shall be governed by and construed in accordance with the laws of the State of Florida without giving effect to its conflict of laws. The parties agree that any appropriate state or federal court sitting in, or most proximate to, Pinellas County, Florida shall have exclusive jurisdiction of any case or controversy arising under or in connection with this Agreement and shall be a proper forum in which to adjudicate such case or controversy. Each party irrevocably consents to the jurisdiction of such courts, and irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such suit, action, or proceeding in any such court and further waives the right to object, with respect to such suit, action, or proceeding, that such court does not have jurisdiction over such party.

18. Non-Solicitation.

Each party hereto agrees that for a period of two (2) years after the later of (a) the Effective Date of this Agreement or (b) the termination or expiration of this Agreement, neither party will employ, solicit for employment, attempt to employ or affirmatively assist any other person, entity, or enterprise in employing or soliciting for employment any person employed by the other party.

![](dc001_ex10-9img01.jpg)

19. Assignment
 and Delegation.

Company shall have the right and power to assign or delegate any of its rights or duties of performance hereunder without the consent of the Consultant. Consultant shall have the right and power to assign any of its rights, or delegate any of its duties of performance hereunder, only with the express written consent of the Company. Any attempted assignment of Consultant's rights, or delegation of Consultant's duties to perform hereunder, without the express written consent of the Company, shall automatically trigger a full and complete release regarding all of Company's performance duties and obligations under this Agreement, without the requirement of actual or constructive notice to Company of said attempted assignment or delegation.

20. Independent
 Contractor.

Neither party nor any of its personnel shall be considered as an agent or employee of the other party. It is understood and agreed that Consultant is an independent contractor with respect to performing work hereunder on behalf of Company and that Consultant shall have full control over, and responsibility for, the manner and means by which such work is provided hereunder.

21. Subcontractors.

Consultant may employ subcontractors to perform a portion, or the entirety, of the work contemplated hereunder, to ensure timely completion hereof. Consultant shall be fully responsible for all work performed by subcontractors to the same extent as if Consultant had performed the tasks.

22. Force
 Majeure.

Neither party shall be responsible for (or be deemed in breach or default hereof as a result of) delays or failures in performance hereunder to the extent that such party was hindered in its performance by any act of God, war, terrorism, civil commotion, application of any law or regulation or other act of any governmental officer or personnel, labor dispute, or any other occurrence beyond the reasonable control of such party.

23. Resolution
 of Conflict.

&nbsp;&nbsp;&nbsp;&nbsp;23.1. <u>Waiting Period:</u> Both parties agree during a fifteen (15) day period after notice is given to
 the other party of a dispute under the terms of this Agreement to use its best efforts to
 resolve any dispute through good faith negotiations. This waiting period is applicable only
 to the Arbitration provisions of this Section and does not apply wherein either party has
 infringed or threatened to infringe the other party's Intellectual Property Rights.

&nbsp;&nbsp;&nbsp;&nbsp;23.2. <u>Arbitration:</u> Any claim or controversy arising among or between the parties hereto, or arising out
 of, or with respect to, any matter contained in this Agreement, or any differences as to
 the interpretation or performance of this Agreement, other than those wherein either party
 has infringed or threatened to infringe the other party's Intellectual Property Rights,
 shall be settled by arbitration in the State of Florida. Such arbitration shall be before
 three arbitrators of the American Arbitration Association (the "AAA") under its
 then prevailing rules.

![](dc001_ex10-9img01.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;23.3. <u>Award of Arbitrators:</u> In any arbitration involving this Agreement, the arbitrators shall not
 make any award that will alter, change, cancel or rescind any provision in this Agreement,
 and their award shall be consistent with the provisions of this Agreement. Any such arbitration
 must be commenced no later than one (1) year from the date such claim or controversy arose,
 or the claim is waived. The award of the arbitrators shall be final and binding and judgment
 may be entered thereon in any court of competent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;23.4. <u>Sharing of Costs:</u> the parties agree that the costs of Arbitration shall be shared equally between
 them.

24. Severability
 of Provisions.

In the event that any provision hereof is found invalid or unenforceable pursuant to judicial decree or decision, the remainder of this Agreement shall remain valid and enforceable according to its terms. Further, to the extent any provision hereof is found to be in part enforceable and in part unenforceable, the unenforceable portion shall be deemed stricken therefrom, and such provision shall be valid and enforceable to the maximum extent permitted under applicable law. Without limiting the foregoing, it is expressly understood and agreed that each and every provision of this Agreement which provides for a limitation of liability, or exclusion of damages, or exclusion of other remedies is intended by the parties to be severable and independent of any other provision and to be enforced as such. Further, it is expressly understood and agreed that in the event any remedy hereunder is determined to have failed of its essential purpose, all limitations of liability, exclusions of damages and exclusions of other remedies set forth herein shall remain in effect.

25. Counterparts.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one original Agreement. Facsimile or electronically authenticated signatures shall be accepted and enforceable in lieu of original signatures.

![](dc001_ex10-9img01.jpg)

**IN WITNESS WHEREOF** the parties hereto have executed this Agreement as of the Effective Date first above written:

---

| |
|:---|
| **For the Company:** |
| /s/ Eran Kabakov |
| Eran Kabakov, Chief Executive Officer<br> Docola, Inc. |
| Apr 28, 2020 |
| Date |

---

---

| | | | |
|:---|:---|:---|:---|
| **For the Consultant:** |  |  |  |
| **** | **** | **** | **** |
| Geri L. Baumblatt |  |  |  |
| Geri L. Baumblatt (Apr 27, 2020) |  |  |  |
| Signature |  |  |  |
| Geri L. Baumblatt | , | Consultant |  |
| Full name |  | Title |  |
| Apr 27, 2020 |  |  |  |
| Date |  |  |  |

---